Sepiapterin reductase inhibitors

Abstract
Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.
Description
BACKGROUND

Tetrahydrobiopterin (BH4) is an enzyme cofactor for various aromatic amino acid hydroxylases, including phenylalanine, tyrosine and tryptophan hydroxylases, as well as being an important cofactor for other enzymes such as the nitric oxide synthases (inducible NOS (iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS)), and alkylglycerol monooxygenase. As such, BH4 is involved in regulating production of various neurotransmitters (e.g., serotonin and dopamine) and nitric oxide. Deficiencies in BH4 are associated with deficiencies in neurotransmitters including serotonin and dopamine. Reduced BH4 production is also associated with reduced pain sensitivity after injury.


The last step in the de novo pathway for BH4 biosynthesis is conversion of 6-pyruvoyltetrahydropterin to BH4 by the action of sepiapterin reductase. Sepiapterin reductase (SPR) is inhibited by the clinically approved drug sulfasalazine and other sulfa drugs, thereby interfering with the de novo biosynthesis of BH4.


SUMMARY

Disclosed herein are compounds of formulae I, I′, II, II′, III, III′, IV, IV′, V, and V′, and pharmaceutically acceptable salts thereof:




embedded image


embedded image


Also disclosed are compositions (e.g., pharmaceutical compositions) comprising one or more of the compounds disclosed herein and a pharmaceutically acceptable carrier.


Further disclosed are methods of using one or more of the compounds disclosed herein, or a pharmaceutical composition thereof. The methods include methods of inhibiting sepiapterin reductase (SPR), methods of treating a subject suffering from pain, methods of treating a subject suffering from inflammation, and/or methods of treating a subject suffering from an immunological disorder.


These and other embodiments and features of the present invention will become apparent from the following detailed description of the preferred embodiments.







DETAILED DESCRIPTION

Disclosed herein are inhibitors of sepiapterin reductase (SPR) and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation. In mouse models, administration of an SPR inhibitor reduced pain hypersensitivity and BH4 levels in target tissues (Latremoliere et al., Neuron, 86:1393-1406 (2015)).


The use of the terms “a,” “an,” “the,” and similar referents in the context of describing the invention (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated. Recitation of ranges of values herein merely are intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended to better illustrate the invention and is not a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.


As used herein, the term “alkyl” refers to straight chained and branched hydrocarbon groups, including but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl, t-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, and 2-ethybutyl. The term Cm-n means the alkyl group has “m” to “n” carbon atoms. The term “alkylene” refers to an alkyl group having a substituent. An alkyl (e.g., methyl), or alkylene (e.g., —CH2—), group can be substituted with one or more, and typically one to three, of independently selected halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups, for example.


As used herein, the term “halo” refers to fluoro, chloro, bromo, and iodo. The term “hydroxy” is defined as —OH. The term “alkoxy” is defined as —OR, wherein R is alkyl. The term “amino” is defined as —NH2, and the term “alkylamino” is defined as —NR2, wherein at least one R is alkyl and the second R is alkyl or hydrogen. The term “carbamoyl” is defined as —C(═O)NR2. The term “carboxy” is defined as —C(═O)OH or a salt thereof. The term “nitro” is defined as —NO2. The term “cyano” is defined as —CN. The term “trifluoromethyl” is defined as —CF3. The term “trifluoromethoxy” is defined as —OCF3.


As used herein, the term “aryl” refers to a monocyclic or polycyclic aromatic group, preferably a monocyclic or bicyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, pyrenyl, biphenyl, and terphenyl. Aryl also refers to bicyclic and tricyclic carbon rings, where one ring is aromatic and the others are saturated, partially unsaturated, or aromatic, for example, dihydronaphthyl, indenyl, indanyl, or tetrahydronaphthyl (tetralinyl). Unless otherwise indicated, an aryl group can be unsubstituted or substituted with one or more, and in particular one to four, groups independently selected from, for example, halo, alkyl, alkenyl, —OCF3, —NO2, —CN, —NC, —OH, alkoxy, amino, alkylamino, —CO2H, —CO2alkyl, —OCOalkyl, aryl, and heteroaryl.


As used herein, the term “benzyl” refers to —CH2-phenyl. Unless otherwise indicated, a benzyl group can be unsubstituted or substituted with one or more, and in particular one to four, groups independently selected from, for example, halo, alkyl, alkenyl, —OCF3, —NO2, —CN, —NC, —OH, alkoxy, amino, alkylamino, —CO2H, —CO2alkyl, —OCOalkyl, aryl, and heteroaryl.


As used herein, the term “heterocyclic” refers to a heteroaryl or heterocycloalkyl ring system. As used herein, the term “carbocyclic” refers to an aryl or cycloalkyl ring system.


As used herein, the term “heteroaryl” refers to a monocyclic or polycyclic ring system (for example, bicyclic) containing one or two aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring. Each ring of a heteroaryl group can contain one or two O atoms, one or two S atoms, and/or one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. In certain embodiments, the heteroaryl group has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms. Examples of monocyclic heteroaryl groups include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl, and triazolyl. Examples of bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzothiophenyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl, quiazolinyl, thiadiazolopyrimidyl, and thienopyridyl. Unless otherwise indicated, a heteroaryl group can be unsubstituted or substituted with one or more, and in particular one to four, substituents selected from, for example, halo, alkyl, alkenyl, —OCF3, —NO2, —CN, —NC, —OH, alkoxy, amino, alkylamino, —CO2H, —CO2alkyl, —OCOalkyl, aryl, and heteroaryl.


As used herein, the term “cycloalkyl” means a monocyclic or polycyclic (e.g., bicyclic), saturated or partially unsaturated, ring system containing three or more (e.g., three to twelve or three to eight) carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, optionally substituted with one or more, and typically one to three, of independently selected halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups, for example.


As used herein, the term “heterocycloalkyl” means a monocyclic or polycyclic (e.g., bicyclic), saturated or partially unsaturated, ring system containing 3 or more (e.g., 4 to 12) total atoms, of which one to five of the atoms are independently selected from nitrogen, oxygen, and sulfur and the remaining atoms are carbon. Nonlimiting examples of heterocycloalkyl groups are azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, dihydropyrrolyl, morpholinyl, thiomorpholinyl, dihydropyridinyl, oxacycloheptyl, dioxacycloheptyl, thiacycloheptyl, diazacycloheptyl, each optionally substituted with one or more, and typically one to three, of independently selected halo, C1-6 alkyl, C1-6 alkoxy, cyano, amino, carbamoyl, nitro, carboxy, C2-7 alkenyl, C2-7 alkynyl, or the like on an atom of the ring.


The compounds disclosed herein include all pharmaceutically acceptable isotopically-labeled compounds wherein one or more atoms of the compounds disclosed herein are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature, examples of which include isotopes of hydrogen, such as 2H and 3H. In some cases, one or more hydrogen atoms of the compounds disclosed herein are specifically 2H (deuterium). Isotopically-labeled compounds as disclosed herein can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples and schemes using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.


Certain of the compounds as disclosed herein may exist as stereoisomers (i.e., isomers that differ only in the spatial arrangement of atoms) including optical isomers and conformational isomers (or conformers). The compounds disclosed herein include all stereoisomers, both as pure individual stereoisomer preparations and enriched preparations of each, and both the racemic mixtures of such stereoisomers as well as the individual diastereomers and enantiomers that may be separated according to methods that are known to those skilled in the art. Additionally, the compounds disclosed herein include all tautomeric forms of the compounds.


In one aspect, the disclosure provides a compound of formula I or I′, or a pharmaceutically acceptable salt thereof:




embedded image


wherein:



custom character is an optional double bond;


Z is CR1 or NR1, or if the double bond is present, then Z is CR1 or N;


Y is NR2 or CR2, or if the double bond is present, then Y is N or CR2;


X is N or CR5a;


R1 and R2, taken together with the atoms to which they are attached form a 4-, 5-, 6-, or 7-membered ring; or


R1 and R2 are independently selected from the group consisting of H, C1-5alkyl, C3-5cycloalkyl, C1-5haloalkyl, and halo;


R5 and R5a are independently selected from the group consisting of H and C1-5alkyl;


L is heteroaryl-C0-5alkylene-, aryl-C0-5alkylene-, —S—C1-5alkylene-aryl, —S—C1-5alkylene-heteroaryl, —C1-5alkylene-S-aryl, or —C1-5alkylene-S-heteroaryl;


R3 and R4, taken together with nitrogen atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered spiro, fused, and/or bridged polycyclic (e.g., bicyclic) ring; or


R3 is selected from the group consisting of H, C1-5alkyl, C3-10cycloalkyl, C1-5haloalkyl, aryl, heteroaryl, and C1-5alkylene-G,


R4 is selected from the group consisting of C1-5alkyl, C3-10cycloalkyl, C1-5haloalkyl, aryl, heteroaryl, and C1-5alkylene-G; and


each G is independently selected from the group consisting of CN, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.


In some embodiments, the compound of formula I does not include a compound having a structure as recited in Table D, below.


In some embodiments, the disclosure provides a compound having a formula IA or IA′:




embedded image


wherein:


Y is NR2 or CR2, or if the double bond is present, then Y is CR2; and


R1 and R2, taken together with the atoms to which they are attached form a 4-, 5-, 6-, or 7-membered ring.


Compounds of formula IA or IA′ include, but are not limited to, compounds having a structure selected from the group consisting of:




embedded image



Compounds of formula IA or IA′ also include, but are not limited to, compounds having a structure:




embedded image


In some embodiments, R1 and R2, taken together with the atoms to which they are attached form a heteroaryl ring, an aryl ring, a heterocycloalkyl ring, or a cycloalkyl ring. In some embodiments, R1 and R2, taken together with the atoms to which they are attached form a pyrrole ring, a cyclopentene ring, a thiophene ring, a dihydrofuran ring, a cyclohexene ring, a pyrazole ring, a thiazole ring, a benzene ring, an imidazole ring, or a cyclobutene ring.


In some embodiments, the disclosure provides a compound having a formula IB or IB′:




embedded image


wherein R1 and R2 are independently selected from the group consisting of H, C1-5alkyl, C3-5cycloalkyl, C1-5haloalkyl, and halo.


In some embodiments,




embedded image


is selected from the group consisting of:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


In some embodiments, L is —S—C1-5 alkylene-aryl, —S—C1-5 alkylene-heteroaryl, —C1-5alkylene-S-aryl, or —C1-5alkylene-S-heteroaryl. In other embodiments, L is aryl-C1-5alkylene- or heteroaryl-C1-5alkylene-. In still other embodiments, L is heteroaryl or aryl, such as, but not limited to a 5- or 6-membered heteroaryl ring. Suitable L groups include, but are not limited to, pyrazolyl, triazolyl, thiazolyl, pyridinyl, imidazolyl, phenyl, thiophenyl, pyrrolyl, and indolyl.


In some embodiments, L is




embedded image


n is 0 or 1;


Q is CH, CR6, or N;


each R6 is selected from the group consisting of C1-5alkyl, C3-5cycloalkyl, heterocycloalkyl, C1-5haloalkyl, halo, benzyl, C1-5haloalkylene-OH, C1-5alkylene-CN, C1-5alkoxy, C1-5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, —NHR11, —NR11CO2R11a, —SO2R11, —SO2NHR11, —SOR11, —CO2R11, —CONHR11, aryl, and heteroaryl; and


R11 and R11a are each independently selected from the group consisting of H, C1-5alkyl, C1-5haloalkyl, —C0-5alkylene-C3-6cycloalkyl, —C0-5alkylene-heterocycloalkyl, —C0-5alkylene-aryl, and —C0-5alkylene-heteroaryl. In some cases,




embedded image


In some embodiments, L is




embedded image


n is 0, 1, or 2;


R6 is selected from the group consisting of C1-5alkyl, C3-5cycloalkyl, heterocycloalkyl, C1-5haloalkyl, halo, benzyl, C1-5haloalkylene-OH, C1-5alkylene-CN, C1-5alkoxy, C1-5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, —NHR11, —NR11CO2R11a, —SO2R11, —SO2NHR11, —SOR11, —CO2R11, —CONHR11, aryl, and heteroaryl; and


R11 and R11a are each independently selected from the group consisting of H, C1-5alkyl, C1-5haloalkyl, —C0-5alkylene-C3-6cycloalkyl, —C0-5alkylene-heterocycloalkyl, —C0-5alkylene-aryl, and —C0-5alkylene-heteroaryl. Suitable L groups include, but are not limited to,




embedded image


In some embodiments, L has a structure selected from




embedded image



and is substituted with 0, 1, or 2 R6 substituents.


In some cases, L is selected from the group consisting of




embedded image


embedded image


embedded image


In some cases, one or more hydrogen atoms of the L groups disclosed herein are replaced with 2H (deuterium). In some cases, L has a structure selected from




embedded image



and is substituted with 1 or 2 deutero C1-5alkyl substituents, such as CH2D, CHD2, or CD3. In some cases, L has a structure selected from




embedded image


In some embodiments, R3 and R4, taken together with the nitrogen atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered ring, including, but not limited to, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl, oxaziridinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, azepanyl, diazepanyl, or diazabicycloheptane.


In some embodiments,




embedded image


m is 0, 1, 2, or 3;


R7 and R9 are each independently selected from the group consisting of halo, C1-5alkyl, C3-5cycloalkyl, heterocycloalkyl, C1-5haloalkyl, C1-5haloalkylene-OH, C1-5alkylene-CN, C1-5alkoxy, C1-5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, —NHR8, —NR8CO2R8a, —SO2R8, —CO2R8, —CONHR8, aryl, and heteroaryl, or


two R7 groups, together with the carbon atom(s) to which they are attached, form a 3-, 4-, 5-, 6-, 7-, or 8-membered cycloalkyl, a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocycloalkyl, aryl, or a 5- or 6-membered heteroaryl ring; and


R8 and R8a are each independently selected from the group consisting of H, C1-5alkyl, C1-5haloalkyl, —C0-5alkylene-C3-6cycloalkyl, —C0-5alkylene-heterocycloalkyl, —C0-5alkylene-aryl, and —C0-5alkylene-heteroaryl; or


one R7 group and R9, together with the atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl or heteroaryl ring.


In some embodiments,




embedded image


R7 and R9 are each independently selected from the group consisting of halo, C1-5alkyl, C3-5 cycloalkyl, heterocycloalkyl, C1-5haloalkyl, C1-5haloalkylene-OH, C1-5alkylene-CN, C1-5alkoxy, C1-5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, —NHR8, —NR8CO2R8a, —SO2R8, —CO2R8, —CONHR8, aryl, and heteroaryl; and


R8 and R8a are each independently selected from the group consisting of H, C1-5alkyl, C1-5haloalkyl, —C0-5alkylene-C3-6cycloalkyl, —C0-5alkylene-heterocycloalkyl, —C0-5alkylene-aryl, and —C0-5alkylene-heteroaryl.


In some embodiments, R7 or R9 is selected from the group consisting of C3-5cycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, aryl, and heteroaryl. In some embodiments, R7 is oxazolyl or pyridinyl, each of which is optionally substituted with CN or F. In some embodiments, R7 is selected from the group consisting of




embedded image


In some embodiments, R9 is C3-5cycloalkyl. In some embodiments, R9 is cyclopropyl or cyclobutyl, each of which is optionally substituted with 1, 2, 3, or 4 F atoms. In some embodiments, wherein R9 is selected from the group consisting of




embedded image


In some embodiments,




embedded image


In some embodiments,




embedded image



and the two R7 groups are present on adjacent carbon atoms, and in some cases, the two R7 groups form a 4-, 5-, 6-, or 7-membered heterocyclic group or carbocyclic group with the carbon atoms to which they are attached. In some embodiments,




embedded image



and the two R7 groups are present on the same carbon atom, and in some cases, the two R7 groups form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl group or cycloalkyl group with the carbon atom to which they are attached.


In some embodiments, at least one R7 or R9 is F, CF3, CH3, CH2CH3, —CH2CF3, cyclopropyl, 1-cyano-cyclopropyl, CN, —C(CH3)2CN, —CH(CN)CH2CH3, 3,3-difluoropyrrolidine, —OH, —OCH3, —OCH2CH3, —OCH2CF3, —C(OH)(CF3)2, —C(OH)CH3CF3, —CO2C(CH3)3, —CONHC(CH3)3, —N(CH3)CO2C(CH3)3, phenoxy, phenylsulfonyl, 3,4-difluorobenzenesulfonyl, phenyl, fluorophenyl, difluorophenyl, cyanophenyl, indolyl, difluoropyrrolidinyl, or benzothiazolyl, or two R7 groups, together with the carbon atoms to which they are attached, form a fused benzene ring. In some embodiments, at least one R7 is 3-indolyl, 6-fluoro-3-indolyl, N-methyl-3-indolyl, 4-indolyl, 2-benzothiazolyl, or 5-fluoro-2-benzothiazolyl.


In some embodiments, R9 is —C0-5alkylene-aryl. In some embodiments, R9 is 2,4-difluorophenyl, 5-fluorophenyl, phenyl, or 2-chlorophenyl.


In some embodiments, R3 and R4, taken together with the nitrogen atom to which they are attached form a 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered spiro, fused, or bridged polycyclic (e.g., bicyclic ring). Suitable 6- to 14-membered spiro, fused, or bridged bicyclic rings include, but are not limited to, 10-azabicyclodecane, 9-azabicyclononane, 8-azabicyclooctane (e.g., 8-azabicyclo[3.2.1]octane), azabicycloheptane (e.g., 7-azabicycloheptane), 3-azabicyclohexane (e.g., 3-azabicyclo[3.1.0]hexane), diazabicyclononane (e.g., 1,4-diazabicyclo[4.3.0]nonane), diazabicyclooctane, diazabicycloheptane, diazaspirononane, azaspirononane, diazaspirooctane, azaspirooctane, spiroksobenzofuran-piperidine, diazaspiroheptane, azaspiroheptane, octahydrocyclopenta[b]pyrrole, or octahydrocyclopenta[c]pyrrole. In some embodiments, the 6- to 14-membered spiro, fused, or bridged polycyclic (e.g, bicyclic) ring is substituted with one or two substituents independently selected from the group consisting of halo, C1-5alkyl, C1-5haloalkyl, C1-5alkoxy, aryloxy, heteroaryloxy, CN, OH, —SO2R10, CO2R10, CONHR10, C3-5cycloalkyl, oxo, aryl, and heteroaryl; and R10 is selected from the group consisting of H, C1-5alkyl, —C0-5alkylene-aryl, and —C0-5alkylene-heteroaryl. In some embodiments, at least one substituent of the 6- to 14-membered spiro, fused, or bridged polycyclic (e.g., bicyclic) ring is cyclopropyl, F, —CO2C(CH3)3, —CH2CF3, CF3, fluorophenyl, cyanophenyl, OH, or phenyl.


In some embodiments, R3 is selected from the group consisting H, CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CF3, —CH2CH2CN, —CH2CH(OH)CF3, and benzyl; and R4 is selected from the group consisting of CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CF3, —CH2CF2CF3, cyclohexyl, cyclopentyl, benzyl,




embedded image


embedded image


embedded image


In some embodiments,




embedded image


Suitable




embedded image



groups also include, but are not limited to, the following:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


Exemplary compounds of formula I include, but are not limited to, the compounds listed in Table A.










TABLE A





Ref.



No.
Compound







Q-817


embedded image







Q-816


embedded image







Q-815


embedded image







Q-813


embedded image







Q-812


embedded image







Q-804


embedded image







Q-784


embedded image







Q-777


embedded image







Q-772


embedded image







Q-768


embedded image







Q-760


embedded image







Q-739


embedded image







Q-737


embedded image







Q-691


embedded image







Q-635


embedded image







Q-586


embedded image







Q-572


embedded image







Q-520


embedded image







Q-518


embedded image







Q-461


embedded image











Exemplary compounds of formula I also include, but are not limited to, the compounds listed in Table B.










TABLE B





Ref.



No.
Compound







Q-951


embedded image







Q-937


embedded image







Q-931


embedded image







Q-928


embedded image







Q-924


embedded image







Q-909


embedded image







Q-908


embedded image







Q-902


embedded image







Q-891


embedded image







Q-884


embedded image







Q-876


embedded image







Q-869


embedded image







Q-850


embedded image







Q-823


embedded image







Q-819


embedded image







Q-797


embedded image







Q-757


embedded image







Q-749


embedded image







Q-745


embedded image







Q-681


embedded image







Q-615


embedded image







Q-599


embedded image







Q-598


embedded image







Q-590


embedded image







Q-571


embedded image







Q-567


embedded image







Q-565


embedded image







Q-545


embedded image







Q-521


embedded image







Q-446


embedded image











Provided herein are compounds as disclosed in Table C:










TABLE C









embedded image


Q-280







embedded image


Q-281







embedded image


Q-282







embedded image


Q-283







embedded image


Q-284







embedded image


Q-285







embedded image


Q-286







embedded image


Q-287







embedded image


Q-290







embedded image


Q-291







embedded image


Q-292







embedded image


Q-298







embedded image


Q-299







embedded image


Q-300







embedded image


Q-301







embedded image


Q-302







embedded image


Q-303







embedded image


Q-304







embedded image


Q-305







embedded image


Q-306







embedded image


Q-307







embedded image


Q-308







embedded image


Q-310







embedded image


Q-311







embedded image


Q-312







embedded image


Q-313







embedded image


Q-314







embedded image


Q-316







embedded image


Q-317







embedded image


Q-318







embedded image


Q-319







embedded image


Q-320







embedded image


Q-321







embedded image


Q-322







embedded image


Q-323







embedded image


Q-327







embedded image


Q-328







embedded image


Q-329







embedded image


Q-330







embedded image


Q-331







embedded image


Q-332







embedded image


Q-333







embedded image


Q-334







embedded image


Q-339







embedded image


Q-340







embedded image


Q-341







embedded image


Q-342







embedded image


Q-343







embedded image


Q-344







embedded image


Q-345







embedded image


Q-346







embedded image


Q-347







embedded image


Q-348







embedded image


Q-349







embedded image


Q-350







embedded image


Q-351







embedded image


Q-352







embedded image


Q-353







embedded image


Q-354







embedded image


Q-358







embedded image


Q-359







embedded image


Q-361







embedded image


Q-362







embedded image


Q-363







embedded image


Q-364







embedded image


Q-365







embedded image


Q-366







embedded image


Q-367







embedded image


Q-368







embedded image


Q-369







embedded image


Q-370







embedded image


Q-371







embedded image


Q-372







embedded image


Q-373







embedded image


Q-374







embedded image


Q-375







embedded image


Q-376







embedded image


Q-377







embedded image


Q-378







embedded image


Q-379







embedded image


Q-380







embedded image


Q-381







embedded image


Q-382







embedded image


Q-383







embedded image


Q-384







embedded image


Q-385







embedded image


Q-387







embedded image


Q-388







embedded image


Q-389







embedded image


Q-390







embedded image


Q-393







embedded image


Q-394







embedded image


Q-395







embedded image


Q-396







embedded image


Q-397







embedded image


Q-398







embedded image


Q-399







embedded image


Q-400







embedded image


Q-401







embedded image


Q-402







embedded image


Q-403







embedded image


Q-404







embedded image


Q-405







embedded image


Q-406







embedded image


Q-407







embedded image


Q-408







embedded image


Q-409







embedded image


Q-410







embedded image


Q-411







embedded image


Q-412







embedded image


Q-413







embedded image


Q-414







embedded image


Q-415







embedded image


Q-416







embedded image


Q-417







embedded image


Q-418







embedded image


Q-419







embedded image


Q-420







embedded image


Q-421







embedded image


Q-422







embedded image


Q-423







embedded image


Q-424







embedded image


Q-425







embedded image


Q-426







embedded image


Q-427







embedded image


Q-428







embedded image


Q-429







embedded image


Q-431







embedded image


Q-432







embedded image


Q-433







embedded image


Q-434







embedded image


Q-435







embedded image


Q-436







embedded image


Q-437







embedded image


Q-438







embedded image


Q-439







embedded image


Q-440







embedded image


Q-441







embedded image


Q-442







embedded image


Q-443







embedded image


Q-444







embedded image


Q-445







embedded image


Q-446







embedded image


Q-447







embedded image


Q-448







embedded image


Q-449







embedded image


Q-450







embedded image


Q-451







embedded image


Q-452







embedded image


Q-453







embedded image


Q-454







embedded image


Q-455







embedded image


Q-456







embedded image


Q-457







embedded image


Q-458







embedded image


Q-459







embedded image


Q-460







embedded image


Q-461







embedded image


Q-462







embedded image


Q-463







embedded image


Q-464







embedded image


Q-465







embedded image


Q-466







embedded image


Q-467







embedded image


Q-468







embedded image


Q-469







embedded image


Q-470







embedded image


Q-471







embedded image


Q-472







embedded image


Q-473







embedded image


Q-474







embedded image


Q-475







embedded image


Q-476







embedded image


Q-477







embedded image


Q-478







embedded image


Q-479







embedded image


Q-480







embedded image


Q-481







embedded image


Q-482







embedded image


Q-483







embedded image


Q-485







embedded image


Q-486







embedded image


Q-487







embedded image


Q-488







embedded image


Q-489







embedded image


Q-490







embedded image


Q-491







embedded image


Q-492







embedded image


Q-493







embedded image


Q-494







embedded image


Q-495







embedded image


Q-496







embedded image


Q-497







embedded image


Q-498







embedded image


Q-499







embedded image


Q-500







embedded image


Q-501







embedded image


Q-502







embedded image


Q-503







embedded image


Q-504







embedded image


Q-505







embedded image


Q-506







embedded image


Q-507







embedded image


Q-508







embedded image


Q-509







embedded image


Q-510







embedded image


Q-511







embedded image


Q-513







embedded image


Q-514







embedded image


Q-515







embedded image


Q-517







embedded image


Q-518







embedded image


Q-519







embedded image


Q-520







embedded image


Q-521







embedded image


Q-522







embedded image


Q-523







embedded image


Q-524







embedded image


Q-525







embedded image


Q-526







embedded image


Q-527







embedded image


Q-528







embedded image


Q-529







embedded image


Q-530







embedded image


Q-531







embedded image


Q-532







embedded image


Q-533







embedded image


Q-534







embedded image


Q-535







embedded image


Q-536







embedded image


Q-537







embedded image


Q-540







embedded image


Q-541







embedded image


Q-542







embedded image


Q-543







embedded image


Q-544







embedded image


Q-545







embedded image


Q-546







embedded image


Q-547







embedded image


Q-548







embedded image


Q-549







embedded image


Q-550







embedded image


Q-551







embedded image


Q-552







embedded image


Q-553







embedded image


Q-555







embedded image


Q-556







embedded image


Q-557







embedded image


Q-558







embedded image


Q-559







embedded image


Q-560







embedded image


Q-561







embedded image


Q-562







embedded image


Q-563







embedded image


Q-564







embedded image


Q-565







embedded image


Q-566







embedded image


Q-567







embedded image


Q-568







embedded image


Q-569







embedded image


Q-570







embedded image


Q-571







embedded image


Q-572







embedded image


Q-573







embedded image


Q-574







embedded image


Q-575







embedded image


Q-576







embedded image


Q-577







embedded image


Q-578







embedded image


Q-579







embedded image


Q-580







embedded image


Q-582







embedded image


Q-583







embedded image


Q-584







embedded image


Q-585







embedded image


Q-586







embedded image


Q-587







embedded image


Q-588







embedded image


Q-589







embedded image


Q-590







embedded image


Q-591







embedded image


Q-592







embedded image


Q-593







embedded image


Q-594







embedded image


Q-595







embedded image


Q-596







embedded image


Q-597







embedded image


Q-598







embedded image


Q-599







embedded image


Q-600







embedded image


Q-601







embedded image


Q-602







embedded image


Q-603







embedded image


Q-604







embedded image


Q-605







embedded image


Q-606







embedded image


Q-607







embedded image


Q-608







embedded image


Q-609







embedded image


Q-610







embedded image


Q-611







embedded image


Q-612







embedded image


Q-614







embedded image


Q-615







embedded image


Q-616







embedded image


Q-617







embedded image


Q-618







embedded image


Q-619







embedded image


Q-620







embedded image


Q-621







embedded image


Q-622







embedded image


Q-623







embedded image


Q-624







embedded image


Q-626







embedded image


Q-627







embedded image


Q-630







embedded image


Q-632







embedded image


Q-633







embedded image


Q-634







embedded image


Q-635







embedded image


Q-681







embedded image


Q-687







embedded image


Q-690







embedded image


Q-691







embedded image


Q-693







embedded image


Q-696







embedded image


Q-697







embedded image


Q-698







embedded image


Q-700







embedded image


Q-701







embedded image


Q-702







embedded image


Q-703







embedded image


Q-704







embedded image


Q-705







embedded image


Q-706







embedded image


Q-707







embedded image


Q-708







embedded image


Q-709







embedded image


Q-710







embedded image


Q-711







embedded image


Q-712







embedded image


Q-713







embedded image


Q-714







embedded image


Q-715







embedded image


Q-716







embedded image


Q-718







embedded image


Q-719







embedded image


Q-720







embedded image


Q-721







embedded image


Q-722







embedded image


Q-723







embedded image


Q-724







embedded image


Q-725







embedded image


Q-726







embedded image


Q-727







embedded image


Q-730







embedded image


Q-731







embedded image


Q-732







embedded image


Q-734







embedded image


Q-735







embedded image


Q-736







embedded image


Q-737







embedded image


Q-738







embedded image


Q-739







embedded image


Q-741







embedded image


Q-743







embedded image


Q-744







embedded image


Q-745







embedded image


Q-746







embedded image


Q-747







embedded image


Q-748







embedded image


Q-749







embedded image


Q-750







embedded image


Q-751







embedded image


Q-752







embedded image


Q-753







embedded image


Q-754







embedded image


Q-755







embedded image


Q-756







embedded image


Q-757







embedded image


Q-758







embedded image


Q-759







embedded image


Q-760







embedded image


Q-761







embedded image


Q-762







embedded image


Q-764







embedded image


Q-765







embedded image


Q-768







embedded image


Q-770







embedded image


Q-771







embedded image


Q-772







embedded image


Q-773







embedded image


Q-774







embedded image


Q-775







embedded image


Q-777







embedded image


Q-779







embedded image


Q-780







embedded image


Q-781







embedded image


Q-782







embedded image


Q-783







embedded image


Q-784







embedded image


Q-785







embedded image


Q-788







embedded image


Q-789







embedded image


Q-790







embedded image


Q-791







embedded image


Q-792







embedded image


Q-793







embedded image


Q-794







embedded image


Q-795







embedded image


Q-796







embedded image


Q-797







embedded image


Q-798







embedded image


Q-799







embedded image


Q-800







embedded image


Q-802







embedded image


Q-803







embedded image


Q-804







embedded image


Q-805







embedded image


Q-806







embedded image


Q-807







embedded image


Q-808







embedded image


Q-809







embedded image


Q-812







embedded image


Q-813







embedded image


Q-814







embedded image


Q-815







embedded image


Q-816







embedded image


Q-817







embedded image


Q-818







embedded image


Q-819







embedded image


Q-820







embedded image


Q-821







embedded image


Q-822







embedded image


Q-823







embedded image


Q-824







embedded image


Q-825







embedded image


Q-826







embedded image


Q-827







embedded image


Q-828







embedded image


Q-829







embedded image


Q-830







embedded image


Q-831







embedded image


Q-832







embedded image


Q-833







embedded image


Q-835







embedded image


Q-836







embedded image


Q-837







embedded image


Q-839







embedded image


Q-840







embedded image


Q-842







embedded image


Q-843







embedded image


Q-844







embedded image


Q-845







embedded image


Q-846







embedded image


Q-847







embedded image


Q-848







embedded image


Q-849







embedded image


Q-850







embedded image


Q-851







embedded image


Q-852







embedded image


Q-853







embedded image


Q-854







embedded image


Q-855







embedded image


Q-856







embedded image


Q-857







embedded image


Q-858







embedded image


Q-859







embedded image


Q-860







embedded image


Q-861







embedded image


Q-862







embedded image


Q-863







embedded image


Q-865







embedded image


Q-866







embedded image


Q-867







embedded image


Q-868







embedded image


Q-869







embedded image


Q-870







embedded image


Q-871







embedded image


Q-872







embedded image


Q-873







embedded image


Q-874







embedded image


Q-875







embedded image


Q-876







embedded image


Q-877







embedded image


Q-878







embedded image


Q-879







embedded image


Q-880







embedded image


Q-881







embedded image


Q-882







embedded image


Q-883







embedded image


Q-884







embedded image


Q-885







embedded image


Q-886







embedded image


Q-887







embedded image


Q-888







embedded image


Q-890







embedded image


Q-891







embedded image


Q-892







embedded image


Q-893







embedded image


Q-894







embedded image


Q-895







embedded image


Q-896







embedded image


Q-897







embedded image


Q-899







embedded image


Q-900







embedded image


Q-901







embedded image


Q-902







embedded image


Q-905







embedded image


Q-906







embedded image


Q-907







embedded image


Q-908







embedded image


Q-909







embedded image


Q-910







embedded image


Q-911







embedded image


Q-912







embedded image


Q-913







embedded image


Q-914







embedded image


Q-915







embedded image


Q-916







embedded image


Q-917







embedded image


Q-918







embedded image


Q-919







embedded image


Q-920







embedded image


Q-921







embedded image


Q-922







embedded image


Q-923







embedded image


Q-924







embedded image


Q-925







embedded image


Q-926







embedded image


Q-927







embedded image


Q-928







embedded image


Q-929







embedded image


Q-930







embedded image


Q-931







embedded image


Q-932







embedded image


Q-933







embedded image


Q-934







embedded image


Q-935







embedded image


Q-936







embedded image


Q-937







embedded image


Q-938







embedded image


Q-939







embedded image


Q-940







embedded image


Q-941







embedded image


Q-942







embedded image


Q-943







embedded image


Q-944







embedded image


Q-945







embedded image


Q-946







embedded image


Q-947







embedded image


Q-948







embedded image


Q-949







embedded image


Q-950







embedded image


Q-951







embedded image


Q-952







embedded image


Q-953







embedded image


Q-572a







embedded image


Q-572b







embedded image


Q-954







embedded image


Q-955







embedded image


Q-956







embedded image


Q-957







embedded image


Q-958







embedded image


Q-959







embedded image


Q-960







embedded image


Q-961







embedded image


Q-962







embedded image


Q-963







embedded image


Q-964







embedded image


Q-965







embedded image


Q-966







embedded image


Q-967







embedded image


Q-968







embedded image


Q-969







embedded image


Q-970







embedded image


Q-971







embedded image


Q-972







embedded image


Q-973







embedded image


Q-974







embedded image


Q-975







embedded image


Q-976







embedded image


Q-977







embedded image


Q-978







embedded image


Q-979







embedded image


Q-980







embedded image


Q-981







embedded image


Q-982







embedded image


Q-983







embedded image


Q-984







embedded image


Q-985







embedded image


Q-986







embedded image


Q-987







embedded image


Q-988







embedded image


Q-989







embedded image


Q-990







embedded image


Q-991







embedded image


Q-992







embedded image


Q-993







embedded image


Q-994







embedded image


Q-995







embedded image


Q-996







embedded image


Q-997







embedded image


Q-998







embedded image


Q-999







embedded image


Q-1000







embedded image


Q-1001







embedded image


Q-1002







embedded image


Q-1003







embedded image


Q-1004







embedded image


Q-1005







embedded image


Q-1006







embedded image


Q-1007







embedded image


Q-1008







embedded image


Q-1009







embedded image


Q-1010







embedded image


Q-1011







embedded image


Q-1012







embedded image


Q-1013







embedded image


Q-1014







embedded image


Q-1015







embedded image


Q-1016







embedded image


Q-1017







embedded image


Q-1018







embedded image


Q-1019







embedded image


Q-1020







embedded image


Q-1021







embedded image


Q-1022







embedded image


Q-1023







embedded image


Q-1024







embedded image


Q-1025







embedded image


Q-1026







embedded image


Q-1027







embedded image


Q-1028







embedded image


Q-1029







embedded image


Q-1030







embedded image


Q-1031







embedded image


Q-1032







embedded image


Q-1033







embedded image


Q-1034







embedded image


Q-1035







embedded image


Q-1036







embedded image


Q-1037







embedded image


Q-1038







embedded image


Q-1039







embedded image


Q-1040







embedded image


Q-1041







embedded image


Q-1042







embedded image


Q-1043







embedded image


Q-1044







embedded image


Q-1045







embedded image


Q-1046







embedded image


Q-1047







embedded image


Q-1048







embedded image


Q-1049







embedded image


Q-1050







embedded image


Q-1051







embedded image


Q-1052







embedded image


Q-1053







embedded image


Q-1054







embedded image


Q-1055







embedded image


Q-1056







embedded image


Q-1057







embedded image


Q-1058







embedded image


Q-1059







embedded image


Q-1060







embedded image


Q-1061







embedded image


Q-1062







embedded image


Q-1063







embedded image


Q-1064







embedded image


Q-1065







embedded image


Q-1066







embedded image


Q-1067







embedded image


Q-1070







embedded image


Q-1071







embedded image


Q-1072







embedded image


Q-1073







embedded image


Q-1074







embedded image


Q-1075







embedded image


Q-1076







embedded image


Q-1077







embedded image


Q-1078







embedded image


Q-1079







embedded image


Q-1080







embedded image


Q-1081







embedded image


Q-1082







embedded image


Q-1083







embedded image


Q-1084







embedded image


Q-1085







embedded image


Q-1086







embedded image


Q-1087







embedded image


Q-1088







embedded image


Q-1089







embedded image


Q-1090







embedded image


Q-1091







embedded image


Q-1092







embedded image


Q-1093







embedded image


Q-1094







embedded image


Q-1095







embedded image


Q-1096







embedded image


Q-1097







embedded image


Q-1098







embedded image


Q-1099







embedded image


Q-1100







embedded image


Q-1101







embedded image


Q-1102







embedded image


Q-1103







embedded image


Q-1104







embedded image


Q-1105







embedded image


Q-1106







embedded image


Q-1107







embedded image


Q-1108







embedded image


Q-1109







embedded image


Q-1110







embedded image


Q-1111







embedded image


Q-1112







embedded image


Q-1113







embedded image


Q-1114







embedded image


Q-1115







embedded image


Q-1116







embedded image


Q-1117







embedded image


Q-1118







embedded image


Q-1119







embedded image


Q-1120







embedded image


Q-1121







embedded image


Q-1122







embedded image


Q-1123







embedded image


Q-1124







embedded image


Q-1125







embedded image


Q-1126







embedded image


Q-1127







embedded image


Q-1128







embedded image


Q-1129







embedded image


Q-1130







embedded image


Q-1131







embedded image


Q-1132







embedded image


Q-1133







embedded image


Q-1134







embedded image


Q-1135







embedded image


Q-1136







embedded image


Q-1137







embedded image


Q-1138







embedded image


Q-1139







embedded image


Q-1140







embedded image


Q-1141







embedded image


Q-1142







embedded image


Q-1143







embedded image


Q-1144







embedded image


Q-1145







embedded image


Q-1146







embedded image


Q-1147







embedded image


Q-1148







embedded image


Q-1149







embedded image


Q-1150







embedded image


Q-1151







embedded image


Q-1152







embedded image


Q-1153







embedded image


Q-1154







embedded image


Q-1155







embedded image


Q-1156







embedded image


Q-1157







embedded image


Q-1158







embedded image


Q-1159







embedded image


Q-1160







embedded image


Q-1161







embedded image


Q-1162







embedded image


Q-1163







embedded image


Q-1164







embedded image


Q-1165







embedded image


Q-1166







embedded image


Q-1167







embedded image


Q-1168







embedded image


Q-1169







embedded image


Q-1170







embedded image


Q-1171







embedded image


Q-1172







embedded image


Q-1173







embedded image


Q-1174







embedded image


Q-1175







embedded image


Q-1176







embedded image


Q-1177







embedded image


Q-1178







embedded image


Q-1179







embedded image


Q-1180







embedded image


Q-1181







embedded image


Q-1182







embedded image


Q-1183







embedded image


Q-1184







embedded image


Q-1185







embedded image


Q-1186







embedded image


Q-1187







embedded image


Q-1188







embedded image


Q-1189







embedded image


Q-1190







embedded image


Q-1191







embedded image


Q-1192







embedded image


Q-1193







embedded image


Q-1194







embedded image


Q-1195







embedded image


Q-1196







embedded image


Q-1197







embedded image


Q-1198







embedded image


Q-1199







embedded image


Q-1200







embedded image


Q-1201







embedded image


Q-1202







embedded image


Q-1203







embedded image


Q-1204







embedded image


Q-1205







embedded image


Q-1206







embedded image


Q-1207







embedded image


Q-1208







embedded image


Q-1209







embedded image


Q-1210







embedded image


Q-1211







embedded image


Q-1212







embedded image


Q-1213







embedded image


Q-1214







embedded image


Q-1215







embedded image


Q-1216







embedded image


Q-1217







embedded image


Q-1218







embedded image


Q-1219







embedded image


Q-1220







embedded image


Q-1221







embedded image


Q-1222







embedded image


Q-1223







embedded image


Q-1224







embedded image


Q-1225







embedded image


Q-1226







embedded image


Q-1227







embedded image


Q-1228







embedded image


Q-1229







embedded image


Q-1230







embedded image


Q-1231







embedded image


Q-1232







embedded image


Q-1233







embedded image


Q-1234







embedded image


Q-1235







embedded image


Q-1236







embedded image


Q-1237







embedded image


Q-1238







embedded image


Q-1239







embedded image


Q-1240







embedded image


Q-1241







embedded image


Q-1242







embedded image


Q-1243







embedded image


Q-1244







embedded image


Q-1245







embedded image


Q-1246







embedded image


Q-1247







embedded image


Q-1249







embedded image


Q-1250







embedded image


Q-1251







embedded image


Q-1254







embedded image


Q-1255







embedded image


Q-1256







embedded image


Q-1259







embedded image


Q-1260







embedded image


Q-1263







embedded image


Q-1266







embedded image


Q-1269







embedded image


Q-1288







embedded image


Q-1289







embedded image


Q-1291







embedded image


Q-1292







embedded image


Q-1295







embedded image


Q-1296







embedded image


Q-1301







embedded image


Q-1305







embedded image


Q-1306







embedded image


Q-1311







embedded image


Q-1313







embedded image


Q-1320







embedded image


Q-1322







embedded image


Q-1341







embedded image


Q-1343







embedded image


Q-1344







embedded image


Q-1345







embedded image


Q-1346







embedded image


Q-1362







embedded image


Q-1365







embedded image


Q-1483







embedded image


Q-1535







embedded image


Q-1539







embedded image


Q-1558







embedded image


Q-1560







embedded image


Q-1563







embedded image


Q-1564







embedded image


Q-1565







embedded image


Q-1581







embedded image


Q-1591







embedded image


Q-1597







embedded image


Q-1641







embedded image


Q-1728







embedded image


Q-1794







embedded image


Q-1796







embedded image


Q-1797







embedded image


Q-1798







embedded image


Q-1799







embedded image


Q-1800







embedded image


Q-1801







embedded image


Q-1804







embedded image


Q-1805







embedded image


Q-1807







embedded image


Q-1814







embedded image


Q-1815







embedded image


Q-1818







embedded image


Q-1819







embedded image


Q-1820







embedded image


Q-1821







embedded image


Q-1822







embedded image


Q-1823







embedded image


Q-1824







embedded image


Q-1825







embedded image


Q-1826







embedded image


Q-1827







embedded image


Q-1829







embedded image


Q-1830







embedded image


Q-1831







embedded image


Q-1832







embedded image


Q-1833







embedded image


Q-1834







embedded image


Q-1835







embedded image


Q-1836







embedded image


Q-1837







embedded image


Q-1838







embedded image


Q-1839







embedded image


Q-1840







embedded image


Q-1841







embedded image


Q-1842







embedded image


Q-1845







embedded image


Q-1846







embedded image


Q-1847







embedded image


Q-1848







embedded image


Q-1857







embedded image


Q-1858







embedded image


Q-1859







embedded image


Q-1861







embedded image


Q-1862







embedded image


Q-1864







embedded image


Q-1866







embedded image


Q-1875







embedded image


Q-1876







embedded image


Q-1882







embedded image


Q-1884







embedded image


Q-1885







embedded image


Q-1886







embedded image


Q-1889







embedded image


Q-1925







embedded image


Q-1932







embedded image


Q-1984







embedded image


Q-1985







embedded image


Q-2007







embedded image


Q-2008







embedded image


Q-2009







embedded image


Q-2016







embedded image


Q-2017







embedded image


Q-2031







embedded image


Q-2032







embedded image


Q-2041







embedded image


Q-2043







embedded image


Q-2048







embedded image


Q-2054







embedded image


Q-2055









In one aspect, the disclosure provides a compound of formula II or II′, or a pharmaceutically acceptable salt thereof:




embedded image


wherein L is heteroaryl or aryl; and


R3 is selected from the group consisting of H, C1-5alkyl, C3-10cycloalkyl, C1-5haloalkyl, aryl, heteroaryl, and C1-5alkylene-G;


R4 is selected from the group consisting of C1-5alkyl, C3-10cycloalkyl, C1-5haloalkyl, aryl, heteroaryl, and C1-5alkylene-G; or


R3 and R4, taken together with the nitrogen atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered spiro, fused, or bridged bicyclic ring, and


each G is independently selected from the group consisting of CN, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.


In one aspect, the disclosure provides a compound of formula III or III′, or a pharmaceutically acceptable salt thereof:




embedded image


wherein:



custom character is an optional double bond;


Z is CR1 or NR1, or if the double bond is present, then Z is CR1 or N;


Y is CR2 or NR2, or if the double bond is present, then Y is CR2 or N;


X is CH or N;


R1 and R2 are independently selected from the group consisting of H, C1-5alkyl, C3-5cycloalkyl, C1-5haloalkyl, and halo; or


R1 and R2, taken together with the atoms to which they are attached form a 5- to 6-membered ring;


R5 is selected from the group consisting of H and C1-5alkyl;


L is heteroaryl-C0-5alkylene-, aryl-C0-5alkylene-, —S—C1-5alkylene-aryl, —S—C1-5alkylene-heteroaryl, —C1-5alkylene-S-aryl, or —C1-5alkylene-S-heteroaryl;


A is selected from the group consisting of




embedded image


In some embodiments, the compound of formula III or III′ does not include a compound having a structure:




embedded image


In one aspect, the disclosure provides a compound of formula IV or IV′, or a pharmaceutically acceptable salt thereof:




embedded image


wherein:



custom character is an optional double bond;


Y is NR2, or if the double bond is present, then Y is CR2;


R1 and R2, taken together with the atoms to which they are attached form a 5-membered ring;


n is 0 or 1;


each R6 is selected from the group consisting of C1-5alkyl, C3-5cycloalkyl, C1-5haloalkyl, halo, and benzyl;


Q is CH, CR6, or N;


R3 and R4, taken together with nitrogen atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered spiro, fused, or bridged bicyclic ring.


In some embodiments,




embedded image


m is 0, 1, 2, or 3;


R7 and R9 are each independently selected from the group consisting of halo, C1-5alkyl, C3-5cycloalkyl, heterocycloalkyl, C1-5haloalkyl, C1-5haloalkylene-OH, C1-5alkylene-CN, C1-5alkoxy, C1-5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, —NHR8, —NR8CO2R8a, —SO2R8, —CO2R8, —CONHR8, aryl, and heteroaryl, or


two R7 groups, together with the carbon atom(s) to which they are attached, form a 3-, 4-, 5-, 6-, 7-, or 8-membered cycloalkyl, a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocycloalkyl, aryl, or a 5- or 6-membered heteroaryl ring; and


R8 and R8a are each independently selected from the group consisting of H, C1-5alkyl, C1-5haloalkyl, —C0-5alkylene-C3-6cycloalkyl, —C0-5alkylene-heterocycloalkyl, —C0-5alkylene-aryl, and —C0-5alkylene-heteroaryl; or


one R7 group and R9, together with the atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl or heteroaryl ring.


In some embodiments,




embedded image



and is optionally substituted with one to four substituents selected from the group consisting of F, Cl, and C1-3alkyl.


In some embodiments,




embedded image


In some embodiments, two R7 groups are present on adjacent carbon atoms, and in some cases, the two R7 groups and the carbons to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl group or cycloalkyl group. In some embodiments, two R7 groups are present on the same carbon atom, and in some cases, the two R7 groups and the carbon to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl or cycloalkyl group. In some embodiments, the 6- to 14-membered spiro, fused, or bridged polycyclic (e.g., bicyclic) ring is substituted with one or two substituents independently selected from the group consisting of halo, C1-5alkyl, C1-5haloalkyl, C1-5alkoxy, aryloxy, heteroaryloxy, CN, OH, —SO2R10, —CO2R10, CONHR10, C3-5cycloalkyl, aryl, and heteroaryl; and R10 is selected from the group consisting of H, C1-5alkyl, —C0-5alkylene-aryl, and —C0-5alkylene-heteroaryl. In some embodiments, the 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl or cycloalkyl group is substituted with one or two substituents selected from the group consisting of fluoro, hydroxy, cyano, methyl, ethyl, trifluoromethyl, trifluoroethyl, cyanopropyl, methoxy, trifluoromethoxy, trifluoroethoxy, hexafluorohydroxypropyl, cyclopropyl, 1-cyano-cyclopropyl, 1-trifluoromethylcyclopropyl, 3,3-difluoropyrrolidine, C(O)-t-butoxy, phenyl, fluorophenyl, difluorophenyl, cyanophenyl, indolyl, difluoropyrrolindinyl, benzothiazolyl, and N(methyl)C(O)t-butoxy.


Suitable 6- to 14-membered spiro, fused, or bridged bicyclic rings include, but are not limited to, 10-azabicyclodecane, 9-azabicyclononane, 8-azabicyclooctane (e.g., 8-azabicyclo[3.2.1]octane), azabicycloheptane (e.g., 7-azabicycloheptane), 3-azabicyclohexane (e.g., 3-azabicyclo[3.1.0]hexane), diazabicyclononane (e.g., 1,4-diazabicyclo[4.3.0]nonane), diazabicyclooctane, diazabicycloheptane, diazaspirononane, azaspirononane, diazaspirooctane, azaspirooctane, spiroksobenzofuran-piperidine, diazaspiroheptane, azaspiroheptane, octahydrocyclopenta[b]pyrrole, or octahydrocyclopenta[c]pyrrole. In some embodiments, the 6- to 14-membered spiro, fused, or bicyclic ring is substituted with one or two substituents independently selected from the group consisting of halo, C1-5alkyl, C1-5haloalkyl, C1-5alkoxy, aryloxy, heteroaryloxy, CN, OH, —SO2R10, —CO2R10, —CONHR10, C3-5cycloalkyl, aryl, and heteroaryl; and R10 is selected from the group consisting of H, C1-5alkyl, —C0-5alkylene-aryl, and —C0-5alkylene-heteroaryl.


In one aspect, the disclosure provides a compound of formula V or V′, or a pharmaceutically acceptable salt thereof:




embedded image


wherein:



custom character is an optional double bond;


Y1 is N, or if the double bond is present, then Y1 is C;




embedded image



is a 5-membered ring;


n is 0 or 1;


each R6 is selected from the group consisting of C1-5alkyl, C3-5cycloalkyl, C1-5haloalkyl, halo, and benzyl;


Q is CH, CR6, or N;


R3 and R4, taken together with nitrogen atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered spiro, fused, and/or bridged polycyclic ring.


In some embodiments,




embedded image



is a pyrrole ring, a cyclopentene ring, a thiophene ring, a dihydrofuran ring, a pyrazole ring, a thiazole ring, or an imidazole ring. In some embodiments,




embedded image



is selected from the group consisting of:




embedded image


embedded image


embedded image



In some embodiments,




embedded image



and is optionally substituted with one to four substituents selected from the group consisting of F, Cl, and C1-3alkyl. In some embodiments,




embedded image



In some embodiments,




embedded image


In some embodiments,




embedded image



In some embodiments,




embedded image



is selected from the group consisting of




embedded image



In some embodiments,




embedded image


In some embodiments, R3 and R4, taken together with nitrogen atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered ring. Suitable 3-, 4-, 5-, 6-, or 7-membered rings include, but are not limited to, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl, oxaziridinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, azepanyl, diazepanyl, or diazabicycloheptane.


In some embodiments,




embedded image


m is 0, 1, 2, or 3;


R7 and R9 are each independently selected from the group consisting of halo, C1-5alkyl, C3-5 cycloalkyl, heterocycloalkyl, C1-5haloalkyl, C1-5haloalkylene-OH, C1-5alkylene-CN, C1-5alkoxy, C1-5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, —NHR8, —NR8CO2R8a, —SO2R8, —CO2R8, —CONHR8, aryl, and heteroaryl, or


two R7 groups, together with the carbon atom(s) to which they are attached, form a 3-, 4-, 5-, 6-, 7-, or 8-membered cycloalkyl, a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocycloalkyl, aryl, or a 5- or 6-membered heteroaryl ring; and


R8 and R8a are each independently selected from the group consisting of H, C1-5alkyl, —C0-5alkylene-aryl, and —C0-5alkylene-heteroaryl; or


one R7 group and R9, together with the atoms to which they are attached, form a 5- or 6-membered heterocyclic or heteroaryl ring.


In some embodiments,




embedded image


R7 and R9 are each independently selected from the group consisting of halo, C1-5alkyl, C3-5 cycloalkyl, heterocycloalkyl, C1-5haloalkyl, C1-5haloalkylene-OH, C1-5alkylene-CN, C1-5alkoxy, C1-5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, —NHR8, —NR8CO2R8a, —SO2R8, —CO2R8, —CONHR8, aryl, and heteroaryl; and


R8 and R8a are each independently selected from the group consisting of H, C1-5alkyl, —C0-5alkylene-aryl, and —C0-5alkylene-heteroaryl.


In some embodiments, R7 or R9 is selected from the group consisting of C3-5cycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, aryl, and heteroaryl. In some embodiments, R7 is oxazolyl or pyridinyl, each of which is optionally substituted with CN or F. In some embodiments, R7 is selected from the group consisting of




embedded image


In some embodiments, R9 is C3-5cycloalkyl. In some embodiments, R9 is cyclopropyl or cyclobutyl, each of which is optionally substituted with 1, 2, 3, or 4 F atoms. In some embodiments, R9 is selected from the group consisting of




embedded image


In some embodiments, the compound is selected from




embedded image


embedded image


embedded image



or a pharmaceutically acceptable salt thereof.


Further disclosed are compounds listed in Table D, below, for use in inhibiting SPR.










TABLE D









embedded image


Q-001







embedded image


Q-002







embedded image


Q-003







embedded image


Q-004







embedded image


Q-005







embedded image


Q-006







embedded image


Q-007







embedded image


Q-008







embedded image


Q-009







embedded image


Q-010







embedded image


Q-011







embedded image


Q-012







embedded image


Q-013







embedded image


Q-014







embedded image


Q-015







embedded image


Q-016







embedded image


Q-017







embedded image


Q-018







embedded image


Q-019







embedded image


Q-020







embedded image


Q-021







embedded image


Q-022







embedded image


Q-023







embedded image


Q-024







embedded image


Q-025







embedded image


Q-026







embedded image


Q-027







embedded image


Q-028







embedded image


Q-029







embedded image


Q-030







embedded image


Q-031







embedded image


Q-055







embedded image


Q-214







embedded image


Q-248







embedded image


Q-279










Methods of Using SPR Inhibitors


The uses of the compounds and compositions disclosed herein include use as an SPR inhibitor, an analgesic, a treatment for acute or chronic pain, an anti-inflammatory, and/or as an immune cell regulator. The disclosed methods include inhibiting sepiapterin reductase (SPR) by a method comprising contacting SPR with a compound or composition disclosed herein in an amount effective to inhibit SPR. In some aspects, the contacting is in vitro. In other aspects, the contacting is in vivo. In various aspects, contacting comprises administering the compound or the composition to a subject in need thereof. In various aspects, the subject is a mammal. In a preferred aspect, the mammalian subject is human.


It is contemplated that the SPR inhibitor compounds, compositions, and methods are useful in the treatment of diseases and disorders associated with the BH4 synthesis pathway, such as, but not limited to, pain, inflammation, and immunological disorders. In addition, it is contemplated that the SPR inhibitor compounds, compositions, and methods are useful in the treatment of diseases and disorders associated with increased levels of BH4, such as, but not limited to, pain, inflammation, and immunological disorders, compared with normal subjects not known to suffer from pain, inflammation, and/or immunological disorders. In other aspects, the subject suffers from pain (e.g., acute or chronic pain), inflammation, and/or an immunological disorder.


The disclosed methods include methods of treating a subject suffering from pain, such as acute pain or chronic pain, comprising administering to the subject a therapeutically effective amount of a compound or composition as disclosed herein. The disclosed methods also include methods of treating a subject suffering from inflammation, such as chronic inflammation, comprising administering to the subject a therapeutically effective amount of a compound or composition as disclosed herein. The disclosed methods further include methods of treating a subject suffering from an immunological disorder, comprising administering to the subject a therapeutically effective amount of a compound or composition as disclosed herein.


Pain includes, but is not limited to, AIDS/HIV-related pain, ankylosing spondylitis, arachnoiditis, back pain, breakthrough pain, burning mouth syndrome, bursitis, cancer pain, carpal tunnel syndrome pain, cauda equina syndrome, central pain syndrome, Charcot-Marie-Tooth disease, chronic functional abdominal pain, chronic pancreatitis pain, complex regional pain syndrome, corneal neuropathic pain, degenerative disc disease, Dercum's disease, dermatomyositis, diabetic peripheral neuropathy, Ehlers-Danlos syndrome, endometriosis, erythromelalgia, failed back surgery syndrome, fibromyalgia, intercostal neuraligia, interstitial cystitis, irritable bowel syndrome, juvenile dermatositis, leg pain, loin pain-haematuria syndrome, meralgia paresthetica, migraine, multiple sclerosis pain, musculoskeletal pain, myofascial pain, myositis, neuropathic pain, occipital neuralgia, osteoarthritis pain, Paget's disease, pelvic pain, peripheral neuropathy, phantom limb pain, pinched nerve, polymyalgia rhuematica, polymyositis, post-herniorraphy pain syndrome, post-mastectomy pain syndrome, post-stroke pain, post-thorocotomy pain syndrome, post-traumatic neuropathy, postherpetic neuralgia, post-polio syndrome, primary lateral sclerosis, psoriatic arthritis, pudendal neuralgia, Raynaud's disease, restless leg syndrome, rheumatoid arthritis, sacroiliac joint dysfunction, sarcoidosis, sciatica, postherpetic neuralgia, sickle cell pain, Sjogren's syndrome, spasmodic torticollis, sphincter of Oddi dysfunction, spinal cord injury, spinal stenosis, syringomyelia, Tarlov cysts, thoracic outlet syndrome (TOS), temporomandibular joint disorder, transverse myelitis, trigeminal neuralgia, ulcerative Colitis, vascular pain, vulvodynia, and whiplash pain.


Immunological disorders include, but are not limited to, acid-induced lung injury, acne (PAPA), acute respiratory distress syndrome, ageing, headache, AIDS, alcoholic hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis (NASH), allergen induced asthma, allergic bronchpulmonay aspergillosis, Alzheimer's disease, amyotropic lateral sclerosis (ALS), angina pectoris, anhidrotic ecodermal dysplasia-ID, ankylosiing spondylitis, antiphospholipid syndrome, aphthous stomatitis, appendicitis, arthritis, asthma, atopic dermatitis, autoimmune diseases, bee sting-induced inflammation, Behcet's disease, Bell's palsey, Blau syndrome, bronchiolitis, burns, cancer, cardiac hypertrophy, catabolic disorders, cataracts, cerebral aneurysm, Cystic Fibrosis, chemical irritant-induced inflammation, chronic heart failure, chronic lung disease of prematurity, chronic obstructive pulmonary disease, colitis, complex regional pain syndrome, congenital muscular dystrophies, connective tissue diseases, crohn's disease, cryopyrin-associated periodic syndromes, cyrptococcosis, cystic fibrosis, deficiency of the interleukin-1-receptor antagonist (DIRA), dermatitis, dermatomyositis, DIPG (Diffuse Intrinsic Pontine Glioma), endometriosis, endotoxemia, eosiniphilic esophagitis, familial amyloidotic polyneuropathy, familial cold urticarial, familial mediterranean fever, fetal growth, FSHD, glaucoma, glomerular disease, glomerular nephritis, gut diseases, peritoneal endometriosis, head injury, hearing loss, heart disease, Henoch-Scholein purpura, hepatitis, hereditary periodic fever syndrome, Herpes zoster and simplex, HIV-1, Huntington's disease, hyaline membrane disease, hypercholesterolemia, hyperimmunoglobulinemia D with recurrent fever (HIDS), hypoplastic and tother anemias, incontinentia pigmenti, infectious mononucleosis, inflammatory bowel disease, inflammatory lung disease, inflammatory neuropathy, inflammatory pain, insect bite-induced inflammation, irritant-induced inflammation, ischemia/reperfusion, Kawasaki Disease, kidney disease, kidney injury caused by parasitic infections[m1], leptospiriosis, leukemia, limb girdle muscular dystrophy 2A, limb girdle muscular dystrophy 2B, lung injury, lupus, lupus nephritis, lymphoma, meningitis, mesothelioma, Muckle-Wells syndrome (urticaria deafness amyloidosis), multiple sclerosis, muscle wasting, muscular dystrophy, myasthenia gravis, mycarditis, mycosis fungoides, myelodysplastic syndrome, myositis, nasal sinusitis, necrotizing enterocolitis, neonatal onset multisystem inflammatory disease (NOMID), nephrotic eyndrome, neuritis, neuropathological diseases, non-allergen induced asthma, obesity, ocular allergy, organ transplant, osterarthritis, otitis media, paget's disease, pancreatitis, Parkinson's disease, pericarditis, periodic fever, periodonitis, pertussis, pharyngitis and adenitis (PFAPA syndrome), plant irritant-induced inflammation, Pneumosystis infection, poison ivy/urushiol oil-induced inflammation, polyarteritis nodosa, polycystic kidney disease, polymyositis, pontine glioma, psoriasis, psychosocial stress diseases, pulmonary disease, pulmonary fibrosis, pulmonary hypertension, pyoderma gangrenosum, pyogenic sterile arthritis, renal disease, retardation, retinal disease, rheumatic disease, sarcoidosis, sebborrhea, sepsis, sickle cell, silica-induced diseases, Sjogren's syndrome, skin diseases, sleep apnea, solid tumors including brain tumors, spinal cord injury, statin induced myopathy, stroke, subarachnoid hemorrhage, sunburn, thrombocytopenia, tissue transplant, TNF receptor associated periodic syndrome (TRAPS), toxoplasmosis, traumatic brain injury, tuberculosis, type 1 diabetes, type 2 diabetes, ulcerative colitis, uveitis, and wound repair.


A “therapeutically effective amount” means an amount effective to treat or to prevent development of, or to alleviate the existing symptoms of, the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. Generally, a “therapeutically effective dose” refers to that amount of the compound that results in achieving the desired effect. For example, in one preferred embodiment, a therapeutically effective amount of a compound disclosed herein decreases SPR activity by at least 5%, compared to control, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90%.


The amount of compound administered can be dependent on the subject being treated, on the subject's age, health, sex, and weight, the kind of concurrent treatment (if any), severity of the affliction, the nature of the effect desired, the manner and frequency of treatment, and the judgment of the prescribing physician. The frequency of dosing also can be dependent on pharmacodynamic effects on arterial oxygen pressures. However, the most preferred dosage can be tailored to the individual subject, as is understood and determinable by one of skill in the art, without undue experimentation. This typically involves adjustment of a standard dose (e.g., reduction of the dose if the patient has a low body weight).


While individual needs vary, determination of optimal ranges of effective amounts of the compound is within the skill of the art. For administration to a human in the curative or prophylactic treatment of the conditions and disorders identified herein, for example, typical dosages of the compounds of the present invention can be about 0.05 mg/kg/day to about 50 mg/kg/day, for example at least 0.05 mg/kg, at least 0.08 mg/kg, at least 0.1 mg/kg, at least 0.2 mg/kg, at least 0.3 mg/kg, at least 0.4 mg/kg, or at least 0.5 mg/kg, and preferably 50 mg/kg or less, 40 mg/kg or less, 30 mg/kg or less, 20 mg/kg or less, or 10 mg/kg or less, which can be about 2.5 mg/day (0.5 mg/kg×5 kg) to about 5000 mg/day (50 mg/kg×100 kg), for example. For example, dosages of the compounds can be about 0.1 mg/kg/day to about 50 mg/kg/day, about 0.05 mg/kg/day to about 10 mg/kg/day, about 0.05 mg/kg/day to about 5 mg/kg/day, about 0.05 mg/kg/day to about 3 mg/kg/day, about 0.07 mg/kg/day to about 3 mg/kg/day, about 0.09 mg/kg/day to about 3 mg/kg/day, about 0.05 mg/kg/day to about 0.1 mg/kg/day, about 0.1 mg/kg/day to about 1 mg/kg/day, about 1 mg/kg/day to about 10 mg/kg/day, about 1 mg/kg/day to about 5 mg/kg/day, about 1 mg/kg/day to about 3 mg/kg/day, about 3 mg/day to about 500 mg/day, about 5 mg/day to about 250 mg/day, about 10 mg/day to about 100 mg/day, about 3 mg/day to about 10 mg/day, or about 100 mg/day to about 250 mg/day. Such doses may be administered in a single dose or it may be divided into multiple doses.


An SPR inhibitor is contemplated to be useful in the treatment of any condition wherein the lowering of BH4 levels will provide benefits. The SPR inhibitor is useful alone, or in combination with other compounds, which may act to promote the reduction of BH4 levels. The present section provides a description of how the SPR inhibitors of the invention may be therapeutically administered to a subject in need thereof.


One of the therapeutic embodiments of the invention is the provision, to a subject in need thereof, compositions comprising one or more SPR inhibitors. In one aspect, the SPR inhibitor formulation for therapy in a subject is selected based on the route of administration and in certain aspects includes liposome and micelle formulations as well as classic pharmaceutical preparations.


In various aspects, administration of the compositions is systemic or local, and in still other aspects comprises a single site injection of a therapeutically-effective amount of the SPR inhibitor composition. Any route known to those of skill in the art for the administration of a therapeutic composition of the invention is contemplated including, for example, intravenous, intramuscular, subcutaneous, oral, or a catheter for long-term administration.


Combination Therapy:


In addition to therapies based solely on the delivery of the SPR inhibitor composition, combination therapy is specifically contemplated. In the context of the invention, it is contemplated that the SPR inhibitor composition therapy is used similarly in conjunction with other agents commonly used for the treatment of elevated levels of BH4 and/or SPR.


The combination therapy compositions are provided in a combined amount effective to produce the desired therapeutic outcome in the treatment of reduced levels of BH4 and/or make a detectable change in an indication as described herein. This process involves administering the SPR inhibitor and the second agent(s) or factor(s) at the same time. Methods thus include administering a single composition or pharmacological formulation that includes both agents, or administering two distinct compositions or formulations, at the same time, wherein one composition includes the SPR inhibitor therapeutic composition and the other includes the second therapeutic agent.


Alternatively, the SPR inhibitor treatment precedes or follows the second therapeutic agent treatment by intervals ranging from minutes to weeks. In embodiments where the second therapeutic agent and the SPR inhibitor are administered separately, one generally ensures that a significant period of time did not transpire between the times of each delivery, such that the second therapeutic agent and the SPR inhibitor are able to exert an advantageously combined effect. In such instances, it is contemplated that one administers both modalities within about 12-24 hours of each other, or alternately, within about 6-12 hours of each other, or alternately, with a delay time of only about 12 hours. However, in some situations, it is desirable to extend the time period for treatment significantly, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.


Systemic delivery of SPR inhibitors to patients is a very efficient method for delivering a therapeutically effective amount of the compound to counteract the immediate clinical manifestations of a disease or disorder. Alternatively, local delivery of the SPR inhibitor and/or the second therapeutic agent is appropriate in certain circumstances. In a certain embodiment, it is contemplated that the SPR inhibitor is delivered to a patient for an extended period of time. It is further contemplated that the SPR inhibitor is taken throughout a patient's lifetime to lower SPR activity levels.


Dosing and Pharmaceutical Formulations


Also provided herein are pharmaceutical compositions that includes a compound as disclosed herein, together with a pharmaceutically acceptable excipient such as a diluent or carrier. Compounds and pharmaceutical compositions suitable for use in the present invention include those wherein the compound can be administered in an effective amount to achieve its intended purpose. Administration of the compound described in more detail below.


Suitable pharmaceutical formulations can be determined by the skilled artisan depending on the route of administration and the desired dosage. See, e.g., Remington's Pharmaceutical Sciences, 1435-712 (18th ed., Mack Publishing Co, Easton, Pa., 1990). Formulations may influence the physical state, stability, rate of in vivo release and rate of in vivo clearance of the administered agents. Depending on the route of administration, a suitable dose may be calculated according to body weight, body surface areas or organ size. Further refinement of the calculations necessary to determine the appropriate treatment dose is routinely made by those of ordinary skill in the art without undue experimentation, especially in light of the dosage information and assays disclosed herein as well as the pharmacokinetic data obtainable through animal or human clinical trials.


The phrases “pharmaceutically acceptable” or “pharmacologically acceptable” refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such excipients for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the therapeutic compositions, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions. In exemplary embodiments, the formulation may comprise corn syrup solids, high-oleic safflower oil, coconut oil, soy oil, L-leucine, calcium phosphate tribasic, L-tyrosine, L-proline, L-lysine acetate, DATEM (an emulsifier), L-glutamine, L-valine, potassium phosphate dibasic, L-isoleucine, L-arginine, L-alanine, glycine, L-asparagine monohydrate, L-serine, potassium citrate, L-threonine, sodium citrate, magnesium chloride, L-histidine, L-methionine, ascorbic acid, calcium carbonate, L-glutamic acid, L-cystine dihydrochloride, L-tryptophan, L-aspartic acid, choline chloride, taurine, m-inositol, ferrous sulfate, ascorbyl palmitate, zinc sulfate, L-carnitine, alpha-tocopheryl acetate, sodium chloride, niacinamide, mixed tocopherols, calcium pantothenate, cupric sulfate, thiamine chloride hydrochloride, vitamin A palmitate, manganese sulfate, riboflavin, pyridoxine hydrochloride, folic acid, beta-carotene, potassium iodide, phylloquinone, biotin, sodium selenate, chromium chloride, sodium molybdate, vitamin D3 and cyanocobalamin.


As used herein, “pharmaceutically acceptable salts” include, for example base addition salts and acid addition salts.


Pharmaceutically acceptable base addition salts may be formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible. Examples of metals used as cations are sodium, potassium, magnesium, ammonium, calcium, or ferric, and the like. Examples of suitable amines include isopropylamine, trimethylamine, histidine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine.


Pharmaceutically acceptable acid addition salts include inorganic or organic acid salts. Examples of suitable acid salts include the hydrochlorides, formates, acetates, citrates, salicylates, nitrates, phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include, for example, formic, acetic, citric, oxalic, tartaric, or mandelic acids, hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, trifluoroacetic acid (TFA), propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane 1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene 2-sulfonic acid, naphthalene 1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose 6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid.


Pharmaceutical compositions containing the compounds disclosed herein can be manufactured in a conventional manner, e.g., by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen.


For oral administration, suitable compositions can be formulated readily by combining a compound disclosed herein with pharmaceutically acceptable excipients such as carriers well known in the art. Such excipients and carriers enable the present compounds to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by adding a compound as disclosed herein with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, for example, fillers and cellulose preparations. If desired, disintegrating agents can be added. Pharmaceutically acceptable ingredients are well known for the various types of formulation and may be for example binders (e.g., natural or synthetic polymers), lubricants, surfactants, sweetening and flavoring agents, coating materials, preservatives, dyes, thickeners, adjuvants, antimicrobial agents, antioxidants and carriers for the various formulation types.


When a therapeutically effective amount of a compound disclosed herein is administered orally, the composition typically is in the form of a solid (e.g., tablet, capsule, pill, powder, or troche) or a liquid formulation (e.g., aqueous suspension, solution, elixir, or syrup).


When administered in tablet form, the composition can additionally contain a functional solid and/or solid carrier, such as a gelatin or an adjuvant. The tablet, capsule, and powder can contain about 1 to about 95% compound, and preferably from about 15 to about 90% compound.


When administered in liquid or suspension form, a functional liquid and/or a liquid carrier such as water, petroleum, or oils of animal or plant origin can be added. The liquid form of the composition can further contain physiological saline solution, sugar alcohol solutions, dextrose or other saccharide solutions, or glycols. When administered in liquid or suspension form, the composition can contain about 0.5 to about 90% by weight of a compound disclosed herein, and preferably about 1 to about 50% of a compound disclosed herein. In one embodiment contemplated, the liquid carrier is non-aqueous or substantially non-aqueous. For administration in liquid form, the composition may be supplied as a rapidly-dissolving solid formulation for dissolution or suspension immediately prior to administration.


When a therapeutically effective amount of a compound disclosed herein is administered by intravenous, cutaneous, or subcutaneous injection, the composition is in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred composition for intravenous, cutaneous, or subcutaneous injection typically contains, in addition to a compound disclosed herein, an isotonic vehicle. Such compositions may be prepared for administration as solutions of free base or pharmacologically acceptable salts in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions also can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations can optionally contain a preservative to prevent the growth of microorganisms.


Injectable compositions can include sterile aqueous solutions, suspensions, or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions, suspensions, or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must resist the contaminating action of microorganisms, such as bacteria and fungi, by optional inclusion of a preservative. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. In one embodiment contemplated, the carrier is non-aqueous or substantially non-aqueous. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size of the compound in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.


Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.


Slow release or sustained release formulations may also be prepared in order to achieve a controlled release of the active compound in contact with the body fluids in the GI tract, and to provide a substantially constant and effective level of the active compound in the blood plasma. For example, release can be controlled by one or more of dissolution, diffusion, and ion-exchange. In addition, the slow release approach may enhance absorption via saturable or limiting pathways within the GI tract. For example, the compound may be embedded for this purpose in a polymer matrix of a biological degradable polymer, a water-soluble polymer or a mixture of both, and optionally suitable surfactants. Embedding can mean in this context the incorporation of micro-particles in a matrix of polymers. Controlled release formulations are also obtained through encapsulation of dispersed micro-particles or emulsified micro-droplets via known dispersion or emulsion coating technologies.


For administration by inhalation, compounds of the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin, for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.


The compounds disclosed herein can be formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion). Formulations for injection can be presented in unit dosage form (e.g., in ampules or in multidose containers), with an added preservative. The compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing, and/or dispersing agents.


Pharmaceutical formulations for parenteral administration include aqueous solutions of the compounds in water-soluble form. Additionally, suspensions of the compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension. Optionally, the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds and allow for the preparation of highly concentrated solutions. Alternatively, a present composition can be in powder form for constitution with a suitable vehicle (e.g., sterile pyrogen-free water) before use.


Compounds disclosed herein also can be formulated in rectal compositions, such as suppositories or retention enemas (e.g., containing conventional suppository bases). In addition to the formulations described previously, the compounds also can be formulated as a depot preparation. Such long-acting formulations can be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.


In particular, a compound disclosed herein can be administered orally, buccally, or sublingually in the form of tablets containing excipients, such as starch or lactose, or in capsules or ovules, either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. Such liquid preparations can be prepared with pharmaceutically acceptable additives, such as suspending agents. A compound also can be injected parenterally, for example, intravenously, intramuscularly, subcutaneously, or intracoronarily. For parenteral administration, the compound is best used in the form of a sterile aqueous solution which can contain other substances, for example, salts, or sugar alcohols, such as mannitol, or glucose, to make the solution isotonic with blood.


For veterinary use, a compound disclosed herein is administered as a suitably acceptable formulation in accordance with normal veterinary practice. The veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal.


In some cases, all the necessary components for the treatment of an SPR-related disorder using a compound as disclosed herein either alone or in combination with another agent or intervention traditionally used for the treatment of such disease may be packaged into a kit. Specifically, the present invention provides a kit for use in the therapeutic intervention of the disease comprising a packaged set of medicaments that include the compound disclosed herein as well as buffers and other components for preparing deliverable forms of said medicaments, and/or devices for delivering such medicaments, and/or any agents that are used in combination therapy with the compound disclosed herein, and/or instructions for the treatment of the disease packaged with the medicaments. The instructions may be fixed in any tangible medium, such as printed paper, or a computer readable magnetic or optical medium, or instructions to reference a remote computer data source such as a world wide web page accessible via the internet.


Synthesis of Compounds Disclosed Herein


The compounds disclosed herein can be prepared following the methods outlined in detail in the Examples, using suitable modifications to the starting reagents. One of skill in the art, in view of the teachings of the Examples and using typical organic chemistry techniques, can synthesize a compound as disclosed herein.


In some cases, compounds of formula I can be prepared by converting an appropriate thiouracil to a hydrazine intermediate, coupling the hydrazine intermediate with an appropriate enamine reagent to form a compound of formula I or an intermediate having a pyrazolyl moiety, and further reacting the intermediate having a pyrazolyl moiety so as to couple with an appropriate amine (for example, using reagents such as HATU or HATU/HOAt) to provide a compound of formula I as shown in the Scheme 1 and Scheme 2.




embedded image




embedded image


In some cases, compounds of formula I can be prepared by converting an appropriate dichloropyrimidine to a hydrazine intermediate, coupling the hydrazine intermediate with an appropriate enamine reagent to form an intermediate having a pyrazolyl moiety, and further reacting the intermediate having a pyrazolyl moiety so as to couple with an appropriate amine (for example, using reagents such as HATU or HATU/HOAt) to provide a compound of formula I as shown in Schemes 3 and 4.




embedded image




embedded image


In some cases, compounds of formula I can be prepared by converting an appropriate cyclopentanone to a hydrazine intermediate, coupling the hydrazine intermediate with an appropriate enamine reagent to form an intermediate having a pyrazolyl moiety, and further reacting the intermediate having a pyrazolyl moiety so as to couple with an appropriate amine (for example, using reagents such as HATU or HATU/HOAt) to provide a compound of formula I as shown in Scheme 5.




embedded image


In some cases, compounds of formula I can be prepared by coupling an appropriate hydrazine intermediate with an appropriate enamine, enol ether, aldehyde, or ketone reagent to form an intermediate having a pyrazolyl moiety, and further reacting the intermediate having a pyrazolyl moiety so as to couple with an appropriate amine (for example, using reagents such as HATU or HATU/HOAt) to provide a compound of formula I as shown in Scheme 6.




embedded image


In some cases, compounds of formula I can be prepared by coupling an appropriate hydrazine intermediate with an appropriate dialdehyde reagent to form an intermediate having a pyrazolyl moiety, and further reacting the intermediate having a pyrazolyl moiety so as to couple with an appropriate amine (for example, using reagents such as HATU or HATU/HOAt) to provide a compound of formula I as shown in Scheme 7.




embedded image


In some cases, compounds of formula I can be prepared by coupling an appropriate chloropyrimidine or sulfonyl pyrimidine with an appropriate pyrazolyl moiety to form a compound of formula I or an intermediate having a pyrazolyl moiety, and further reacting the intermediate having a pyrazolyl moiety so as to couple with an appropriate amine (for example, using reagents such as HATU or HATU/HOAt) to provide a compound of formula I as shown in Schemes 8, 9, 10 and 11.




embedded image




embedded image




embedded image




embedded image


In some cases, compounds of formula I can be prepared by coupling an appropriate bromo-cyclopropylideneacetate with an appropriate pyrazolyl moiety to form an intermediate having a pyrazolyl moiety, and further reacting the intermediate having a pyrazolyl moiety so as to couple with an appropriate amine (for example, using reagents such as HATU or HATU/HOAt) to provide a compound of formula I as shown in Scheme 12.




embedded image


In some cases, compounds of formula I can be prepared by coupling an appropriate azide with an appropriate β-keto ester to form an intermediate having a triazolyl moiety, and further reacting the intermediate having a triazolyl moiety so as to couple with an appropriate amine (for example, using reagents such as HATU or HATU/HOAt) to provide a compound of formula I as shown in Scheme 13.




embedded image


Amines that are not commercially available can be prepared by standard procedures. In some cases, amines that are not commercially available can be prepared by coupling an appropriate aryl bromide with a mono-protected cyclic diamine, followed by deprotection of the amine protecting group to obtain the amine, for example, as shown in Scheme 14.




embedded image


In some cases, amines that are not commercially available can be prepared by reducing an appropriate protected aminoketone to obtain the corresponding alcohol, protecting the alcohol with an appropriate protecting group, further reacting with an appropriate reagent so as to convert the protected alcohol to a desired functional group (e.g., a cyano group), followed by deprotection of the amine protecting group to obtain the amine, for example, as shown in Scheme 15.




embedded image



Assessment of SPR Inhibitory Activity


The compounds disclosed herein can be assessed for SPR inhibitory activity. Typically, a compound is assayed by an enzymatic assay (e.g., a TR-FRET assay) and/or a cellular assay (e.g., SKN-N-BE(2) cells or human PBMC (Peripheral Blood Mononuclear Cells)) as described below.


TR-FRET Assay: A TR-FRET (homogeneous, time-resolved, fluorescence resonance energy transfer) assay was used to assess activity of compounds following standard assay conditions. Terbium labeled SNAP-hSPR and SSZ (sulfasalazine) labeled SNAP-EGFP were used as the protein pair in this assay according to the procedure described in Haruki et al., Science, 430:987 (2013). Compounds were screened at different concentrations and IC50 values calculated.


SKN-N-BE(2) Cellular Assay: SK-N-BE (2) cells were seeded in sterile, 96-well plates and incubated for 12-24 hours at 37° C. with 5% CO2 supply. Media was removed and fresh DMEM/F-12 media (containing Glutamine & Pen/Strep but no FBS) was added. Compounds (at different concentrations) were added to different wells. The plates were then incubated for 6-48 hours at 37° C. with 5% CO2 supply. Plates were then centrifuged and the supernatant was removed. The plates were then optionally washed once with PBS. They were then sealed and stored at −80° C. or immediately used. The cells were lysed and the level of BH4 was assessed by LC-MS.


hPBMC Assay: PBMCs were either purchased or isolated from fresh human blood and used either as a fresh preparation or frozen for later use. The assay system was prepared by pre-treating the assay plates overnight with a solution containing anti-human CD3 antibody. Human PBMCs were suspended in assay medium and plated into the assay plates at a density of 1-4×105 cells per well. The desired concentration of the test compound was added to each well. A solution of human anti-CD28 antibody was also added to each well. Plates were incubated for 12-48 hours at 37° C. and 5% CO2. Assay plates were centrifuged for 5-15 minutes at 1-3000 RMP and supernatants were removed. The cells were lysed, sealed and used directly or frozen at −80° C. LC-MS was used to quantify the amount of inhibition of BH4 production.


Assessment of Pain Behavior


The compounds disclosed herein can be assessed for effect on pain behavior. Typically, a compound is assayed by a behavioral pharmacology model as described below.


Behavioral Pharmacology Model: Compounds were administered by oral gavage to rats that had undergone one of two nerve injury surgeries: spared nerve injury to injure two of the three peripheral branches of the sciatic nerve or chronic constriction injury of the sciatic nerve. Paw withdrawal thresholds to mechanical stimulation using calibrated von Frey filaments were used as measurement of neuropathic pain-like behaviors.


EXAMPLES

In the examples and throughout the specification, the following abbreviations are used.















conc.
concentrated


DCM
dichloromethane


DMF
N,N-dimethylformamide


DMSO
dimethylsulfoxide


Et2O
diethyl ether


EtOAc or EA
ethyl acetate


MeOH
methanol


EtOH
ethanol


THF
tetrahydrofuran


DIPEA
N,N-diisopropylethylamine


DAST
diethylaminosulfur trifluoride


LDA
lithium diisopropylamide


mCPBA
3-chloroperoxybenzoic acid


Pd(OAc)2
palladium(II) acetate


TEA
triethylamine


DIAD
diisopropyl azodicarboxylate


NaHCO3
Sodium bicarbonate


Na2CO3
Sodium Carbonate


MgSO4
Magnesium sulphate


Na2SO4
Sodium Sulphate


SiO2
silica


h
hour


r.t.
room temperature


RT
retention time


br
broad


M
mass


HPLC
High Performance Liquid Chromatography


LC-MS
Liquid Chromatography Mass Spectrometry


ES+
Electrospray Positive Ionisation


ES−
Electrospray Negative Ionisation


brine
aqueous sodium chloride solution


EDC
1-(3-dimethylaminopropyl)-3-



ethylcarbodiimide hydrochloride


HATU
O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-



tetramethyluronium hexafluorophosphate


Pd(PPh3)4
tetrakis(triphenylphosphine)palladium(0)


HOAt
1-Hydroxy-7-azabenzotriazole


PE
Petroleum ether


SGC
Silica gel chromatography


TLC
Thin layer chromatography


GC-MS
Gas chromatography mass spectrometry


PdCl2(dppf)
[1,1′-



bis(diphenylphosphino)ferrocene]dichloropalladium(II)


T3P
Propylphosphonic anhydride


COMU
(1-Cyano-2-ethoxy-2-



oxoethylidenaminooxy)dimethylamino-



morpholino-carbenium



hexafluorophosphate


SCX
propylsulfonic acid bonded sorbent



purification cartridge










General Procedures


The following analytical LC-MS methods were used.














Method A: (2 min IPC)


MET/CR/1673


Column: Supelco Ascentis Express C18, 30 mm × 2.1 mm, 2.7 μm


Flow rate: 1.0 ml/min


Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid


(MeCN) 0.1%


Injection Vol: 3 μl


Temp.: 40° C.


Detection: 215 nm (nominal)


Gradient Time (minutes) - % B


0.00-5


1.50-100


1.60-100


1.61-5


Method B: (1.7 min IPC)


MET/CR/1410


Column: Kinetex Core-Shell C18, 50 mm × 2.1 mm, 5.0 μm


Flow rate: 1.2 ml/min


Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid


(MeCN) 0.1%


Injection Vol: 3 μl


Temp.: 40° C.


Detection: 215 nm (nominal)


Gradient Time (minutes) - % B


0.00-5


1.20-100


1.30-100


1.31-5


Method C: (7 min IPC)


MET/u-HPLC (low pH 7 min method)


Column: Phenomenex Kinetex-XB C18, 2.1 mm × 100 mm, 1.7 μm


Flow rate: 0.6 ml/min


Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid


(MeCN) 0.1%


Injection Vol: 3 μl


Temp.: 40° C.


Detection: 215 nm (nominal)


Gradient Time (minutes) - % B


0.00-5


5.30-100


5.80-100


5.82-5









The following preparative HPLC and SFC methods were used.














Method D:


SFC: 10% Methanol: 90% CO2 on a 25 cm OJ-H Column, at 15 ml/min.


Method E:


Generic high pH prep method (Gilson 3 and Gilson 5)


Column: Waters Xbridge C18 (30 × 100 mm, 10 um)


Flow rate: 40 ml/min


Mobile Phase: A, Water + 0.2% Ammonium hydroxide, B, Acetonitrile +


0.2% Ammonium hydroxide


Injection Vol.: 1500 μl


Temperature: r.t.


Detection: 215 nm


Gradient Time (minutes) - % B


0.0-5


2.5-5


16.05-95


18.2-95


19.1-5


20-5


Method F:


Generic neutral pH prep method (Waters 1)


Column: Waters Sunfire C18 (30 × 100 mm, 10 um), Part no. 186003971


Flow rate: 40 ml/min


Mobile Phase: A, Water, B, Acetonitrile


Injection Vol: 1500 μl


Temperature: r.t.


Detection: 215 nm


Gradient Time (minutes) - % B


0-10


2-10


2.5-15


14.5-100


15.5-100


16-10


17-10


Method G:


Generic low pH prep method (Waters 2)


Column: Waters Sunfire C18 (30 × 100 mm, 10 um), Part no. 186003971


Flow rate: 40 ml/min


Mobile Phase: A, Water + 0.1% Formic acid, B, Acetonitrile + 0.1%


Formic acid


Injection Vol.: 1500 μl


Temperature: r.t.


Detection: 215 nm


Gradient Time (minutes) - % B


0-5


2-5


2.5-10


14.5-10


15.5-100


16-5









The following preparative chiral separation and analysis methods were used.
















Method H:



Separation



Column: SFC ChiralPak AS (250 mm × 20 mm, 5 um)



Flow rate: 50 mL/min



Eluent: MeOH/CO2 50% (TFA was added as a modifier)



Injection Vol: 0.7 mL (7 mg)



Detection: 218 nm



Method I:



Analysis



Column: SFC ChiralPak AS (250 mm × 4.6 mm, 5 um)



Flow rate: 4 mL/min



Eluent: MeOH/CO2 45% (TFA was added as a modifier)



Method J:



Separation



Column: HPLC Lux C1 (20 mm × 250 mm, 5 um)



Flow rate: 21 mL/min



Eluent: HEPT/EtOH (50:50) (TFA was added as a modifier)



Injection Vol: 0.5 mL (10 mg)



Detection: 210 nm



Method K:



Analysis



Column: HPLC Lux C1 (4.6 mm × 250 mm, 5 um)



Eluent: HEPT/EtOH (40:60) (TFA was added as a modifier)



Flow rate: 4 mL/min.



Method L:



Separation



Column: ChiralPak AD (20 mm × 250 mm, 20 um)



Eluent: EtOH (TFA was added as a modifier)



Flow rate was 21 mL/min



Method M:



Analysis



Column: HPLC using a YMC AMY-C (4.6 mm × 250 mm, 5 um)



Eluent EtOH (TFA was added as a modifier)



Flow rate: 1 mL/min



Method N:



Separation



Column: HPLC Chiralcel OD-H 25 cm



Eluent: ethanol + 0.1% formic acid



Flow rate: 5 ml/min



Method O:



Separation



Column: Lux A2 (20 mm × 250 mm, 5 um)



Eluent: EtOH (TFA was added as a modifier)



Flow rate: 21 mL/min



Detection: 210 nm









The following LC-MS methods were used.














Method A′:


Column: SunFire C18 (4.6 × 50 mm, 3.5 um)


Mobile phase: H2 O (0.05% TFA) (A)/ACN (0.05% TFA) (B)


Elution program: Gradient from 5 to 100% of B in 1.3 min at 2 mL/min


Temperature: 50° C.


Detection: UV (214, 254 nm) and MS (ESI, Pos mode, 110 to 1000 amu)


Method B′:


Column: Chromolith Fast Gradien RP-18e, 50-3 mm


Mobile Phase: A: Water (0.01% TFA) B: ACN (0.01% TFA)


Gradient: 5% B increase to 100% B within 0.8 min, 100% B for 1.1 min.


Flow Rate: 1.5 mL/min


Column Temperature: 40° C.


Mass Range: 103-1100


Method C′:


Column: Sunfire C18 4.6 × 50 mm, 3.5 um


Mobile phase: H2O (0.01% TFA) (A)/ACN (0.01% TFA) (B)


Elution program: Gradient from 5 to 95% of B in 1.4 min at 2.0 ml/min


Temperature: 45° C.


Detection: UV (214, 254 nm) and MS (ESI, POS mode, 113 to 1200 amu)


Method D′:


Column: Sunfire C18 2.5 um3 * 30 mm


Mobile Phase: A: water (0.01% TFA) B: ACN (0.01% TFA)


Gradient: 5%-95% B in 1.5 min


Flow Rate: 1.5 mL/min


Mass Range: 110-1000 UV: 214 nm; 254 nm


Oven Temperature: 50° C.


Method E′:


Column: SunFire C18, 4.6 * 50 mm, 3.5 um


Mobile Phase: A: Water (0.01% TFA) B: ACN (0.01% TFA)


Gradient: 5% B increase to 95% B within 1.2 min, 95% B for 1.3 min,


back to 5% B within 0.01 min.


Flow Rate: 2.0 mL/min


Column Temperature: 50° C.


Method F′:


Column: Xbridge C18 (4.6 × 50 mm, 3.5 um)


Mobile phase: H2O (10 mmol NH4HCO3) (A)/ACN(B)


Elution program: Gradient from 5 to 95% of B in 1.3 min at 1.8 ml/min


Temperature: 50° C.


Detection: UV (214, 254 nm) and MS (ESI, POS mode, 110 to 1000 amu)


Method G′:


Column: Xbridge, 3.5um, 50 * 4.6 mm


Mobile Phase: A: 10 m mol/L NH4HCO3 in water B: ACN


Gradient: 5% B increase to 95% B within 1.5 min, 95% B for 1.0 min,


back to 5% B within 0.01 min.


Flow Rate: 2 mL/min


Oven Temperature: 50° C.


Method H′:


Column: Xbridge C18 4.6 * 50 mm 3.5 um


Mobile Phase: A: 10 mM NH4HCO3 in water B: ACN


Gradient: 5% B increase to 95% B within 1.2 min, 95% B for 1.3 min,


back to 5% B within 0.01 min.


Flow Rate: 2.0 mL/min


Oven Temperature: 50° C.


Method I′:


Column: Gemini-NX 3u C18 (4.6 × 50 mm, 3 um)


Mobile phase: H2O (10 mmol NH4HCO3) (A)/ACN (B)


Elution program: Gradient from 10 to 95% of B in 1.5 min at 1.8 mL/min


Temperature: 50° C.


Detection: UV (214, 254 nm) and MS (ESI, Pos mode, 70 to 900 amu)


Method J′:


Column: Xbridge C18(2) (4.6 × 50 mm, 3.5 um)


Mobile phase: H2O (10 mmol NH4HCO3) (A)/ACN (B)


Elution program: Gradient from 10 to 95% of B in 1.5 min at 1.8 mL/min


Temperature: 50° C.


Detection: UV (214, 254 nm) and MS (ESI, Pos mode, 110 to 1100 amu)


Method K′:


Column: YMC C18 Plus, 4.6 * 50 mm, 3 um, 12 nm


Mobile Phase: A: water (10 mM Ammonium hydrogen carbonate) B:


ACN


Gradient: 5%-95% B in 1.6 min


Flow Rate: 1.6 mL/min


Oven Temperature: 50° C.


MS Range: 110-1100









Preparative Example 1—Method 1: Formation of Intermediates from Corresponding Thiouracils



embedded image


Intermediate 1: Preparation of 2-hydrazinyl-6-methyl-3,4-dihydropyrimidin-4-one
Step 1: Synthesis of 6-methyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one



embedded image


To water (500 mL) was added NaOH (97%, 15.7 g, 381 mmol) and the suspension stirred at r.t. for 10 mins. 6-methyl-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one (98%, 53.5 g, 369 mmol) was added and the mixture stirred until fully dissolved for 10 mins. Iodomethane (28.99 mL, 461 mmol) was added dropwise and the mixture stirred at r.t. for 4 h. The colorless solid was filtered, washed with ice cold water (2×100 mL) and dried under vacuum at 60° C. to afford the title compound (57 g, 98%) as a colorless solid.


Method A: LC-MS m/z=156.9 [M+H]+; RT=0.61 min.


Step 2: Synthesis of 2-hydrazinyl-6-methyl-3,4-dihydropyrimidin-4-one (Intermediate 1)



embedded image


To a stirred solution of 6-methyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one (11.9 g, 76.18 mmol) in EtOH (30 mL) was added hydrazine hydrate (15.75 mL, 0.32 mol) and stirred at 80° C. for 5.5 h. The reaction mixture was allowed to cool to r.t. and the resulting precipitate was collected and dried by vacuum filtration, washing with water (3 mL) to afford the title compound (9.20 g, 85%) as an off white powder.


Method A: LC-MS m/z=140.90 [M+H]+; RT=0.18 min.


Intermediate 2: Preparation of 5-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid
Step 1: Synthesis of methyl-5-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylate



embedded image


To a stirred suspension of hydrazinyl-6-methyl-3,4-dihydropyrimidin-4-one (Intermediate 1, 6.82 g, 48.66 mmol) in EtOH (70 mL) was added methyl (2Z)-2-[(dimethylamino)methylidene]-3-oxobutanoate (8.33 g, 48.66 mmol) (Intermediate 3) followed by addition of AcOH (9.75 mL) and stirred at 80° C. for 1 h. The reaction mixture was cooled to r.t., at which point the product precipitated out of solution, and was filtered under vacuum, washing sparingly with EtOH, to afford the title compound (6.02 g, 50%) as a fluffy pale peach powder.


Method A: LC-MS m/z=248.95 [M+H]+; RT=1.01 min.


Step 2: Synthesis of 5-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid (Intermediate 2)



embedded image


To a stirred suspension of methyl-5-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylate (6.02 g, 24.25 mmol) in THF (40 mL) was added 3M aq NaOH solution (40.42 mL), followed by water (20 mL) to aid dissolution and stirred at r.t. for 1 h. The reaction mixture was concentrated in vacuo to remove the THF and then acidified to pH 6 using 1M aq HCl solution. The resultant white solid was filtered under vacuum, washing with Et2O, and dried to afford the title compound (5.45 g, 96%) as an off white powder.


Method A: LC-MS m/z=234.9 [M+H]+; RT=0.84 min.


Intermediate 3: Preparation of methyl-2-[(dimethylamino)methylidene]-3-oxobutanoate



embedded image


Methyl 3-oxobutanoate (40 g, 0.34 mol) and 1,1-dimethoxy-N,N-dimethylmethanamine (54.92 mL, 0.41 mol) were combined and stirred at 80° C. for 2 hours. The reaction mixture was concentrated in vacuo and the resulting oil was dried for 24 hours under vacuum to afford 56.53 g (86.3%) of the title compound as a dark red solid: 1H NMR (500 MHz, DMSO-d6) δ 7.62 (s, 1H), 3.63 (s, 3H), 3.24-2.96 (m, 3H), 2.90-2.58 (m, 3H), 2.13 (s, 3H).


Intermediate 4: Preparation of 2-ethyl-2,3-dihydro-1H-indole



embedded image


The intermediate was formed using the procedure from US Patent Publication 2011/0021500.


A solution of 2-ethyl-1H-indole (1 g, 6.89 mmol) in acetic acid (15 ml) at r.t. was treated portion wise with sodium cyanoborohydride (2.03 g, 32.37 mmol); addition caused effervescence and a slight exotherm. The resultant suspension was stirred at r.t. for 20 h. The reaction mixture was concentrated in vacuo and the residue treated with 4M aq HCl solution (30 mL) with scrubbing. The mixture was stirred at r.t. for 1 h, then cooled to 0° C. and treated with 4M aq NaOH solution (40 mL). Once the addition was complete the mixture was extracted with EtOAc (×2). The extracts were washed with brine, dried over MgSO4 and concentrated in vacuo to afford the title compound (1.1 g, 97%) as a pale yellow mobile oil.


Method A: LC-MS m/z=147.9 [M+H]+; RT=0.96 min.


Example 1—Synthesis of 6-methyl-2-[5-methyl-4-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one



embedded image


To a stirred solution of 5-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid (Intermediate 2, 6.60 g, 28.18 mmol) in DMF (80 mL) was added COMU (13.28 g, 31.00 mmol), DIPEA (12.06 mL, 70.45 mmol) and 1,2,3,4-tetrahydroisoquinoline (3.93 mL, 31.00 mmol) and stirred at r.t. for 1 h. The reaction mixture was quenched by addition of saturated NaHCO3 solution (20 mL) and water (20 mL) and extracted with DCM (4×100 mL). The combined organic extracts were dried over sodium sulphate, concentrated in vacuo and triturated using MeCN to afford the title compound (4.71 g, 48%) as an off white powder.


Method C: LC-MS m/z=350.1 [M+H]+; RT=2.54 min.


Examples 2-39—Synthesis of Dihydropyrimidinones

Examples 2-39 were prepared according to the procedure described in Example 1 by reacting Intermediate 2 (5-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid) with the appropriate amine and the coupling agent specified in Table 1. All amines used in Table 1 were commercially available except for example 38 which was synthesized using Intermediate 4 (2-ethyl-2,3-dihydro-1H-indole).















TABLE 1





Ex-



LC-MS
MS



ample
Ref.


(RT)
(M + H)+
Coupling


No.
No.
LBN
Structure
Method C
Method C
Agent





















2
Q-328
EV-AP2301-002


embedded image


1.54
340.1
COMU





3
Q-341
EV-AP2305-001


embedded image


2.27
316.2
TBTU





4
Q-346
EV-AP2309-001


embedded image


1.97
290.2
TBTU





5
Q-347
EV-AP2310-001


embedded image


2.25
304.2
TBTU





6
Q-348
EV-AP2311-001


embedded image


1.94
290.2
TBTU





7
Q-359
EV-AP2325-001


embedded image


2.65
370.2
COMU





8
Q-368
EV-AP2328-001


embedded image


2.50
370.2
COMU





9
Q-329
EV-AP2300-002


embedded image


2.12
314.1
COMU





10
Q-344
EV-AN7494-001


embedded image


1.45
326.1
COMU





11
Q-345
EV-AN7496-002


embedded image


1.44
340.1
COMU





12
Q-327
EV-AP2502-001


embedded image


2.34
499.2
TBTU





13
Q-350
EV-AP2503-001


embedded image


1.70
276.2
COMU





14
Q-351
EV-AP2504-001


embedded image


2.56
318.2
COMU





15
Q-352
EV-AP2508-001


embedded image


1.47
304.2
COMU





16
Q-302
EV-AO7503-002


embedded image


2.39
336.1
HATU





17
Q-303
EV-AO7504-002


embedded image


2.88
350.2
HATU





18
Q-304
EV-AO7506-002


embedded image


1.48
352.1
HATU





19
Q-305
EV-AO7508-002


embedded image


3.32
368.2
HATU





20
Q-318
EV-AO7513-002


embedded image


2.44
338.1
COMU





21
Q-362
EV-AO7565-002


embedded image


2.94
364.2
COMU





22
Q-363
EV-AO7566-002


embedded image


2.66
350.2
COMU





23
Q-364
EV-AO7567-002


embedded image


2.47
366.1
COMU





24
Q-367
EV-AO7570-002


embedded image


2.09
330.1
COMU





25
Q-385
EV-AO7572-002


embedded image


3.26
392.2
COMU





26
Q-373
EV-AO7573-002


embedded image


2.96
378.2
COMU





27
Q-374
EV-AO7574-002


embedded image


2.774
364.2
COMU





28
Q-286
EV-AN0091-004


embedded image


2.34
375.1
TBTU





29
Q-287
EV-AN0093-003


embedded image


1.77
358.2
TBTU





30
Q-300
EV-AN0094-002


embedded image


1.36
351.1
TBTU





31
Q-307
EV-AN0099-002


embedded image


2.68
380.2
COMU





32
Q-313
EV-AO8802-002


embedded image


2.75
364.2
COMU





33
Q-322
EV-AO8803-002


embedded image


0.87
357.2
COMU





34
Q-317
EV-AO5736-002


embedded image


1.45
262.1
COMU





35
Q-316
EV-AO5735-002


embedded image


1.31
248.1
COMU





36
Q-298
EV-AO5715-002


embedded image


3.03
418.2
HATU (Et3N)





37
Q-299
EV-AO5716-002


embedded image


1.11
380.2
HATU (Et3N)





38
Q-420
EV-AB8097-002


embedded image


3.07
364.3
COMU





39
Q-347
EV-AP2310-001


embedded image


2.25
304.2
TBTU









Examples 40-43—Chiral Separation

Examples 40-43 in Table 2 were prepared by chiral separation of racemic compounds in Table 1. The stereochemistry was arbitrarily assigned.
















TABLE 2









LC-MS
MS
Column



Ex.
Ref.


(RT)
(M + H)+
Retention*
Separation


No.
No.
LBN
Structure
Method C
Method C
(min)
Method







40
Q-339
EV-AO8802-004


embedded image


2.75
364.2
3.09 Method I
H





41
Q-340
EV-AO8802-005


embedded image


2.75
364.2
5.09 Method I
H





42
Q-372
EV-AO7553-002


embedded image


2.58
350.2
6.69 Method K
J





43
Q-361
EV-AO7553-003


embedded image


2.81
350.2
8.35 Method K
J









Example 44—Synthesis of 5-chloro-6-methyl-2-[5-methyl-4-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one



embedded image


To a solution of 6-methyl-2-[5-methyl-4-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one (Example 1, Q-279 (EV-AO7529-002), 100 mg, 0.286 mmol) in AcOH (2 mL) was added NCS (40 mg, 0.301 mmol) and stirred at 90° C. for 1 h. The reaction mixture was concentrated in vacuo and triturated using MeCN to afford the title compound (60 mg, 54%) as a white powder.


Method C: LC-MS m/z=384.2 [M+H]+; RT=2.99 min.


Example 45—Synthesis of 5-chloro-6-methyl-2-[5-methyl-4-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one



embedded image


Chlorination of 6-methyl-2-[5-methyl-4-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one (Example 7, Q-359 (EV-AP2325-001) using the procedure described in Example 44 afforded the title compound (54 mg, 42%) as a white powder.


Method C: LC-MS m/z=404.2 [M+H]+; RT=2.88 min.


Example 46—Synthesis of 6-methyl-2-[5-methyl-4-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one



embedded image


To a stirred solution of 6-methyl-2-[5-methyl-4-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one (Example 1, Q-279 (EV-AO7529-002), 165 mg, 0.472 mmol) in THF (3 mL) at 0° C. was added LiAlH4 (216 μl, 0.519 mmol) and stirred at r.t. for 1 h. The reaction mixture was quenched by the addition of water (4 mL), NaOH (4 mL) and then further water (4 mL). The reaction mixture was acidified to pH 5 using acetic acid and then neutralized to pH 7 using saturated sodium bicarbonate solution. The reaction mixture was extracted with DCM (3×40 mL) and the combined organic extracts dried over Na2SO4, concentrated in vacuo and triturated using MeCN (3 mL) to afford the title compound (57 mg, 35%) as a white powder.


Method C: LC-MS m/z=336.1 [M+H]+; RT=1.29 min.


Preparative Example 2—Preparation of Intermediate Thiouracils and Thio Ethers



embedded image


Intermediate 5: Preparation of 2-sulfanylidene-1H,2H,3H,4H-pyrazolo[1,5-a][1,3,5]triazin-4-one
Step 1: Synthesis of ethyl N-[(1H-pyrazol-5-yl)carbamothioyl]carbamate



embedded image


To a solution of 1H-pyrazol-5-amine (3 g, 36.1 mmol) in acetone (50 ml) was added over 5 mins (slight exotherm) ethyl N-carbothioylcarbamate (3.96 ml, 0.03 mol) and stirred at r.t. for 2 h. The yellow solution was treated with ice cold water (50 ml) which caused a transient precipitation. The flask was cooled in ice and a precipitate formed. The solid was collected by filtration, washed with water and dried under vacuum to afford the title compound (5.0 g, 46%) as a yellow solid.


Method A: LC-MS m/z=214.90 [M+H]+; RT=0.94.


Step 2: Synthesis of 2-sulfanylidene-1H,2H,3H,4H-pyrazolo[1,5-a][1,3,5]triazin-4-one



embedded image


To ethyl N-[(1H-pyrazol-5-yl)carbamothioyl]carbamate (2.5 g, 11.67 mmol) was added 2M aq NaOH solution (23.3 ml) and stirred at r.t. for 2 h. The solution was acidified with concentrated H2SO4 and the resultant precipitate filtered under vacuum to afford a pale yellow powder. Purification by recrystallisation using water afforded the title compound (1.54 g, 94%) as a pale yellow powder.


Method A: LC-MS m/z=168.95 [M+H]+; RT=0.19.


Intermediate 6: Preparation of 2-sulfanylidene-1,2,3,4,5,6,7,8-octahydroquinazolin-4-one



embedded image


To a solution of ethyl 2-oxocyclohexane-1-carboxylate (9.40 ml, 58.75 mmol) in MeCN (40 ml) was added thiourea (5.37 g, 70.5 mmol) and DBU (13.15 ml, 88.13 mmol) and stirred at 80° C. overnight.


The reaction mixture was concentrated in vacuo and the residue redissolved in water. The reaction mixture was acidified to pH 3/4 using 5M aq HCl solution, the precipitate filtered, washing with H2O and Et2O, and dried under vacuum to afford the title compound (10.70 g, 98%) as an off white powder.


Method A: LC-MS: m/z=183.0 (M+H)+; RT=0.71.


Intermediate 7: Synthesis of 6-methyl-4-sulfanylidene-1,2,3,4-tetrahydropyrimidin-2-one



embedded image


To a solution of 6-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione (2.0 g, 15.86 mmol) in dioxane (30 ml) was added 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane 2,4-disulfide (6.41 g, 15.86 mmol) and stirred at 100° C. for 2 h. The reaction mixture was cooled to r.t. and the white precipitate filtered under vacuum, washing with dioxane (20 ml), to afford the title compound (1.85 g, 82%) as an off white powder.


Method B: LC-MS: m/z=142.85 (M+H)+; RT=0.36.


Intermediate 8: Synthesis of 3,6-dimethyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one



embedded image


3,6-dimethyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one was prepared from (3E)-1,1,1-trichloro-4-methoxypent-3-en-2-one using the procedure found in: Zanatta, Nilo; Madruga, Claudia C.; Marisco, Patricia C.; Da Rosa, Luciana S.; Da Silva, Fabio M.; Bonacorso, Helio G.; Martins, Marcos A. P.; Journal of Heterocyclic Chemistry; vol. 47; nb. 5; (2010); p. 1234-1239, affording the title compound (4.68 g, 78%) as a brown powder.


Method A: LC-MS: m/z=170.95 (M+H)+; RT=0.97 min.


Examples 47-54

Examples 47-54 in Table 3 were prepared in an analogous fashion to Example 1 starting with the corresponding commercial thiouracil, methyl thioether or the specified intermediate, and coupling the intermediate acid with the appropriate amine using the specified coupling conditions.
















TABLE 3









LC-MS
MS




Ex.
Ref.


(RT)
(M + H)+
Coupling



No.
No.
LBN
Structure
Method C
Method C
Agent
Comments







47
Q-447
EV-AQ0294-002


embedded image


2.53
396.2
T3P
Intermediate 5





48
Q-454
EV-AR5305-002


embedded image


2.19
370.0
T3P
Intermediate 7





49
Q-455
EV-AO7537-002


embedded image


2.58
364.1
COMU
Intermediate 8





50
Q-427
EV-AQ0240-002


embedded image


2.35
395.1
COMU






51
Q-425
EV-AQ0230-002


embedded image


3.04
410.2
COMU
Intermediate 6





52
Q-404
EV-AP2566-003


embedded image


3.10
364.3
COMU






53
Q-383
EV-AP2542-001


embedded image


3.48
392.3
COMU






54
Q-488
EV-AR5353-002


embedded image


2.75
403.2
T3P









Examples 55-56—Chiral Separation

Examples 55-56 in Table 4 were prepared by chiral separation of racemic compounds in Table 3. The stereochemistry was arbitrarily assigned.
















TABLE 4









LC-MS
MS
Column



Ex.
Ref.


(RT)
(M + H)+
Retention*
Separation


No.
No.
LBN
Structure
Method C
Method C
(min)
Method






















55
Q-416
EV-AP2566-004


embedded image


3.11
364.3
5.134
L





56
Q-457
EV-AP2566-005


embedded image


3.10
364.2
7.20
L









Preparative Example 3—Formation of Intermediates from the Corresponding Dichloropyrimidines



embedded image


Intermediate 9: Preparation of 2-chloro-3H,4H-thieno[3,2-d]pyrimidin-4-one



embedded image


To a stirred solution of 2,4-dichlorothieno[3,2-d]pyrimidine (20 g, 97.5 mmol) in THF (80 mL) was added 5M aq NaOH solution (98 mL, 488 mmol) and stirred at 50° C. for 6 h. The reaction mixture was acidified to pH 5 using acetic acid. The solution was then extracted with EtOAc (2×50 mL) and the combined organics were dried over Na2SO4, filtered and concentrated in vacuo to yield the title compound (11.3 g, 60.5 mmol, 62%) as a yellow powder.


Method A: LC-MS m/z=186.9 [M+H]+; RT=0.77 min.


Intermediate 10: Preparation of 2-hydrazinyl-3H,4H-thieno[3,2-d]pyrimidin-4-one



embedded image


To a stirred solution of 2-chloro-3H,4H-thieno[3,2-d]pyrimidin-4-one (11.34 g, 60.8 mmol) in EtOH (90 mL) was added hydrazine hydrate (5.91 mL, 121.5 mmol) and stirred at 80° C. overnight. The reaction mixture was cooled to r.t. and the resultant precipitate was collected via filtration, and washed with water (15 mL) to yield the title compound (7.4 g, 40.6 mmol, 67%) as a pale yellow powder.


Method A: LC-MS m/z=182.9 [M+H]+; RT=0.18 min.


Intermediate 11: 5-methyl-1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid
Step 1: Synthesis of methyl-5-methyl-1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylate



embedded image


To a stirred solution of 2-hydrazinyl-3H,4H-thieno[3,2-d]pyrimidin-4-one (7 g, 38.4 mmol) in EtOH (75 mL) and AcOH (7.70 mL, 134.5 mmol) was added (2Z)-2-[(dimethylamino)methylidene]-3-oxobutanoate (7.89 g, 46.1 mmol) and stirred at 50° C. for 3 h. The reaction mixture was cooled to r.t. and the resulting precipitate was isolated via filtration to yield the title compound (11.2 g, 22.5 mmol, 59%) as a pale yellow powder.


Method A: LC-MS m/z=291.0 [M+H]+; RT=1.15 min.


Step 2: Synthesis of 5-Methyl-1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid



embedded image


To a solution of methyl-5-methyl-1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylate (6.53 g, 22.5 mmol) in 2:1 THF/methanol (37 mL) was added 2.5M aq NaOH solution (54 mL, 135 mmol) and stirred at r.t. for 2 h. The organics were removed in vacuo, the residue acidified to pH 5 with 2M aq HCl solution and the resulting precipitate was collected via filtration to yield the title compound (6.22 g, 19.9 mmol, 89%) as a beige powder.


Method A: LC-MS m/z=277.0 [M+H]+; RT=0.97 min.


Intermediate 12: Preparation of 2-methyl-4-(trifluoromethyl)piperidine (4:1 Mixture of Diastereoisomers)



embedded image


A solution of 2-methyl-4-(trifluoromethyl)pyridine (800 mg, 4.97 mmol) in 25% acetic acid in MeOH (100 ml) [0.05M] was reacted on the H-Cube [10% Pt on C cartridge, 90 bar and 80° C., 1 ml/min. Upon completion, the reaction mixture was treated with a solution of 4M HCl in dioxane (2 ml, 8 mmol) and then concentrated in vacuo to yield a white solid. The solid was dissolved in MeOH, treated with ammonia (7M in MeOH) and concentrated in vacuo to afford the title compound (270 mg, 32%) as a white solid.


Method A: LC-MS m/z=168.00 [M+H]+; RT=0.17 min.


Intermediate 13: Preparation of 4-(1-cyano-1-methylethyl)piperidin-1-ium chloride
Step 1: Synthesis of tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate



embedded image


To a stirred solution of tert-butyl 4-(cyanomethyl)piperidine-1-carboxylate (0.2 g, 8.13 mmol) in dry THF (2 mL) at 0° C. was added slowly KHMDS (1 M in toluene, 2.68 mL, 2.68 mmol). The reaction mixture was allowed to stir for 10 minutes, after which a solution of iodomethane (0.11 mL, 1.78 mmol) in dry THF (2 mL) was added slowly. The reaction was warmed to room temperature and stirred overnight. The reaction mixture was quenched with aqueous ammonium chloride and extracted with ethyl acetate. The extracts were dried (Na2SO4) and concentrated in vacuo to afford the title compound (246 mg, 98%) as a yellow powder: 1H NMR (250 MHz, Chloroform-d) δ 4.20 (s, 2H), 2.63 (m, 2H), 1.80 (m, 2H), 1.47 (s, 3H), 1.46 (s, 9H), 1.33 (s, 6H).


Step 2: Synthesis of 4-(1-cyano-1-methylethyl)piperidin-1-ium chloride



embedded image


Tert-butyl 4-(1-cyano-1-methylethyl)piperidine-1-carboxylate (EV-AQ8828-001, 243 mg, 0.963 mmol) was suspended in HCl (4 M in dioxane, 7 mL) and the reaction was stirred at room temperature for 3 hours. The resultant precipitate was filtered and washed with ether to afford the title compound (95 mg, 51%) as a yellow powder: 1H NMR (500 MHz, DMSO-d6) δ 8.96 (s, 1H), 8.51 (s, 1H), 2.87-2.78 (m, 2H), 1.95-1.87 (m, 2H), 1.72-1.63 (m, 1H), 1.54-1.45 (m, 2H), 1.29 (s, 6H).


Examples 57-74—Synthesis of Thienopyrimidines

Examples 57-74 in Table 5 were prepared using the method described in Example 1 reacting intermediate 11 (5-methyl-1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid) with the appropriate amine using the specified coupling reagent.















TABLE 5









LC-MS
MS



Example
Ref.


(RT)
(M + H)+
Coupling


No
No.
LBN
Structure
Method C
Method C
Agent





















57
Q-403
EV-AP2371-001


embedded image


2.68
398.2
COMU





58
Q-402
EV-AP2366-001


embedded image


3.43
398.3
T3P





59
Q-495
EV-AQ8852-001


embedded image


3.31
420.1
T3P





60
Q-395
EV-AP2364-001


embedded image


3.16
392.2
T3P





61
Q-380
EV-AP2536-001


embedded image


2.79
358.2
COMU





62
Q-397
EV-AP2562-001


embedded image


2.85
358.2
COMU





63
Q-405
EV-AP2570-001


embedded image


2.74
402.3
COMU





64
Q-398
EV-AP2563-001


embedded image


3.51
398.2
COMU





65
Q-354
EV-AP2517-001


embedded image


3.00
392.2
COMU





66
Q-399
EV-AQ0205-002


embedded image


3.64
400.2
T3P





67
Q-400
EV-AQ0207-002


embedded image


3.08
372.2
COMU





68
Q-406
EV-AQ0208-002


embedded image


3.21
480.2
T3P





60
Q-408
EV-AQ0210-002


embedded image


3.54
398.3
COMU





70
Q-412
EV-AQ0216-002


embedded image


3.28
372.2
COMU





71
Q-401
EV-AB8083-002


embedded image


3.28
392.2
T3P





72
Q-422
EV-AQ3802-003


embedded image


3.10,  28% 3.14  63%
425.0
COMU Intermediate 12





73
Q-379
EV-AP2394-001


embedded image


2.90
412.1
T3P





74
Q-531
EV-AS3708-002


embedded image


2.58
411.1
T3P Intermediate 13









Example 75—Preparation of 2-{4-[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]-5-methyl-1H-pyrazol-1-yl}-3H,4H-thieno[3,2-d]pyrimidin-4-one



embedded image


To a solution of 5-methyl-1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid (Intermediate 11, (EV-AP2386-001), 75 mg, 0.27 mmol) in DCM (5 ml) was added thionyl chloride (0.2 ml, 2.71 mmol) followed by DMF (cat, 1 drop) and stirred at 50° C. for 2 h. The reaction mixture was concentrated in vacuo and DCM added and the concentration repeated (×2). The crude acid chloride (assume 0.271 mmol) was suspended in more DCM (5 ml) at 0° C. and (cis)-2,6-dimethylpiperidine (0.04 ml, 0.41 mmol) and triethylamine (0.09 ml, 0.68 mmol) were added dropwise. The reaction mixture was stirred at r.t. for 2 h. The reaction mixture was washed with water (5 mL) and brine solution (5 mL) and the organic fraction was concentrated in vacuo. The crude residue was dissolved in THF: 1M NaOH (1:1, 2 mL) and stirred at r.t. Methanol (0.5 ml) was added. The organics from the reaction mixture were removed in vacuo and the reaction mixture acidified to pH 5 using 1M aq HCl solution. The aqueous was extracted using DCM (2×5 mL) and the combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by prep HPLC (Method G) to afford the title compound (14.2 mg, 14%) as an off-white powder.


Method A: LC-MS m/z=372.2 [M+H]+; RT=3.05 min.


Examples 76-77

Examples in Table 6 were prepared by chiral separation of racemic compounds in Table 5. The stereochemistry was arbitrarily assigned.
















TABLE 6









LC-MS
MS
Column



Example
Ref.


(RT)
(M + H)+
Retention*
Separation


No
No.
LBN
Structure
Method C
Method C
(min)
Method







76
Q-414
EV-AQ0229-001


embedded image


3.29
392.2
6.43 Method M
L





77
Q-415
EV-AQ0229-002


embedded image


3.29
392.2
8.41 Method M
L









Preparative Example 4—Formation of Intermediates from the Corresponding Dichloropyrimidines
Intermediate 14: Preparation of 2-chloro-4-methoxy-6-methylpyrimidine



embedded image




embedded image


To a solution of 2,4-dichloro-6-methylpyrimidine (1 g, 6.14 mmol) in THF (10 ml) was added 0.5M NaOMe in MeOH (18.4 ml, 9.20 mmol) at 0° C. and stirred at r.t. overnight. A further 0.5 equivalents of 0.5 M NaOMe in MeOH (6.14 ml, 3.07 mmol) were added at 0° C. and the reaction stirred at r.t. for 1 h. The reaction mixture was diluted with water (30 ml) and extracted with EtOAc (2×50 ml). The combined organic extracts were washed with brine (20 ml), dried and concentrated in vacuo and the residue purified via column chromatography (100:0-75:25 Heptane-EtOAc) to afford the title compound (275 mg, 28%) as a colourless crystalline solid.


Method A: LC-MS m/z=158.9 [M+H]+; RT=1.05 min.


Intermediate 15: Preparation of 5-chloro-6H,7H-[1,3]thiazolo[5,4-d]pyrimidin-7-one (EV-AQ0263-001)



embedded image


Step 1: Synthesis of 7-(benzyloxy)-5-chloro-[1,3]thiazolo[5,4-d]pyrimidine



embedded image


To a solution of 5,7-dichloro-[1,3]thiazolo[5,4-d]pyrimidine (980 mg, 4.76 mmol) in THF (20 mL) at 0° C. was added benzyl alcohol (495 μl, 4.76 mmol) and sodium hydride (114 mg, 4.76 mmol, 60% in mineral oil) and stirred at r.t. for 22 h. To the reaction mixture was added water (20 ml) and extracted with EtOAc (2×50 ml). The combined organic extracts were washed with brine, dried over sodium sulfate and concentrated in vacuo. Purification by chromatography on SiO2 (gradient 100:0-90:10, Heptane-EtOAc) afforded the title compound (708 mg, 47%) as a white powder.


Method A: LC-MS m/z=277.85 [M+H]+; RT=1.39 min.


Step 2: Synthesis of 5-chloro-6H,7H-[1,3]thiazolo[5,4-d]pyrimidin-7-one



embedded image


7-(benzyloxy)-5-chloro-[1,3]thiazolo[5,4-d]pyrimidine (EV-AQ0259-002, 708 mg, 2.24 mmol) was dissolved in a 1:1 mixture of 37% aq HCl-THF (10 mL) and stirred at room temperature for 18 h. The reaction mixture was filtered under vacuum, washing with THF and Et2O, to afford 5-chloro-6H,7H-[1,3]thiazolo[5,4-d]pyrimidin-7-one (246 mg, 58%) as a pale yellow powder.


Method A: LC-MS m/z=187.80 [M+H]+; RT=0.49 min.


Intermediate 16: Synthesis of 2,4-dichloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine



embedded image


To a solution of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (1.5 g, 7.98 mmol) in THF (30 ml) at 0° C. was added sodium hydride (60% oil suspension, 383 mg, 9.57 mmol) and stirred at 0° C. to r.t. for 20 mins. Iodomethane (0.6 ml, 9.57 mmol) was added and stirred at r.t. for 3 h.


The mixture was quenched by addition of saturated ammonium chloride solution (20 mL). EtOAc was then added resulting in formation of a precipitate. The precipitate was filtered and the filtrate extracted with EtOAc (×2). The combined organic fractions were washed with water, dried over Na2SO4, filtered and concentrated in vacuo to afford the title compound (1.65 g, 97.2%) as a yellow powder.


Method A: LC-MS m/z=201.90, 203.90 [M+H]+; RT=1.21 min.


Examples 78-88

Examples 78-88 in Table 7 were synthesized following the procedure described for Example 57 starting from the corresponding dichloropyrimidine or specified intermediate and coupling the intermediate acid with the appropriate amine using the specified coupling conditions.
















TABLE 7





Ex-



LC-MS
MS




ample
Ref.


(RT)
(M + H)+
Coupling



No
No.
LBN
Structure
Method C
Method C
Agent
Comments







78
Q-410
EV-AP2378-001


embedded image


3.02
412.2
COMU






79
Q-426
EV-AP2597-002


embedded image


2.72
409.2
T3P






80
Q-323
EV-AN7481-001


embedded image


3.26
386.2
COMU






81
Q-320
EV-AO8806-002


embedded image


340.1
2.17
COMU






82
Q-321
EV-AO8807-002


embedded image


338.2
2.96
COMU






83
Q-429
EV-AQ0246-002


embedded image


406.2
3.16
T3P






84
Q-378
EV-AP2343-001


embedded image


375.2
2.62
TBTU






85
Q-436
EV-AQ7107-002


embedded image


2.23
370.2
T3P
Commerical chloro- pyrimidone





86
Q-413
EV-AQ0227-002


embedded image


426.2
3.29
COMU






87
Q-441
EV-AQ0268-002


embedded image


2.53
413.2
T3P
Intermediate 15









Preparative Example 5



embedded image


Intermediate 17: Preparation of 2-hydrazinyl-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-AQ7134-001)



embedded image


Step 1: Synthesis of 2-sulfanylidene-1H,2H,3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a solution of methyl 2-oxocyclopentanecarboxylate (17.83 mL, 143.65 mmol) in acetonitrile (150 mL) was added thiourea (16.4 g, 215.47 mmol) followed by DBU (25.73 mL, 172.38 mmol) and stirred at 80° C. for 24 h. The reaction mixture was concentrated in vacuo and dissolved in water. The solution was acidified to pH3/4 using 5M aq HCl solution and the resulting precipitate was collected and dried under vacuum after washing with water and diethyl ether. The solid was dried further at 40° C. under vacuum overnight to afford the title compound (17.81 g, 73.7%) as a beige powder.


Method A: LC-MS: m/z=168.9 (M+H)+, RT=0.2-0.45 min.


Step 2: Synthesis of 2-(methylsulfanyl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a suspension of 2-sulfanylidene-1H,2H,3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-AS7131-001, 17.81 g, 105.88 mmol) in water (100 mL) was added NaOH (4.66 g, 116.46 mmol) followed by the drop wise addition of iodomethane (7.25 mL, 116.46 mmol). The reaction mixture was stirred at room temperature for 1.5 h, then cooled to 5° C. and the resultant precipitate was collected by vacuum filtration. The solid was washed with ice cold water (50 mL) water and diethyl ether (50 mL) and dried further under vacuum at 40° C. to afford the title compound (17.78 g, 89.4%) as an off white powder.


Method A: LC-MS: m/z=182.9 (M+H)+; RT=0.89 min.


Step 3: Synthesis of 2-hydrazinyl-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a solution of 2-(methylsulfanyl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-AQ7133-001, 17.78 g, 97.56 mmol) in EtOH (30 mL) was added hydrazine hydrate (23.73 mL, 487.81 mmol). The reaction mixture was stirred at 90° C. for 24 h and then at 85° C. for a further 7 h. The cooled reaction mixture was filtered and washed with EtOH (15 mL) and water (10 mL) to afford the title compound (13.1 g, 80.8%) as a white powder.


Method B: LC-MS: m/z=166.9 (M+H)+, RT=0.19 min.


Intermediate 18: Preparation of 5-methyl-1-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid (Q-481, EV-AQ7139-001)



embedded image


Step 1: Synthesis of 2-{5-methyl-4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a solution of 2-hydrazinyl-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-AQ7134-001, 19 g, 114.33 mmol) in ethanol (120 mL) was added methyl 2-[(dimethylamino)methylidene]-3-oxobutanoate (EV-AL6988-001, 21.53 g, 125.77 mmol) followed by acetic acid (22.91 mL, 400.17 mmol). The reaction mixture was stirred at 50° C. for 3.5 h. After 15 mins additional ethanol (170 mL) was added to maintain stirring. The reaction mixture was cooled and the solvent volume reduced to approximately half. The resultant precipitate was collected and dried by vacuum filtration to afford the title compound (21.84 g, 69.6%) as a beige powder.


Method B: LC-MS: m/z=275.0 (M+H)+, RT=0.98 min.


Step 2: Synthesis of 5-methyl-1-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid (Q-481, EV-AQ7139-001)



embedded image


Methyl 5-methyl-1-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylate (EV-AQ7137-001, 21.84 g, 79.63 mmol) was suspended in 3:2:1 water/THF/methanol (300 mL) and 2.5M aq NaOH solution (191 mL) was added. The reaction mixture was stirred at r.t. for 3 h. The organics from the reaction mixture were removed in vacuo. The residue was acidified with 5M aq HCl solution and the resulting precipitate was collected and dried under vacuum filtration at 45° C. for 5 days to afford the title compound (21.6 g, 100%) as a beige powder.


Method C: LC-MS: m/z=261.1 (M+H)+, RT=1.81 min.


Intermediate 19: Preparation of +(syn)-2-methyl-4-(trifluoromethyl)piperidine hydrochloride



embedded image


A solution of 2-methyl-4-(trifluoromethyl)pyridine (3 g, 18.62 mmol) in MeOH (100 ml) was treated with a solution of 4M HCl in dioxane (5.6 ml, 22.3 mmol) followed by platinum (iv) oxide (253 mg, 1.12 mmol) and the resultant suspension was hydrogenated in a pressure vessel at 50 psi and r.t. for 4 h. The catalyst was cautiously removed by filtration over Celite and the filtrate concentrated in vacuo to afford the title compound (3.7 g, 99%) as a white solid.


Method A: LC-MS m/z=168.0 [M+H]+; RT=0.21 min.


Intermediate 20: Synthesis of 2-methyl-4-phenylpiperidin-4-ol hydrochloride EV-AQ7159-002 used in (EV-AQ7163-003)
Step 1: Synthesis of tert-butyl 4-hydroxy-2-methyl-4-phenylpiperidine-1-carboxylate formation using phenyllithium



embedded image


To a solution of phenyllithium (1.8M in Bu2O, 7.16 ml, 12.89 mmol) in THF (15 mL) at −78° C. was added dropwise 1-boc-2-methyl-4-piperidinone (2.5 g, 11.72 mmol) in more THF (5 mL). The reaction mixture was warmed to room temperature and stirred for 3 hours. The reaction was quenched by pouring onto ice water. EtOAc (2×25 mL) was added and the product extracted. The combined organics were dried (Na2SO4), filtered and concentrated in vacuo. The crude residue was purified by chromatography on SiO2 Eluting with 0-100% EtOAc in heptane to afford the title compound (2.97 g, 73.9%) as a yellow oil


Method B: LC-MS: m/z=192.0 (M-Boc)+, RT=1.19 min.


Step 2: Synthesis of 2-methyl-4-phenylpiperidin-4-ol hydrochloride



embedded image


To a solution of tert-butyl 4-hydroxy-2-methyl-4-phenylpiperidine-1-carboxylate (EV-AQ7159-002, 1.5 g, 5.15 mmol) in dioxane (3 mL) was added HCl in dioxane (4M, 6.43 mL, 25.74) and the reaction mixture stirred at room temperature for 1 hour. The reaction mixture was concentrated in vacuo re-dissolved in DCM and concentrated again to afford 1.22 g (83.3%) of the title compound as an orange gum.


Method B: LC-MS: m/z=192.0 (M+H)+, RT=0.21 min.


Intermediate 21: Synthesis of 2-(4-{3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]octane-8-carbonyl}-5-methyl-1H-pyrazol-1-yl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


2-(4-{3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]octane-8-carbonyl}-5-methyl-1H-pyrazol-1-yl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one was prepared by the procedure described for Intermediate 21 (EV-AQ7161-001) substituting 1-boc-2-methyl-4-piperidinone with tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate, affording the title compound (505 mg, 35%) as a an off white powder.


Method B: LC-MS: m/z=203.9 (M+H)+, RT=0.27 mins.


Intermediate 22: Synthesis of 3-phenyl-8-azabicyclo[3.2.1]octane hydrochloride EV-AQ7185-002
Step 1: Synthesis of tert-butyl 3-phenyl-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate



embedded image


To a solution of phenyllithium (2.0M in Bu2O, 3.66 ml, 7.32 mmol) in THF (15 mL) at −78° C. was added dropwise tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (1.5 g, 6.66 mmol) in THF (5 mL). The reaction was warmed to r.t. over 1 h and stirred for another 1 h. 1/3 of the reaction mixture was removed for an analogous chemistry and the remaining 2/3 of the reaction mixture was cooled to −78° C. and treated with methanesulfonyl chloride (1.03 mL, 13.32 mmol) followed by triethylamine (3.06 mL, 21.97 mmol). The reaction mixture was then warmed to r.t. and stirred overnight. The reaction mixture was cooled to −78° C. again and more methanesulfonyl chloride (2.06 mL, 26.64 mmol) and triethylamine (6.12 mL, 43.94 mmol) were added. The reaction mixture was then warmed to r.t. and stirred for 3.5 h. The reaction was diluted with water and extracted with EtOAc (3×20 mL). The combined organics were washed with water (10 mL) and brine (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude residue was purified by chromatography on SiO2 eluenting with Heptane/EtOAc (0-100%) to afford the title compound (480 mg, 36.8%) as an off-white solid.


Method B: LC-MS: m/z=229.95 (M−tBu)+, RT=1.37 min.


Step 2: Synthesis of 3-phenyl-8-azabicyclo[3.2.1]oct-2-ene hydrochloride



embedded image


To a solution of tert-butyl 3-phenyl-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (EV-AQ7180-002, 97%, 480 mg, 1.63 mmol) in dioxane (3 mL) was added HCl in dioxane (4M, 2.04 mL, 8.16 mmol) and the mixture was stirred at r.t. for 4 h. The reaction mixture was concentrated in vacuo re-dissolved in DCM and concentrated again to afford the title compound (355 mg, 93.2%) as an off white powder.


Method B: LC-MS: m/z=186.0 (M+H)+, RT=0.79 min.


Step 3: Synthesis of 3-phenyl-8-azabicyclo[3.2.1]octane hydrochloride



embedded image


3-phenyl-8-azabicyclo[3.2.1]oct-2-ene hydrochloride (EV-AQ7183-001, 355 mg, 1.92 mmol) was dissolved in MeOH: EtOAc (1:1, 45 mL) and subjected to H-cube hydrogenation (1 mL/min, 20 bar, 60° C., controlled H2 mode) over an Pd/C (10%) cat cart. The procedure was repeated at 40 bar, 60° C. and again at 60 bar, 60° C. The reaction mixture was concentrated in vacuo to afford the title compound (305 mg, 76%) as an off white powder.


Method B: LC-MS: m/z=188.0 (M+H)+, RT=0.74 mins.


Intermediate 23: Synthesis of 4-methoxy-4-phenylpiperidin-1-ium chloride EV-AQ8865-001
Step 1: Synthesis of tert-butyl-4-hydroxy-4-phenylpiperidine-1-carboxylate



embedded image


A solution 1-Boc-4-piperidinone (1 g, 5.02 mmol) in THF (5 mL) was added dropwise to a solution of phenyllithium (1.8M in Bu2O, 3.07 mL, 5.52 mmol) in THF (5 mL) at −78° C. The reaction was warmed to r.t. and stirred for 4 h. The reaction was quenched by pouring onto ice water and extracted with EtOAc (2×25 mL). The combined organic extracts were dried over MgSO4 and concentrated in vacuo. The crude residue was purified by chromatography on SiO2, eluenting with Heptane/EtOAc (gradient 100:0-20:80) to afford the title compound (1.095 g, 79%) as a yellow powder.


Method B: LC-MS: m/z=177.9 (M-Boc)+, RT=1.15 min.


Step 2: Synthesis of tert-butyl 4-methoxy-4-phenylpiperidine-1-carboxylate



embedded image


To a stirred solution of 4-hydroxy-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester (1.08 g, 3.91 mmol) in dry THF (25 mL) was added NaH (60% in oil, 0.17 g, 4.30 mmol) and stirred for 1 h before methyl iodide (0.37 mL, 5.86 mmol) was added and stirred overnight. The mixture was retreated with NaH (60%, 0.17 g, 4.30 mmol), followed by methyl iodide (0.37 mL, 5.86 mmol) and stirred overnight. The mixture was retreated for a third time with NaH (60%, 0.17 g, 4.30 mmol), followed by methyl iodide (0.37 mL, 5.86 mmol) and stirred for 4 h. Brine (40 mL) was added and the product extracted with EtOAc (2×50 mL). The combined organic extracts were dried over MgSO4, concentrated in vacuo and purified by chromatography, eluting with Heptane/EtOAc (gradient 100:0-85:15) to afford the title compound (610 mg, 54%) as an off-white powder.


Method B: LC-MS: m/z=192.02 (M-Boc)+, RT=1.30 mins.


Step 3: Synthesis of 4-methoxy-4-phenylpiperidin-1-ium chloride



embedded image


4-methoxy-4-phenylpiperidine-1-carboxylate (603 mg, 2.07 mmol) was dissolved in HCl in dioxane (4M, 6 mL, 24.0 mmol) and stirred at r.t. overnight. The reaction mixture was concentrated in vacuo and triturated with ether to afford the title compound (391 mg, 83%) as a colourless powder.


Method B: LC-MS: m/z=191.9 (M+H)+, RT=0.64 mins.


Intermediate 24: Synthesis of 4-(2,2,2-trifluoroethoxy) piperidine
Step 1: Synthesis of 4-(2,2,2-trifluoroethoxy)pyridine



embedded image


To a solution of 2,2,2-trifluoroethanol (0.96 mL, 13.33 mmol) and NaH (60% in oil, 533.26 mg, 13.33 mmol) was added 4-chloropyridine hydrochloride (1 g, 6.67 mmol) in anhydrous DMSO (20 mL). The reaction mixture was stirred at 0° C. to r.t. overnight. Water (10 mL) was added and the product extracted with DCM (2×50 mL). The combined organic extracts were washed with water (10 mL) and brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford the title compound (510 mg, 38.9%) as a tan gum.


Method B: LC-MS: m/z=178.0 (M+H)+, RT=0.31 min.


Step 2: Synthesis of 4-(2,2,2-trifluoroethoxy) piperidine



embedded image


4-(2,2,2-trifluoroethoxy)pyridine (EV-AQ7197-001, 510 mg, 2.88 mmol) was dissolved in EtOH: acetic acid (3:1, 60 mL) and subjected to H-cube hydrogenation (1 ml/min, 90 bar, 80° C.) over a 5% Rh/C cat cart. The reaction mixture was concentrated in vacuo to afford the title compound (104 mg, 11.9%) as a tan gum.


Method B: LC-MS: m/z=184.0 (M+H)+, RT=0.21-0.33 min.


Intermediate 25: Synthesis of +(syn)-4-methyl-2-(trifluoromethyl)piperidine hydrochloride



embedded image


A solution of 4-methyl-2-(trifluoromethyl)pyridine (1 g, 6.21 mmol) in MeOH (20 ml) was treated with HCl (4M in dioxane, 1.9 mL), followed by platinum (iv) oxide (85 mg, 0.37 mmol) and the resultant suspension was hydrogenated in a pressure vessel at 50 psi and r.t. for 20 h. More platinum (iv) oxide (85 mg, 0.37 mmol) was added along with AcOH (10 ml) and the hydrogenation was continued for 20 h.


The catalyst was removed by filtration over Celite and the filtrate evaporated under vacuum, the residue was triturated with ether to provide the title compound (460 mg, 36%) as a white solid.


Method B: LC-MS m/z=167.95 [M+H]+; RT=0.18 min.


Examples 89-141

Examples in Table 8 were prepared using Method 1 reacting Intermediate 18 (5-methyl-1-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid) with the appropriate amine using the specified coupling reagent.
















TABLE 8









LC-MS
MS




Example
Ref.


(RT)
(M + H)
Coupling



No
No.
LBN
Structure
Method C
Method C
Agent
Comments







89
Q-431
EV- AQ7102-002


embedded image


2.55
382.2
T3P






90
Q-435
EV- AQ7103-002


embedded image


3.17
438.2
T3P, SOCl2






91
Q-446
EV- AQ7126-004


embedded image


2.47
420.2
T3P






92
Q-449
EV- AQ7132-002


embedded image


2.48
440.2
T3P






93
Q-461
EV- AQ7145-002


embedded image


2.1
358.3
T3P






94
Q-462
EV- AQ7146-002


embedded image


3.13
420.2
T3P






95
Q-505
EV- AQ7172-001


embedded image


1.67
405.2
T3P






96
Q-496
EV- AQ7172-002


embedded image


3.03
448.1
T3P






97
Q-418
EV- AQ8866-003


embedded image


2.72
396.2
T3P






98
Q-497
EV- AQ7172-003


embedded image


2.63
417.2
T3P






99
Q-498
EV- AQ7172-004


embedded image


3.06
443.2
T3P






100
Q-499
EV- AQ7173-001


embedded image


3.04
461.1
T3P






101
Q-500
EV- AQ7173-002


embedded image


3.45
450.2
T3P






102
Q-501
EV- AQ7173-003


embedded image


3.18
434.2
T3P






103
Q-502
EV- AQ7176-001


embedded image


3.14
476.1
T3P






104
Q-464
EV- AQ8829-001


embedded image


2.02
353.1
T3P






105
Q-470
EV- AQ8832-001


embedded image


1.9
330.1
T3P






106
Q-477
EV- AQ8837-001


embedded image


2.86
406.2
T3P






107
Q-478
EV- AQ8838-001


embedded image


1.92
344.2
T3P






108
Q-504
EV- AQ8853-001


embedded image


2.5
468.1
T3P






109
Q-424
EV- AQ0237-002


embedded image


2.47
364.2
COMU






110
Q-428
EV- AQ0241-002


embedded image


3.22
404.2
T3P






111
Q-473
EV- AR5330-002


embedded image


2.98
429.2
T3P






112
Q-479
EV- AR5333-002


embedded image


2.83
376.2
T3P






113
Q-490
EV- AR5335-002


embedded image


3.00
378.2
T3P






114
Q-491
EV- AR5343-002


embedded image


3.46
418.2
T3P






115
Q-492
EV- AR5344-002


embedded image


2.94
356.2
T3P






116
Q-489
EV- AR5345-002


embedded image


3.01
475.2
T3P






117
Q-487
EV- AR5346-002


embedded image


2.87
395.2
T3P






118
Q-493
EV- AR5347-002


embedded image


3.73
454.2
T3P






119
Q-485
EV- AR5351-002


embedded image


3.36
419.2
T3P






120
Q-486
EV- AR5352-002


embedded image


2.9
466.1
T3P






121
Q-506
EV- AR5357-002


embedded image


1.68
415.1
T3P






122
Q-507
EV- AR5363-002


embedded image


2.97
477.2
T3P






123
Q-468
EV- AQ3828-001


embedded image


3.07
420.2
T3P






124
Q-476
EV- AQ3831-001


embedded image


2.93
410.2
T3P






125
Q-450
EV- AN9592-005


embedded image


2.85
396.2
T3P






126
Q-423
EV- AQ3801-003


embedded image


2.99 min, 18%, 3.02 min, 74%.
409.0
COMU






127
Q-434
EV- AQ3808-002


embedded image


3.02
409.0
T3P






128
Q-482
EV- AQ3835-002


embedded image


2.16
358.2
T3P






129
Q-518
EV- AQ7198-001


embedded image


367.2
2.23
T3P






130
Q-519
EV- AQ7198-002


embedded image


381.2
2.48
T3P






131
Q-520
EV- AQ7199-001


embedded image


372.2
2.29
T3P






132
Q-451
EV- AN9594-002


embedded image


368.2
3.10
T3P






133
Q-532
EV- AS5411-002


embedded image


421.1
3.05
T3P






134
Q-510
EV- AR7006-003


embedded image


390.3
2.91
T3P






135
Q-469
EV- AQ8831-001


embedded image


395.2
2.52
T3P
Intermediate 13





136
Q-514
EV- AQ8865-001


embedded image


434.2
3.07
T3P






137
Q-521
EV- AS3701-002


embedded image


426.1
2.73
T3P
Intermediate 24





138
Q-509
EV- AQ7187-002


embedded image


446.2
2.56
T3P
Intermediate 21





139
Q-513
EV- AQ7190-002


embedded image


430.3
3.31
T3P
Intermediate 22





140
Q-483
EV- AQ7163-003


embedded image


434.2
2.63
SOCl2
Intermediate 20





141
Q-480
EV- AR5334-002


embedded image


410.1
3.36
SOCl2
Intermediate 25









Examples 142-145

Examples in Table 9 were prepared by chiral separation of racemic compounds in Table 8. The stereochemistry was arbitrarily assigned.
















TABLE 9









LC-MS
MS
Column



Example
Ref.


(RT)
(M + H)+
Retention*
Separation


No
No.
LBN
Structure
Method C
Method C
(min)
method







142
Q-442
EV-AQ3808-004


embedded image


3.01 94%
409.0
16.3 Method N
N





143
Q-459
EV-AQ3808-005


embedded image


3.01 95%
409.0
21.3 Method N
N





144
Q-474
EV-AN9592-006


embedded image


2.84
396.2
7.47 Method O
O





145
Q-475
EV-AN9592-007


embedded image


2.84
396.2
12.48 Method O
O









Preparative Example 6—Direct Cyclisation of Hydrazines



embedded image


Intermediate 26: Preparation of methyl-2-[(dimethylamino)methylidene]-3-oxobutanoate



embedded image


Methyl 3-oxobutanoate (40 g, 0.34 mol) and 1,1-dimethoxy-N,N-dimethylmethanamine (54.92 mL, 0.41 mol) were combined and stirred at 80° C. for 2 h. The reaction mixture was concentrated in vacuo and the resulting oil was dried for 24 h under vacuum to afford the title compound (56.53 g, 86.3%) as a dark red solid.



1H NMR (500 MHz, DMSO-d6) δ 7.62 (s, 1H), 3.63 (s, 3H), 3.24-2.96 (m, 3H), 2.90-2.58 (m, 3H), 2.13 (s, 3H).


Intermediate 27: Preparation of 2-[(dimethylamino)methylidene]-1-(1,2,3,4-tetrahydroisoquinolin-2-yl)butane-1,3-dione (EV-AP2538-001)



embedded image


Step 1: Synthesis of 1-(1,2,3,4-tetrahydroisoquinolin-2-yl)butane-1,3-dione



embedded image


To a solution of 1,2,3,4-tetrahydroisoquinoline (10.0 mL, 78.83 mmol) in toluene (80 mL) was added methyl 3-oxobutanoate (12.76 mL, 118.25 mmol) and triethylamine (13.19 mL, 94.6 mmol) and stirred at 105° C. for 15.5 hours. Water (15 mL) was added to the cooled reaction mixture and the organic phase was extracted. The organics were dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by chromatography on SiO2, eluting with 0-100% EtOAc in heptane to afford the title compound (12.8 g, 70.2%) as viscous yellow oil.


Method A: LC-MS: m/z=218.0 (M+H)+; RT=1.03 min.


Step 2: Synthesis of 2-[(dimethylamino)methylidene]-1-(1,2,3,4-tetrahydroisoquinolin-2-yl)butane-1,3-dione



embedded image


1-(1,2,3,4-tetrahydroisoquinolin-2-yl)butane-1,3-dione (EV-AP2535-001, 2 g, 9.21 mmol) and 1,1-dimethoxy-N,N-dimethylmethanamine (1.47 mL, 11.1 mmol) were combined and stirred at 80° C. for 15 h. The reaction mixture was concentrated in vacuo to afford the title compound (2.51 g, 96.1%) as a beige powder.


Method A: LC-MS: m/z=273.0 (M+H)+; RT=0.99 min.


Intermediate 28: Preparation of (2E)-2-[(dimethylamino)methylidene]-1-[4-(trifluoromethyl)piperidin-1-yl]butane-1,3-dione (EV-AP2553-001)



embedded image


The title compound was prepared in an analogous manner to intermediate EV-AP2535-001 starting with 4-trifluoromethylpiperidine hydrochloride (10.5 g, 55.4 mm) to afford the title compound (13.4 g, 87%) as a dark orange powder.


Method A: LC-MS: m/z=293.0 (M+H); RT=0.97 min.


Intermediate 29: Preparation of 1-(1H-pyrazole-4-carbonyl)-4-(trifluoromethyl)piperidine (EV-AQ8818-001)



embedded image


To a stirred solution of 1H-pyrazole-4-carboxylic acid (1.0 g, 8.92 mmol) and DIPEA (5.4 mL, 31.2 mmol) in THF (15 mL) was added T3P (50% in EtOAc, 10.5 mL, 17.8 mmol) and stirred at r.t. for 5 mins. 4-(trifluoromethyl)piperidine hydrochloride (2.03 g, 10.7 mmol) was then added and the solution was stirred at r.t. overnight. The reaction mixture was cooled, partitioned between DCM (30 mL) and saturated NaHCO3 solution (40 mL) and the aqueous fraction extracted with DCM (2×30 mL). The combined organic fractions were dried over MgSO4 and the solvent removed in vacuo. The resulting oil was purified via chromatography on SiO2 MeOH/DCM (gradient 100:0-90:10) to afford the title compound (673 mg, 61%) as a yellow powder.


Method A: LC-MS m/z=248.0 [M+H]+; RT=0.98 min.


Intermediate 30: Preparation of Synthesis of 6-chloro-2-hydrazinyl-3H,4H-thieno[3,2-d]pyrimidin-4-one
Step 1: Synthesis of methyl 1H,2H,3H,4H-thieno[3,2-d]pyrimidine-2,4-dione



embedded image


A mixture of methyl 3-aminothiophene-2-carboxylate (3.5 g, 22.3 mmol) and urea (8.75 mL, 144.7 mmol) was heated at 180° C. for 5 h. The mixture was cooled to ˜90° C. and water (40 mL) was added. The mixture was stirred at r.t. overnight and the resulting precipitate isolated via filtration to afford the title compound (3.66 mg, 98%) as an off-white powder.


Method A: LC-MS m/z=214.0 [M+H]+; RT=0.79 min.


Step 2: Synthesis of 6-nitro-1H,2H,3H,4H-thieno[3,2-d]pyrimidine-2,4-dione



embedded image


1H,2H,3H,4H-thieno[3,2-d]pyrimidine-2,4-dione (EV-AP2346-001, 3.65 g, 21.7 mmol) was added portion wise to a stirred solution of fuming HNO3 (12 mL) and H2SO4 (95%, 12 mL) at 0° C. The reaction was warmed to r.t. and stirred for 1 h. The precipitated solid was collected via filtration to afford the title compound (1.28 g, 28%) as an orange powder.


Method A: LC-MS m/z=214.0 [M+H]+; RT=0.79 min.


Step 3: Synthesis of 2,4,6-trichlorothieno[3,2-d]pyrimidine



embedded image


A stirred suspension of 6-nitro-1H,2H,3H,4H-thieno[3,2-d]pyrimidine-2,4-dione (EV-AP2349-001, 1.2 g, 21.7 mmol) in phenylphosphonic dichloride (5 mL, 35.3 mmol) was stirred at 180° C. for 4 h. The mixture was cooled to ˜100° C. and transferred slowly onto vigorously stirred ice/water (40 mL). The resulting suspension was stirred at r.t. for 30 mins and was then extracted with DCM (2×40 mL). The combined organic fractions were dried over Na2SO4, concentrated in vacuo, and purified via chromatography on SiO2 (0:100-10:90 MeOH-DCM) followed by further chromatography on SiO2 (0:100-50:50 EtOAc-heptane) to yield the title compound (752 mg, 55%) as a colourless powder.


Method A: LC-MS m/z=240.7 [M+H]+; RT=1.43 min.


Step 4: Synthesis of 2,6-dichloro-3H,4H-thieno[3,2-d]pyrimidin-4-one



embedded image


To a stirred solution of 2,4,6-trichlorothieno[3,2-d]pyrimidine (EV-AP2352-001,749 mg, 3.13 mmol) in THF (12 mL) was added 1M aq NaOH solution (16 mL, 16 mmol) and stirred at r.t. overnight. The solution was acidified to pH ˜5 with 5M aq HCl solution and the resulting precipitate isolated via filtration to afford the title compound (400 mg, 58%) as a colourless powder.


Method A: LC-MS m/z=220.8 [M+H]+; RT=1.02 min.


Step 5: Synthesis of 6-chloro-2-hydrazinyl-3H,4H-thieno[3,2-d]pyrimidin-4-one



embedded image


To a stirred solution of 2,6-dichloro-3H,4H-thieno[3,2-d]pyrimidin-4-one (EV-AP2354-001, 361 mg, 1.63 mmol) in ethanol (5 mL) was added hydrazine hydrate (199 μL, 4.08 mmol) and stirred at 80° C. overnight. The reaction mixture was cooled, the precipitate was collected via filtration and the solid washed with water to afford the title compound (247 mg, 70%) as a yellow powder.


Method A: LC-MS m/z=216.9 [M+H]+; RT=0.74 min.


Intermediate 31: Preparation of 5-chloro-2-hydrazinyl-3,4-dihydropyrimidin-4-one
Step 1: Synthesis of 5-chloro-2-hydrazinyl-3,4-dihydropyrimidin-4-one



embedded image


To a solution of 2,4,5-trichloropyrimidine (5.00 g, 27.3 mmol) in THF (12 mL) was added 1M aq NaOH (35.4 mL, 35.4 mmol) and stirred at r.t. for 3 days. The solution was acidified to pH ˜5 with 5M aq HCl and extracted with DCM (2×40 mL). The combined organic fractions were dried over Na2SO4, concentrated in vacuo and triturated with 1:4 DCM-heptane to afford the title compound (2.33 g, 52%) as an orange powder.


Method A: LC-MS m/z=164.8 [M+H]+; RT=0.38 min.


Step 2: Synthesis of 5-chloro-2-hydrazinyl-3,4-dihydropyrimidin-4-one



embedded image


To a solution of 2,5-dichloro-3,4-dihydropyrimidin-4-one (EV-AP2350-001, 200 mg, 1.21 mmol) in ethanol (3 mL) was added hydrazine hydrate (148 μL, 3.03 mmol) and stirred at 50° C. overnight. The reaction mixture was cooled to r.t. and the resulting precipitate isolated via filtration to afford the title compound (88 mg, 45%) as an off-white powder.


Method A: LC-MS m/z=160.9 [M+H]+; RT=0.17 min.


Intermediate 32: Preparation of 5-tert-butyl-2-hydrazinyl-3,4-dihydropyrimidin-4-one
Step 1: Synthesis of ethyl 2-formyl-3,3-dimethylbutanoate



embedded image


To a solution of ethyl 3,3-dimethylbutanoate (5.814 ml, 34.67 mmol) and ethyl formate (8.366 ml, 104.01 mmol) in DCM (60 ml) at 0° C. under nitrogen was added TiCl4 (52.01 ml, 52.01 mmol) and Et3N (11.61 mL, 83.21 mmol) and stirred at 0° C.—r.t. overnight. To the reaction mixture was added water, which was then extracted with DCM (2×50 ml). The combined organic extracts were washed with brine, dried over Na2SO4, concentrated in vacuo and purified via column chromatography (100:0-0:100 Heptane-EtOAc) to afford the title compound (2.72 mg, 42%) as a free flowing orange oil.



1H NMR (500 MHz, DMSO-d6) δ 9.74 (d, J=3.6 Hz, 1H), 4.21-4.10 (m, 2H), 3.07 (d, J=3.6 Hz, 1H), 1.21 (t, J=7.1 Hz, 3H), 1.07 (s, 9H).


Step 2: Synthesis of 5-tert-butyl-2-(methylsulfanyl)-3,4,5,6-tetrahydropyrimidin-4-one



embedded image


To a solution of ethyl 2-formyl-3,3-dimethylbutanoate (EV-AO7549-002, 92%, 100 mg, 0.534 mmol) in water (2 ml) was added 1M aq NaOH solution (534 μl, 0.534 mmol) and thiourea (122 mg, 1.603 mmol) and stirred at 100° C. for 1 h. The reaction mixture was allowed to cool to r.t. and acidified to pH 2-3 using 1M aq HCl solution to afford a white precipitate. The reaction mixture was filtered, washing with MeCN, to afford the title compound (72 mg, 73%) as a pearly white solid.


Method A: LC-MS m/z=184.9 [M+H]+; RT=0.93 min.


Step 3: Synthesis of 3,6-dimethyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one



embedded image


To water (20 ml) was added NaOH (97%, 286 mg, 6.925 mmol). After the sodium hydroxide had dissolved 5-tert-butyl-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one (EV-A07576-001, 1.16 g, 6.295 mmol) was added and the mixture stirred until dissolved. Iodomethane (435 μl, 6.925 mmol) was added dropwise and the mixture stirred at r.t. overnight. The solid was filtered and washed with ice cold water (2×10 ml) to afford the title compound (686 mg, 54%) as an off white solid.


Method A: LC-MS m/z=198.9 [M+H]+; RT=1.09 min.


Step 4: Synthesis of 5-tert-butyl-2-hydrazinyl-3,4-dihydropyrimidin-4-one



embedded image


To a solution of 5-tert-butyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one (EV-A07579-001, 600 mg, 3.026 mmol) in pyridine (5 ml) was added hydrazine hydrate (1.47 ml, 30.26 mmol) and stirred at 100° C. overnight. The reaction mixture was concentrated in vacuo and triturated using Et2O to afford the title compound (331 mg, 60%) as an off white powder.


Method A: LC-MS m/z=183.0 [M+H]+; RT=0.40 min.


Intermediate 33: Preparation of 2-hydrazinyl-6-(trifluoromethyl)-3,4-dihydropyrimidin-4-one (EV-AO7596-001)



embedded image


2-hydrazinyl-6-(trifluoromethyl)-3,4-dihydropyrimidin-4-one was prepared by an analogous route to Intermediate 32 substituting with 2-sulfanylidene-6-(trifluoromethyl)-1,2,3,4-tetrahydropyrimidin-4-one, which afforded the title compound (212 mg, 31%) as an off white powder.


Method A: LC-MS m/z=194.9 [M+H]+; RT=0.52 min.


Intermediate 34: Preparation of 6-hydrazinyl-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one (EV-AQ7120-001)
Step 1: Synthesis of 4-(benzyloxy)-6-chloro-1H-pyrazolo[3,4-d]pyrimidine



embedded image


To a solution of benzyl alcohol (0.19 mL, 1.85 mmol) in dioxane (3 mL) at 0° C. was added potassium t-butoxide (436.38 mg, 3.89 mmol) followed by 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (350 mg, 1.85 mmol). The reaction mixture was warmed to r.t. over 15 mins and then stirred for 21 h. The reaction mixture was quenched by the addition of sat aq NH4Cl solution (2 mL) and extracted with EtOAc (2×5 mL). The combined organic fractions were dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by chromatography on SiO2, eluting with 0-50% EtOAc in heptane to afford the title compound (325 mg, 41.1%) as a white solid.


Method A: LC-MS: m/z=+261.0, 262.9 (M+H)+; RT=1.28 min.


Step 2: Synthesis of 6-chloro-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one



embedded image


To a solution of 4-(benzyloxy)-6-chloro-1H-pyrazolo[3,4-d]pyrimidine (EV-AQ7113-003, 61%, 325 mg, 0.76 mmol) in THF (2.5 mL) was added 4M HCl in dioxane (1.9 mL) and stirred at r.t. for 1.5 h. Conc. HCl (2.5 mL) was then added and the reaction stirred for a further 2 h. The resulting precipitate was collected and dried under vacuum filtration to afford the title compound (128 mg, 98.7%) as a white powder.


Method A: LC-MS: m/z=+170.9, 172.8 (M+H)+; RT=0.20


Step 3: Synthesis of 6-hydrazinyl-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one



embedded image


To a solution of 6-chloro-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one (EV-AQ7115-001, 128 mg, 0.75 mmol) in ethanol (2 mL) was added hydrazine hydrate (0.18 mL, 3.75 mmol). The reaction vessel was sealed and the reaction mixture irradiated in the microwave at 100° C. for 30 mins. The reaction mixture was cooled and the resulting precipitate was collected and dried under vacuum to afford the title compound (90 mg, 72.2%) as a white powder.


Method A: LC-MS: m/z=+166.9 (M+H)+; RT=0.17 min.


Intermediate 35: Preparation of 2-hydrazinyl-5,6-dimethyl-3,4-dihydropyrimidin-4-one (EV-AP2534-001)
Step 1: Synthesis of 5,6-dimethyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one



embedded image


To a suspension of 5,6-dimethyl-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one (2 g, 12.8 mmol) in water (15 mL) was added sodium hydroxide (527.47 mg, 13.19 mmol) followed by iodomethane (1 mL, 16 mmol) and stirred at r.t. overnight. The reaction mixture was cooled to 5° C. and the resulting precipitate was collected by vacuum filtration. The solid was washed with water and dried under vacuum at 40° C. to afford the title compound (1.67 g, 76%) as a white powder.


Method A: LC-MS m/z=170.9 [M+H]+; RT=0.83 min.


Step 2: Synthesis of 2-hydrazinyl-5,6-dimethyl-3,4-dihydropyrimidin-4-one



embedded image


To 5,6-dimethyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one (EV-AB8059-001, 1 g, 5.87 mmol) was added hydrazine hydrate (1.43 mL, 29.37 mmol) and stirred at 100° C. for 1.5 h. The reaction was then allowed to stand at r.t. over the weekend. A further portion of hydrazine hydrate (1.43 mL, 29.37 mmol) was added and stirred at 100° C. for 1 h. The reaction mixture was cooled to r.t. and ice cold methanol (3 mL) was added. The resultant precipitate was collected by vacuum filtration and washed with more ice cold methanol (5 mL). The solid was dried further under vacuum to afford the title compound (618 mg, 68.2%) as a white powder.


Method A: LC-MS m/z=154.9 [M+H]+; RT=0.17 min.


Intermediate 36: Preparation of 5-chloro-6H,7H-[1,3]thiazolo[4,5-d]pyrimidin-7-one (EV-AQ0249-001)



embedded image


EV-AQ0249-001 was synthesized in an analogous method to the synthesis of EV-AQ0263-001, affording the title compound (190 mg, 56%) as a yellow powder.


Method A: LC-MS m/z=187.85 [M+H]+; RT=0.37 min.


Intermediate 37a: Synthesis of 2-hydrazinyl-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one
Step 1: Synthesis of 2-chloro-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one



embedded image


To a solution of 2,4-dichloropyrrolo[2,1-f][1,2,4]triazine (2 g, 10.6 mmol) in THF (100 ml) was added sodium hydroxide (5M, 10.64 ml, 53.2 mmol) and the reaction mixture was stirred at room temperature for 16 hours and at 50° C. for 4 hours.


The yellow solution was cooled to room temperature and concentrated in vacuo and acidified (pH 3-4, 2M HCl). The resultant precipitate was collected by filtration, washed with water followed by ether, to afford the title compound (1.79 g, 99%) as a pale yellow powder after drying under vacuum.


Method B: LC-MS m/z=160.0 [M+H]+; RT=0.79 min.


Step 2: Synthesis of 2-hydrazinyl-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one



embedded image


Hydrazine hydrate (43.04 μl, 0.88 mmol) was added to a stirred solution of 2-chloro-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one (100 mg, 0.59 mmol) in EtOH (2 ml) and the reaction was stirred at room temperature for 18 hours before the suspension was heated at 80° C. for 40 hours.


More hydrazine hydrate (43.04 μl, 0.88 mmol) was added and the reaction mixture was heated at 80° C. for 16 hours


The yellow suspension was cooled to 4° C., the solid was collected by filtration, washed with cold water (˜0.5 ml) and dried under vacuum to provide the title compound (64 mg, 65%) as a yellow solid.


Method B: LC-MS m/z=166.9 [M+H]+; RT=0.20 min.


Preparation of 2-[5-methyl-4-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3H,4H-thieno[2,3-d]pyrimidin-4-one



embedded image


To a solution of 2-hydrazinyl-3H,4H-thieno[2,3-d]pyrimidin-4-one (formed in an analogous manner to Intermediate 4) (EV-AP2372-001, 120 mg, 0.66 mmol) in ethanol (3 mL) was added 2-[(dimethylamino)methylidene]-1-(1,2,3,4-tetrahydroisoquinolin-2-yl)butane-1,3-dione (Intermediate 27, 90%, 199.3 mg, 0.66 mmol) followed by acetic acid (0.13 mL, 2.31 mmol). The vessel was sealed and the reaction mixture stirred at r.t. for 5 mins and then heated at 80° C. for 5 h. The reaction mixture was concentrated in vacuo. The crude residue was purified by chromatography on SiO2 eluting with 0-10% methanol in DCM. The material was purified further by PREP-HPLC (Method G) to afford the title compound (20.9 mg, 8.1%) as an off white powder.


Method C: LC-MS m/z=392.1 [M+H]+; RT=3.12 min.


Examples 146-156 and 157a

The examples in Table 10 were synthesized by cyclizing the corresponding hydrazine intermediate with either intermediate 27 or intermediate 28 using the procedure described in example 1.















TABLE 10









LC-MS
MS



Example
Ref.


(RT)
(M + H)+



No
No.
LBN
Structure
Method C
Method C
Comments







146
Q-438
EV-AQ7122-002


embedded image


2.19
396.2
Intermediate 34





147
Q-407
EV-AQ0209-002


embedded image


3.25
406.2






148
Q-409
EV-AQ0218-002


embedded image


3.14
426.2






149
Q-448
EV-AQ0295-002


embedded image


2.02
396.2






150
Q-384
EV-AO7582-002


embedded image


3.55
391.5
Intermediate 32





151
Q-393
EV-AO7599-002


embedded image


3.29
404.2
Intermediate 33





152
Q-533
EV-AQ3864-005


embedded image


2.80
394.0
Intermediate 37a





153
Q-433
EV-AQ0254-002


embedded image


2.53
412.1
Intermediate 36





154
Q-394
EV-AP2362-001


embedded image


3.56
426.1
Intermediate 30





155
Q-396
EV-AP2556-002


embedded image


2.89
376.2
Intermediate 17





156
Q-387
EV-AP2358-001


embedded image


2.75
370.1
Intermediate 31





157a
Q-381
EV-AP2539-002


embedded image


2.81
364.2
Intermediate 35









Intermediate 37b: Synthesis of ethyl 2-formyl-3-oxopropanoate EV-AQ8817-001



embedded image


To a stirred suspension of sodium hydride (60%, 1.68 g, 42.1 mmol) in THF (20 mL) was added ethyl formate (8.5 mL, 105.7 mmol). The solution was cooled to 0° C. and a solution of ethyl 3,3-diethoxypropanoate (4 g, 21.0 mmol) in THF (10 mL) was added dropwise over 30 mins and the reaction mixture stirred at r.t. overnight. 2M aq HCl (30 mL) was added under whilst cooling with ice and the reaction stirred at r.t. for 30 mins. The reaction mixture was extracted with diethyl ether (2×50 mL) and the combined organic extracts were dried over MgSO4 and concentrated in vacuo to afford the title compound (3.02 g, 99.7%) as an amber liquid.



1H NMR (250 MHz, Chloroform-d) δ 9.13 (s, 2H), 4.29 (q, J=7.1 Hz, 2H), 1.37-1.28 (m, 3H).


Example 158a—Preparation of 6-methyl-2-[5-methyl-3-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one Q-432 (EV-AQ0253-002)
Step 1: Synthesis of methyl 3-[2-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)hydrazin-1-ylidene]butanoate



embedded image


A solution of 2-hydrazinyl-6-methyl-3,4-dihydropyrimidin-4-one (Intermediate 1, EV-AO5744-001, 826 mg, 5.89 mmol) and methyl 3-oxobutanoate (763 μl, 7.07 mmol) in EtOH (20 ml) was heated at reflux for 3 h. The reaction mixture was cooled to r.t., concentrated in vacuo and triturated with EtOH, washing with EtOH followed by Et2O, to afford the title compound (886 mg, 63%) as a pink solid.


Method A: LC-MS m/z=239.00 [M+H]+; RT=0.71 min.


Step 2: Synthesis of methyl 3-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylate



embedded image


A solution of methyl 3-[2-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)hydrazin-1-ylidene]butanoate (EV-AQ3804-001, 300 mg, 1.26 mmol) in anhydrous DMF (4 ml) at 0° C. was treated dropwise with phosphoric trichloride (352 μl, 3.78 mmol) and stirred at 0° C. for 2 h. The reaction mixture was quenched by the addition of water (1 ml), poured onto crushed ice and left to stand for 30 mins. The solution was neutralised with 1M aq NaOH solution and then concentrated in vacuo. The residue was dissolved in water (20 ml) and extracted with EtOAc (3×50 ml). The organic extracts were washed with brine, dried over magnesium sulfate, concentrated in vacuo and triturated using Et2O to afford methyl 3-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylate (119 mg, 38%) as a pink solid.


Method A: LC-MS m/z=249.00 [M+H]+; RT=1.01 min.


Step 3: Synthesis of 3-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid



embedded image


To a solution of methyl 3-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylate (EV-AQ3806-002, 120 mg, 0.44 mmol) in THF (3 mL) was added 3M aq NaOH solution (0.97 ml) and stirred at r.t. for 2 h. The reaction mixture was concentrated in vacuo to remove the organic solvent and the aqueous solution acidified to pH 3 using 5M aq HCl solution. A beige precipitate formed which was filtered washing with H2O and Et2O to afford 3-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid (110 mg, 95%) as a beige powder.


Method A: LC-MS m/z=235.0 [M+H]+: RT=0.83 min.


Step 4: Synthesis of 6-methyl-2-{3-methyl-4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3,4-dihydropyrimidin-4-one



embedded image


To a suspension of 3-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid (EV-AQ0251-001, 35 mg, 0.15 mmol) in THF (2 ml) was added DIPEA (91 μl, 0.52 mmol), T3P (50% in EtOAc) (176 μl, 0.30 mmol) and 4-(trifluoromethyl)piperidine hydrochloride (34 mg, 0.18 mmol) and stirred at r.t. for 3 h. The reaction mixture was concentrated in vacuo, redissolved in water (10 ml) and extracted with EtOAc (3×20 ml). The combined organic extracts were dried over sodium sulfate, concentrated in vacuo and purified via chromatography on SiO2 (gradient 100:0-80:20, DCM-MeOH) to afford 6-methyl-2-{3-methyl-4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3,4-dihydropyrimidin-4-one (16 mg, 29%) as an off white powder.


Method C: LC-MS m/z=370.2 [M+H]+; RT=2.40 min.


Preparative Example 7—Formation of Products Via Cyclization to Form Substituted Pyrazoles



embedded image


Synthesis of Intermediates
Intermediate 38: Synthesis of 2,4-dichloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine



embedded image


To a solution of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (1.5 g, 7.98 mmol) in THF (30 ml) at 0° C. was added sodium hydride (60% oil suspension, 383 mg, 9.57 mmol) and stirred at 0° C.—r.t. for 20 mins. Iodomethane (0.6 ml, 9.57 mmol) was added and stirred at r.t. for 3 h. The mixture was quenched by addition of saturated ammonium chloride solution (20 mL). EtOAc was then added resulting in formation of a precipitate. The precipitate was filtered and the filtrate extracted with EtOAc (×2). The combined organic fractions were washed with water, dried over Na2SO4, filtered and concentrated in vacuo to afford the title compound (1.65 g, 97.2%) as a yellow powder.


Method A: LC-MS m/z=201.90, 203.90 [M+H]+; RT=1.21


Intermediate 39: Synthesis of 5-chloro-6H,7H-[1,3]thiazolo[5,4-d]pyrimidin-7-one
Step 1: Synthesis of 7-(benzyloxy)-5-chloro-[1,3]thiazolo[5,4-d]pyrimidine



embedded image


To a solution of 5,7-dichloro-[1,3]thiazolo[5,4-d]pyrimidine (980 mg, 4.76 mmol) in THF (20 mL) at 0° C. was added benzyl alcohol (495 μl, 4.76 mmol) and sodium hydride (114 mg, 4.76 mmol, 60% in mineral oil) and stirred at r.t. for 22 h. To the reaction mixture was added water (20 ml) and extracted with EtOAc (2×50 ml). The combined organic extracts were washed with brine, dried over sodium sulfate and concentrated in vacuo. Purification by chromatography on SiO2 (gradient 100:0-90:10, Heptane-EtOAc) afforded the title compound (708 mg, 47%) as a white powder.


Method A: LC-MS m/z=277.85 [M+H]+; RT=1.39 min.


Step 2: Synthesis of 5-chloro-6H,7H-[1,3]thiazolo[5,4-d]pyrimidin-7-one



embedded image


7-(benzyloxy)-5-chloro-[1,3]thiazolo[5,4-d]pyrimidine (EV-AQ0259-002, 708 mg, 2.24 mmol) was dissolved in a 1:1 mixture of 37% aq HCl-THF (10 mL) and stirred at r.t. for 18 h. The reaction mixture was filtered under vacuum, washing with THF and Et2O, to afford the title compound (246 mg, 58%) as a pale yellow powder.


Method A: LC-MS m/z=187.80 [M+H]+; RT=0.49 min.




embedded image


Intermediate 40: Methyl-2-[(dimethylamino)methylidene]-4-methyl-3-oxopentanoate



embedded image


To methyl 4-methyl-3-oxopentanoate (1.98 ml, 13.87 mmol) was added 1,1-dimethoxy-N,N-dimethylmethanamine (2.21 ml, 16.65 mmol) and the solution was stirred at 80° C. for 1 h. The reaction mixture was concentrated in vacuo to afford methyl-2-[(dimethylamino)methylidene]-4-methyl-3-oxopentanoate (2.76 g, 95%) as an orange oil.


Method A: LC-MS m/z=200.0 [M+H]+; RT=1.00


Intermediate 41: Methyl-2-[(dimethylamino)methylidene]-4-methyl-3-oxopentanoate



embedded image


To methyl 4-methyl-3-oxopentanoate (1.98 ml, 13.87 mmol) was added 1,1-dimethoxy-N,N-dimethylmethanamine (2.21 ml, 16.65 mmol) and the solution was stirred at 80° C. for 1 h. The reaction mixture was concentrated in vacuo to afford methyl-2-[(dimethylamino)methylidene]-4-methyl-3-oxopentanoate (2.76 g, 95%) as an orange oil.


Method A: LC-MS m/z=200.0 [M+H]+; RT=1.00


Examples 157b, 158b, and 159-180

The compounds in Table 11 were prepared by cyclization of the intermediate hydrazine with the appropriate enamine followed by coupling using the specified reagent.
















TABLE 11










LC-MS
MS



Ex-




(RT)
(M + H)+
Coup-


ample

Ref.


Method
Method
ling


No
Enamine
No.
LBN
Structure
C
C
Agent







157b


embedded image


Q- 444
EV- AQ0282- 002


embedded image


2.87
398.2
T3P





158b


embedded image


Q- 445
EV- AQ0286- 002


embedded image


3.20
424.2
T3P





159


embedded image


Q- 330
EV- AO7546- 002


embedded image


2.61
330.2
COMU





160


embedded image


Q- 319
EV- AQ0281- 002


embedded image


2.95
377.4
T3P





161


embedded image


Q- 463
EV- AR5315- 002


embedded image


2.91
422.2
T3P





162


embedded image


Q- 353
EV- AP2516- 001


embedded image


3.27
392.3
COMU





163


embedded image


Q- 371
EV- AP2521- 001


embedded image


3.04
358.2
COMU





164


embedded image


Q- 358
EV- AP2324- 001


embedded image


3.40
426.2
COMU







Angew Chem Int Ed 53(3),










757-760, 2014.











165


embedded image


Q- 369
EV- AP2329- 001


embedded image


1.72
456.2
COMU







Angew Chem Int Ed 53(3),










757-760, 2014.











166


embedded image


Q- 370
EV- AP2333- 001


embedded image


3.03
378.2
COMU







Angew Chem Int Ed 53(3),










757-760, 2014.











167


embedded image


Q- 332
EV- AN7498- 001


embedded image


2.71
386.12
COMU






WO2008053043











168


embedded image


Q- 331
EV- AN7499- 001


embedded image


2.36
338.1
COMU






WO2008053043











169


embedded image


Q- 349
EV- AP2500- 001


embedded image


1.69
340.1
COMU






WO2008053043











170


embedded image


Q- 342
EV- AN7486- 001


embedded image


2.95
404.1
COMU






WO2008053043











171


embedded image


Q- 334
EV- AN7489- 001


embedded image


2.56
356.1
TBTU






WO2008053043











172


embedded image


Q- 375
EV- AP2332- 001


embedded image


2.67
364.2
COMU








173


embedded image


Q- 419
EV- AP2578- 001


embedded image


3.04
426.2
COMU








174


embedded image


Q- 458
EV- AP2577- 001


embedded image


3.15
406.2
COMU








175


embedded image


Q- 411
EV- AP2579- 001


embedded image


2.91
372.2
COMU








176


embedded image


Q- 443
EV- AQ4752- 003


embedded image


2.28
356.2
T3P






WO2009148004











177


embedded image


Q- 537
EV- AQ3868- 002


embedded image


2.95
446.1
T3P






WO2009148004











178


embedded image


Q- 536
EV- AQ3869- 002


embedded image


2.97
428.3
T3P






WO2009148004











179


embedded image


Q- 535
EV- AS5419- 002


embedded image


2.42
453.0
T3P






WO2009148004











180


embedded image


Q- 534
EV- AS5418- 002


embedded image


2.89
414.1
T3P






WO2009148004









Preparative Example 8—Formation of Intermediates Via SNAr



embedded image


embedded image


Example 181—Preparation of 1-(1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carbonyl)-4-phenylpiperidine-4-carbonitrile EV-AR5394-002)



embedded image


Step 1: Synthesis of ethyl 1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylate



embedded image


To a solution of 2-chloro-3H,4H-thieno[3,2-d]pyrimidin-4-one (Intermediate 9, 647 mg, 3.47 mmol) in DMF (2 ml) was added ethyl 1H-pyrazole-4-carboxylate (Intermediate Y, 437 mg, 3.12 mmol), caesium carbonate (1.69 g, 5.20 mmol), L-proline (160 mg, 1.39 mmol) and copper (I) iodide (132 mg, 0.69 mmol). The reaction mixture was then de-gassed and stirred at 120° C. overnight. The reaction mixture was concentrated in vacuo and a 0.2M aq EDTA solution (20 ml) and DCM (30 ml) were added and the mixture was stirred at r.t. overnight. The organic phase was separated and the aqueous phase was extracted with DCM (10 ml). The combined organic phases were washed with water, dried over sodium sulfate and concentrated in vacuo to afford the title compound (559, 44%) as a beige powder.


Method B: LC-MS m/z=290.95 [M+H]+; RT=1.02 min.


Step 2: Synthesis of 1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid. Intermediate 42



embedded image


To a solution of methyl ethyl 1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylate (EV-AR5386-001, 80%, 559 mg, 1.54 mmol) in THF (5 mL) and water (5 ml) was added 6M aqueous NaOH solution (2.57 ml) and the reaction mixture stirred at r.t. for 4 h. The reaction mixture was concentrated in vacuo to remove the organic solvent and the aqueous mixture acidified to pH 4 using 5M aq HCl solution. The reaction mixture was extracted with EtOAc (2×50 ml) and the combined organic extracts dried over sodium sulfate and concentrated in vacuo to afford the title compound (307 mg, 72%) as a pale grey powder.


Method B: LC-MS m/z=262.95 [M+H]+; RT=0.82 min.


Step 3: Synthesis of 1-(1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carbonyl)-4-phenylpiperidine-4-carbonitrile



embedded image


To a suspension of 1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid (EV-AR5392-001, 80%, 52 mg, 0.159 mmol) in THF (2 ml) was added DIPEA (69 μl, 0.40 mmol), T3P (50% in EtOAc) (234 μl, 0.40 mmol) and 4-phenylpiperidine-4-carbonitrile (33 mg, 0.17 mmol) and the reaction mixture stirred at r.t. for 2 h. The reaction mixture was concentrated in vacuo and to the crude sample added DCM (2 ml) and saturated NaHCO3 solution (1 ml). The solution was then passed through a phase separator cartridge and concentrated in vacuo. Purification using an SCX cartridge followed by trituration with MeOH afforded the title compound (31 mg, 45%) as an off white powder.


Method C: LC-MS m/z=431.0 [M+H]+; RT=2.83 min.


Examples 182-184

The compounds in Table 12 were prepared in an analogous manner to Example 181 by coupling the appropriate amine with intermediate 42















TABLE 12










LC-MS
MS


Example

Ref.


(RT)
(M + H)+


No
Route
No.
LBN
Structure
Method C
Method C







182
1
Q-524
EV-AR5388-002


embedded image


2.36
470.0





183
1
Q-528
EV-AR5394-002


embedded image


2.88
463.0





184
1
Q-527
EV-AR5395-002


embedded image


2.91
445.1









Intermediate 43: Synthesis of 1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-3-carboxylic acid



embedded image


Step 1: Synthesis of 2-chloro-4-[(2-methoxyethoxy)methoxy]thieno[3,2-d]pyrimidine



embedded image


To a solution of 2-chloro-3H,4H-thieno[3,2-d]pyrimidin-4-one (EV-AP2531-001, 750 mg, 4.02 mmol) and DIPEA (1.03 mL, 6.03 mmol) in THF (15 mL) was added dropwise 1-(chloromethoxy)-2-methoxyethane (0.5 ml, 4.42 mmol) and stirred at r.t. overnight. To the reaction mixture was added EtOAc (50 mL) washed with water (2×15 mL) and brine solution (15 mL). The organic fraction was dried over Na2SO4 and concentrated in vacuo to afford the title compound (1.09, 87.9%) (as a mixture of N and O alkylation products) as a tan oil.


Method A: LC-MS: m/z=274.9, 276.9 (M+H)+; RT=1.03, 1.19 min, A=52 and 37% respectively.


Step 2: Synthesis of ethyl 1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-3-carboxylate



embedded image


To a solution of 2-chloro-4-[(2-methoxyethoxy)methoxy]thieno[3,2-d]pyrimidine (EV-AP2543-001, 902 mg, 3.28 mmol) in DMF (20 mL) was added caesium carbonate (1.71 g, 5.25 mmol) and ethyl 1H-pyrazole-5-carboxylate (506.13 mg, 3.61 mmol) and stirred at 120° C. for 30 mins. The reaction mixture was cooled to 0° C., diluted with 1M aqueous HCl solution (45 mL) and stirred at 0° C. to r.t. for 30 mins. The resulting precipitate was filtered under vacuum and dried to afford the title compound (275 mg, 28%) as a pale brown powder.


Method A: LC-MS: m/z=+291.1 (M+H)+; RT=1.12 min.


Step 3: Synthesis of 1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-3-carboxylic acid Intermediate 43



embedded image


Ethyl 1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-3-carboxylate (EV-AP2547-001, 310 mg, 1.07 mmol) was suspended in 2:2:1 THF/water/methanol (10 mL) and 2.5M aq NaOH solution (2.6 mL) was added. The reaction mixture was stirred at r.t. for 1.5 h. The reaction mixture was concentrated in vacuo and the aqueous solution acidified to pH 4 with 2M aq HCl solution. The resulting precipitate was filtered and dried under vacuum filtration to afford the title compound (260 mg, 91%) as a pale brown powder.


Method A: LC-MS: m/z=+262.9 (M+H)+; RT=0.92 min.


Example 185—2-[3-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3H,4H-thieno[3,2-d]pyrimidin-4-one



embedded image


To a solution of 1-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-1H-pyrazole-3-carboxylic acid (Intermediate 43) (EV-AP2548-001, 80 mg, 0.31 mmol) in DMF (1.0 mL) was added COMU (143.71 mg, 0.34 mmol), DIPEA (0.13 mL, 0.76 mmol) and 1,2,3,4-tetrahydroisoquinoline (0.04 mL, 0.34 mmol) and stirred at r.t. for 2 h. The reaction mixture was concentrated in vacuo and the crude material was purified by PREP-HPLC (Method G) to afford the title compound (28.7 mg, 24.9%) as a fluffy pale yellow solid.


Method C: LC-MS: m/z=+378.1 (M+H)+; RT=2.98 min.


Examples 186-187

The examples in Table 13 were prepared analogously to example 181 coupling intermediate 43














TABLE 13









LC-MS
MS


Example
Ref.


(RT)
(M + H)+


No
No.
LBN
Structure
Method C
Method C







186
Q-389
EV-AP2550-001


embedded image


2.74
344.1





187
Q-390
EV-AP2551-001


embedded image


2.88
398.1









Example 188—Preparation of 2-methyl-6-{3-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3,4-dihydropyrimidin-4-one (Q-437, EV-AQ7121-003)



embedded image


Step 1: Synthesis of ethyl 1-(2-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-1H-pyrazole-3-carboxylate



embedded image


To a microwave vessel was added 6-chloro-2-methyl-3,4-dihydropyrimidin-4-one (450 mg, 3.11 mmol), ethyl 1H-pyrazole-5-carboxylate (610.74 mg, 4.36 mmol), caesium carbonate (1.72 g, 5.29 mmol), L-proline (143.36 mg, 1.25 mmol) and copper (I) iodide (118.57 mg, 0.62 mmol) in DMF (10 mL). The reaction mixture was de-gassed by bubbling through nitrogen gas for 5 mins and then irradiated in the microwave at 140° C. for 4 h. Additional 6-chloro-2-methyl-3,4-dihydropyrimidin-4-one (150 mg, 1.04 mmol) was added and the reaction irradiated at 140° C. for a further 1.5 h. EtOAc was added to the cooled reaction mixture and the organic layer washed with brine (×2). The organics were dried over Na2SO4, concentrated in vacuo and purified by chromatography on SiO2, eluting with 0-100% EtOAc in heptane followed by a flush with 50% methanol in EtOAc to afford the title compound (294 mg, 11.4%) as a beige powder.


Method A: LC-MS: m/z=+249.0 (M+H)+; RT=1.00 min.


Step 2: Synthesis of 1-(2-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-1H-pyrazole-3-carboxylic acid



embedded image


Ethyl 1-(2-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-1H-pyrazole-3-carboxylate (EV-AQ7119-001, 30%, 240 mg, 0.29 mmol) was suspended in 2:2:1 THF/water/methanol (10 mL) and 2.5M aq NaOH (1.7 mL) was added. The reaction mixture was stirred at r.t. for 25 mins. The organics from the reaction mixture were removed in vacuo. The residue was acidified with 2M aq HCl solution and the resulting precipitate was collected and dried under vacuum filtration to afford the title compound (55 mg, 86.1%) as a beige powder:


Method A: LC-MS: m/z=+221.0 (M+H)+; RT=0.78.


Step 3: Synthesis of 2-methyl-6-{3-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3,4-dihydropyrimidin-4-one



embedded image


To a solution of 1-(2-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-1H-pyrazole-3-carboxylic acid (EV-AQ7123-001 75 mg, 0.34 mmol) in THF (2 mL) was added DIPEA (0.20 mL, 1.19 mmol) and T3P 50% in EtOAc (0.40 mL, 0.68 mmol). The reaction mixture was stirred at r.t. for 10 mins and 4-(trifluoromethyl)piperidin-1-ium. HCl (77.5 mg, 0.41 mmol) was added before stirring for a further 14 h. The reaction mixture concentrated in vacuo and the crude residue partitioned between water (1 mL) and DCM (5 mL). The organic phase was extracted, washed with saturated NaHCO3 solution (1 ml), water (1 mL) and brine solution (5 mL) and dried over Na2SO4 and concentrated in vacuo. The crude residue was purified by Prep HPLC (method G) to afford the title compound (43.2 mg, 35.7%) as an off white powder.


Method C: LC-MS: m/z=+356.2 (M+H)+; RT=2.32 min.


Intermediate 44 Synthesis of 1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yL)-1H-pyrazole-3-carboxylic acid



embedded image


Step 1: Synthesis of 2-chloro-4-[(4-methoxyphenyL)methoxy]-6-methylpyrimidine



embedded image


To a stirred solution of (4-methoxyphenyL)methanol (3.39 g, 3.05 mL, 24.5 mmol) in THF (40 mL) at 0° C. was added NaH (60% in oil, 1.47 g, 36.8 mmol). After 1 h, a solution of 2,4-dichloro-6-methylpyrimidine (4.0 g, 24.5 mmol) in THF (15 mL) was added dropwise and stirred at 0° C. to r.t. overnight. The reaction mixture was quenched by the addition of saturated aq NH4Cl solution (40 mL) and extracted with EtOAc (3×75 mL). The combined organic fractions were washed with brine solution (40 mL), dried over Na2SO4 and concentrated in vacuo. The resulting residue was purified via chromatography on SiO2, eluent Heptane/EtOAc (gradient 100:0-75:25), to afford the title compound (2.37 g, 36%) as a colourless crystalline solid.


Method A: LC-MS m/z=256.0 [M+H]+; RT=1.39 min.


Step 2: Synthesis of ethyl-1-{4-[(4-methoxyphenyL)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-3-carboxylate



embedded image


To a stirred solution of ethyl-1H-pyrazole-5-carboxylate (0.945 g, 6.74 mmol) in THF (65 mL) at 0° C. was added NaH (60%, 290 mg, 7.25 mmol) and stirred at 0° C. for 30 mins. 2-chloro-4-[(4-methoxyphenyL)methoxy]-6-methylpyrimidine (1.70 g, 6.42 mmol) was then added and the reaction mixture stirred at reflux for 4 days. The cooled reaction mixture was quenched with saturated NH4Cl aqueous solution (40 mL) and extracted with EtOAc (2×40 mL). The combined organic fractions were dried (Na2SO4), concentrated in vacuo and purified via chromatography on SiO2, eluting with Heptane/EtOAc (gradient 100:0-70:30) to afford the title compound (1.23 g, 52%) as a colourless powder.


Method A: LC-MS m/z=369.1 [M+H]+; RT=1.43 min.


Step 3: Synthesis of ethyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yL)-1H-pyrazole-3-carboxylate



embedded image


To a stirred solution of ethyl-1-{4-[(4-methoxyphenyL)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-3-carboxylate (1.06 g, 2.73 mmol) in EtOAc (25 mL) was added Pd on carbon (10%, 100 mg) and the solution exposed to an atmosphere of H2 (g) overnight. The solution was filtered through celite, washing with EtOAc, the filtrate concentrated in vacuo and the residue purified via chromatography, eluting with Heptane/EtOAc (gradient 100:0-20:80) to afford the title compound (400 mg, 59%) as a colourless powder.


Method A: LC-MS m/z=249.0 [M+H]+; RT=1.01 min.


Step 4: Synthesis of 1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yL)-1H-pyrazole-3-carboxylic acid



embedded image


To a stirred solution of ethyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yL)-1H-pyrazole-3-carboxylate (386 mg, 1.56 mmol) in 2:1 THF/methanol (8 mL) was added 3M aqueous NaOH solution (3.1 mL) and the reaction mixture was stirred at r.t. for 2 h. The organics were removed in vacuo, the residue acidified to pH 4/5 with 2M aqueous HCl solution and extracted with EtOAc (3×20 mL). The combined organics were dried over Na2SO4 and concentrated in vacuo to afford the title compound (337 mg, 98%) as a colourless powder.


Method A: LC-MS m/z=220.9 [M+H]+; RT=0.79 min.


Examples 189-190

The examples in Table 14 were prepared by coupling intermediate 44 with the appropriate amine using COMU as the coupling agent.














TABLE 14









LC-MS
MS


Example
Ref.


(RT)
(M + H)+


No.
No.
LBN
Structure
Method C
Method C







189
Q-376
EV-AP2337-001


embedded image


2.63
322.2





190
Q-377
EV-AP2338-001


embedded image


2.84
336.2









Example 191—7-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-5H,6H-imidazo[1,2-c]pyrimidin-5-one



embedded image


Step 1: Synthesis of 7-chloro-5-(methylsulfanyL)imidazo[1,2-c]pyrimidine hydrochloride



embedded image


To a stirred solution of 6-chloro-2-(methylsulfanyL)pyrimidin-4-amine (1.5 g, 8.54 mmol) in dioxane (4 mL) was added chloroacetaldehyde (50%, 1.63 mL, 12.8 mmol) and stirred at 95° C. overnight. The reaction mixture was cooled in an ice bath and the resulting precipitate filtered and washed with dioxane to afford the title compound (1.41 g, 70%) as a colourless powder.


Method A: LC-MS m/z=199.8 [M+H]+; RT=0.93 min


Step 2: Synthesis of 7-chloro-5H,6H-imidazo[1,2-c]pyrimidin-5-one



embedded image


To a stirred solution of methyl 7-chloro-5-(methylsulfanyL)imidazo[1,2-c]pyrimidine hydrochloride (EV-AQ8808-001, 1.32 g, 5.59 mmol) in methanol (4 mL) was added 2M aqueous KOH solution (10 mL, 20 mmol) and stirred at reflux overnight. The solution was cooled to r.t. and acidified to pH 5/6 using 5M aq HCl solution. The resulting precipitate was isolated via vacuum filtration to afford the title compound (704 mg, 74%) as a tan powder.


Method A: LC-MS m/z=169.9 [M+H]+; RT=0.23 min


Step 3: 7-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-5H,6H-imidazo[1,2-c]pyrimidin-5-one



embedded image


To a stirred solution of 7-chloro-5H,6H-imidazo[1,2-c]pyrimidin-5-one (EV-AQ8809-001,100 mg, 0.59 mmol) and cesium carbonate (288 mg, 0.89 mmol) in DMF (3 mL) was added 1-(1H-pyrazole-4-carbonyL)-4-(trifluoromethyL)piperidine (intermediate 29, EV-AQ8818-001,175 mg, 0.71 mmol) and the reaction was stirred at 70° C. for 2 h and 100° C. for 3 h. Copper iodide (22 mg, 0.12 mmol) and L-proline (27 mg, 0.24 mmol) were added the reaction heated at 100° C. overnight. The reaction was transferred to the microwave at heated at 150° C. for 6 hours. The reaction was cooled to r.t., concentrated in vacuo and purified via PREP-HPLC (Method G) to yield the title compound (70 mg, 31%) as a colourless powder.


Method C: LC-MS m/z=379.2 [M+H]+; RT=2.00 min.


Example 192—Preparation of 2-chloro-7-fluoro-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one

Q-525 (EV-AS3703-002)




embedded image


Step 1: Synthesis of 2-chloro-7-fluoro-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one



embedded image


To a solution of 2,4-dichloro-7-fluoropyrrolo[2,1-f][1,2,4]triazine (WO2011/88045 A1, 2011) (446 mg, 2.16 mmol) in THF (20 ml) was added 5M aq NaOH solution (2.16 ml, 10.82 mmol) and stirred at r.t. for 22 h. The reaction mixture was concentrated in vacuo and the residue acidified to pH 5 using 2M aq HCl solution. The resulting precipitate was collected under vacuum filtration, washing with diethyl ether, to afford the title compound (283 mg, 35%) as an off-white powder.


Method B: LC-MS m/z=187.9 [M+H]+; RT=0.86 min.


Step 2: Synthesis of 7-fluoro-2-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one



embedded image


The title compound was prepared in an analogous manner to Example 191 using 2-chloro-7-fluoro-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one (140 mg, 0.75 mmol) and purifying by preparative HPLC [method G] to give 7-fluoro-2-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one one (42 mg, 14%) as an off white powder.


Method C: LC-MS m/z=398.0 [M+H]+; RT=2.82 min.


Example 193—Preparation of 2-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (Q-526, EV-AR5391-002)
Step 1: Synthesis of 2-chloro-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a solution of 2,4-dichloro-5H,6H,7H-cyclopenta[d]pyrimidine (3 g, 15.87 mmol) in THF (15 mL) was added 6M aq NaOH solution (10 eq, 26.45 ml) and the reaction stirred at 50° C. for 48 h. The reaction mixture was concentrated in vacuo to remove the organic solvent. The resulting aqueous solution was acidified to pH 4 with 5M aq HCl solution and extracted with EtOAc (2×50 ml), dried over sodium sulfate and concentrated in vacuo to afford the title compound (2.09 g, 75%) as a pale orange powder.


Method B: LC-MS m/z=170.9 [M+H]+; RT=0.68 min.


Step 2: Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a solution of 2-chloro-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-AR5385-002, 200 mg, 1.17 mmol) in DMF (2 ml) was added 1-(1H-pyrazole-4-carbonyl)-4-(trifluoromethyl)piperidine (EV-AQ8818-001, 319 mg, 1.29 mmol), caesium carbonate (573 mg, 1.76 mmol), L-proline (54 mg, 0.47 mmol) and copper (I) iodide (45 mg, 0.23 mmol). The reaction mixture was then de-gassed and stirred at 120° C. for 20 h. The reaction mixture was concentrated in vacuo and then a 0.2M aq solution of EDTA (20 ml) and DCM (30 ml) were added and the mixture stirred at r.t. for 4 h. The organic phase was separated and the aqueous phase extracted with DCM (20 ml). The combined organic extracts were washed with water (10 ml), dried over sodium sulfate and concentrated in vacuo. Purification by PREP-HPLC (Method G) afforded the title compound (140 mg, 31%) as a beige powder.


Method C: LC-MS m/z=382.1 [M+H]+; RT=2.51 min


Example 194

The example in Table 15 was prepared by the procedure described in Example 192, starting instead with 2,4-dichlorothieno[3,2-d]pyrimidine.














TABLE 15









LC-MS
MS


Example
Ref.


(RT)
(M + H)+


No
No.
LBN
Structure
Method C
Method C







194
Q-517
EV-AR5376-002


embedded image


2.67
397.1









Example 195—Preparation of 2-{4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3H,4H,5H,7H-furo[3,4-d]pyrimidin-4-one (Q-453, EV-AQ8825-001)
Step 1: Synthesis of 2-chloro-3H,4H,5H,7H-furo[3,4-d]pyrimidin-4-one



embedded image


To a stirred solution of 2,4-dichloro-5H,7H-furo[3,4-d]pyrimidine (EV-AQ8821-001, 1 g, 5.24 mmol) in THF (10 mL) was added 1M aq NaOH solution (10.5 mL, 10.5 mmol) and stirred at r.t. overnight. The solution was acidified to pH 4/5 with acetic acid and extracted with DCM (3×30 mL). The combined organic extracts were dried over MgSO4 and concentrated in vacuo to afford the title compound (890 mg, 99%) as an orange powder.


1H NMR (500 MHz, DMSO-d6) δ 4.88 (t, J=3.3 Hz, 2H), 4.81 (t, J=3.3 Hz, 2H).


Step 2: Synthesis of 2-{4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3H,4H,5H,7H-furo[3,4-d]pyrimidin-4-one



embedded image


To a stirred solution of 7-chloro-5H,6H-imidazo[1,2-c]pyrimidin-5-one (EV-AQ8821-001,100 mg, 0.58 mmol) and caesium carbonate (283 mg, 0.87 mmol) in DMF (3 mL) was added 1-(1H-pyrazole-4-carbonyL)-4-(trifluoromethyL)piperidine (Intermediate V, EV-AQ8818-001,143 mg, 0.58 mmol) and stirred under microwave conditions at 120° C. for 5 h. The reaction was cooled to r.t., concentrated in vacuo and purified via PREP-HPLC (Method G) to afford (59 mg, 27%) as a colourless powder.


Method C: LC-MS m/z=382.2 [M−H]+; RT=2.28 min


Example 196—Preparation of 6-methyl-2-[3-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one (Q-308, EV-AN7470-001)
Step 1: Synthesis of 4-[(4-methoxyphenyl)methoxy]-6-methyl-2-(methylsulfanyl)pyrimidine



embedded image


To solution of 6-methyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one Intermediate 1 Step 1 (EV-AO5743-001, 7 g, 44.8 mmol) in water (50 ml) and dioxane (100 ml) was added NaOH (2.15 g, 53.8 mmol) followed by 1-(chloromethyl)-4-methoxybenzene (8.42 g, 53.8 mmol) and stirred at 50° C. for 1 h. The reaction mixture was cooled to r.t. and the resultant precipitate filtered under vacuum and purified by chromatography on SiO2, eluting with Heptane/EtOAc (gradient 100:0-0:100) to afford the title compound (1.54 g, 11.4%) as an oil.


Method A: LC-MS: m/z=+277.0 (M+H)+; RT=1.40 min.


Step 2: Synthesis of 2-methanesulfonyl-4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidine



embedded image


To a solution of 4-[(4-methoxyphenyl)methoxy]-6-methyl-2-(methylsulfanyl)pyrimidine (EV-AN0086-002, 1.5 g, 5.43 mmol) in DCM (15 mL) under nitrogen at 0° C. was added mCPBA (75%, 2.50 g, 10.86 mmol) and stirred at r.t. for 1 h. The reaction was diluted with chloroform (50 mL) and more mCPBA (200 mg, 0.87 mmol) was added and the reaction stirred at r.t. for a further 1 h. The reaction was quenched by addition of 0.5M aq sodium thiosulfate solution (20 mL). The organic layer was extracted and washed with saturated NaHCO3 solution (3×20 mL), dried over Na2SO4 and concentrated in vacuo to afford the title compound (1.64 g, 104%) as a pale yellow oil.


Method A: LC-MS: m/z=+331.1 (M+Na)+, RT=1.23 min.


Step 3: Synthesis of ethyl 1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-3-carboxylate



embedded image


To a solution of ethyl 1H-pyrazole-5-carboxylate (95.44 mg, 0.68 mmol) in DMF (5 mL) at 0° C. was added NaH (60% in oil, 31.13 mg, 0.78 mmol) and stirred at 0° C.—r.t. for 30 mins. 2-methanesulfonyl-4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidine (EV-A05710-002, 200 mg, 0.65 mmol) in DMF (5 mL) was added and the reaction mixture stirred at r.t. for 1.5 h. The reaction mixture was quenched by the addition of water (10 mL) and extracted with EtOAc (3×15 mL). The combined organic fractions were washed with water (3×10 mL), brine solution (10 mL), dried over Na2SO4, and concentrated in vacuo. Purification by chromatography on SiO2 eluting with Heptane/EtOAc (gradient 100:0-0:100) to afford the title compound (154 mg, 62.5%) as a clear oil.


Method A: LC-MS: m/z=391.1 (M+Na)+; RT=1.43.


Step 4: Intermediate 46 Synthesis of 1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-3-carboxylic acid



embedded image


Ethyl 1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-3-carboxylate (EV-AN7466-001, 125 mg, 0.34 mmol) was suspended in 2:2:1 THF/water/methanol (7.5 mL) and 2.5M aq NaOH solution (0.81 mL) was added. The reaction mixture was stirred at r.t. for 30 mins. The organics were removed in vacuo and the aqueous solution acidified with 2M aq HCl solution. The resultant precipitate was collected and dried under vacuum filtration. The filtrate was then extracted with EtOAc (2×10 mL) and the combined extracts dried over Na2SO4, concentrated in vacuo and combined with the precipitate to afford the title compound (115 mg, 93.6%) as an off white powder.


Method A: LC-MS: m/z=363.1 (M+Na)+; RT=1.24 min.


Step 5: Synthesis of 2-(1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-3-carbonyl)-1,2,3,4-tetrahydroisoquinoline



embedded image


To a solution of 1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-3-carboxylic acid (EV-AN7466-001, 115 mg, 0.34 mmol) in DMF (1.5 mL) was added COMU (159.18 mg, 0.37 mmol), DIPEA (0.14 mL, 0.84 mmol) and 1,2,3,4-tetrahydroisoquinoline (0.05 mL, 0.37 mmol) and stirred at r.t. overnight. To the reaction mixture was added ice water and extracted with EtOAc (2×5 mL). The combined organic extracts were washed with saturated NaHCO3 solution (5 mL), brine solution (5 mL), dried over Na2SO4 and concentrated in vacuo. Purification by chromatography on SiO2, eluting with Heptane/EtOAc (gradient 100:0-0:100), afforded the title compound (119 mg, 70.4%) as an opaque gum.


Method A: LC-MS: m/z=+456.0 (M+H)+; RT=1.52 min.


Step 6: Synthesis of 6-methyl-2-[3-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one



embedded image


To a solution of 2-(1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-3-carbonyl)-1,2,3,4-tetrahydroisoquinoline (EV-AN7468-001, 89 mg, 0.2 mmol) in DCM (2 mL) was added TFA (0.16 mL) and stirred at r.t. for 2 h. The reaction mixture was concentrated in vacuo, re-dissolved in DCM, washed with saturated NaHCO3 solution, dried over Na2SO4 and concentrated in vacuo. Purification by PREP-HPLC (Method G) method) followed by a free base with saturated NaHCO3 solution afforded the title compound (35.7 mg, 54.5%) as an off white solid.


Method A: LC-MS: m/z=+336.1 (M+H)+; RT=2.50.


Examples 197-198

The examples in Table 16 were made in an analogous manner to example 197 coupling Intermediate 46 with the appropriate amine followed by deprotection.















TABLE 16










LC-MS
MS


Example

Ref.


(RT)
(M + H)+


No
Route
No.
LBN
Structure
Method C
Method C







197
5a
Q-343
EV-AN7493-001


embedded image


1.48
290.1


198
5a
Q-333
EV-AN7492-001


embedded image


2.24
288.1









Example 199—2-{3,5-dimethyl-4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]-1H-pyrazol-1-yl}-6-methyl-3,4-dihydropyrimidin-4-one EV-AN7461-001



embedded image


The title compound (20.1 mg, 25.6%) was prepared in an analogous manner to Example 196, reacting ethyl 2-(3,5-dimethyl-1H-pyrazol-4-yl)acetate with Example 196 step 2 using HATU for the coupling with pyrrolidine.


Method C: LC-MS: m/z=316.2 (M+H)+; RT=2.05 min.


Example 200—Preparation of 6-methyl-2-[5-methyl-3-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one (Q-365, EV-AO7568-002)



embedded image


Step 1: Synthesis of ethyl-1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-5-methyl-1H-pyrazole-3-carboxylate



embedded image


To a solution of 2-methanesulfonyl-4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidine (Example 196 Step 2, 500 mg, 1.622 mmol) in DMF (10 mL) at 0° C. was added NaH (60% in oil) (60%, 78 mg, 1.946 mmol) and then ethyl 5-methyl-1H-pyrazole-3-carboxylate (275 mg, 1.784 mmol) and the reaction mixture stirred at r.t. for 2 h. The reaction mixture was quenched by the addition of water (10 mL) and extracted with EtOAc (3×20 mL). The combined organic extracts were washed with water (2×10 mL), brine solution (10 mL), dried over Na2SO4, concentrated in vacuo and purified via chromatography on SiO2 (gradient 100:0-0:100, Heptane-EtOAc), to afford the title compound (406 mg, 65%) as a colourless oil.


Method A: LC-MS m/z=383.1 [M+H]+; RT=1.45 min.


Step 2: Synthesis of 1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-5-methyl-1H-pyrazole-3-carboxylic acid



embedded image


To a solution of ethyl 1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-5-methyl-1H-pyrazole-3-carboxylate (EV-AO7559-002, 406 mg, 1.062 mmol) in 2:2:1 THF/water/methanol (25 mL) was added 2.5M aqueous NaOH (2.55 ml) and the reaction mixture stirred at r.t. overnight. The reaction mixture was concentrated in vacuo and the residue acidified with 2M aq HCl solution to pH 6 to afford a white precipitate which was filtered and dried under vacuum to give the title compound (340 mg, 90%) as a white powder.


Method A: LC-MS m/z=377.0 [M+H]+; RT=1.26 min.


Step 3: Synthesis of 2-(1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-5-methyl-1H-pyrazole-3-carbonyl)-1,2,3,4-tetrahydroisoquinoline



embedded image


To a stirred solution of 5-methyl-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid (EV-AO7561-001, 150 mg, 0.423 mmol) in DMF (2 ml) were added COMU (199 mg, 0.466 mmol), DIPEA (181 μl, 1.058 mmol) and 1,2,3,4-tetrahydroisoquinoline (59 μl, 0.466 mmol). The resulting mixture was stirred at r.t. for 2 h. The reaction mixture was concentrated in vacuo to remove the DMF and the crude residue redissolved in water (50 ml). The reaction mixture was quenched by addition of saturated sodium bicarbonate solution (20 ml) extracted with DCM (3×100 ml). The combined organic extracts were dried over sodium sulphate, concentrated in vacuo and purified via chromatography on SiO2 (gradient 100:0-0:100, Heptane-EtOAc) to afford the title compound (152 mg, 61%) as a yellow viscous oil.


Method A: LC-MS m/z=470.2 [M+H]+; RT=1.51 min.


Step 4: Synthesis of 6-methyl-2-[5-methyl-3-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one



embedded image


2-(1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-5-methyl-1H-pyrazole-3-carbonyl)-1,2,3,4-tetrahydroisoquinoline (EV-AO7563-002, 80%, 152 mg, 0.259 mmol) was dissolved in MeOH (10 mL) and subjected to H-cube conditions (1 ml/min, 1 bar, 50° C., Full H2 mode) over a Pd/C (10%) cat cartridge. The solvent was then removed in vacuo and the residue purified by trituration using MeCN to afford the title compound (61 mg, 67%) as a white powder.


Method C: LC-MS m/z=350.2 [M+H]+; RT=2.81 min


Example 201—Synthesis of 6-methyl-2-[5-methyl-3-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one



embedded image


The title compound was prepared analogously to Example 200 using ethyl 4-methyl-1H-pyrazole-3-carboxylate in place of ethyl 5-methyl-1H-pyrazole-3-carboxylate.


Method C: LC-MS m/z=350.2 [M+H]+; RT=2.81 min.


Example 203—Preparation of 2-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3H,4H-pyrrolo[2,1f][1,2,4]triazin-4-one (Q-467, EV-AQ3851-002)
Step 1: Synthesis of 2-methanesulfonyl-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one



embedded image


To 2-(methylsulfanyl)-3H,4H-pyrrolo[2,1-f][1,2,4] triazin-4-one (900 mg, 4.97 mmol) in AcOH (18 ml) was added hydrogen peroxide (35%, 8.7 ml, 0.1 mol) and the resultant suspension was stirred r.t. for 39 h, during which time the suspension dissolved and a precipitate formed. The precipitate was collected by vacuum filtration, washed with water followed by ether to afford the title compound (950 mg, 88%) as a white solid.


Method B: LC-MS m/z=213.9 [M+H]+; RT=0.73 min.


Step 2: Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one



embedded image


1-(1H-pyrazole-4-carbonyl)-4-(trifluoromethyl)piperidine (EV-AQ3840-001, 243.49 mg, 0.98 mmol) was added to a solution of 2-methanesulfonyl-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-4-one (200 mg, 0.94 mmol) and caesium carbonate (458.44 mg, 1.41 mmol) in DMF (4 ml) and stirred under microwave conditions at 175° C. for 9 h. The reaction mixture was concentrated in vacuo, redissolved in water and extracted with EtOAc (×2). The combined organic extracts were washed with brine, dried over MgSO4 and concentrated in vacuo to afford a clear gum. Purification by PREP-HPLC afforded the title compound (37 mg, 10%) as a white solid. Meanwhile a solid had precipitated from the aqueous, the solid was collected under vacuum filtration, washed with water followed by ether and dried under vacuum overnight to afford a further batch of the title compound (113 mg, 32%) as a white solid.


Method C: LC-MS m/z=380.0 [M+H]+; RT=2.66 min.


Example 204—Preparation of 6-methyl-2-{1-[3-oxo-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]-1H-pyrazol-4-yl}-3,4-dihydropyrimidin-4-one (Q-291, EV-AN7447-001) and Example 205—4-methyl-6-{1-[3-oxo-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]-1H-pyrazol-4-yl}-1,2-dihydropyrimidin-2-one (Q-292, EV-AN7447-002)



embedded image


Step 1: Synthesis of ethyl 3-[3,5-dimethyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propanoate



embedded image


To a solution of pyrazole-4-boronic acid pinacol ester (500 mg, 2.58 mmol) in acetonitrile (10 mL) was added ethyl acrylate (0.42 mL, 3.87 mmol), followed by DBU (0.39 mL, 2.58 mmol) and stirred at r.t. for 15.5 h. The reaction mixture was concentrated in vacuo and purified by chromatography on SiO2, eluting with Heptane/EtOAc (gradient 100:0-0:100) to afford the title compound (310 mg, 38%) as a clear oil.


Method A: LC-MS: m/z=+295.0 (M+H)+; RT=1.25 min.


Step 2: Synthesis of 2-chloro-4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidine and 4-chloro-6-methyl-2-[2-(trimethylsilyl)ethoxy]pyrimidine



embedded image


To a stirred solution of 2-(trimethylsilyl)ethanol (3.5 mL) in THF (7 mL) at 0° C. was added NaH (60% in oil, 490.74 mg, 12.27 mmol). The reaction mixture was warmed to r.t. over 15 mins and then cooled again to 0° C. To the reaction mixture was added 2,4-dichloro-6-methylpyrimidine (2 g, 12.27 mmol) in THF (8 mL) and stirred at 0° C. for 1.5 h. The reaction mixture was quenched by the addition of saturated NH4Cl aqueous solution (10 mL) and extracted with EtOAc (3×25 mL). The combined organic extracts were washed with brine solution (10 mL), dried over Na2SO4 and concentrated in vacuo. Purification by chromatography on SiO2, eluting with Heptane/EtOAc (gradient 100:0-50:50) to afford the title compound (2.21 g, 72.2%, 2.7:1 mixture of regioisomers) as a white solid.


Method A: LC-MS: m/z=216.9, 218.9 (M+H)+; RT=1.62 min.


Step 3: Synthesis of ethyl 3-(4-{4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidin-2-yl}-1H-pyrazol-1-yl)propanoate and ethyl 3-(4-{6-methyl-2-[2-(trimethylsilyl)ethoxy]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanoate



embedded image



(EV-AN7442-001)


To a solution of 2-chloro-4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidine (EV-AN7439-004,185 mg as a mixture of regioisomers, 0.76 mmol), ethyl 3-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propanoate (EV-AN7436-002, 93%, 358.56 mg, 1.13 mmol) and CsF (172.2 mg, 1.13 mmol) in DME, ethanol (2:1, 7.5 mL) was added Pd(PPh3)4 (87.33 mg, 0.08 mmol) and stirred under microwave conditions at 120° C. for 15 mins. The reaction mixture was cooled to r.t. and water (10 mL) and EtOAc (15 mL) were added. The organic fraction was extracted and the aqueous phase re-extracted with more EtOAc (2×5 mL). The combined organics were washed with brine solution (5 mL), dried over Na2SO4 and concentrated in vacuo. Purification by chromatography on SiO2 eluting with Heptane/EtOAc (gradient 100:0-0:100) to afford the title compound (285 mg, 81.1%, 2:1 mixture of regioisomers) as a clear oil.


Method A: LC-MS: m/z=+377.2 (M+H)+; RT=1.45 min.


Step 4: Synthesis 3-(4-{4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidin-2-yl}-1H-pyrazol-1-yl)propanoic acid and 3-(4-{6-methyl-2-[2-(trimethylsilyl)ethoxy]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanoic acid



embedded image



(EV-AN7445-001)


Ethyl 3-(4-{4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidin-2-yl}-1H-pyrazol-1-yl)propanoate (EV-AN7442-001, 285 mg (as a mixture of regioisomers), 0.76 mmol) was suspended in 2:2:1 THF/water/methanol (12.5 mL) and sodium hydroxide (147.13 mg, 3.68 mmol) was added. The reaction mixture was stirred at r.t. for 1 h. The organics were removed in vacuo and the aqueous solution acidified with 2M aq HCl solution and extracted with EtOAc (2×10 mL). The combined organics were dried over Na2SO4 and concentrated in vacuo to afford the title compound (239 mg, 94%, 2:1 mixture of regioisomers) as a colourless oil.


Method A: LC-MS: m/z=+349.2 (M+H)+; RT=1.27 min.


Step 5: Synthesis of 3-(4-{4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidin-2-yl}-1H-pyrazol-1-yl)-1-(1,2,3,4-tetrahydroisoquinolin-2-yl)propan-1-one and 3-(4-{6-methyl-2-[2-(trimethylsilyl)ethoxy]pyrimidin-4-yl}-1H-pyrazol-1-yl)-1-(1,2,3,4-tetrahydroisoquinolin-2-yl)propan-1-one



embedded image


To a solution of 3-(4-{4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidin-2-yl}-1H-pyrazol-1-yl)propanoic acid (EV-AN7445-001, 120 mg (as a mixture of regioisomers), 0.29 mmol) in DMF (4 ml) was added TBTU (278.63 mg, 0.87 mmol), DIPEA (0.12 mL, 0.72 mmol) and 1,2,3,4-tetrahydroisoquinoline (0.06 mL, 0.43 mmol) and stirred at r.t. for 15 h. To the reaction mixture was added ice water and extracted with EtOAc (2×5 mL). The combined organic extracts were washed with brine (5 mL), dried over Na2SO4 and concentrated in vacuo to afford the title compound (162 mg, 87%, as a mixture of regioisomers) as a colourless oil.


Method: LC-MS: m/z=+464.2 (M+H)+; RT=1.47 min.


Step 6: Synthesis of 6-methyl-2-{1-[3-oxo-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]-1H-pyrazol-4-yl}-3,4-dihydropyrimidin-4-one (Q-291, EV-AN7447-001) and 4-methyl-6-{1-[3-oxo-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]-1H-pyrazol-4-yl}-1,2-dihydropyrimidin-2-one



embedded image


3-(4-{4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidin-2-yl}-1H-pyrazol-1-yl)-1-(1,2,3,4-tetrahydroisoquinolin-2-yl)propan-1-one (EV-AN7446-001, 162 mg (as a mixture of regioisomers), 0.25 mmol) was dissolved in DCM (4 mL) and TFA (1 mL) was added. The reaction mixture was stirred for 1.5 h and then concentrated in vacuo. The crude residue was re-dissolved in DCM and washed with saturated NaHCO3 solution, dried over Na2SO4 and concentrated in vacuo afforded the title compounds as a mixture of regioisomers.


Purification by PREP-HPLC (Method G) afforded the first eluting isomer 6-methyl-2-{1-[3-oxo-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]-1H-pyrazol-4-yl}-3,4-dihydropyrimidin-4-one, Example 204 (Q-291, EV-AN7447-001) (20.2 mg, 22.1%) as an off white powder.


Method C: LC-MS: m/z=364.2 (M+H)+; RT=2.02


The second eluting isomer 4-methyl-6-{1-[3-oxo-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]-1H-pyrazol-4-yl}-1,2-dihydropyrimidin-2-one Example 205 (Q-292, EV-AN7447-002) (12.2 mg, 12.5%) was isolated as a beige powder.


Example 206—6-methyl-2-{1-[3-oxo-3-(pyrrolidin-1-yl)propyl]-1H-pyrazol-4-yl}-3,4-dihydropyrimidin-4-one (Q-283, EV-AN7448-001)

The title compound was prepared in an analogous manner to Example 204 provide the title compound (12.02 mg, 16.6%). The regioisomer could not be obtained in sufficient purity for testing.


Method C: LC-MS: m/z=302.1 (M+H)+; RT=1.40


Example 207—2-{3,5-dimethyl-1-[3-oxo-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]-1H-pyrazol-4-yl}-6-methyl-3,4-dihydropyrimidin-4-one



embedded image


The title compound was prepared in an analogous fashion to Example 204 using 3,5-dimethyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole in step 1 to provide the title compound (21.9 mg, 38.5).


Method C: LC-MS: m/z=392.2 (M+H)+; RT=2.15


Example 208—4-{3,5-dimethyl-1-[3-oxo-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]-1H-pyrazol-4-yl}-6-methyl-1,2-dihydropyrimidin-2-one (Q-285, EV-AN7453-002)

The title compound was prepared in an analogous fashion to Example 204 using 3,5-dimethyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole in step 1 to provide the title compound (17.5 mg, 31.1).


Method C: LC-MS: m/z=392.2 (M+H)+; RT=1.82 min.


Example 209—2-{3,5-dimethyl-1-[3-oxo-3-(pyrrolidin-1-yl)propyl]-1H-pyrazol-4-yl}-6-methyl-3,4-dihydropyrimidin-4-one



embedded image


The title compound (20.1 mg, 25.6%) was prepared in an analogous manner to Example 208 coupling with pyrrolidine.


Method C: LC-MS: m/z=330.2 (M+H)+; RT=1.57 min.


Example 210—Preparation of 4-methyl-6-{5-methyl-4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-1,2-dihydropyridin-2-one (Q-439, EV-AQ8815-001) and Example 211—4-methyl-6-{3-methyl-4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-1,2-dihydropyridin-2-one (Q-440, EV-AQ8815-002)
Step 1: Synthesis of 6-chloro-2-hydrazinylidene-4-methyl-1,2-dihydropyridine



embedded image


2,6-dichloro-4-methylpyridine (102 mg, 0.63 mmol) was heated to ˜110° C. in hydrazine hydrate (1 mL) for 3 hours. The solution was cooled to 0° C. and water (3 mL) was added. The resulting precipitate was isolated via filtration and washed with ice-cold water to yield 6-chloro-2-hydrazinylidene-4-methyl-1,2-dihydropyridine (32 mg, 32%) as a pale yellow powder.


LC-MS m/z=157.9 [M+H]+; RT=0.42 min.


Step 2: Synthesis of 2-chloro-4-methyl-6-{5-methyl-4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}pyridine and 2-chloro-4-methyl-6-{3-methyl-4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}pyridine



embedded image


To a stirred solution of (2E)-2-[(dimethylamino)methylidene]-1-[4-(trifluoromethyL)piperidin-1-yl]butane-1,3-dione (EV-AP2353-001, 927 mg, 3.17 mmol) in EtOH (7 mL) and AcOH (635 μL 11.1 mmol) was added 2-chloro-6-hydrazinyl-4-methylpyridine (500 mg, 3.17 mmol) and the reaction mixture was stirred at 80° C. overnight. The reaction was cooled ant the solvent removed in vacuo, the resulting residue was partitioned between DCM (50 mL) and sat. NaHCO3 (60 mL), the aqueous fraction was extracted with DCM (2×50 mL) and the combined organic fractions were dried (MgSO4) and concentrated in vacuo to yield 2-chloro-4-methyl-6-{5-methyl-4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}pyridine (1.08 g, 88%, mixture of regioisomers) as a yellow powder.


LC-MS m/z=387.1 [M+H]+; RT=1.41-1.43 min.


Step 3: Synthesis of 2-(benzyloxy)-4-methyl-6-{5-methyl-4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}pyridine and 2-(benzyloxy)-4-methyl-6-{3-methyl-4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}pyridine



embedded image


To a stirred solution of 2-chloro-4-methyl-6-{5-methyl-4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}pyridine (1.08 g, 2.79 mmol) (Crude mixture from containing regioisomers) in dioxane (15 mL) was added phenylmethanol (0.32 mL, 3.07 mmol), followed by t-BuOK (345 mg, 3.07 mmol) and the solution was heated to reflux overnight. A further 1.1 equivalents of t-BuOK (345 mg, 3.07 mmol) and phenylmethanol (0.32 mL, 3.07 mmol) were added and the reaction was refluxed for a further 3 hours. Saturated NH4Cl (50 mL) was added to the cooled solution and the mixture was extracted with EtOAc (2×80 mL), the combined organic fractions were dried over MgSO4, the solvent removed in vacuo and the resulting residue purified via chromatography on SiO2 eluting with 0:100-100:0 EtOAc-heptane) to afford the title compounds (593 mg, 82%, mixture of isomers) as an off-white powder.


LC-MS m/z=459.2 [M+H]+; RT=1.56-1.60 min.


Step 4: Synthesis of 4-methyl-6-{5-methyl-4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-1,2-dihydropyridin-2-one and 4-methyl-6-{3-methyl-4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-1,2-dihydropyridin-2-one



embedded image


To a stirred solution of 2-(benzyloxy)-4-methyl-6-{5-methyl-4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}pyridine (530 mg, 1.16 mmol, as a mixture of regioisomers) in EtOAc (25 mL) was added Pd on carbon (10%, 100 mg) and the solution exposed to an atmosphere of H2 (g) overnight. The solution was filtered through celite washing with EtOAc, the filtrate concentrated in vacuo and the residue purified via PREP-HPLC (Method G) to yield 4-methyl-6-{5-methyl-4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-1,2-dihydropyridin-2-one (42 mg, 10%) as a yellow powder and 4-methyl-6-{3-methyl-4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-1,2-dihydropyridin-2-one (118 mg, 28%) as a yellow powder.


LC-MS m/z=369.1 [M+H]+; RT=3.46 min.




embedded image


LC-MS m/z=369.1 [M+H]+; RT=3.67 min


Example 212—Preparation of 4-methyl-6-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-1,2-dihydropyridin-2-one, Q-460, EV-AQ7135-001



embedded image


Step 1: Synthesis of 2-chloro-4-methyl-6-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}pyridine



embedded image


To a solution of 1-(1H-pyrazole-4-carbonyl)-4-(trifluoromethyl)piperidine (EV-AQ8818-001, 91.55 mg, 0.37 mmol) and caesium carbonate (150.83 mg, 0.46 mmol) in DMF (2 mL) was added 2,6-dichloro-4-methylpyridine (50 mg, 0.31 mmol). The reaction mixture was stirred at 100° C. for 6 h. The reaction mixture was concentrated under vacuum. The residue was diluted with water and extracted with EtOAc. The organics were washed with brine (×2), dried over Na2SO4 and concentrated under vacuum. The crude residue was purified by chromatography on SiO2 eluting with 0-100% EtOAc in heptane to afford the title compound (45 mg, 39.1%) as an off-white powder.


Method A: LC-MS: m/z=373.1 (M+H)+; RT=1.43 min.


Step 2: Synthesis of 2-(benzyloxy)-4-methyl-6-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}pyridine



embedded image


To a solution of 2-chloro-4-methyl-6-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}pyridine (EV-AQ7130-001, 45 mg, 0.12 mmol) in dioxane (2 mL) was added benzyl alcohol (0.01 mL, 0.13 mmol) and potassium tert-butoxide (14.9 mg, 0.13 mmol) and the solution was heated at 90° C. for 4 h. The reaction mixture was concentrated under vacuum and purified by chromatography on SiO2 eluting with 0-100% EtOAc in heptane to afford the title compound (72 mg, 33.5%).


Method A: LC-MS: m/z=445.1 (M+H)+; RT=1.60 min.


Step 3: Synthesis of 4-methyl-6-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-1,2-dihydropyridin-2-one, Q-460, EV-AQ7135-001

Pd on carbon (10%, 17 mg) was added to a stirred solution of 2-(benzyloxy)-4-methyl-6-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}pyridine (EV-AQ7129-002, 72 mg, 0.16 mmol) in ethanol (5.0 mL) and the solution was stirred under an atmosphere of H2 overnight. More Pd on carbon (10%, 17 mg) was added to the reaction and the stir under an atmosphere of H2 was continued for a further 5 h. The solution was filtered through Celite, washing with EtOAc. The filtrate was concentrated under vacuum and the residue purified by Prep-HPLC (Method G) to afford the title compound (8.2 mg, 14.3%) as an off-white powder


Method C: LC-MS: m/z=355.2 (M+H)+; RT=2.84 min.


Example 213—Preparation of 6-{5-methyl-4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-4-(trifluoromethyl)-1,2-dihydropyridin-2-one



embedded image


Step 1: Synthesis of 2-chloro-6-hydrazinyl-4-(trifluoromethyl)pyridine



embedded image


Hydrazine hydrate (0.05 mL, 0.93 mmol) was added to a suspension of 2,6-dichloro-4-(trifluoromethyl)pyridine (100 mg, 0.46 mmol) in ethanol (2 mL) and the reaction vessel was sealed and heated at 40° C. for 1.5 h and then at 70° C. for another 5.5 h.


The solution was concentrated and the resulting solid was triturated with water to afford the title compound (70 mg, 51.5%) as a pale brown solid.


Method B: LC-MS: m/z=211.9 (M+H)+; RT=0.91 min.


Step 2: Synthesis of methyl 1-[6-chloro-4-(trifluoromethyl)pyridin-2-yl]-5-methyl-1H-pyrazole-4-carboxylate



embedded image


To a solution of 2-chloro-6-hydrazinyl-4-(trifluoromethyl)pyridine (EV-AQ7141-001, 770 mg, 3.64 mmol) and methyl 2-[(dimethylamino)methylidene]-3-oxobutanoate (90%, 934.57 mg, 4.91 mmol) in ethanol (22 mL) was added acetic acid (0.729 mL, 12.74 mmol) and the reaction mixture was stirred at r.t. for 5 mins and then heated at 50° C. for 1 h. The mixture was concentrated under vacuum and purified by chromatography on SiO2 Eluting with 0-100% EtOAc in heptane to afford the title compound (1.04 g, 88.5%) as a white powder.


Method B: LC-MS: m/z=320.0 (M+H)+; RT=1.35 min.


Step 3: Synthesis of methyl 1-[6-(benzyloxy)-4-(trifluoromethyl)pyridin-2-yl]-5-methyl-1H-pyrazole-4-carboxylate



embedded image


To a solution of methyl 1-[6-chloro-4-(trifluoromethyl)pyridin-2-yl]-5-methyl-1H-pyrazole-4-carboxylate (EV-AQ7144-001, 600 mg, 1.88 mmol) in dioxane (10 mL) was added benzyl alcohol (0.21 mL, 2.06 mmol) and potassium tert-butoxide (231.68 mg, 2.06 mmol). The reaction mixture was stirred at 60° C. for 0.5 h. The reaction mixture was concentrated under vacuum, diluted with water (10 mL), and extracted with EtOAc (25 mL). The organics were washed with brine, dried (Na2SO4) and concentrated under vacuum. The crude material was purified by chromatography on SiO2 eluting with 0-50% EtOAc in heptane to afford the title compound (629 mg, 48%) (mixture with the benzyl ester) of as a clear oil.


Method B: LC-MS: m/z=392.1 (M+H)+; RT=1.39 min.


Step 3: Synthesis of 5-methyl-1-[6-oxo-4-(trifluoromethyl)-1,6-dihydropyridin-2-yl]-1H-pyrazole-4-carboxylic acid



embedded image


Pd on carbon (10%, 86 mg) was added to a stirred solution of methyl 1-[6-(benzyloxy)-4-(trifluoromethyl)pyridin-2-yl]-5-methyl-1H-pyrazole-4-carboxylate (EV-AQ7147-001, (mixture with the benzyl ester) (629 mg, 1.61 mmol)) in ethyl acetate (15.0 mL) and the solution was stirred under an atmosphere of H2 overnight. The reaction mixture was filtered through Celite, washing with EtOAc. The filtrate was concentrated in vacuo and purified by chromatography on SiO2 Eluting with 0-100% EtOAc in heptane to afford the title compound (107 mg, 21.6%) as an off white powder.


Method B: LC-MS: m/z=287.9 (M+H)+; RT=1.01


Step 4: Synthesis of 6-{5-methyl-4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-4-(trifluoromethyl)-1,2-dihydropyridin-2-one, Q-466, EV-AQ7151-002

To a solution of 5-methyl-1-[6-oxo-4-(trifluoromethyl)-1,6-dihydropyridin-2-yl]-1H-pyrazole-4-carboxylic acid (200 mg, 0.70 mmol) in THF (6.0 mL) was added DIPEA (0.417 mL, 2.44 mmol) and T3P 50% in EtOAc (0.821 ml, 1.39 mmol). The reaction mixture was stirred at r.t. for 10 mins and 4-(trifluoromethyl)piperidin-1-ium. HCl (158.45 mg, 0.84 mmol) was added before stirring for a further 1 h. The reaction mixture concentrated in vacuo and the crude residue was then suspended in water (5 mL) and DCM (10 mL). The organics were extracted and the aqueous phase was then acidified to pH3-4 and extracted with more DCM (5 mL). The combined organics were dried (Na2SO4), filtered and concentrated in vacuo. The crude material was purified by PREP-HPLC (Method G) method) to afford the title compound (19.1 mg, 6.4%) of as an off-white powder.


Method C: LC-MS: m/z=423.1 (M+H)+; RT=3.41


Example 214—Preparation of 5-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-6H,7H-thieno[2,3-c]pyridin-7-one (Q-511, EV-AR5370-002)
Step 1: Synthesis of 5-chloro-7-[(4-methoxyphenyl)methoxy]-6H,7H-thieno[2,3-c]pyridine



embedded image


To a solution of 5-chloro-7-[(4-methoxyphenyl)methoxy]thieno[2,3-c]pyridine (EV-AR5360-001, 200 mg, 0.65 mmol) in DMF (3 ml) was added caesium carbonate (341 mg, 1.05 mmol) and 1-(1H-pyrazole-4-carbonyl)-4-(trifluoromethyl)piperidine (Intermediate 29, EV-AQ8818-001, 178 mg, 0.719 mmol) and stirred at 140° C. for 5 h. The reaction mixture was concentrated in vacuo and purified by PREP-HPLC (Method G) to afford the title compound (56 mg, 44%) as an off white powder.


Method B: LC-MS m/z=185.8 [M+H]+; RT=0.86 min.


Step 2: Synthesis of 5-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]-1H-pyrazol-1-yl}-6H,7H-thieno[2,3-c]pyridin-7-one



embedded image


To a solution of 5-chloro-7-[(4-methoxyphenyl)methoxy]-6H,7H-thieno[2,3-c]pyridine (EV-AR5366-003, 56 mg, 0.302 mmol) in DMF (1 ml) was added 1-(1H-pyrazole-4-carbonyl)-4-(trifluoromethyl)piperidine (Intermediate 29, 89 mg, 0.362 mmol), caesium carbonate (147 mg, 0.453 mmol), L-proline (14 mg, 0.121 mmol) and copper (I) iodide (11 mg, 0.06 mmol). The reaction mixture was then de-gassed and stirred at 140° C. for 16 h. The reaction mixture was cooled to r.t., diluted with EtOAc (20 ml) and washed with brine (2×10 ml). The organic extracts were dried over sodium sulfate, concentrated in vacuo and purified by PREP-HPLC (Method G) followed by trituration using MeCN, to afford the title compound (32 mg, 27%) as an off white powder.


Method C: LC-MS m/z=397.1 [M+H]+; RT=2.67 min.


Example 216—Preparation of 2-{5-[4-(trifluoromethyl)piperidine-1-carbonyl]-1,3-thiazol-2-yl}-3H,4H-thieno[3,2-d]pyrimidin-4-one
Step 1: Synthesis of 2-(ethoxycarbonyl)-1,3-thiazole-5-carboxylic acid



embedded image


To a solution of bromopyruvic acid (2.0 g, 11.98 mmol) in anhydrous 1, 4-dioxane (20 ml) was added ethyl amino(thioxo)acetate (1.60 g, 11.98 mmol) and stirred at 100° C. overnight. The reaction mixture was cooled to room temperature, basified with saturated NaHCO3 solution and extracted with EtOAc (2×20 ml). The organic extracts were discarded. The aqueous extracts were then acidified to pH 3/4 using 5M aq HCl solution and extracted with EtOAc (2×50 ml). The organic extracts were dried over sodium sulfate and concentrated in vacuo to afford the title compound (1.34 g, 54%) as an orange powder.


Method B: LC-MS m/z=201.85 [M+H]+; RT=0.80 min.


Step 2: Synthesis of ethyl 5-[4-(trifluoromethyl)piperidine-1-carbonyl]-1,3-thiazole-2-carboxylate



embedded image


To a suspension of 2-(ethoxycarbonyl)-1,3-thiazole-5-carboxylic acid (EV-AS5405-001, 1.34 g, 6.66 mmol) in THF (15 ml) was added DIPEA (2.9 ml, 16.7 mmol), T3P (50% in EtOAc) (9.8 ml, 16.7 mmol) and 4-(trifluoromethyl)piperidine hydrochloride (1.39 g, 7.33 mmol) and stirred at r.t. for 2 h. The reaction mixture was concentrated in vacuo and to the crude residue added DCM (40 ml) and saturated NaHCO3 solution (20 ml). The organic layer was extracted, washed with water (10 ml), dried over sodium sulfate and concentrated in vacuo to afford the title compound (2.13 g, 75%) as a brown powder.


Method B: LC-MS m/z=337.0 [M+H]+; RT=1.09 min.


Step 3: Synthesis of 5-[4-(trifluoromethyl)piperidine-1-carbonyl]-1,3-thiazole-2-carboxylic acid



embedded image


To a solution of ethyl 5-[4-(trifluoromethyl)piperidine-1-carbonyl]-1,3-thiazole-2-carboxylate (EV-AS5406-001, 79%, 2.10 g, 4.93 mmol) in THF (10 mL) and water (5 ml) was added 3M aqueous NaOH solution (8.22 ml) and stirred at r.t. for 2 h. The reaction mixture was concentrated in vacuo to remove the organic solvent and the aqueous mixture acidified to pH 2/3 using 5M aq HCl solution. The reaction mixture was extracted with EtOAc (2×50 ml) and the combined organic extracts dried over sodium sulfate and concentrated in vacuo to afford the title compound (874 mg, 40%) as a brown solid.


Method B: LC-MS m/z=308.85 [M+H]+; RT=0.87 min.


Step 4: Synthesis of N-(2-carbamoylthiophen-3-yl)-5-[4-(trifluoromethyl)piperidine-1-carbonyl]-1,3-thiazole-2-carboxamide



embedded image


To a solution of 5-[4-(trifluoromethyl)piperidine-1-carbonyl]-1,3-thiazole-2-carboxylic acid (EV-AS5407-001, 70%, 872 mg, 1.98 mmol) in THF (10 ml) was added HATU (904 mg, 2.38 mmol), DIPEA (848 μl, 4.95 mmol) and 3-aminothiophene-2-carboxamide (310 mg, 2.18 mmol) and stirred at r.t. for 2 h. The reaction mixture was concentrated in vacuo and redissolved in DCM (2 ml) and water (1 ml). The reaction mixture was filtered through a phase separator cartridge, concentrated in vacuo and purified by chromatography, eluting with DCM/MeOH (gradient 100:0-95:5) to afford the title compound (1.03 g, 88%) as an orange oil.


Method B: LC-MS m/z=432.90 [M+H]+; RT=1.09 min.


Step 5: Synthesis of 2-{5-[4-(trifluoromethyl)piperidine-1-carbonyl]-1,3-thiazol-2-yl}-3H,4H-thieno[3,2-d]pyrimidin-4-one



embedded image


To a solution of N-(2-carbamoylthiophen-3-yl)-5-[4-(trifluoromethyl)piperidine-1-carbonyl]-1,3-thiazole-2-carboxamide (EV-AS5408-002, 73%, 45 mg, 0.076 mmol) in MeOH (3 ml) was added 1M aq NaOH solution (380 μl, 0.38 mmol) and stirred at 70° C. for 2 h. The reaction mixture was filtered to remove the precipitate, the filtrate extracted with EtOAc (2×10 ml) and the organic extracts discarded. The aqueous extracts were then acidified to pH 4/5 using 2M aq HCl solution. A white precipitate formed which was filtered, washing with water and purified by PREP-HPLC (Method G) to afford the title compound (12 mg, 38%) as a white powder.


Method C: LC-MS m/z=415.0 [M+H]+; RT=2.84 min.


Example 218—Preparation of 2-(5-methyl-4-{2,2,2-trifluoro-1-[4-(trifluoromethyl)piperidin-1-yl]ethyl}-1H-pyrazol-1-yl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (Q-503, EV-AQ7177-001)



embedded image


Step 1: Synthesis of 2-[5-methyl-4-(trifluoroacetyl)-1H-pyrazol-1-yl]-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a solution of 2-hydrazinyl-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-AQ7134-001, 150 mg, 0.9 mmol, Intermediate 17) in THF (15 mL) at −10° C. was added dropwise 3-(ethoxymethylidene)-1,1,1-trifluoropentane-2,4-dione (prepared using the procedure described in Journal of Fluorine Chemistry. 136, 38-42; 2012) (EV-AQ7167-001, 199.17 mg, 0.95 mmol) in THF (5 mL) over 20 mins and stirred at −10° C. for 30 mins and at r.t. for a further 1 h. The reaction mixture was concentrated in vacuo and dissolved in DCM. The organics were washed with brine, dried over Na2SO4 and concentrated in vacuo to afford the title compound (310 mg, 92.4%) as an orange powder, which ionised in the LC-MS as a mixture of ketone and dehydrate.


Method B: LC-MS m/z=331.0 [M+H]+; RT=0.98 min; 313.0 [M+H]+; RT=1.14 min


Step 2: Synthesis of 2-[5-methyl-4-(2,2,2-trifluoro-1-hydroxyethyl)-1H-pyrazol-1-yl]-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a solution of NaBH4 (49.68 mg, 1.31 mmol) in MeOH (1 mL) was added 1M aqueous NaOH solution (0.1 mL) followed by 2-[5-methyl-4-(trifluoroacetyl)-1H-pyrazol-1-yl]-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-AQ7169-001, 100 mg, 0.32 mmol) in MeOH (2 mL) and stirred at r.t. for 1 h. The reaction mixture was quenched with water (˜2 mL) and concentrated in vacuo. The residue was dissolved in EtOAc, washed with water (3 mL) and brine (3 mL), dried over Na2SO4 and concentrated in vacuo to afford the title compound (95 mg, 94.4%) as an orange powder.


Method B: LC-MS m/z=315.0 [M+H]+; RT=0.99 min


Step 3: Synthesis of 2-(5-methyl-4-{2,2,2-trifluoro-1-[4-(trifluoromethyl)piperidin-1-yl]ethyl}-1H-pyrazol-1-yl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a solution of 2-[5-methyl-4-(2,2,2-trifluoro-1-hydroxyethyl)-1H-pyrazol-1-yl]-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-AQ7174-001, 90 mg, 0.29 mmol) in DCM (3.5 mL) at −10° C. was added Et3N (0.12 mL, 0.86 mmol) followed by triflic anhydride (0.08 mL, 0.50 mmol) and stirred at −10° C. for 1 h. The reaction mixture was washed with cold saturated NaHCO3 solution (3 mL) and water (3 mL). The organic extracts were then dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in THF (3 mL), cooled to 0° C., added to a stirred solution of 4-(trifluoromethyl)piperidin-1-ium HCl (108.6 mg, 0.57 mmol) and potassium carbonate (118.74 mg, 0.86 mmol) and stirred at 0° C.—r.t. for 15 h. The reaction mixture was concentrated in vacuo and partitioned between DCM (2 mL) and water (1 mL). The organics were isolated using a phase separator cartridge, concentrated in vacuo and purified by PREP-HPLC (Method G) to afford the title compound (21 mg, 16.3%) as brown powder.


Method C: LC-MS m/z=450.1 [M+H]+; RT=2.98 min


Example 219—Preparation of 3-methyl-5-{5-methyl-4-[4-(trifluoromethyL)piperidine-1-carbonyl]-1H-pyrazol-1-yl}phenol (Q-494, EV-AR5355-002)

Step 1: Synthesis of 2-[4-(hydroxymethyL)-5-methyl-1H-pyrazol-1-yl]-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one




embedded image


To a solution of methyl 5-methyl-1-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylate (Intermediate 18 step 1, EV-AQ7137-001, 1 g, 3.65 mmol) in THF (20 mL) at 0° C. was added dropwise lithium aluminium hydride (2.4 M solution in THF, 1.82 mL, 4.35 mmol) and stirred at r.t. for 15 h. The reaction mixture was quenched by the addition of water (15 mL) and filtered through Celite, washing with methanol (15 mL). The filtrate was concentrated in vacuo to afford the title compound (650 mg, 62%) as a pale yellow powder:


Method B: LC-MS m/z=245 [M+H]+; RT=0.89 min


Step 2: Synthesis of 5-methyl-1-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}-1H-pyrazole-4-carbaldehyde



embedded image


To a solution of 2-[4-(hydroxymethyL)-5-methyl-1H-pyrazol-1-yl]-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-AQ7157-001, 650 mg, 2.64 mmol) in DCM (20 mL) and MeOH (10 mL) was added manganese (IV) oxide (1.84 g, 21.12 mmol) and stirred at r.t. for 15 h. A further portion of manganese (IV) oxide (1.84 g, 21.12 mmol) was added and stirred at r.t. for 6 h. A further portion of manganese (IV) oxide (0.92 g, 10.56 mmol) was added and stirred at r.t. for 4 days. The reaction mixture was filtered through Celite, washing with DCM and MeOH, and the filtrate concentrated in vacuo to afford the title compound (558 mg, 68%) as a beige powder.


Method B: LC-MS m/z=245 [M+H]+; RT=0.89 min


Step 3: Synthesis of 1-[(5-methyl-1-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}-1H-pyrazol-4-yL)methyl]piperidin-2-one



embedded image


To a solution of 5-methyl-1-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}-1H-pyrazole-4-carbaldehyde (EV-AQ7158-001, 80%, 90 mg, 0.295 mmol) in anhydrous MeOH (3 mL) was added ethyl 5-aminopentanoate hydrochloride (59 mg, 0.324 mmol) and Et3N (164 μl, 1.179 mmol) and stirred at r.t. for 1 h. To the reaction mixture was added NaBH4 (13 mg, 0.354 mmol) and stirred at 45° C. for 16 h. The reaction mixture was stirred at 50° C. for a further 3 h. The reaction mixture was cooled to r.t. and diluted with water (10 mL). The aqueous mixture was then acidified to pH 4 using 5 M aq HCl solution and extracted with EtOAc (2×30 mL). The combined extracts were dried over sodium sulfate, concentrated in vacuo and purified via PREP-HPLC (Method G) to afford the title compound (5 mg, 5%) as an off white powder.


Method C: LC-MS m/z=328.1 [M+H]+; RT=2.19 min.


Example 220
Step 1: Synthesis of ethyl 1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-4-carboxylate



embedded image


To a solution of ethyl 1H-pyrazole-4-carboxylate (143 m g, 1.022 mol) in DMF (5 mL) at 0° C. was added NaH (60% in oil) (60%, 45 mg, 1.12 mmol). The reaction mixture was warmed to r.t. over 30 minutes before 2-methanesulfonyl-4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidine (Example 196 step 2, EV-AO5710-002, 300 mg, 0.97 mmol) was added in more DMF (1 mL). The reaction mixture was stirred at r.t. for 3 h. The reaction mixture was quenched by the addition of water (20 mL) and extracted with EtOAc (3×30 mL). The combined organic fractions were washed with brine (20 mL), dried (Na2SO4) and concentrated under vacuum to an opaque gum which was purified by chromatography on SiO2 eluting with 12-100% EtOAc in heptane to afford the title compound (266 mg, 66% yield) as a white powder.


Method A: LC-MS: m/z=+391.10 (M+Na)+1.41 min


Step 2: Synthesis of 1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid



embedded image


To a solution of ethyl 1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-4-carboxylate (EV-AN0096-002 (266 mg, 0.64 mmol) in THF (10 ml) was added NaOH (3M, 1 ml) and the reaction was stirred at room temperature for 18 h. More NaOH (2.5M, 1.5 ml) was added along with MeOH (1 ml) and the reaction stirred for a further 7 h. The Organic solvent was evaporated in vacuo and the aqueous phase acidified to pH1 with HCl (1M). The mixture was extracted with EtOAc (3×30 ml), washed with brine (2×20 ml), dried (Na2SO4) and evaporated to afford the title compound (199 mg, 64%) as a colourless gum.


Method A: LC-MS: m/z=+363.0 (M+Na)+1.20 min


Step 3: Synthesis of 2-(1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-4-carbonyl)-1,2,3,4-tetrahydroisoquinoline



embedded image


To a stirred solution of 1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid (EV-AN0090-001, 199 mg, 0.58 mmol) in DMF (1 ml) was added DIPEA (255 μl, 1.46 mmol) followed by TBTU (225 mg, 0.7 mmol). The reaction was stirred for 3 min after which time 1,2,3,4-tetrahydroisoquinoline (101 mg, 0.76 mmol) was added and then the reaction was placed under N2. The reaction was stirred for 16 hours and then quenched with water (20 ml) and extracted with DCM (3×30 ml). The organics were washed with brine (2×50 ml), dried (Na2SO4) and evaporated under vacuum, followed by azeotrope with heptane (2×50 mL) to remove residual DMF. The crude product was purified by chromatography on SiO2 eluting with 25-100% EtOAc in heptane gradient to afford the title compound (220 mg, 72%) as a colourless gum.


Method C: LC-MS: m/z=456.2 (M+H)+1.40 min


Step 4: Synthesis of 6-methyl-2-[4-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-pyrazol-1-yl]-3,4-dihydropyrimidin-4-one



embedded image


2-(1-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-1H-pyrazole-4-carbonyl)-1,2,3,4-tetrahydroisoquinoline (EV-AO8800-002, 220 mg, 0.42 mmol) was dissolved in DCM (3 mL) and TFA (0.35 mL) was added. The reaction mixture was stirred for 1 hour and 30 minutes and then concentrated under vacuum. The crude residue was then re-dissolved in DCM (30 ml) and washed with sodium bicarbonate solution (sat, 2×10 ml), dried (Na2SO4) and concentrated under vacuum. The crude material was purified by preparative HPLC (Method G) to afford the title compound (46 mg, 33%) as an off white solid


Method C: LC-MS: m/z=336.1 (M+H)+2.38 min


Example 221—Preparation of 6-methyl-2-[4-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-1,2,3-triazol-1-yl]-3,4-dihydropyrimidin-4-one (Q-312, EV-A05730-002)
Step 1: Synthesis of 5-methyl-3H,7H-[1,2,3,4]tetrazolo[1,5-a]pyrimidin-7-one



embedded image


To a solution of hydrazinyl-6-methyl-3,4-dihydropyrimidin-4-one (Intermediate 1, EV-AN7477-001, 0.5 g, 3.6 mmol) in ice cold acetic acid (3 mL) was added dropwise a solution of sodium nitrite (0.37 g, 5.4 mmol) in water (0.4 mL). The reaction mixture was stirred at 5° C. for 1 hour and then concentrated in vacuo. The residue was triturated from water, filtered and dried in vacuo to afford the title compound (335 mg, 59%) as a colourless solid.


Method A: LC-MS m/z=152.1 [M+H]+; RT=0.24 min


Step 2: Synthesis of methyl 1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-1,2,3-triazole-4-carboxylate



embedded image


A solution of tert-butanol-water 1:1 (4 mL) was degassed with a stream of nitrogen for 5 minutes and methyl-3H,7H-[1,2,3,4]tetrazolo[1,5-a]pyrimidin-7-one (EV-AO05708-001, 200 mg, 1.32 mmol), copper (I) chloride (26 mg, 0.26 mmol) and methyl propionate (98%, 227 mg, 2.65 mmol) were added. The reaction mixture was stirred at 70° C. for 6 hours. The reaction mixture was diluted with CHCl3-10% IPA (5 mL) and washed with water (5 mL) and brine (5 mL). The aqueous phase was re-extracted with CHCl3-10% IPA (3×5 mL) and the combined organics were dried (Na2SO4) and concentrated in vacuo. Purification by chromatography on SiO2, eluting with DCM/Ammonia (7M in methanol) 0-100%) afforded the title compound (183 mg, 53%) as a pale solid.


Method A: LC-MS m/z=235.9 [M+H]+; RT=0.90 min


Step 3: Synthesis of 1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-1,2,3-triazole-4-carboxylic acid



embedded image


To a solution of methyl 1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-1,2,3-triazole-4-carboxylate (EV-AO5726-001, 190 mg, 0.71 mmol) in methanol (3 mL) was added 1M KOH (1.25 mL, 1.25 mmol) and the mixture was stirred at r.t. for 4 hours. The reaction mixture was concentrated in vacuo and acidified with HCl (3M, 0.4 mL). The resulting precipitate was collected by filtration, washed with water (2×1 mL) and dried under vacuum to afford the title compound (137 mg, 83%) as a light brown solid.


Method A: LC-MS m/z=221.9 [M+H]+; RT=0.70 min.


Step 4: Synthesis of 6-methyl-2-[4-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-1,2,3-triazol-1-yl]-3,4-dihydropyrimidin-4-one, Q-312, EV-A05730-002



embedded image


To a solution of 1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-1,2,3-triazole-4-carboxylic acid (EV-A05728-001 (130 mg, 0.56 mmol) in DMF (2 mL) was added DIPEA (233.05 μl, 1.4 mmol and COMU (98%, 268.42 mg, 0.61 mmol). The reaction mixture was stirred at r.t. for 2 minutes and 1,2,3,4-tetrahydroisoquinoline (98%, 83.48 mg, 0.61 mmol) was added and the reaction stirred at r.t. for a further 24 hours. Further COMU (98%, 268.42 mg, 0.61 mmol) and 1,2,3,4-tetrahydroisoquinoline (98%, 83.48 mg, 0.61 mmol) were added and the mixture stirred at r.t. for 2 hr.


The reaction mixture was concentrated in vacuo and diluted with DCM (10 ml). The mixture was washed with HCl (1 M 2×5 mL), water (5 mL) and brine (5 mL), dried (Na2SO4) and concentrated in vacuo. Purification by chromatography on SiO2 eluting with DCM/methanol (0-2%) followed by preparative HPLC (Method G) afforded the title compound (36 mg, 19%) as a colourless solid.


Method C: LC-MS: m/z=337.1 (M+H)+; RT=2.56 min


Example 222—Preparation of 2-{5-[4-(trifluoromethyl)piperidine-1-carbonyl]pyridin-2-yl}-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one 0-472 (EV-AR5325-002)
Step 1: Preparation of 2-(5-bromopyridin-2-yl)-1H,2H,3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a solution of 5-bromopyridine-2-carboximidamide (917 mg, 4.584 mmol) in dry MeOH (10 ml) was added methyl-2-oxocyclopentane-1-carboxylate (1.1 eq, 569 μl, 4.584 mmol), followed by NaOMe (5.4 M in MeOH) (1.1 eq, 934 μl, 5.043 mmol) and stirred at 60° C. for 20 h. A further portion of methyl-2-oxocyclopentane-1-carboxylate (0.1 eq, 57 μl, 0.458 mmol) and NaOMe (5.4 M in MeOH) (0.1 eq, 85 μl, 0.458 mmol) was added and stirred at 60° C. for 1 h. The reaction mixture was concentrated in vacuo, the residue redissolved in water and the solution acidified to pH 3 using 2 M aqueous HCl solution. The precipitate was filtered under vacuum filtration, washed with water and Et2O, and dried to afford the title compound (832 mg, 62%) as a cream powder.


Method C: LC-MS m/z=295.0 [M+H]+; RT=2.53 min.


Step 2: Preparation of methyl-6-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}pyridine-3-carboxylate



embedded image


To a suspension of 2-(5-bromopyridin-2-yl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-AR5317-001, 690 mg, 2.36 mmol) in THF (3 ml) was added MeOH (3 ml), Mo(CO)6 (249 mg, 0.945 mmol), Pd(OAc)2 (53 mg, 0.236 mmol), tBu3P (96 mg, 0.472 mmol) and DBU (705 μl, 4.724 mmol) and stirred at 120° C. overnight. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3×20 mL). The combined organic extracts were washed with saturated brine solution (10 mL), dried over Na2SO4, concentrated in vacuo and purified via chromatography on SiO2 eluting with (100:0-95:5, DCM-MeOH) followed by trituration using THF to afford the title compound (109 mg, 17%) as an off white powder.


Method C: LC-MS m/z=272.1 [M+H]+; RT=2.27 min.


Step 3: Preparation of 5-cyclopropyl-1-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}-1H-pyrazole-4-carboxylic acid



embedded image


To a solution of methyl 6-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}pyridine-3-carboxylate (EV-AR5321-002, 100 mg, 0.369 mmol) in THF (5 mL) was added 3M aqueous NaOH solution (737 μl, 2.21 mmol) and stirred at r.t. for 1 h. The reaction mixture was concentrated in vacuo to remove the organic solvent and the aqueous mixture acidified to pH 4 using 5M aq HCl solution; a white precipitate formed. The reaction mixture was filtered under vacuum to afford the title compound (65 mg, 53%) as an off white powder.


Method B: LC-MS m/z=258.0 [M+H]+; RT=0.84 min.


Step 4: Preparation of 2-{5-[4-(trifluoromethyl)piperidine-1-carbonyl]pyridin-2-yl}-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a suspension of 6-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}pyridine-3-carboxylic acid (EV-AR5324-001, 64 mg, 0.249 mmol) in THF (3 ml) was added DIPEA (130 μl, 0.746 mmol), T3P (50% in EtOAc) (440 μl, 0.746 mmol) and 4-(trifluoromethyl)piperidine hydrochloride (52 mg, 0.274 mmol) and stirred at r.t. for 2 h. The reaction mixture was concentrated in vacuo and redissolved in EtOAc (20 ml). The reaction mixture was then washed with water (10 ml), the organic extracts dried over sodium sulfate, concentrated in vacuo and purified via PREP-HPLC (Method G) to afford the title compound (45 mg, 46%) as a white powder.


Method C: LC-MS m/z=393.2 [M+H]+; RT=2.65 min.


Example 223—Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]pyridin-2-yl}-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one
Step 1: Preparation of 4-bromopyridine-2-carboxamidine hydrochloride



embedded image


To a solution of 4-bromopyridine-2-carbonitrile (1 g, 5.46 mmol) in anhydrous MeOH (4 mL) was added sodium methoxide in MeOH (0.5 M, 2.19 mL, 1.1 mmol) and stirred at r.t. for 4 h. To the reaction mixture was added ammonium chloride (0.32 g, 6 mmol) and stirred at r.t. overnight. The reaction was diluted with ether (10 mL) and stirred at r.t. for 30 mins. A precipitate formed that was collected by filtration, washed with ether (2×4 mL) and dried under vacuum to afford the title compound (967 mg, 74.8%) as a white powder.


Method B: LC-MS m/z=199.8, 201.9 [M+H]+; RT=0.2 min.


Step 2: Preparation of 2-(4-bromopyridin-2-yl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


Methyl 2-oxocyclopentane-1-carboxylate (609.16 μl, 4.91 mmol) and 4-bromopyridine-2-carboxamidine hydrochloride (0.97 g, 4.09 mmol) were dissolved in NaOMe in MeOH (0.5 M, 9.8 mL, 4.9 mmol) at r.t. under an atmosphere of nitrogen, and stirred at 60° C. overnight. The reaction mixture was concentrated in vacuo, the residue re-dissolved in water and the solution acidified to pH 3 using 2 M aq HCl solution. The precipitate was collected by filtration, washed with water and diethyl ether, and dried to afford the title compound (783 mg, 65.6%) as a brown powder.


Method B: LC-MS m/z=293.85/295 [M+H]+; RT=1.04 min.


Step 3: Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]pyridin-2-yl}-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a solution of 2-(4-bromopyridin-2-yl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (50 mg, 0.17 mmol) in anhydrous 1,4-dioxane (2 mL) under nitrogen was added 4-(trifluoromethyl)piperidin-1-ium chloride (97.36 mg, 0.51 mmol), palladium acetate (2.88 mg, 0.01 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphane) (14.86 mg, 0.03 mmol), tripotassium phosphate (0.09 ml, 1.03 mmol), hexakis(oxomethylidene)molybdenum (18.07 mg, 0.07 mmol) and N,N-dimethylpyridin-4-amine (41.82 mg, 0.34 mmol). The reaction vessel was de-gassed and back filled with nitrogen (×3), sealed and heated at 140° C. for 45 mins. The reaction mixture was diluted with EtOAc, concentrated on to silica and purified by chromatography on SiO2 eluting with 0-5% MeOH/DCM then 5-15% rapid flush to yield a brown gum. The crude material was dissolved in IPA (0.3 mL) and treated with (2E)-but-2-enedioic acid (0.01 ml, 0.09 mmol) solution in IPA and stirred at r.t. for 4 mins before diethyl ether (1 mL) was added. A precipitate slowly formed over 3 h and was left standing overnight. The precipitate was collected by filtration, washed with ether (2×1 mL) and dried under vacuum to provide the title compound (9.7 mg, 14.2%) as a pale beige solid.


Method C: LC-MS m/z=393.1 [M+H]+; RT=2.59 min.


Example 224—Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]pyridin-2-yl}-3H,4H-thieno[3,2-d]pyrimidin-4-one
Step 1: Preparation of phenyl 2-cyanopyridine-4-carboxylate



embedded image


4-bromopyridine-2-carbonitrile (150 mg, 0.82 mmol), phenyl formate (0.12 ml, 1.07 mmol), palladium(II) acetate (5.52 mg, 0.02 mmol), tri-tert-butylphosphonium tetrafluoroborate (28.54 mg, 0.1 mmol) and N,N-diethylethanamine (0.15 ml, 1.07 mmol) were added to a microwave vessel under an atmosphere of nitrogen. The reaction vessel was de-gassed and back filled with nitrogen (×3), sealed and heated at 140° C. for 20 mins under microwave irradiation. A further portion of palladium(II) acetate (5.52 mg, 0.02 mmol) and tri-tert-butylphosphonium tetrafluoroborate (28.54 mg, 0.1 mmol) was added and the reaction vessel de-gassed and back filled with nitrogen (×3), sealed and heated at 140° C. for 45 mins under microwave irradiation. The resultant mixture was diluted with water (4 mL) and DCM (3 mL), stirred vigorously and the phases separated using a phase separator cartridge. The aqueous was re-extracted with DCM (×2) and the organic extracts separated using a phase separator. The combined organic extracts were concentrated in vacuo and purified by chromatography on SiO2, eluting with Heptane/EtOAc (gradient 100:0-55:45) to afford the title compound (94 mg, 51%) as a pale yellow gum that solidified on standing.


Method B: LC-MS m/z=224.9 [M+H]+; RT=1.11 min.


Step 2: Preparation of 4-[4-(trifluoromethyl)piperidine-1-carbonyl]pyridine-2-carbonitrile



embedded image


To a solution of phenyl 2-cyanopyridine-4-carboxylate (101 mg, 0.45 mmol) in anhydrous THF (1 mL), under an atmosphere of nitrogen, was added 4-(trifluoromethyl)piperidin-1-ium chloride (128.12 mg, 0.68 mmol), N,N-diethylethanamine (0.13 ml, 0.9 mmol) and N,N-dimethylpyridin-4-amine (2.75 mg, 0.02 mmol) and the suspension stirred at 45° C. for 4-5 h. The reaction mixture was diluted with DCM, concentrated on to silica (1.5 g) and purified by chromatography on SiO2 eluting with Heptane/EtOAc (gradient 100:0-70:30), followed by DCM/MeOH (gradient 100:0-45:55), to afford the title compound (102 mg, 80%) as a colourless glass.


Method B: LC-MS m/z=284.0 [M+H]+; RT=1.02 min


Step 3: Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]pyridin-2-yl}-3H,4H-thieno[3,2-d]pyrimidin-4-one



embedded image


To a solution of 4-[4-(trifluoromethyl)piperidine-1-carbonyl]pyridine-2-carbonitrile (0.1 g, 0.36 mmol) and methyl 3-aminothiophene-2-carboxylate (0.06 g, 0.4 mmol) in THF (2.5 mL) at 0° C. under an atmosphere of nitrogen was added potassium tert-butoxide (0.04 g, 0.4 mmol) and stirred at 0° C.—r.t. for 3 h. The reaction mixture was concentrated in vacuo, diluted with saturated ammonium chloride (5 mL) and water and stirred at r.t. The mixture was extracted with DCM (×2), followed by EtOAc, and the combined organic extracts dried over Na2SO4 and concentrated in vacuo. The crude residue was stirred in diethyl ether (9 mL) for 30 mins at r.t. and the resultant solid was filtered, washing with diethyl ether (×2) and dried under vacuum to yield the title compound (58 mg, 38.6%) as a white solid.


Method C: LC-MS m/z=409.1 [M+H]+; RT=2.75 min


Example 225—Synthesis of 2-(4-{[4-(trifluoromethyl)piperidin-1-yl]sulfonyl}pyridin-2-yl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


In a pressure tube palladium(II) acetate (0.01 g, 0.03 mmol), N,N,N-tributylbutan-1-aminium bromide (182 mg, 0.56 mmol), triphenylphosphine (20 mg, 0.08 mmol), sodium formate (77 mg, 1.13 mmol), 1,10-phenanthroline hydrate (1:1) (0.02 g, 0.08 mmol) and dipotassium oxidosulfanesulfonate oxide (0.23 g, 1.03 mmol) were stirred vigorously in anhydrous DMSO (3 mL), under an atmosphere of nitrogen before 2-(4-bromopyridin-2-yl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (Example 223 step 2)(0.15 g, 0.51 mmol) was added and the vessel sealed and heated at 70° C. for 3 h. The reaction mixture was cooled to r.t., diluted with MeOH (5 mL) and stirred for 5-10 mins. The mixture was filtered through a small pad of Celite®, washing with MeOH (3×2 mL), concentrated in vacuo and triturated with diethyl ether (2×4 mL). The resulting solid was azeotroped with toluene, cooled to 0° C. and treated with 4-(trifluoromethyl)piperidin-1-ium chloride (0.11 g, 0.56 mmol), DIPEA (223.59 μl, 1.28 mmol) and 1-chloropyrrolidine-2,5-dione (41.55 μl, 0.51 mmol) in DMF (1 mL) and stirred at r.t. for 72 h. The reaction mixture was diluted with water (10 mL), extracted with EtOAc (3×25 mL) and the combined extracts washed with water (×4) and brine. The organics were dried over Na2SO4, concentrated in vacuo and triturated with ether. The solid was suspended in MeOH (˜4-5 mL) and heated to dissolution. The solution was concentrated in vacuo and triturated with ether to afford the title compound (96 mg, 44%) as a pale yellow solid.


Method C: LC-MS m/z=429.1 [M+H]+; RT=3.15 min


Example 226—Synthesis of 2-[4-(cyclopentyloxy)-1H-pyrazol-1-yl]-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one



embedded image


To a solution of 2-chloro-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (Example 193 step 1, 74 mg, 0.43 mmol) and 4-(cyclopentyloxy)-1H-pyrazole (85 mg, 0.46 mmol) in DMF (3 mL) was added cesium carbonate (434 mg, 1.33 mmol). The mixture was irradiated at 170° C. in the microwave for an hour. After a further 1 hour under these conditions the cooled reaction mixture was diluted with HCl (1M 20 mL) and extracted with EtOAc (20 mL), the organic fraction was dried (MgSO4), concentrated under vacuum and purified by PERP-HPLC (method G) to yield the title compound (32 mg, 26%) as a as a colourless powder.


Method C: LC-MS m/z=287.1 [M+H]+; RT=3.10 min


Example 227—Synthesis of 2-(piperidin-4-yl)butanenitrile hydrochloride
Step 1: Synthesis of tert-butyl 4-(1-cyanopropyl)piperidine-1-carboxylate



embedded image


2.5 M n-BuLi in THF (0.28 mL, 0.7 mmol) was added to a solution of diisopropylamine (54 mg, 0.536 mmol) in THF (2 mL) at −78° C. The solution was stirred for 30 min and then a solution of tert-butyl 4-(cyanomethyl)piperidine-1-carboxylate (100 mg, 0.446 mmol) was added dropwise at −78° C. The resulting solution was stirred for 1 h and iodoethane (83.6 mg, 0.536 mmol) was added. The reaction mixture was stirred overnight. The reaction was quenched with sat. NH4Cl (5 mL), extracted with EtOAc (30 mL×2), the combined organics were dried over Na2SO4, concentrated to yield the product (110 mg, 98% yield) which was used in the next step without purification.


LC-MS: m/z=197 (M−55)+, RT=1.70 min.


Step 2: Synthesis of 2-(piperidin-4-yl)butanenitrile hydrochloride



embedded image


4.0 M HCl in dioxane (2 mL) was added to a solution of tert-butyl 4-(1-cyanopropyl) piperidine-1-carboxylate (110 mg, 0.436 mmol) in DCM (2 mL). The solution was stirred at r.t for 4 h. Then the reaction was removed the solvent to yield the product (85 mg, 99%) as white solid.


LC-MS: m/z=153 (M+H)+


Example 228—Synthesis of 4-ethylpiperidine-4-carbonitrile hydrochloride
Step 1: Synthesis of tert-butyl 4-cyano-4-ethylpiperidine-1-carboxylate



embedded image


2.5 M n-BuLi in THF (7.2 mL, 18 mmol) was added to a solution of diisopropylamine (1.818 g, 18 mmol) in THF (20 mL) at −78° C. The solution was stirred for 30 min and then the solution was added to the solution of tert-butyl 4-cyanopiperidine-1-carboxylate (3.15 g, 15 mmol) in THF (40 mL) dropwise at −78° C. The resulting solution was stirred for 1 h and iodoethane (83.6 mg, 0.536 mmol) was added. The reaction mixture was stirred overnight. The reaction was quenched with sat. NH4Cl (10 mL) and water (20 mL), extracted with EtOAc (50 mL×2), the combined organics were dried over Na2SO4, concentrated to yield the product (3.4 g, 95.2% yield) which used in the next step without purification.


LC-MS: m/z=183 (M−55)+, RT=1.879 min.


Step 2: Synthesis of 4-ethylpiperidine-4-carbonitrile hydrochloride



embedded image


4.0 M HCl in dioxane (10 mL) was added to the solution of tert-butyl 4-cyano-4-ethylpiperidine-1-carboxylate (3.4 g, 14.3 mmol) in DCM (10 mL). The solution was stirred at r.t. overnight. Then the reaction was removed the solvent to yield the product (2.48 g, 99%) as pale white solid.


LC-MS: m/z=139 (M+H)+, RT=1.076 min.


Example 229—Synthesis of 2-(5-(4-(trifluoromethyl)piperidine-1-carbonyl)thiophen-2-yl)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (Q-609)



embedded image


Step 1: Synthesis of 2-chloro-4-(4-methoxybenzyloxy)-6,7-dihydro-5H-cyclopenta[d]pyrimidine



embedded image


To a 100 mL of RBF was added (4-methoxyphenyl) methanol (460 mg, 3.33 mmol), 15 mL of THF and NaH (60%) (160 mg, 4.0 mmol). The mixture was stirred at r.t. for 30 min. Then 2,4-dichloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine (600 mg, 3.19 mmol) was added and the mixture was stirred at r.t. for 3 h. The reaction mixture was treated with water (20 ml) and extracted with EtOAc (100 ml). The organic layer was concentrated and purified by combiflash (isco, silica gel, UV 254, 40 g, EA/PE=1/10) to give product. LC-MS: m/z=291 (M+H)+, RT=2.012 min.


Step 2: Synthesis of 2-chloro-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one



embedded image


To a 100 mL of RBF was added 2-chloro-4-(4-methoxybenzyloxy)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (350 mg, 1.2 mmol), 8 mL of DCM and 2 ml of CF3COOH. The mixture was stirred at r.t. for 3 h. The reaction mixture was treated with TEA until pH=8 and then purified by combiflash (isco, silica gel, UV 254, 40 g, EA/PE=1/1) to give product. LC-MS: m/z=171 (M+H)+, RT=1.246 min.


Step 3: Synthesis of 5-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)thiophene-2-carboxylic acid



embedded image


To a 100 mL of RBF was added 2-chloro-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (100 mg, 0.58 mmol), 5-boronothiophene-2-carboxylic acid (350 mg, 2.03 mmol), 3 mL of DME, 1.5 mL of EtOH, 0.5 mL of Na2CO3 (2N) and Pd(PPh3)4 (100 mg, 0.086 mmol). The mixture was stirred at 110° C. for 1 h. Then the reaction mixture was purified by combi flash (isco, silica gel, UV 254, 20 g, MeOH/DCM=1/20) to give product LC-MS: m/z=263 (M+H)+, RT=1.358 min.


Step 4: Synthesis of 2-(5-(4-(trifluoromethyl)piperidine-1-carbonyl)thiophen-2-yl)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one



embedded image


To a 100 mL of RBF was added 5-(4-oxo-4, 5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)thiophene-2-carboxylic acid (80 mg, 0.30 mmol), 4-(trifluoromethyl)piperidine hydrochloride (60 mg, 0.31 mmol), HOAT (40 mg, 0.30 mmol), HATU (80 mg, 0.34 mmol), 5 ml of THF and 0.05 ml of TEA. The mixture was stirred at r.t. for 16 h. Then the reaction mixture was purified by combi flash (isco, silica gel, UV 254, 20 g, MeOH/DCM=1/20) to give product. LC-MS (method C′): m/z=398 (M+H)+, RT=1.703 min.


Example 230—Synthesis of 2-(3-(4-(trifluoromethyl) piperidine-1-carbonyl) phenyl)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (Q-593)



embedded image


Step 1: Synthesis of 3-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)benzoic acid



embedded image


To a 100 mL of RBF was added 2-chloro-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (90 mg, 0.53 mmol), 3-boronobenzoic acid (200 mg, 1.20 mmol), K2CO3 (120 mg, 0.87 mmol), 5 mL of dioxane, 1 mL of water and Pd(PPh3)4 (40 mg, 0.034 mmol). The mixture was stirred at 100° C. for 40 h. Then the reaction mixture was purified by combiflash (isco, silica gel, UV 254, 20 g, MeOH/DCM=1/10) to give product. LC-MS: m/z=257 (M+H)+, RT=0.994 min.


Step 2: Synthesis of 2-(3-(4-(trifluoromethyl)piperidine-1-carbonyl)phenyl)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one



embedded image


To a 100 mL of RBF was added 3-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)benzoic acid (60 mg, 0.23 mmol), 4-(trifluoromethyl)piperidine hydrochloride (50 mg, 0.26 mmol), HOAT (40 mg, 0.30 mmol), HATU (60 mg, 0.25 mmol), 3 ml of THF and 0.05 ml of TEA. The mixture was stirred at r.t. for 16 h. Then the reaction mixture was purified by combiflash (isco, silica gel, UV 254, 20 g, MeOH/DCM=1/20) to give product. LC-MS (method G′): m/z=392 (M+H)+, RT=1.608 min.


Example 231—Synthesis of 2-(4-(3-(3,3-difluoropyrrolidin-1-yl)azetidine-1-carbonyl)-5-methyl-1H-pyrazol-1-yl)-6,6-dimethyl-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (Q-1564)



embedded image


embedded image


Step 1: Synthesis of 3,3-dimethylhexanedioic acid



embedded image


4,4-dimethylcyclohexanone (9 g, 71.3 mmol) and KMnO4 (22.5 g, 142.6 mmol) were taken up in 450 mL of H2O. To this, an aqueous solution of NaOH (1 g, 25 mmol) in 10 mL of H2O was added at r.t. This mixture was stirred at r.t. for 48 hrs. Aqueous sodium bisulfate was then added until the purple color disappeared. A brown solid was filtered off, and the filtrate was brought to pH=2 with conc. HCl. The solution was extracted with EtOAc (150 mL×2). The combined organics were dried and concentrated to yield the product. LC-MS: m/z=175.1 (M+H)+, RT=0.35 min.


Step 2: Synthesis of dimethyl 3,3-dimethylhexanedioate



embedded image


To a solution of 3,3-dimethylhexanedioic acid (7.8 g, 44.8 mmol) in MeOH (100 mL) was added conc. H2SO4 (1 g, 10 mmol). The mixture was stirred at 80° C. for 2 hrs and concentrated. NaHCO3 solution was added to the residue to pH=7. The mixture was extracted with EtOAc (50 mL×2). The combined organic layers were dried over Na2SO4 and concentrated under vacuum to yield the product. LC-MS: m/z=203.1 (M+H)+, RT=1.89 min.


Step 3: Synthesis of methyl 4,4-dimethyl-2-oxocyclopentanecarboxylate



embedded image


The mixture of Na (230 mg, 10 mmol) in MeOH (8 mL) was stirred at r.t. for 5 minutes. Dimethyl 3,3-dimethylhexanedioate (1 g, 5 mmol) was added. The mixture was stirred at r.t. for 30 minutes and concentrated under vacuum to remove MeOH. THF (8 mL) was added to the residue, and the mixture was stirred at r.t. for 12 hrs. The mixture was poured into H2O (20 mL). HCl (2N) was added to pH=7. The mixture was extracted with EtOAc (50 mL×2). The organic layers were concentrated and purified by column (silica gel, PE/EtOAc=1/1) to yield the product. LC-MS: m/z=171.1 (M+H)+, RT=1.77 min.


Step 4: Synthesis of 6,6-dimethyl-2-(methylthio)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one



embedded image


To a solution of methyl 4,4-dimethyl-2-oxocyclopentanecarboxylate (750 mg, 4.4 mmol) in H2O (20 mL) was added methyl carbamimidothioate (594 mg, 6.6 mmol) and Na2CO3 (1.87 g, 17.6 mmol). The mixture was stirred at r.t. for 12 hrs. The mixture was extracted with EtOAc (20 mL×2). The organic layers were concentrated and purified by column (silica gel, PE/EtOAc=2/1) to yield the product. LC-MS: m/z=211.1 (M+H)+, RT=1.61 min.


Step 5: Synthesis of 2-hydrazinyl-6,6-dimethyl-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one



embedded image


To a solution of 6,6-dimethyl-2-(methylthio)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (250 mg, 1.2 mmol) in EtOH (5 mL) was added NH2NH2.H2O (1 mL). The mixture was stirred at 90° C. for 12 hrs and concentrated under vacuum to yield the product which was used in next step directly without purification. LC-MS: m/z=195.2 (M+H)+, RT=1.23 min.


Step 6: Synthesis of methyl 1-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate



embedded image


To a solution of 2-hydrazinyl-6,6-dimethyl-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (230 mg, 1.2 mmol) in EtOH (5 mL) was added (Z)-methyl 2-((dimethylamino)methylene)-3-oxobutanoate (246 mg, 1.4 mmol) and AcOH (0.5 mL). The mixture was stirred at 50° C. for 2 hrs and concentrated under vacuum. The crude residue was purified by column (silica gel, PE/EtOAc=1/3) to yield the product. LC-MS: m/z=303.1 (M+H)+, RT=1.99 min.


Step 7: Synthesis of 1-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid



embedded image


To a solution of methyl 1-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d] pyrimidin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (140 mg, 0.5 mmol) in THF (5 mL) was added a solution of NaOH (60 mg, 1.5 mmol) in H2O (3 mL). The mixture was stirred at 35° C. for 3 hrs and concentrated under vacuum to remove THF. EtOAc (10 mL) was added to extract the impurity. The aqueous phase was adjusted to pH=4 with HCl (2N). The solid was filtered to yield the product. LC-MS: m/z=289.1 (M+H)+, RT=1.11 min.


Step 8: Synthesis of 2-(4-(3-(3,3-difluoropyrrolidin-1-yl)azetidine-1-carbonyl)-5-methyl-1H-pyrazol-1-yl)-6,6-dimethyl-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one



embedded image


To a solution of 1-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid (49 mg, 0.17 mmol) in THF (6 mL) was added NMM (68 mg, 0.68 mmol), HATU (76 mg, 0.2 mmol), HOAt (26 mg, 0.2 mmol) and 1-(azetidin-3-yl)-3,3-difluoropyrrolidine (46 mg, 0.2 mmol). The mixture was stirred at r.t. for 2 hrs and concentrated under vacuum. The residue was purified by Prep-HPLC (NH4HCO3) to yield the product. LC-MS (method J′): m/z=433.2 (M+H)+, RT=1.46 min.


Example 232—Synthesis of 2-(2-methyl-3-(4-(trifluoromethyl) piperidine-1-carbonyl)-1H-pyrrol-1-yl)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one) (Q-622



embedded image


Step 1: Synthesis of 2-methyl-1H-pyrrole-3-carboxylic acid



embedded image


To the solution of ethyl 2-methyl-1H-pyrrole-3-carboxylate (785 mg, 5.12 mmol) in dioxane (8 mL) was added a solution of lithium hydroxide (1.08 g, 25.62 mmol) in H2O (8 mL). After addition, the reaction mixture was stirred under refluxed for 4 h. The mixture was partitioned with EtOAc and HCl (1M, a.q.). The organic phase was washed with brine, dried over Na2SO4 and concentrated to get the title compound. LC-MS: m/z=126.2 (M+H)+, RT=0.32 min.


Step 2: Synthesis of (2-methyl-1H-pyrrol-3-yl)(4-(trifluoromethyl)piperidin-1-yl)methanone



embedded image


To the solution of 2-methyl-1H-pyrrole-3-carboxylic acid (100 mg, 0.8 mmol) and 4-(trifluoromethyl)piperidine (147 mg, 0.96 mmol) in DMF (2 mL) were added HATU (456 mg, 1.2 mmol) and DIPEA (206 mg, 1.6 mmol). The reaction mixture was stirred at r.t. for 15 h. The mixture was concentrated and purified by SGC (eluting with PE/EtOAc=1/2, silica gel) to give the title compound. LC-MS: m/z=261.1 (M+H)+, RT=1.62 min.


Step 3: Synthesis of 2-(2-methyl-3-(4-(trifluoromethyl)piperidine-1-carbonyl)-1H-pyrrol-1-yl)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one



embedded image


To the solution of 2-chloro-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (90 mg, 0.53 mmol) and (2-methyl-1H-pyrrol-3-yl)(4-(trifluoromethyl)piperidin-1-yl)methanone (164 mg, 0.63 mmol) in DMF (2 mL) were added Cs2CO3 (344 mg, 1.06 mmol), L-proline (30 mg, 0.26 mmol) and CuI (50 mg, 0.26 mmol). The reaction mixture was stirred at 140° C. for 15 h. The mixture was purified by pre-HPLC (high pH) to give the title compound. LC-MS (method G′): m/z=395.0 (M+H)+, RT=1.42 min.


Example 233—Synthesis of 5-methyl-1-(4-oxo-4, 5, 6, 7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-4-(4-(trifluoromethyl) piperidine-1-carbonyl)-1H-pyrazole-3-carboxamide (Q-1884)



embedded image


Step 1: Synthesis of Benzyl Cyanoformate



embedded image


Benzyl chloroformate (5 g, 0.029 mol) and 1, 4-diazabicyclo [2.2.2] octane (22 mg; 0.20 mmol) were added to a dry reaction vessel under a dry nitrogen atmosphere. Trimethylsilyl nitrile (2.9 g, 0.029 mol) was added dropwise over about 1 hr. The mixture was maintained at between 20° C.-30° C. until the reaction reached completion in about 3 hr. After distilling off the trimethylsilyl chloride, 4.3 g of crude product was obtained, which was used directly in the next step. GC-MS: m/z=161 M+, RT=9.249 min.


Step 2: Synthesis of 4-benzyl 1-tert-butyl 2-acetyl-3-aminofumarate



embedded image


To a solution of tert-butyl 3-oxobutanoate (982 mg, 6.22 mmol and benzyl cyanoformate (1 g, 6.21 mmol) in DCM (3 mL) was added zinc(II) acetyl acetonate (82 mg, 0.31 mmol) and the reaction mixture was stirred at r.t. for 2 h. The reaction mixture was evaporated, and the residue was taken up in Et2O (20 mL) and the suspension was filtered over celite. The cake was washed with Et2O (15 mL) and the filtrate evaporated. The residue was purified by silica gel chromatography (PE/EA=12/1) to afford the title compound. LC-MS: m/z=342 (M+Na)+, RT=1.596 min.


Step 3: Synthesis of 3-benzyl 4-tert-butyl 5-methyl-1-(4-oxo-4, 5, 6, 7-tetrahydro-3H-cyclo-penta [d]pyrimidin-2-yl)-1H-pyrazole-3, 4-dicarboxylate



embedded image


To a solution of 4-benzyl 1-tert-butyl 2-acetyl-3-aminofumarate (575 mg, 1.80 mmol) in 5 mL of EtOH was added 2-hydrazinyl-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (300 mg, 1.81 mmol). The suspension was heated to reflux for 15 h. After being cooled to r.t., the suspension was filtered and the filtrate was concentrated. The residue was purified by silica gel chromatography using (PE/EA=12/1) to afford the title compound. LC-MS: m/z=395 (M−55)+, RT=2.188 min.


Step 4: Synthesis of tert-butyl 3-carbamoyl-5-methyl-1-(4-oxo-4, 5, 6, 7-tetrahydro-3H-cyclo-penta [d]pyrimidin-2-yl)-1H-pyrazole-4-carboxylate



embedded image


A solution of 3-benzyl 4-tert-butyl 5-methyl-1-(4-oxo-4, 5, 6, 7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-3,4-dicarboxylate (440 mg, 0.98 mmol) in 8 mL of 7 M NH3 solution in MeOH was put into a sealed tube and heated at 50° C. for 15 h. After being cooled to r.t., the solution was concentrated to give title compound. LC-MS: m/z=304 (M−55)+, RT=1.504 min.


Step 5: Synthesis of 3-carbamoyl-5-methyl-1-(4-oxo-4, 5, 6, 7-tetrahydro-3H-cyclopenta[d]-pyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid



embedded image


To a solution of tert-butyl 3-carbamoyl-5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta-[d]pyrimidin-2-yl)-1H-pyrazole-4-carboxylate (30 mg, 0.084 mmol) in 2 mL of DCM was added 1 mL of TFA and the mixture was stirred at r.t. for 3 h. Then the reaction mixture was diluted with toluene and concentrated to give the desired product. LC-MS: m/z=304 (M+H)+, RT=0.407 min.


Step 6: Synthesis of 5-methyl-1-(4-oxo-4, 5, 6, 7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-4-(4-(trifluoromethyl) piperidine-1-carbonyl)-1H-pyrazole-3-carboxamide



embedded image


To a mixture of 3-carbamoyl-5-methyl-1-(4-oxo-4, 5, 6, 7-tetrahydro-3H-cyclopenta[d]pyramidin-2-yl)-1H-pyrazole-4-carboxylic acid (26 mg, 0.084 mmol) and 4-(trifluoromethyl) piperidine hydrochloride (16 mg, 0.084 mmol) in 2 mL of DMF was added NMM (0.05 mL, 0.45 mmol), HOAt (14 mg, 0.10 mmol) and HATU (38 mg, 0.10 mmol). The reaction mixture was stirred at r.t. for 2 h and filtered. The filtrate was purified by prepared HPLC (NH4HCO3) to give the desired product. LC-MS (method F′): m/z=439 (M+H)+, RT=1.356 min.


Example 234—Synthesis of 6-fluoro-2-(4-(4-(trifluoromethyl)piperidine-1-carbonyl)-1H-pyrazol-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one (Q-616)



embedded image


embedded image


Step 1: (1H-pyrazol-4-yl)(4-(trifluoromethyl)piperidin-1-yl)methanone



embedded image


To a 100 mL of RBF was added 1H-pyrazole-4-carboxylic acid (500 mg, 4.46 mmol), 4-(trifluoromethyl)piperidine hydrochloride (1.0 g, 5.29 mmol), HATU (1.2 g, 5.10 mmol), HOAT (700 mg, 5.14 mmol), 40 mL of THF and 2 mL of TEA. The mixture was stirred at RT for 16 h. The reaction mixture was concentrated and purified by combiflash (isco, silica gel, UV 254, 40 g, MeOH/DCM=1/10) to give product LC-MS: m/z=248 (M+H)+, RT=1.434 min.


Step 2: Synthesis of (R)-1-tert-butyl 2-methyl 4,4-difluoropyrrolidine-1,2-dicarboxylate



embedded image


To a 500 mL of RBF was added (R)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate (4.0 g, 16.4 mmol) and 200 mL of DCM. The mixture was cooled to 0° C. and DAST (24.0 g, 150.0 mmol) in 100 ml of DCM was added drop wise over 1 h. Then the mixture was stirred at r.t. for 16 h. The reaction mixture was treated with NaHCO3 (aq) and extracted with DCM (300 ml), the organic layer was concentrated to give product. LC-MS: m/z=166 (M−100)+, RT=0.344 min.


Step 3: Synthesis of (R)-methyl 4,4-difluoropyrrolidine-2-carboxylate



embedded image


To a 100 mL of RBF was added (R)-1-tert-butyl 2-methyl 4,4-difluoropyrrolidine-1,2-dicarboxylate (4.0 g, 15.1 mmol) and 40 mL of HCl (4 M in dioxane). The mixture was stirred at RT for 16 h. Then the reaction mixture was concentrated to give product. LC-MS: m/z=166 (M+H)+, RT=0.347 min.


Step 4: Synthesis of methyl 1-amino-4-fluoro-1H-pyrrole-2-carboxylate



embedded image


To a 250 mL of RBF was added (R)-methyl 4,4-difluoropyrrolidine-2-carboxylate (2.4 g, 14.5 mmol) in 80 ml of THF was added 24 g of MnO2. The mixture was stirred at 70° C. for 16 h. The reaction mixture was filtered and the filtrate was concentrated and purified by combiflash (isco, silica gel, UV 254, 40 g, EA/PE=1/3) to give product. LC-MS: m/z=144 (M+H)+, RT=1.528 min.


Step 5: Synthesis of methyl 1-amino-4-fluoro-1H-pyrrole-2-carboxylate



embedded image


To a 500 mL of RBF was added NH4Cl (6.0 g, 112 mmol) in 200 ml of Et2O. The mixture was cooled to −5° C. and 9.4 ml of NH4OH was added drop wise with vigorous stirring. Then 145 ml of NaClO was added drop wise over 2 h. The mixture was stirred for 15 min and the layer was separated. The organic layer was washed with brine and dried with CaCl2 and used in the next step without further purification. Then to a 100 ml of RBF was added methyl 4-fluoro-1H-pyrrole-2-carboxylate (1.7 g, 11.8 mmol) and 30 ml of DMF. The mixture was cooled to 0° C. and NaH (60%) (600 mg, 15.0 mmol) was added. After 45 min, the previously prepared NH2Cl (100 ml) was added dropwise. The mixture was stirred at r.t. for 2 h. The reaction mixture was extracted with EtOAc (200 ml), the organic layer was concentrated and purified by combiflash (isco, silica gel, UV 254, 40 g, EA/PE=1/5) to give product. LC-MS: m/z=159 (M+H)+, RT=1.49 min.


Step 6: Synthesis of methyl 1-(3-benzoylthioureido)-4-fluoro-1H-pyrrole-2-carboxylate



embedded image


To a 250 mL of RBF was added methyl 1-amino-4-fluoro-1H-pyrrole-2-carboxylate (1.7 g, 10.76 mmol), 80 ml of THF and benzoyl isothiocyanate (1.8 g, 11.04 mmol). The mixture was stirred at RT under N2 for 16 h. The reaction mixture was concentrated and purified by combi flash (isco, silica gel, UV 254, 40 g, EA/PE=1/4) to give product. LC-MS: m/z=322 (M+H)+, RT=1.823 min.


Step 7: Synthesis of 6-fluoro-2-mercaptopyrrolo [1,2-f][1,2,4]triazin-4(3H)-one



embedded image


To a 100 mL of RBF was added methyl 1-(3-benzoylthioureido)-4-fluoro-1H-pyrrole-2-carboxylate (1.5 g, 4.67 mmol) and 10 ml of NaOH (2N). The mixture was stirred at 85° C. under N2 for 1.5 h. The reaction mixture was cooled to 0° C. and EtOH (5 ml), HOAc (2 ml) was added and stirred at r.t. for 30 min. The reaction mixture was filtered and washed with Et2O (20 ml) to give product. LC-MS: m/z=186 (M+H)+, RT=0.67 min.


Step 8: Synthesis of 6-fluoro-2-(methylthio)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one



embedded image


To a 100 mL of RBF was added 6-fluoro-2-mercaptopyrrolo[1,2-f][1,2,4]triazin-4(3H)-one (700 mg, 3.78 mmol) and 20 ml of THF was added MeI (700 mg, 4.92 mmol). The mixture was stirred at 45° C. under N2 for 1 h. The reaction mixture was treated with NaHCO3 (aq) and filtered to give product. LC-MS: m/z=200 (M+H)+, RT=1.551 min.


Step 9: Synthesis of 6-fluoro-2-(methylsulfonyl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one



embedded image


To a 50 mL of RBF was added 6-fluoro-2-(methylthio)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one (100 mg, 0.50 mmol) and 4 ml of HOAc was added 2 ml of H2O2. The mixture was stirred at 170° C. in a microwave for 15 h. The reaction mixture was filtered to give product. LC-MS: m/z=232 (M+H)+, RT=1.368 min.


Step 10: Synthesis of 6-fluoro-2-(4-(4-(trifluoromethyl) piperidine-1-carbonyl)-1H-pyrazol-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one



embedded image


To a microwave tube was added 6-fluoro-2-(methylsulfonyl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one (100 mg, 0.43 mmol), (1H-pyrazol-4-yl)(4-(trifluoromethyl)piperidin-1-yl)methanone (110 mg, 0.44 mmol), Cs2CO3 (160 mg, 0.49 mmol) and 2 ml of NMP. The mixture was stirred at r.t. for 2 days. The reaction mixture was concentrated and purified by combi flash (isco, silica gel, UV 254, 20 g, MeOH/DCM=1/10) to give product. LC-MS (method G′): m/z=399 (M+H)+, RT=1.399 min.


Examples 235-236

Examples 235-236 in Table 17 were prepared in an analogous fashion to Example 234 starting with the corresponding starting materials.













TABLE 17





Ex.

LC-MS




No.
Ref. No.
(Retention Time)
MS (M + H)+
LC-MS Method







235
Q-741
1.565
413.1
F′


236
Q-746
1.497
384.1
F′









Example 237—Synthesis of 7-fluoro-2-(4-(4-(trifluoromethyl)piperidine-1-carbonyl)-1H-pyrazol-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one (Q-525)



embedded image


Step 1: Synthesis of 2,4-dichloro-7-fluoropyrrolo[1,2-f][1,2,4]triazine



embedded image


A mixture of 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (6.0 g, 31.9 mmol) and 1-(chloromethyl)-4-fluoro-1,4-diazonia-bicyclo[2.2.2]octane tetrafluoroborate (22.6 g, 63.8 mmol) in acetonitrile (250 mL) was stirred at 45° C. for 16 h under N2 atmosphere. The mixture was concentrated, the residue was diluted with DCM (400 mL), washed with H2O (50 mL×3), and dried over Na2SO4. The filtrate was concentrated to give the crude product. LC-MS: m/z=206.0 (M+H)+, RT=1.873 min.


Step 2: Synthesis of 2-chloro-7-fluoropyrrolo[1,2-f][1,2,4]triazin-4(3H)-one



embedded image


To a mixture of 2,4-dichloro-7-fluoropyrrolo[1,2-f][1,2,4]triazine (6.33 g, 30.7 mmol) in THF/H2O (30 ml/30 mL) was added sodium hydroxide (6.16 g, 154 mmol). The mixture was stirred at 50° C. for 4 h, and cooled to r.t. The mixture was adjusted to pH=3-4 with 4N HCl and extracted with EtOAc (100 mL×4). The combined organics were dried over Na2SO4 and concentrated to give 5.2 g of the crude product. 2 g of the crude product was purified by prep-HPLC (TFA/CH3CN/H2O) to give the product. LC-MS: m/z=188.0 (M+H)+, RT=1.486 min.


Step 3: Synthesis of 7-fluoro-2-(4-(4-(trifluoromethyl)piperidine-1-carbonyl)-1H-pyrazol-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one



embedded image


To a mixture of 2-chloro-7-fluoropyrrolo[1,2-f][1,2,4]triazin-4(3H)-one (302 mg, 1.61 mmol), (1H-pyrazol-4-yl)(4-(trifluoromethyl)piperidin-1-yl)methanone (398 mg, 1.61 mmol) and Cs2CO3 (1049 mg, 3.22 mmol) in dry DMF (20 mL) were added L-proline (93 mg, 0.8 mmol) and CuI (152 mg, 0.8 mmol) under N2 atmosphere. The mixture was stirred at 140° C. for 20 h. The mixture was cooled to r.t., diluted with H2O (100 mL), pH adjusted to 3-4 with 1N HCl, and extracted with EtOAc (100 mL×5). The combined organics were dried over Na2SO4 and concentrated. The residue was purified by prep-HPLC (TFA/CH3CN/H2O) to give the crude product which was further purified by prep-HPLC (NH4HCO3/CH3CN/H2O) to give the product. LC-MS (method D′): m/z=399.2 (M+H)+, RT=1.002 min.


Examples 238-239

Examples 238-239 in Table 18 were prepared in an analogous fashion to Example 237 starting with the corresponding starting materials.













TABLE 18





Ex.

LC-MS




No.
Ref. No.
(Retention Time)
MS (M + H)+
LC-MS Method







238
Q-732
1.429
381.2
F′


239
Q-738
1.479
380.2
F′









Example 240—Synthesis of 2-(5-methyl-4-(4-(4-(trifluoromethoxy)phenylsulfonyl)piperazine-1-carbonyl)-1H-pyrazol-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one (Q-1798)



embedded image


Step 1: Synthesis of tert-butyl-4-(5-methyl-1-(4-oxo-3,4-dihydropyrrolo[1,2-f][1,2,4]triazin-2-yl)-1H-pyrazole-4-carbonyl)piperazine-1-carboxylate



embedded image


To the solution of 5-methyl-1-(4-oxo-3,4-dihydropyrrolo[1,2-f][1,2,4]triazin-2-yl)-1H-pyrazole-4-carboxylic acid (2 g, 7.715 mmol) and tert-butyl-piperazine-1-carboxylate (1.6 g, 8.487 mmol) in THF (40 mL) were added HATU (3.52 g, 9.258 mmol), HOAT (1.05 g, 7.715 mmol) and TEA (2.34 g, 23.146 mmol), the reaction mixture was stirred at r.t. for 15 h. The mixture was concentrated and purified by SGC (eluting with DCM/MeOH=20/1) to give the title compound. LC-MS: m/z=428.3 (M+H)+, RT=1.535 min.


Step 2: Synthesis of 2-(5-methyl-4-(piperazine-1-carbonyl)-1H-pyrazol-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one dihydrochloride



embedded image


To the solution of tert-butyl-4-(5-methyl-1-(4-oxo-3,4-dihydropyrrolo[1,2-f][1,2,4]triazin-2-yl)-1H-pyrazole-4-carbonyl)piperazine-1-carboxylate (3.88 g, 9.077 mmol) in DCM (50 mL) was added HCl (20 mL, 4 M in dioxane). The reaction mixture was stirred at r.t. for 15 h. The mixture was concentrated to give the title compound. LC-MS: m/z=328.2 (M+H)+, RT=1.146 min.


Step 3: Synthesis of 2-(5-methyl-4-(4-(4-(trifluoromethoxy)phenylsulfonyl)piperazine-1-carbonyl)-1H-pyrazol-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one



embedded image


To the solution of 2-(5-methyl-4-(piperazine-1-carbonyl)-1H-pyrazol-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one dihydrochloride (50 mg, 0.125 mmol) and TEA (51 mg, 0.50 mmol) in DCM (3 mL) was added 4-(trifluoromethoxy)benzene-1-sulfonyl chloride (39 mg, 0.15 mmol). The reaction mixture was stirred at r.t. for 15 h. The mixture was purified by prep-HPLC (high pH) to give the title compound. LC-MS (method J′): m/z=552.2 (M+H)+, RT=1.671 min.


Examples 241-289

Examples 241-289 in Table 19 were prepared in an analogous fashion to Example 240 starting with the corresponding starting materials.













TABLE 19





Ex.

LC-MS




No.
Ref. No.
(Retention Time)
MS (M + H)+
LC-MS Method



















241
Q-1794
1.51
493.2
J′


243
Q-1796
1.62
536.2
J′


243
Q-1797
1.436
434.2
J′


244
Q-1798
1.671
552.2
J′


245
Q-1799
1.524
486.2
J′


246
Q-1800
1.719
524.3
J′


247
Q-1801
1.630
520.2
J′


248
Q-1804
1.84
498.1
C′


249
Q-1805
1.488
503.2
J′


250
Q-1807
1.86
486.1
C′


251
Q-1814
1.695
542.1
J′


252
Q-1815
1.701
561.3
J′


253
Q-1819
1.562
502.2
J′


254
Q-1820
1.691
510.2
J′


255
Q-1821
1.502
474.2
J′


256
Q-1822
1.606
502.2
J′


257
Q-1823
1.553
486.2
J′


258
Q-1824
1.51
493.2
J′


259
Q-1825
1.648
536.1
J′


260
Q-1826
1.646
536.2
J′


261
Q-1827
1.461
546.2
J′


262
Q-1829
1.527
512.2
J′


263
Q-1830
1.681
536.2
J′


264
Q-1831
1.623
518.2
J′


265
Q-1832
1.6
472
C′


266
Q-1833
1.72
525.1
C′


267
Q-1834
1.647
536.2
J′


268
Q-1835
1.757
604.2
J′


269
Q-1836
1.73
536
A′


270
Q-1837
1.62
546.2
J′


271
Q-1838
1.51
493.2
J′


272
Q-1839
1.84
528.1
C′


273
Q-1840
1.82
570
A′


274
Q-1841
1.961
518.1
C′


275
Q-1842
1.955
508.0
C′


276
Q-1845
1.748
512.1
C′


277
Q-1846
1.720
435.1
C′


278
Q-1847
1.498
493.2
J′


279
Q-1848
1.511
487.2
J′


280
Q-1857
1.7
469.1
C′


281
Q-1858
1.680
542.1
J′


282
Q-1859
1.508
519.2
J′


283
Q-1861
1.966
552.1
C′


284
Q-1862
1.850
503.0
C′


285
Q-1864
1.56
519.2
E′


286
Q-1875
1.823
532.1
C′


287
Q-1876
1.93
520
C′


288
Q-1882
1.832
526.5
C′


289
Q-1885
1.940
544.0
C′









Example 290—Synthesis of 2-(5-methyl-4-(2,6-diazaspiro[4.5]decane-2-carbonyl)-1H-pyrazol-1-yl)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (Q-577)



embedded image


Step 1: Synthesis of tert-butyl 2-(5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carbonyl)-2,6-diazaspiro[4.5]decane-6-carboxylate



embedded image


The mixture of 5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid (50 mg, 0.19 mmol), tert-butyl 2,6-diazaspiro[4.5]decane-6-carboxylate (55 mg, 0.19 mmol), HATU (109.6 mg, 0.29 mmol), HOAt (39 mg, 0.29 mmol) and TEA (0.05 mL, 0.38 mmol) was stirred at r.t. for 2 h. The reaction was concentrated. The residue was purified by prep-TLC (DCM/MeOH=15/1, silica, UV254) to get the title compound. LC-MS: m/z=483 (M+H)+, RT=1.544 min.


Step 2: Synthesis of 2-(5-methyl-4-(2,6-diazaspiro[4.5]decane-2-carbonyl)-1H-pyrazol-1-yl)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one



embedded image


To a solution of tert-butyl 2-(5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclo penta[d]pyrimidin-2-yl)-1H-pyrazole-4-carbonyl)-2,6-diazaspiro[4.5]decane-6-carboxylate (50 mg, 0.1 mmol) in DCM (1 mL) was added HCl (4M in dioxane, 1 mL). The mixture was stirred at r.t. for 1 h. The reaction was concentrated. The residue was purified by prep-HPLC (high pH) to get the title compound. LC-MS (method C′): m/z=383 (M+H)+, RT=1.21 min.


Examples 291-292

Examples 291-292 in Table 20 were prepared in an analogous fashion to Example 290 starting with the corresponding starting materials.













TABLE 20





Ex.

LC-MS




No.
Ref. No.
(Retention Time)
MS (M + H)+
LC-MS Method



















291
Q-595
1.069
399
H′


292
Q-714
1.185
329.1
A′









Example 293—Synthesis of 3-(4-(5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carbonyl)piperazine-1-carbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid (Q-627)
Example 293—Synthesis of 3-(4-(5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carbonyl)piperazine-1-carbonyl)bicyclo[1.1.1]pentane-1-carbonitrile (Q-632)



embedded image


embedded image


Step 1: Synthesis of dimethyl bicyclo[1.1.1]pentane-1,3-dicarboxylate



embedded image


To a solution of bicyclo[1.1.1]pentane-1,3-dicarboxylic acid (1 g, 6.4 mmol) in MeOH (50 mL) was added SOCl2 (6 mL) dropwise. The reaction was stirred at 80° C. for 15 h. The reaction was concentrated. The residue was treated with aq. NaHCO3 (80 mL) and extracted with DCM (2×60 mL). The combined organic layers were concentrated to get the title compound.


Step 2: Synthesis of 3-(methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid



embedded image


To a solution of dimethyl bicyclo[1.1.1]pentane-1,3-dicarboxylate (1.1 g, 5.98 mmol) in THF/MeOH (1/1, 10 mL) was added NaOH (2M, 3 mL). The reaction was stirred at r.t. for 15 h. The reaction was concentrated. The residue was treated with water (50 mL), adjusted pH=5 with HCl (2M), and extracted with DCM (2×50 mL). The combined organic layers were concentrated to get the title compound.


Step 3: Synthesis of tert-butyl 4-(3-(methoxycarbonyl)bicyclo[1.1.1]pentane-1-carbonyl) piperazine-1-carboxylate



embedded image


The mixture of 3-(methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid (600 mg, 3.53 mmol), tert-butyl piperazine-1-carboxylate (656 mg, 3.53 mmol), EDCI (1.01 g, 5.29 mmol), HOBt (715 mg, 5.29 mmol) and TEA (1 mL, 7.06 mmol) in THF (30 mL) was stirred at room temperature for 15 h. The reaction was treated with water (50 mL), extracted with EtOAc (2×50 mL). The combined organic layers were concentrated to get the title compound. LC-MS: m/z=283 (M−56+H)+; RT=1.68 min.


Step 4: Synthesis of methyl 3-(piperazine-1-carbonyl)bicyclo[1.1.1]pentane-1-carboxylate hydrochloride



embedded image


To a solution of tert-butyl 4-(3-(methoxycarbonyl)bicyclo[1.1.1]pentane-1-carbonyl)piperazine-1-carboxylate (1.05 g, 3.1 mmol) in DCM (10 mL) was added HCl (4M in dioxane, 10 mL). The mixture was stirred at r.t. for 2 h. The reaction was concentrated to get the title compound (850 mg, 99%). LC-MS: m/z=239 (M+H)+, RT=0.92 min.


Step 5: Synthesis of methyl 3-(4-(5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carbonyl)piperazine-1-carbonyl)bicyclo[1.1.1]pentane-1-carboxylate



embedded image


The mixture of 5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid (585 mg, 2.25 mmol), methyl 3-(piperazine-1-carbonyl)bicyclo[1.1.1]pentane-1-carboxylate hydrochloride (850 mg, 3.1 mmol), HATU (1.28 g, 3.37 mmol), HOAt (460 mg, 3.37 mmol) and TEA (1 mL) in THF (30 mL) was stirred at r.t. for 15 h. The reaction was concentrated. The residue was purified by combi-flash (40 g, DCM/MeOH=20/1, silica, UV254) to get the title compound. LC-MS: m/z=481 (M+H)+, RT=1.48 min.


Step 6: Synthesis of 3-(4-(5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carbonyl)piperazine-1-carbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid



embedded image


To a solution of methyl 3-(4-(5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carbonyl)piperazine-1-carbonyl)bicyclo[1.1.1]pentane-1-carboxylate (120 mg, 0.25 mmol) in THF/MeOH (1/1, 4 mL) was added LiOH (2 M, 1 mL). The reaction mixture was stirred at r.t. for 1 h. The reaction was treated with water (20 mL), adjust pH=5 with HCl (2M). The mixture was extracted with EtOAc (2×30 mL). The combined organic layers were concentrated. The residue was purified by prep-HPLC (low pH) to get the title compound. LC-MS (method C′): m/z=467 (M+H)+, RT=1.34 min.


Step 7: Synthesis of 3-(4-(5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carbonyl)piperazine-1-carbonyl)bicyclo[1.1.1]pentane-1-carboxamide



embedded image


The mixture of 3-(4-(5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carbonyl)piperazine-1-carbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid (80 mg, 0.17 mmol), NH4Cl (13.6 mg, 0.26 mmol), HOBt (49.2 mg, 0.26 mmol), EDCI (34.7 mg, 0.26 mmol) and TEA (0.07 mL) in THF (5 mL) was stirred at r.t. for 15 h. The reaction was concentrated. The residue was purified by prep-HPLC (low pH) to get the title compound. LC-MS: m/z=466 (M+H)+, RT=1.28 min.


Step 8: Synthesis of 3-(4-(5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carbonyl)piperazine-1-carbonyl)bicyclo[1.1.1]pentane-1-carbonitrile



embedded image


To a solution of 3-(4-(5-methyl-1-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)-1H-pyrazole-4-carbonyl)piperazine-1-carbonyl)bicyclo[1.1.1]pentane-1-carboxamide (45 mg, 0.1 mmol) in DCM (3 mL) was added TEA (0.6 mL) and trifluoroacetic anhydride (0.4 mL). The mixture was stirred at r.t. for 15 h. The reaction was concentrated. The residue was purified by prep-HPLC (high pH) to get the title compound. LC-MS (method F′): m/z=448 (M+H)+, RT=1.35 min.


Example 295—Synthesis of 2-(4-(2,2-dimethyl-4-(2,2,2-trifluoroethyl)piperazine-1-carbonyl)-5-methyl-1H-pyrazol-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one (Q-949)



embedded image


Step 1: Preparation of 5-methyl-1-(4-oxo-3,4-dihydropyrrolo[1,2-f][1,2,4]triazin-2-yl)-1H-pyrazole-4-carbonyl chloride



embedded image


To a solution of 5-methyl-1-(4-oxo-3,4-dihydropyrrolo[1,2-f][1,2,4]triazin-2-yl)-1H-pyrazole-4-carboxylic acid (50 mg, 0.193 mmol) and oxalyl dichloride (74 mg, 0.579 mmol) in DCM (8 mL) was added DMF (3 drops) at r.t. The mixture was stirred at r.t. for 2 h until the reaction was completed. The mixture was concentrated to give the crude product (80 mg) which was used to next step directly.


Step 2: Preparation of 2-(4-(2,2-dimethyl-4-(2,2,2-trifluoroethyl)piperazine-1-carbonyl)-5-methyl-1H-pyrazol-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4(3H)-one



embedded image


A solution of 5-methyl-1-(4-oxo-3,4-dihydropyrrolo[1,2-f][1,2,4]triazin-2-yl)-1H-pyrazole-4-carbonyl chloride (80 mg, 0.288 mmol), 3,3-dimethyl-1-(2,2,2-trifluoroethyl)piperazine hydrochloride (74 mg, 0.317 mmol) and TEA (87 mg, 0.864 mmol) in DCM (8 mL) was stirred at r.t. overnight. The mixture was concentrated to remove solvent, and the residue was purified with prep-HPLC (high pH) to the target. LC-MS (method F′): m/z=438.1 (M+H)+, RT=1.67 min.


Examples 296-299

Examples 296-299 in Table 21 were prepared in an analogous fashion to Example 295 starting with the corresponding starting materials.













TABLE 21





Ex.

LC-MS




No.
Ref. No.
(Retention Time)
MS (M + H)+
LC-MS Method



















296
Q-1142
1.388
479.3
J′


297
Q-1143
1.516
461.3
J′


298
Q-1295
1.29
376.3
D′


299
Q-1345
1.57
405.1
K′









Examples 300-946

Examples 300-946 in Table 22 were prepared according to the methods described herein starting with appropriate starting materials.














TABLE 22







LC-MS





Ex.
Ref.
(Retention

LC-MS
Coupling


No.
No.
Time)
MS (M + H)+
Method
Agent




















300
Q-0540
1.108
308.0
B′



301
Q-0541
0.937
277.2
B′



302
Q-0542
0.958
277.2
B′



303
Q-0543
1.43
413
G′
HATU/HOAt


304
Q-0544
0.932
287.3
B′



305
Q-0545
1.389
405.1
G′
HATU/HOAt


306
Q-0546
1.087
487.2
F′
HATU/HOAt


307
Q-0547
1.033
274.0
H′



308
Q-0548
1.765
474.0
C′
HATU/HOAt


309
Q-0549
1.007
459.1
F′
HATU/HOAt


310
Q-0550
1.389
445
H′
HATU/HOAt


311
Q-0551
1.469
459.0
G′
HATU/HOAt


312
Q-0552
1.496
483.0
G′
HATU/HOAt


313
Q-0553
1.32
421
G′
HATU/HOAt


314
Q-0555
1.755
456.1
C′
HATU/HOAt


315
Q-0556
1.185
385
G′
HATU/HOAt


316
Q-0557
1.237
400
G′
HATU/HOAt


317
Q-0558
1.014
258.2
B′



318
Q-0559
1.455
477
G′
HATU/HOAt


319
Q-0560
1.462
459
G′
HATU/HOAt


320
Q-0561
1.768
445.1
C′
HATU/HOAt


321
Q-0562
1.286
397
G′
HATU/HOAt


322
Q-0563
1.34
397
G′
HATU/HOAt


323
Q-0564
1.61
423
G′
HATU/HOAt


324
Q-0565
1.164
461.3
B′
HATU/HOAt


325
Q-0566
1.449
274.02
C′



326
Q-0567
1.103
441.3
B′
HATU/HOAt


327
Q-0568
1.104
429.4
B′
HATU/HOAt


328
Q-0569
1.218
370.1
H′
HATU/HOAt


329
Q-0570
1.540
439.1
H′
HATU/HOAt


330
Q-0571
1.408
443.2
H′
HATU/HOAt


331
Q-0572
1.343
395
G′
HATU/HOAt


332
Q-0573
1.483
459
G′
HATU/HOAt


333
Q-0574
1.469
477
G′
HATU/HOAt


334
Q-0575
1.171
369.2
C′
HATU/HOAt


335
Q-0576
1.288
384.1
H′
HATU/HOAt


336
Q-0578
1.29
407.2
H′
HATU/HOAt


337
Q-0579
1.489
499
G′
HATU/HOAt


338
Q-0580
1.603
384.2
H′
HATU/HOAt


339
Q-0582
1.284
445
H′
HATU/HOAt


340
Q-0583
0.938
345
G′
HATU/HOAt


341
Q-0584
0.969
359
H′
HATU/HOAt


342
Q-0585
1.475
442.0
G′
HATU/HOAt


343
Q-0586
1.380
380.0
G′
HATU/HOAt


344
Q-0587
1.484
479
H′
HATU/HOAt


345
Q-0588
1.029
343.1
G′
HATU/HOAt


346
Q-0589
0.934
329.0
G′
HATU/HOAt


347
Q-0590
1.489
479.0
H′
HATU/HOAt


348
Q-0591
1.42
502.9
G′
HATU/HOAt


349
Q-0592
1.515
457
G′
HATU


350
Q-0594
1.675
470
G′
HATU/HOAt


351
Q-0596
1.668
362.1
C′
HATU/HOAt


352
Q-0597
1.089
520.2
B′
HATU


353
Q-0598
1.396
493.9
G′
HATU/HOAt


354
Q-0599
1.458
427.9
G′
HATU/HOAt


355
Q-0600
1.349
394.0
G′
HATU/HOAt


356
Q-0601
1.444
475.0
G′
HATU/HOAt


357
Q-0602
1.171
386.0
G′
HATU/HOAt


358
Q-0603
1.804
495
C′
HATU/HOAt


359
Q-0604
1.494
478.0
G′
HATU/HOAt


360
Q-0605
1.584
488
H′
HATU/HOAt


361
Q-0606
1.441
412.9
G′
HATU/HOAt


362
Q-0607
1.502
477.9
G′
HATU/HOAt


363
Q-0608
1.477
460.0
G′
HATU/HOAt


364
Q-0610
0.723
369.2
B′
HATU/HOAt


365
Q-0611
0.975
457.2
B′
HATU/HOAt


366
Q-0612
1.481
481.1
C′
HATU/HOAt


367
Q-0614
1.046
342.1
H′
HATU/HOAt


368
Q-0615
0.951
443.3
B′
HATU


369
Q-0617
1.092
358.0
H′
HATU/HOAt


370
Q-0618
1.246
318.1
H′



371
Q-0619
1.612
292.1
E′



372
Q-0620
1.026
439.3
B′
HATU/HOAt


373
Q-0621
1.050
358.1
H′
HATU/HOAt


374
Q-0623
1.277
398.1
H′
HATU/HOAt


375
Q-0624
1.410
460.1
H′
HATU/HOAt


376
Q-0626
1.56
423.2
F′
HATU/HOAt


377
Q-0630
1.280
466.2
A′
EDCI/HOBt


378
Q-0633
1.405
328.2
F′
HATU/HOAt


379
Q-0634
1.463
327.2
F′
HATU/HOAt


380
Q-0635
1.504
354.1
F′
HATU/HOAt


381
Q-0681
1.557
353.1
F′
HATU/HOAt


382
Q-0690
2
403
F′
HATU/HOAt


383
Q-0691
1.559
404.1
E′
HATU/HOAt


384
Q-0693
1.399
368.1
F′
HATU/HOAt


385
Q-0696
1.609
497.2
F′
HATU/HOAt


386
Q-0697
1.568
498.2
F′
HATU/HOAt


387
Q-0698
1.584
384.2
F′
HATU/HOAt


388
Q-0700
1.698
384.1
E′
HATU/HOAt


389
Q-0701
1.519
480.1
F′
HATU/HOAt


390
Q-0702
1.56
429.2
F′
HATU/HOAt


391
Q-0703
1.341
354.2
F′
HATU/HOAt


392
Q-0704
1.547
426.1
F′
HATU/HOAt


393
Q-0705
1.476
340.1
F′
HATU/HOAt


394
Q-0706
1.543
354.2
F′
HATU/HOAt


395
Q-0707
1.576
465.1
F′
HATU/HOAt


396
Q-0708
1.505
339.1
F′
HATU/HOAt


397
Q-0709
2
353
F′
HATU/HOAt


398
Q-0710
1.426
381.2
F′
HATU/HOAt


399
Q-0711
1.541
370.1
F′
HATU/HOAt


400
Q-0712
1.408
412.1
F′
HATU/HOAt


401
Q-0713
1.555
395.1
F′
HATU/HOAt


402
Q-0715
1.518
440.2
F′
HATU/HOAt


403
Q-0716
1.547
489.1
F′
HATU/HOAt


404
Q-0718
1.580
465.1
E′
HATU/HOAt


405
Q-0719
1.429
479.2
F′
HATU/HOAt


406
Q-0720
1.337
380.3
F′
HATU/HOAt


407
Q-0721
1.473
493.2
F′
HATU/HOAt


408
Q-0722
1.156
343.2
F′
HATU/HOAt


409
Q-0723
1.4
429.3
F′
HATU/HOAt


410
Q-0724
1.598
426.1
F′
HATU/HOAt


411
Q-0725
1.607
367.1
A′
HATU/HOAt


412
Q-0726
1.712
415.1
A′
HATU/HOAt


413
Q-0727
1.625
367.2
F′
HATU/HOAt


414
Q-0730
1.717
372.1 (M − 55)+
A′
HATU/HOAt


415
Q-0731
1.617
391.2
E′
HATU/HOAt


416
Q-0734
1.566
426.1
F′
HATU, HOAt


417
Q-0735
1.397
427.1
C′
HATU/HOAt


418
Q-0736
1.378
442.3
C′
HATU/HOAt


419
Q-0737
1.664
411.1
A′
HATU/HOAt


420
Q-0739
1.494
454.3
F′
HATU/HOAt


421
Q-0743
1.311
355.2
F′
HATU/HOAt


422
Q-0744
1.802
396.1
F′
HATU/HOAt


423
Q-0745
1.758
455.2
A′
HATU/HOAt


424
Q-0747
1.617
427.1
F′
HATU/HOAt


425
Q-0748
1.474
454.3
F′
HATU/HOAt


426
Q-0749
1.526
412.1
F′
HATU/HOAt


427
Q-0750
1
428
F′
HATU/HOAt


428
Q-0751
1.437
369.8
I′
HATU/HOAt


429
Q-0752
1.424
411.7
I′
HATU/HOAt


430
Q-0753
1.525
398
F′
HATU/HOAt


431
Q-0754
1.589
445.1
F′
HATU/HOAt


432
Q-0755
1.356
371.1
F′
HATU/HOAt


433
Q-0756
1
342
F′
HATU/HOAt


434
Q-0757
1.584
421.1
F′
HATU/HOAt


435
Q-0758
1.768
413.1
A′
HATU/HOAt


436
Q-0759
1.575
390.1
F′
HATU/HOAt


437
Q-0760
1.404
410.2
F′
HATU/HOAt


438
Q-0761
1.539
389.1
F′
HATU/HOAt


439
Q-0762
1.702
398.1 (M − 55)+
A′
HATU/HOAt


440
Q-0764
1.425
368.1
F′
HATU/HOAt


441
Q-0768
1.593
412.1 (M − 55)+
F′
HATU/HOAt


442
Q-0770
1.53
412.1
F′
HATU/HOAt


443
Q-0771
1.584
411.1
F′
HATU/HOAt


444
Q-0772
1.595
468.2
F′
HATU/HOAt


445
Q-0773
1.432
462 (M + Na)+
F′
HATU/HOAt


446
Q-0774
1.327
247
A′



447
Q-0775
1.464
367.1
F′
HATU/HOAt


448
Q-0777
1.487
381.1
F′
HATU/HOAt


449
Q-0779
1.398
261.0
A′



450
Q-0780
1.434
289.1
F′



451
Q-0781
1.528
382.1
F′
HATU/HOAt


452
Q-0782
1.490
439.1
F′
HATU/HOAt


453
Q-0783
1.518
411.1
F′
HATU/HOAt


454
Q-0784
1.562
425.1
F′
HATU/HOAt


455
Q-0785
1.537
454.2
F′
HATU/HOAt


456
Q-0788
1.525
454.2
F′
HATU/HOAt


457
Q-0789
1.393
335.1
F′
HATU/HOAt


458
Q-0790
1.53
454.2
F′
HATU/HOAt


459
Q-0791
1.378
325.1
F′
HATU/HOAt


460
Q-0792
1.482
437.1
F′
HATU/HOAt


461
Q-0793
1.347
369.2
E′
HATU/HOAt


462
Q-0794
1.353
299.2
E′
HATU/HOAt


463
Q-0795
1.371
385.1
F′
HATU/HOAt


464
Q-0796
1.475
389.1
F′
HATU/HOAt


465
Q-0797
1.485
445.2
F′
HATU/HOAt


466
Q-0798
1.658
468.2
F′
HATU/HOAt


467
Q-0799
1.439
375.1
F′
HATU/HOAt


468
Q-0800
1.41
366.2
F′
HATU/HOAt


469
Q-0802
1.558
404.2
F′
HATU/HOAt


470
Q-0803
1.560
411.0
A′
HATU/HOAt


471
Q-0804
1.444
375.1
F′
HATU/HOAt


472
Q-0805
1.415
423.1
F′
HATU/HOAt


473
Q-0806
1.504
384.1 (M − 55)+
F′
HATU/HOAt


474
Q-0807
1.420
361.1
F′
HATU/HOAt


475
Q-0808
1.577
367.2
F′
HATU/HOAt


476
Q-0809
1.537
398.1 (M − 55)+
F′
HATU/HOAt


477
Q-0812
1.411
404.2
F′
HATU/HOAt


478
Q-0813
1.533
353.1
F′
HATU/HOAt


479
Q-0814
1.340
355.1
F′
HATU/HOAt


480
Q-0815
1.401
383.1
F′
HATU/HOAt


481
Q-0816
1.467
375.1
F′
HATU/HOAt


482
Q-0817
1.459
392.2
F′
HATU/HOAt


483
Q-0818
1.460
418.1
F′
HATU/HOAt


484
Q-0819
1.534
353.1
F′
HATU/HOAt


485
Q-0820
1.664
468.2
F′
HATU/HOAt


486
Q-0821
1.301
382.1
A′
HATU/HOAt


487
Q-0822
1.585
357
A′
HATU/HOAt


488
Q-0823
1.597
422.2
E′
HATU/HOAt


489
Q-0824
1.3
367.1
F′
HATU/HOAt


490
Q-0825
1.365
366.1
F′
HATU/HOAt


491
Q-0826
1.503
394.1
F′
HATU/HOAt


492
Q-0827
1.651
438.0
F′
HATU/HOAt


493
Q-0828
1.715
472.1
F′
HATU/HOAt


494
Q-0829
1.509
429.2
F′
HATU/HOAt


495
Q-0830
1.651
438.1
F′
HATU/HOAt


496
Q-0831
1.367
406.1
F′
HATU/HOAt


497
Q-0832
1.535
396.1
F′
HATU/HOAt


498
Q-0833
1.703
472.1
F′
HATU/HOAt


499
Q-0835
1.593
439.1
F′
HATU/HOAt


500
Q-0836
1.647
473.1
F′
HATU/HOAt


501
Q-0837
1.635
437.1
A′
HATU/HOAt


502
Q-0839
1.389
275.1
F′



503
Q-0840
1.702
472.1
F′
HATU/HOAt


504
Q-0842
1.501
384.1 (M − 55)+
F′
HATU/HOAt


505
Q-0843
1.305
405.1
A′
HATU/HOAt


506
Q-0844
1.510
407.1
F′
HATU/HOAt


507
Q-0845
1.389
430.2
F′
HATU/HOAt


508
Q-0846
1.611
430.2
F′
HATU/HOAt


509
Q-0847
1.088
368.2
E′
HATU/HOAt


510
Q-0848
1.411
396.1
A′
HATU/HOAt


511
Q-0849
1.413
380.2
F′
HATU/HOAt


512
Q-0850
1.507
428.2
F′
HATU/HOAt


513
Q-0851
1.566
442.2
F′
HATU/HOAt


514
Q-0852
1.600
496.2
F′
HATU/HOAt


515
Q-0853
1.333
366.1
A′
HATU/HOAt


516
Q-0854
1.674
499.2
F′
HATU/HOAt


517
Q-0855
1.502
406.2
F′
HATU/HOAt


518
Q-0856
1.348
368.1
F′
HATU/HOAt


519
Q-0857
1.499
384.1 (M − 55)+
F′
HATU/HOAt


520
Q-0858
1.556
408.2
F′
HATU/HOAt


521
Q-0859
1.367
434.1
F′
HATU/HOAt


522
Q-0860
1.506
440.1
F′
HATU/HOAt


523
Q-0861
1.534
464.1 (M + Na)+
F′
HATU/HOAt


524
Q-0862
1.267
382.1
F′
HATU/HOAt


525
Q-0863
1.386
343.1
F′
HATU/HOAt


526
Q-0865
1.580
412.1 (M − 55)+
F′
HATU/HOAt


527
Q-0866
1.270
365.1
F′
HATU/HOAt


528
Q-0867
1.497
428.2
F′
HATU/HOAt


529
Q-0868
1.287
406.2
F′
HATU/HOAt


530
Q-0869
1.560
455.1
F′
HATU/HOAt


531
Q-0870
1.738
498.1
F′
HATU/HOAt


532
Q-0871
1.443
433.1
F′
HATU/HOAt


533
Q-0872
1.261
382.1
F′
HATU/HOAt


534
Q-0873
1.245
365.1
F′
HATU/HOAt


535
Q-0874
1.54
378.1
A′
HATU/HOAt


536
Q-0875
1.654
430.1
F′
HATU/HOAt


537
Q-0876
1.65
448.2
F′
HATU/HOAt


538
Q-0877
1.511
456.2
F′
HATU/HOAt


539
Q-0878
1.509
476.2 (M + Na)+
F′
HATU/HOAt


540
Q-0879
1.264
396.1
F′
HATU/HOAt


541
Q-0880
1.548
448.3
F′
HATU/HOAt


542
Q-0881
1.346
382.1
F′
HATU/HOAt


543
Q-0882
1.507
431.2
F′
HATU/HOAt


544
Q-0883
1.365
352.1
F′
HATU/HOAt


545
Q-0884
1.616
436.1
F′
HATU/HOAt


546
Q-0885
1.631
442.2
F′
HATU/HOAt


547
Q-0886
1.325
396.2
F′
HATU/HOAt


548
Q-0887
1.57
442.2
F′
HATU/HOAt


549
Q-0888
1.32
384.2
A′
HATU/HOAt


550
Q-0890
1.618
260.1
C′



551
Q-0891
1.341
422.2
F′
HATU/HOAt


552
Q-0892
1.558
442
F′
HATU/HOAt


553
Q-0893
2
451
F′
HATU/HOAt


554
Q-0894
1.704
464.1
F′
HATU/HOAt


555
Q-0895
1.223
381.2
F′
HATU/HOAt


556
Q-0896
1.474
389.1
F′
HATU/HOAt


557
Q-0897
1.54
476.1 (M + Na)+
F′
HATU/HOAt


558
Q-0899
1.569
442.1
F′
HATU/HOAt


559
Q-0900
1.499
375.1
F′
HATU/HOAt


560
Q-0901
1.275
434.1
F′
HATU/HOAt


561
Q-0902
1.557
421.1
F′
HATU/HOAt


562
Q-0905
1.597
515.2
F′
HATU/HOAt


563
Q-0906
1.688
404.1
D′
HATU/HOAt


564
Q-0907
1.598
411.1
D′
HATU/HOAt


565
Q-0908
1.538
424.1
F′
HATU/HOAt


566
Q-0909
1.569
431.1
F′
HATU/HOAt


567
Q-0910
1.818
389
D′
HATU/HOAt


568
Q-0911
1.419
450.2
F′
HATU/HOAt


569
Q-0912
1.642
482
F′
HATU/HOAt


570
Q-0913
1.512
450.2
F′
HATU/HOAt


571
′Q-0914
1.538
476.1 (M + Na)+
F′
HATU/HOAt


572
Q-0915
1.577
442.3
J′
HATU/HOAt


573
Q-0916
2
456
F′
HATU/HOAt


574
Q-0917
1.745
383.2
C′
HATU/HOAt


575
Q-0918
1.293
367.1
F′
HATU/HOAt


576
Q-0919
1.284
394.2
J′
HATU/HOAt


577
Q-0920
1.925
395.1
D′
HATU/HOAt


578
Q-0921
1.435
339.2
J′
HATU/HOAt


579
Q-0922
1.332
369.1
F′
HATU/HOAt


580
Q-0923
1.388
366.1
F′
HATU/HOAt


581
Q-0924
1.528
469.3
J′
HATU/HOAt


582
Q-0925
4.538
438.1
F′
HATU/HOAt


583
Q-0926
1.463
377.1
F′
HATU/HOAt


584
Q-0927
1.525
353.1
F′
HATU/HOAt


585
Q-0928
1.520
469.3
J′
HATU/HOAt


586
Q-0929
1.504
454.1
F′
HATU/HOAt


587
Q-0930
1.467
450.2
F′
HATU/HOAt


588
Q-0931
1.890
354.2
C′
HATU/HOAt


589
Q-0932
1.515
498.3
F′
HATU/HOAt


590
Q-0933
1.402
422.2
C′
HATU/HOAt


591
Q-0934
1.553
367.2
J′
HATU/HOAt


592
Q-0935
1.298
410.2
J′
HATU/HOAt


593
Q-0936
1.889
461.1
C′
HATU/HOAt


594
Q-0937
1.330
405.2
J′
HATU/HOAt


595
Q-0938
1.5
397.1
F′
HATU/HOAt


596
Q-0939
1.680
486.2
J′
HATU/HOAt


597
Q-0940
1.667
457.2
J′
HATU/HOAt


598
Q-0941
1.500
392.2
J′
HATU/HOAt


599
Q-0942
1.287
393.2
J′
HATU/HOAt


600
Q-0943
1.980
436.2
C′
HATU/HOAt


601
Q-0944
1.989
435.2
C′
HATU/HOAt


602
Q-0945
1.322
404.1
C′
HATU/HOAt


603
Q-0946
1.502
452
J′
HATU/HOAt


604
Q-0947
1.828
381
C′
HATU/HOAt


605
Q-0948
1.379
393.2
F′
HATU/HOAt


606
Q-0950
1.298
398.2
F′
HATU/HOAt


607
Q-0951
1.518
450.2
F′
HATU/HOAt


608
Q-0952
1.453
429.1
F′
HATU/HOAt


609
Q-0953
1.479
435.3
J′
HATU/HOAt


610
Q-0954
1.328
436.3
J′
HATU/HOAt


611
Q-0955
1.352
434.3
J′
HATU/HOAt


612
Q-0956
1.609
424.2
J′
HATU/HOAt


613
Q-0957
1.391
396.2
J′
HATU/HOAt


614
Q-0958
1.331
434.2
F′
HATU/HOAt


615
Q-0959
1.61
409.1
F′
HATU/HOAt


616
Q-0960
1.647
435.2
J′
HATU/HOAt


617
Q-0961
1.406
357.2
J′
HATU/HOAt


618
Q-0962
1.498
422.2
J′
HATU/HOAt


619
Q-0963
1.585
461.2
J′
HATU/HOAt


620
Q-0964
1.555
449.2
J′
HATU/HOAt


621
Q-0965
1.572
401.2
J′
HATU/HOAt


622
Q-0966
1.501
395.2
J′
HATU/HOAt


623
Q-0967
1.605
463.2
J′
HATU/HOAt


624
Q-0968
1.612
456.3
J′
HATU/HOAt


625
Q-0969
1.420
410.2
J′
HATU/HOAt


626
Q-0970
1.781
486.2
C′
HATU/HOAt


627
Q-0971
1.253
403.2
J′
HATU/HOAt


628
Q-0972
1.993
490.1 (M + Na)+
C′
HATU/HOAt


629
Q-0973
1.329
371.2
F′
HATU/HOAt


630
Q-0974
2.082
459.3
C′
HATU/HOAt


631
Q-0975
1.520
480.2
J′
HATU/HOAt


632
Q-0976
1.695
357.2
C′
HATU/HOAt


633
Q-0977
1.282
433.2
F′
HATU/HOAt


634
Q-0978
1.853
406.2
C′
HATU/HOAt


635
Q-0979
1.745
379.1
C′
HATU/HOAt


636
Q-0980
1.708
424.1
C′
HATU/HOAt


637
Q-0981
1
372
J′
HATU/HOAt


638
Q-0982
1.519
409.3
J′
HATU/HOAt


639
Q-0983
1.425
434.2
C′
HATU/HOAt


640
Q-0984
1.958
461.2
C′
HATU/HOAt


641
Q-0985
1.279
354.2
J′
HATU/HOAt


642
Q-0986
1.852
434.2
C′
HATU/HOAt


643
Q-0987
1.424
397.1
F′
HATU/HOAt


644
Q-0988
1.515
420.2
F′
HATU/HOAt


645
Q-0989
1.619
458.3
J′
HATU/HOAt


646
Q-0990
1.746
455.1
F′
HATU/HOAt


647
Q-0991
1.928
415.1
C′
HATU/HOAt


648
Q-0992
1.871
424.2
C′
HATU/HOAt


649
Q-0993
1.348
418.2
F′
HATU/HOAt


650
Q-0994
1.587
418.2
D′
HATU/HOAt


651
Q-0995
1
446
C′
HATU/HOAt


652
Q-0996
1.576
425.1
F′
HATU/HOAt


653
Q-0997
1.448
460.1
F′
HATU/HOAt


654
Q-0998
1.539
385.1
F′
HATU/HOAt


655
Q-0999
1.472
406.2
F′
HATU/HOAt


656
Q-1000
1.562
441.1
F′
HATU/HOAt


657
Q-1001
1.643
364.2
C′
HATU/HOAt


658
Q-1002
1.667
364.2
C′
HATU/HOAt


659
Q-1003
1.812
422.1
C′
HATU/HOAt


660
Q-1004
1.863
430.1
C′
HATU/HOAt


661
Q-1005
1.474
354
F′
HATU/HOAt


662
Q-1006
1.523
425.1
F′
HATU/HOAt


663
Q-1007
1.448
411.1
F′
HATU/HOAt


664
Q-1008
1.552
411.1
F′
HATU/HOAt


665
Q-1009
1.280
386.2
A′
HATU/HOAt


666
Q-1010
1.321
400.2
D′
HATU/HOAt


667
Q-1011
1.447
460.1
F′
HATU/HOAt


668
Q-1012
1.429
464.2
F′
HATU/HOAt


669
Q-1013
1.42
396
F′
HATU/HOAt


670
Q-1014
1.513
425.1
F′
HATU/HOAt


671
Q-1015
1.584
478.2
F′
HATU/HOAt


672
Q-1016
1.37
414.2
F′
HATU/HOAt


673
Q-1017
1.819
395.2
C′
HATU/HOAt


674
Q-1018
1.528
478.2
D′
HATU/HOAt


675
Q-1019
1.832
464.2
C′
HATU/HOAt


676
Q-1020
1.540
410.2
F′
HATU/HOAt


677
Q-1021
1.355
400.1
F′
HATU/HOAt


678
Q-1022
1.33
369.2
F′
HATU/HOAt


679
Q-1023
1.772
376.2
C′
HATU/HOAt


680
Q-1024
1.832
376.1
C′
HATU/HOAt


681
Q-1025
1.35
400.2
F′
HATU/HOAt


682
Q-1026
1.367
414.2
F′
HATU/HOAt


683
Q-1027
1.331
414.2
C′
HATU/HOAt


684
Q-1028
2
437
D′
HATU/HOAt


685
Q-1029
1.810
464.2
C′
HATU/HOAt


686
Q-1030
1.339
400.2
J′
HATU/HOAt


687
Q-1031
1.315
386.2
J′
HATU/HOAt


688
Q-1032
1.326
438.2
J′
HATU/HOAt


689
Q-1033
1.483
428.1 (M − H)−
F′
HATU/HOAt


690
Q-1034
1.461
390.2
F′
HATU/HoAt


691
Q-1035
1.589
450.2
J′
HATU/HOAt


692
Q-1036
1.566
464.2
J′
HATU/HOAt


693
Q-1037
1.844
481.1
F′
HATU/HOAt


694
Q-1038
1.934
393.2
C′
HATU/HOAt


695
Q-1039
1.427
359.1
F′
HATU/HOAt


696
Q-1040
1.494
341.1
F′
HATU/HOAt


697
Q-1041
1.416
395.2
J′
HATU/HOAt


698
Q-1042
1.803
440.1
D′
HATU/HOAt


699
Q-1043
1.474
455.2
J′
HATU/HOAt


700
Q-1044
1.556
425.1
F′
HATU/HOAt


701
Q-1045
1.545
469.3
J′
HATU/HOAt


702
Q-1046
1.505
492.2
F′
HATU/HOAt


703
Q-1047
1.866
412
J′
HATU/HOAt


704
Q-1048
1.891
354.2
C′
HATU/HOAt


705
Q-1049
1.786
378.2
C′
HATU/HOAt


706
Q-1050
1.747
349.1
D′
HATU/HOAt


707
Q-1051
1.680
437.2
J′
HATU/HOAt


708
Q-1052
1.949
453.2
J′
HATU/HOAt


709
Q-1053
1.487
406.1
F′
HATU/HOAt


710
Q-1054
1.903
425.2
C′
HATU/HOAt


711
Q-1055
1
410
J′
HATU/HOAt


712
Q-1056
2.054
487.2
C′
HATU/HOAt


713
Q-1057
1.401
464.3
F′
HATU/HOAt


714
Q-1058
1.381
465.2
F′
HATU/HOAt


715
Q-1059
1.373
356.1
J′
HATU/HOAt


716
Q-1060
1.472
424.2
J′
HATU/HOAt


717
Q-1061
1.696
451.2
C′
HATU/HOAt


718
Q-1062
1.773
412.2
C′
HATU/HOAt


719
Q-1063
1.745
413.2
C′
HATU/HOAt


720
Q-1064
2.066
435.2
C′
HATU/HOAt


721
Q-1065
2.049
435.2
C′
HATU/HOAt


722
Q-1066
1.425
425.2
J′
HATU/HOAt


723
Q-1067
1.390
426.2
J′
HATU/HOAt


724
Q-1070
1.271
466.2
F′
HATU/HOAt


725
Q-1071
1.991
409.1
C′
HATU/HOAt


726
Q-1072
1.802
395.2
C′
HATU/HOAt


727
Q-1073
1.431
407.2
J′
HATU/HOAt


728
Q-1074
1.563
463.1
F′
HATU/HOAt


729
Q-1075
1.517
464.1
F′
HATU/HOAt


730
Q-1076
1.7
411.2
C′
HATU/HOAt


731
Q-1077
1.284
467.3
F′
HATU/HOAt


732
Q-1078
1.945
450.1
C′
HATU/HOAt


733
Q-1079
1.486
471.2
I′
HATU/HOAt


734
Q-1080
1.522
470.2
I′
HATU/HOAt


735
Q-1081
1.759
451.2
A′
HATU/HOAt


736
Q-1082
1.490
422.1
C′
HATU/HOAt


737
Q-1083
1.691
422.1
A′
HATU/HOAt


738
Q-1084
1.551
488.1
C′
HATU/HOAt


739
Q-1085
1.401
478.2
F′
HATU/HOAt


740
Q-1086
1.533
506.3
F′
HATU/HOAt


741
Q-1087
1.430
407.1
F′
HATU/HOAt


742
Q-1088
1.373
436.3
F′
HATU/HOAt


743
Q-1089
1.344
437.3
F′
HATU/HOAt


744
Q-1090
1.617
453.2
C′
HATU/HOAt


745
Q-1091
1.35
454.2
J′
HATU/HOAt


746
Q-1092
1.387
408.3
E′
HATU/HOAt


747
Q-1093
1.446
435.1
J′
HATU/HOAt


748
Q-1094
1.499
394.2
C′
HATU/HOAt


749
Q-1095
1.614
421.2
J′
HATU/HOAt


750
Q-1096
1.572
422.2
J′
HATU/HOAt


751
Q-1097
1.570
487.2
C′
HATU/HOAt


752
Q-1098
1.466
373.2
J′
HATU/HOAt


753
Q-1099
1.669
487.2
C′
HATU/HOAt


754
Q-1100
1.648
488.2
C′
HATU/HOAt


755
Q-1101
1.490
487.2
C′
HATU/HOAt


756
Q-1102
1.82
413.3
C′
HATU/HOAt


757
Q-1103
1.799
393.2
C′
HATU/HOAt


758
Q-1104
1.41
436.2
J′
HATU/HOAt


759
Q-1105
1.494
422.2
J′
HATU/HOAt


760
Q-1106
1.752
422.2
C′
HATU/HOAt


761
Q-1107
1
437
J′
HATU/HOAt


762
Q-1108
2
478.2
J′
HATU/HOAt


763
Q-1109
1.349
451.2
F′
HATU/HOAt


764
Q-1110
1.986
446.3
C′
HATU/HOAt


765
Q-1111
1.851
438.2
C′
HATU/HOAt


766
Q-1112
1.792
383.2
C′
HATU/HOAt


767
Q-1113
1.753
384.2
C′
HATU/HOAt


768
Q-1114
1.422
408.2
C′
HATU/HOAt


769
Q-1115
1.584
422.2
A′
HATU/HOAt


770
Q-1116
1.866
438.1
C′
HATU/HOAt


771
Q-1117
1.469
422.2
J′
HATU/HOAt


772
Q-1118
1.755
425.1
C′
HATU/HOAt


773
Q-1119
1.437
377.2
J′
HATU/HOAt


774
Q-1120
1.640
418.1
C′
HATU/HOAt


775
Q-1121
1.396
394.1
J′
HATU/HOAt


776
Q-1122
1.923
421.1
C′
HATU/HOAt


777
Q-1123
1.545
435.2
F′
HATU/HOAt


778
Q-1124
1.921
409.2
C′
HATU/HOAt


779
Q-1125
1.398
410.2
J′
HATU/HOAt


780
Q-1126
1.549
379.2
J′
HATU/HOAt


781
Q-1128
1.781
394.1
C′
HATU/HOAt


782
Q-1129
1.312
394.1
J′
HATU/HOAt


783
Q-1130
1.517
421.1
F′
HATU/HOAt


784
Q-1131
1.704
459.2
J′
HATU/HOAt


785
Q-1132
1.657
423.2
F′
HATU/HOAt


786
Q-1134
1.974
479.1
C′
HATU/HOAt


787
Q-1135
1.637
505.2
J′
HATU/HOAt


788
Q-1136
1.35
488.2
F′
HATU/HOAt


789
Q-1137
1.896
463.1
C′
HATU/HOAt


790
Q-1138
2.162
521.1
C′
HATU/HOAt


791
Q-1139
2.191
555.1
C′
HATU/HOAt


792
Q-1140
1.894
506.1
C′
HATU/HOAt


793
Q-1141
1.571
455.2
J′
HATU/HOAt


794
Q-1144
1.731
394.1
C′
HATU/HOAt


795
Q-1145
1.820
464.1
C′
HATU/HOAt


796
Q-1146
2.125
492.1
C′
HATU/HOAt


797
Q-1147
2.069
492.1
C′
HATU/HOAt


798
Q-1148
2.135
526.1
C′
HATU/HOAt


799
Q-1149
1.566
489.2
J′
HATU/HOAt


800
Q-1150
1.588
473.1
C′
HATU/HOAt


801
Q-1151
1.602
505.2
J′
HATU/HOAt


802
Q-1152
1.753
521.2
J′
HATU/HOAt


803
Q-1153
2.078
555.1
C′
HATU/HOAt


804
Q-1154
1.912
506.1
C′
HATU/HOAt


805
Q-1155
1.748
521.2
J′
HATU/HOAt


806
Q-1156
1.683
505.2
J′
HATU/HOAt


807
Q-1157
1.919
489.2
D′
HATU/HOAt


808
Q-1158
1.842
459.1
D′
HATU/HOAt


809
Q-1159
2.031
539.1
C′
HATU/HOAt


810
Q-1160
2.009
476.1
C′
HATU/HOAt


811
Q-1161
1.350
472.2
J′
HATU/HOAt


812
Q-1162
1.366
472.2
J′
HATU/HOAt


813
Q-1163
1.886
522.1
C′
HATU/HOAt


814
Q-1164
1.593
488.2
D′
HATU/HOAt


815
Q-1165
2.043
505.1
C′
HATU/HOAt


816
Q-1166
2.114
492.0
C′
HATU/HOAt


817
Q-1167
2.139
526.1
C′
HATU/HOAt


818
Q-1168
1.383
394.2
C′
HATU/HOAt


819
Q-1170
1.482
440.2
J′
HATU/HOAt


820
Q-1171
1.648
539.2
J′
HATU/HOAt


821
Q-1172
1.989
512.1
C′
HATU/HOAt


822
Q-1173
2.183
555.1
C′
HATU/HOAt


823
Q-1174
1.683
447.2
J′
HATU/HOAt


824
Q-1175
1.668
539.2
J′
HATU/HOAt


825
Q-1176
1.63
505.2
J′
HATU/HOAt


826
Q-1177
1.521
349.1
E′
HATU/HOAt


827
Q-1178
1.838
541.1
C′
HATU/HOAt


828
Q-1179
1.997
522
C′
HATU/HOAt


829
Q-1180
1.937
506.2
C′
HATU/HOAt


830
Q-1181
2.010
512.1
C′
HATU/HOAt


831
Q-1182
1.477
488.1
C′
HATU/HOAt


832
Q-1183
1.469
438.2
J′
HATU/HOAt


833
Q-1184
1.959
368.1
C′
HATU/HOAt


834
Q-1185
1.689
405.1
C′
HATU/HOAt


835
Q-1186
2.022
449.1
C′
HATU/HOAt


836
Q-1187
1.550
459.1
C′
HATU/HOAt


837
Q-1188
1.856
506.1
C′
HATU/HOAt


838
Q-1189
1.41
396.3
J′
HATU/HOAt


839
Q-1190
1.524
506.2
J′
HATU/HOAt


840
Q-1191
1.402
383.2
J′
HATU/HOAt


841
Q-1192
1.78
395.2
C′
HATU/HOAt


842
Q-1193
1.863
490.1
C′
HATU/HOAt


843
Q-1194
1.456
436.1
C′
HATU/HOAt


844
Q-1196
1.963
506.1
C′
HATU/HOAt


845
Q-1197
1.865
506.1
C′
HATU/HOAt


846
Q-1198
1.537
453.2
J′
HATU/HOAt


847
Q-1199
2.083
449.2
C′
HATU/HOAt


848
Q-1200
2.004
450.2
C′
HATU/HOAt


849
Q-1201
1.405
369.2
C′
HATU/HOAt


850
Q-1202
1.575
489.2
J′
HATU/HOAt


851
Q-1203
1.525
496.2
J′
HATU/HOAt


852
Q-1205
1.366
382.3
J′
HATU/HOAt


853
Q-1206
1.690
459.1
C′
HATU/HOAt


854
Q-1207
1.857
397.2
C′
HATU/HOAt


855
Q-1208
1.786
395.1
C′
HATU/HOAt


856
Q-1209
1.377
381.2
J′
HATU/HOAt


857
Q-1210
2.026
512.2
C′
HATU/HOAt


858
Q-1211
1.928
512.2
C′
HATU/HOAt


859
Q-1212
1.559
496.3
J′
HATU/HOAt


860
Q-1213
1.318
396.2
J′
HATU/HOAt


861
Q-1214
1.615
384.2
C′
HATU/HOAt


862
Q-1215
1.926
445.2
C′
HATU/HOAt


863
Q-1216
2
458.3
J′
HATU/HOAt


864
Q-1217
1.780
394.1
C′
HATU/HOAt


865
Q-1218
1.584
438.2
J′
HATU/HOAt


866
Q-1219
1.88
417.1
C′
HATU/HOAt


867
Q-1220
1.847
409.2
C′
HATU/HOAt


868
Q-1221
1.331
355.2
C′
HATU/HOAt


869
Q-1222
1.516
354.2
J′
HATU/HOAt


870
Q-1223
1.427
397.2
J′
HATU/HOAt


871
Q-1224
1.645
391.1
C′
HATU/HOAt


872
Q-1225
1.759
423.1
C′
HATU/HOAt


873
Q-1226
1.708
409.1
C′
HATU/HOAt


874
Q-1227
1.895
451.1
C′
HATU/HOAt


875
Q-1228
1.767
439.1
C′
HATU/HOAt


876
Q-1229
1.418
461.2
J′
HATU/HOAt


877
Q-1230
1.626
505.2
J′
HATU/HOAt


878
Q-1231
1.874
506.1
C′
HATU/HOAt


879
Q-1232
1.668
427.1
C′
HATU/HOAt


880
Q-1233
1.578
426.2
J′
HATU/HOAt


881
Q-1234
1.792
461.1
C′
HATU/HOAt


882
Q-1235
1.474
488.1
C′
HATU/HOAt


883
Q-1236
1.924
522.1
C′
HATU/HOAt


884
Q-1237
1.762
362.1
C′
HATU/HOAt


885
Q-1238
2.05
460.1
C′
HATU/HOAt


886
Q-1239
1.404
375.2
J′
HATU/HOAt


887
Q-1240
1.542
436.2
J′
HATU/HOAt


888
Q-1241
1.272
382.1
C′
HATU/HOAt


889
Q-1243
1.368
404.2
J′
HATU/HOAt


890
Q-1244
1.254
369.1
C′
HATU/HOAt


891
Q-1246
1.646
390.1
C′
HATU/HOAt


892
Q-1247
1.401
405.2
J′
HATU/HOAt


893
Q-1249
1.388
386.2
J′
HATU/HOAt


894
Q-1250
1.786
417.1
C′
HATU/HOAt


895
Q-1251
1.162
328.2
J′
HATU/HOAt


896
Q-1254
1.35
404.2
J′
HATU/HOAt


897
Q-1255
1.537
404.1

HATU/HOAt


898
Q-1256
1.477
410.2
J′
HATU/HOAt


899
Q-1259
1.677
375.1
C′
HATU/HOAt


900
Q-1260
1.719
410.1
C′
HATU/HOAt


901
Q-1263
1.409
375.2
J′
HATU/HOAt


902
Q-1266
1.778
424.1
C′
HATU/HOAt


903
Q-1269
1.699
394.1
C′
HATU/HOAt


904
Q-1288
2
524.1
C′
HATU/HOAt


905
Q-1289
2
524.2
J′
HATU/HOAt


906
Q-1291
1.603
422.1
C′
HATU/HOAt


907
Q-1292
4.560
438.2
E′
HATU/HOAt


908
Q-1296
1.345
411.2
J′
HATU/HOAt


909
Q-1301
1.400
394.3
D′
HATU/HOAt


910
Q-1305
1.461
422.2
F′
HATU/HOAt


911
Q-1306
1.485
389.2
E′
HATU/HOAt


912
Q-1311
1.680
432.1
C′
HATU/HOAt


913
Q-1313
1.537
403.2
E′
HATU/HOAt


914
Q-1320
1.753
394.1
C′
HATU/HOAt


915
Q-1322
1.612
418.2
C′
HATU/HOAt


916
Q-1341
1.450
450.2
E′
HATU/HOAt


917
Q-1343
1.256
407.2
J′
HATU/HOAt


918
Q-1344
1.709
413.1
C′
HATU/HOAt


919
Q-1346
1.673
378.1
C′
HATU/HOAt


920
Q-1362
1.462
432.2
J′
HATU/HOAt


921
Q-1365
1.547
436.2
J′
HATU/HOAt


922
Q-1483
1.633
425.1
C′
HATU


923
Q-1535
1.506
468.2
J′
HOAt/HATU


924
Q-1539
1.607
406.1
C′
HATU/HOAt


925
Q-1558
1.402
434.2
J′
HATU/HOAt


926
Q-1560
1.493
423.0
C′
HATU/HOAt


927
Q-1563
1.524
439.2
J′
HATU/HOAt


928
Q-1565
1.479
404.2
J′
HATU/HOAt


929
Q-1581
1.663
420.1
C′
HATU/HOAt


930
Q-1591
1.494
482.2
J′
HOAt/HATU


931
Q-1597
1.757
289.1
C′



932
Q-1641
1.424
303.2
J′



933
Q-1728
1.448
488.1
F′
HATU/HOAt


934
Q-1818
1.561
474.3
J′
HATU/HOAt


935
Q-1866
1.889
504.1
C′
HATU/HOAt


936
Q-1886
1.573
460.1
J′
HATU/HOAt


937
Q-1889
1.925
425.1
C′
HATU/HOAt


938
Q-1925
1.343
364.1
D′
HATU/HOAt


939
Q-1932
1.381
365.0
J′
HATU/HOAt


940
Q-1984
1.784
467.0
C′
HATU/HOAt


941
Q-1985
1.561
405.1
C′
HATU/HOAt


942
Q-2007
1.285
460.3
D′
HATU/HOAt


943
Q-2008
1.756
426.0
C′
HATU/HOAt


944
Q-2009
1.850
444.0
C′
HATU/HOAt


945
Q-2016
1.509
412.1
J′
HATU/HOAt


946
Q-2017
1.556
439.0
J′
HATU/HOAt









Preparative Example 9—Formation of Amines
Preparation of 4-(azetidin-3-yl)-2-fluoropyridine TFA salt



embedded image


Step 1: (1-(tert-butoxycarbonyl)azetidin-3-yl)zinc(II) iodide



embedded image


1,2-Dibromoethane (1.992 g, 10.6 mmmol) was added to the suspension of Zn (2.86 g, 44.1 mmol) in dry THF (40 mL) under N2 atmosphere. The mixture was refluxed for 15 min and cooled to r.t. TMSCl (764 mg, 7.08 mmol) was added to the mixture slowly. After the addition, the mixture was stirred for 45 min at r.t. and then tert-butyl 3-iodoazetidine-1-carboxylate (5 g, 17.7 mmol) in dry THF (10 mL) was added. The mixture was stirred for 2 h at 40° C. to give the zinc reagent solution, which was used in next step directly.


Step 2: Synthesis of tert-butyl 3-(2-fluoropyridin-4-yl)azetidine-1-carboxylate



embedded image


4-Bromo-2-fluoropyridine (3 g, 17.142 mmol) in THF (10 ml) was added to the mixture of Pd(dba)3 (1.57 g, 1.714 mmol) and Pd(2-furyl)3 (1.2 g, 5.143 mmol) under N2 atmosphere. Then (1-(tert-butoxycarbonyl)azetidin-3-yl)zinc(II) iodide (7.2 g, 20.571 mmol) solution in THF (50 mL) was added. The mixture was stirred at 60° C. for 5 h. The reaction was quenched with H2O (10 mL). The precipitate was filtered. The filtrate was extracted with EtOAc (30 mL×2) and washed with water (200 mL). The combined organics were dried over Na2SO4. The solvent was then removed and the residue was purified by silica gel chromatography with CH2Cl2/MeOH: 50/1 to yield the product. LC-MS: m/z=253 (M+H)+, RT=1.457 min.


Step 3: Synthesis of 4-(azetidin-3-yl)-2-fluoropyridine TFA salt



embedded image


TFA (5 mL) was added to a solution of tert-butyl 3-(2-fluoropyridin-4-yl)azetidine-1-carboxylate (1.926 g, 7.634 mmol) in DCM (5 mL). The solution was stirred at r.t. for 3 h. The solvent was removed from the reaction to yield the product which was used in the next step without further purification. LC-MS: m/z=153 (M+H)+.


Preparation 1-(3,3-difluorocyclobutyl)piperazine



embedded image


Step 1: Synthesis of 1-benzyl-4-(3,3-difluorocyclobutyl)piperazine.




embedded image


To a 100 mL of RBF was added N-benzyl-2-chloro-N-(2-chloroethyl)ethanamine hydrochloride (2.3 g, 8.61 mmol), 3,3-difluorocyclobutanamine hydrochloride (1.0 g, 6.99 mmol), 20 mL of EtOH, and 6 mL of DIPEA. The mixture was stirred at reflux under N2 for 16 h. The reaction mixture was concentrated and purified by combi flash (isco, silica gel, UV 254, 40 g, EA/PE=1/3) to give the product. LC-MS (UV 214) 267.2 (M+H)+, RT=2.01 min.


Step 2: Synthesis of 1-(3,3-difluorocyclobutyl)piperazine



embedded image


To a 100 mL of RBF was added 1-benzyl-4-(3,3-difluorocyclobutyl)piperazine (1.0 g, 3.76 mmol), 30 mL of EtOAc, 0.05 mL of HOAc, and 400 mg of Pd(OH)2. The mixture was stirred at r.t. under H2 (2 atm) for 16 h. The reaction mixture was filtered and the filtrate was concentrated to give the title product. LC-MS (UV 214) 177.2 (M+H)+, RT=1.17 min.


Preparation of 1-(2,2-difluorocyclobutyl)piperazine hydrochloride



embedded image


Step 1: Synthesis of tert-butyl-4-(2-oxocyclobutyl)piperazine-1-carboxylate



embedded image


To the solution of 1,2-bis(trimethylsilyloxy)cyclobut-1-ene (12.5 g, 54.24 mmol) in MeOH (40 mL) was added dropwise a solution of tert-butyl-piperazine-1-carboxylate (10.1 g, 54.24 mmol) in MeOH (60 mL) over 30 min. After addition, the reaction mixture was stirred at r.t. for 15 h. The mixture was concentrated and purified by SGC (eluting with DCM/MeOH=20/1) to get the title compound. LC-MS: m/z=199.1 (M−56)+, RT=1.80 min.


Step 2: Synthesis of tert-butyl-4-(2,2-difluorocyclobutyl)piperazine-1-carboxylate



embedded image


To the solution of tert-butyl-4-(2-oxocyclobutyl)piperazine-1-carboxylate (7.2 g, 28.31 mmol) in DCM (50 mL) was added DAST (13.69 g, 84.93 mmol). The reaction mixture was stirred at r.t. for 15 h. It was then quenched with sat. NaHCO3 (100 mL), extracted with DCM (80 mL×3), and the combined organics were dried over Na2SO4 and concentrated. The residue was purified by SGC (eluting with PE/EtOAc=10/1-1/1) to give the title compound. LC-MS: m/z=277.2 (M+H)+, RT=2.01 min.


Step 3: Synthesis of 1-(2,2-difluorocyclobutyl)piperazine hydrochloride



embedded image


To a solution of tert-butyl-4-(2,2-difluorocyclobutyl)piperazine-1-carboxylate (950 mg, 3.44 mmol) in DCM (10 mL) was added HCl (4 mL, 4 M in dioxane). The reaction mixture was stirred at r.t. for 15 h, concentrated, and washed with EtOAc (40 mL) to give the title compound. LC-MS: m/z=177.2 (M+H)+, RT=1.15 min.


Preparation of 2-(piperidin-4-yl)oxazole-4-carbonitrile hydrochloride



embedded image


Step 1: Synthesis of methyl 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)-2,5-dihydrooxazole-4-carboxylate



embedded image


The mixture of methyl 2-amino-3-hydroxypropanoate (80 g, 516.4 mmol) and DABCO (157.74 g, 1408.45 mmol) in 2 liters of DCM was stirred for 40 min. Then tert-butyl 4-formylpiperidine-1-carboxylate (100 g, 469.48 mmol) was added to the mixture and stirred for 40 min at r.t. The mixture was cooled to 0° C. and then NBS (68.68 g, 516.4 mmol) in 500 mL of DCM was added dropwise to the mixture. The mixture was warmed to r.t. and stirred overnight. The reaction was quenched with sat. aq. Na2S2O5, extracted with DCM (300 Ml×2), and washed with aq. NaHCO3. The combined organics were dried over Na2SO4, concentrated and purified by SGC (PE/EA=3/2) to get the title compound. LC-MS: m/z=335 (M+23)+, RT=1.97 min.


Step 2: Synthesis of methyl 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)oxazole-4-carboxylate



embedded image


A mixture of methyl 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)-2,5-dihydrooxazole (10 g, 32.25 mmol), NBS (5.74 g, 32.25 mmol), and K2CO3 (5.34 g, 38.7 mmol) in 100 mL of DCE was heated to 80° C. and stirred for 2 h. The mixture was then cooled to 0° C. and quenched with sat. aq. Na2S2O3, extracted with DCM (100 mL×3), and washed with aq. NaHCO3. The combined organics were dried over Na2SO4, concentrated and purified by SGC (PE/EA=3/2) to get the title compound. LC-MS: m/z=333 (M+23)+, RT=1.48 min.


Step 3: Synthesis of 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)oxazole-4-carboxylic acid



embedded image


A solution of methyl 2-(1-(tert-butoxycarbonyl)piperidin-4-yl) oxazole-4-carboxylate (6 g, 19.35 mmol) and LiOH.H2O (2.438 g, 58.06 mmol) in THF/H2O (40 mL, v/v=1/1) was stirred for 16 h at 25° C. The mixture was adjusted to pH=3 with 1N HCl and then extracted with EA (60 mL×3). The combined organics were dried over Na2SO4. The solvent was removed under reduced pressure. The residue was used for the next step directly. LC-MS: m/z=319 (M+23)+, RT=1.34 min.


Step 4: Synthesis of tert-butyl 4-(4-carbamoyloxazol-2-yl)piperidine-1-carboxylate



embedded image


The mixture of 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)oxazole-4-carboxylic acid (4 g, 13.51 mmol), NH4Cl (1.702 g, 27.02 mmol), HATU (6.16 g, 16.212 mmol), HOAt (2.204 g, 16.212 mmol) and TEA (4.093 g, 40.53 mmol) in 50 mL of THF was stirred overnight at r.t. The reaction was quenched with water, extracted with EA (60 mL×3), and washed with aq. NaCl. The combined organics were dried over Na2SO4, concentrated, and purified by SGC (PE/EA=1/4) to get the title compound. LC-MS: m/z=318 (M+23)+, RT=1.77 min.


Step 5: Synthesis of tert-butyl 4-(4-cyanooxazol-2-yl) piperidine-1-carboxylate



embedded image


To a solution of tert-butyl 4-(4-carbamoyloxazol-2-yl) piperidine-1-carboxylate (2.5 g, 8.474 mmol) in TEA (10 mL) and THF (10 mL) was added TFAA (4 mL) dropwise at 0° C. The reaction mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure, and the residue was purified by SGC (PE/EA=2/1) to get the title compound. LC-MS: m/z=300 (M+23)+; RT=2.01 min.


Step 6: 2-(piperidin-4-yl) oxazole-4-carbonitrile hydrochloride



embedded image


To a solution of tert-butyl 4-(4-cyanooxazol-2-yl)piperidine-1-carboxylate (1.3 g, 4.693 mmol) in EA (5 mL) was added 3N HCl/EA (5 mL). The mixture was stirred for 1 h at r.t. The resulting precipitate was collected and dried under vacuum after washing with diethyl ether to afford the title compound. LC-MS: m/z=178 (M+1)+, RT=0.21 min.


Preparation of 5-(azetidin-2-yl)-2-fluoropyridine hydrochloride



embedded image


Step 1: Synthesis of (E)-N-((6-fluoropyridin-3-yl)methylene)-2-methylpropane-2-sulfinamide



embedded image


A mixture of 6-fluoronicotinaldehyde (4.7 g, 37.6 mmol) and titanium isopropoxide (1.37 g, 75.2 mmol) in dry THF (90 mL) was stirred at r.t. for 30 mins under nitrogen. Then a solution of 2-methyl-2-propanesulfinamide (4.56 g, 37.6 mmol) in dry THF (10 mL) was added. The reaction mixture was stirred at r.t. for 16 h, diluted with EtOAc (200 mL) and MeOH (50 mL), and then brine (100 mL) was added slowly. The mixture was stirred at r.t. for 30 mins and filtered. The solid was washed with EtOAc (200 mL×2). The filtrate was extracted with EtOAc (200 mL×3). The combined organics were washed with brine (50 mL×2), dried over Na2SO4, and concentrated. The residue was purified by SGC (PE/EtOAc=5/1) to give the title compound. LC-MS: m/z=303 (M+H)+, RT=1.61 min.


Step 2: Synthesis of methyl 3-(1,1-dimethylethylsulfinamido)-3-(6-fluoropyridin-3-yl) propanoate



embedded image


To a suspension of Zn dust (13.13 g, 200.7 mmol) in dry THF (130 mL) was added 1, 2-Dibromoethane (7.53 g, 40.1 mmol). The mixture was stirred at reflux for 20 mins and then was cooled to r.t. TMSCl (2.91 g, 26.8 mmol) was added and stirred for 1 h at r.t. Then methyl 2-bromoacetate (10.05 g, 66.9 mmol) was added and stirred for 2 h at 50° C. The mixture was cooled to r.t. The resulting solution was dropped into a solution of (E)-N-((6-fluoropyridin-3-yl) methylene)-2-methylpropane-2-sulfinamide (5.09 g, 22.3 mmol) in dry THF (20 mL) at 0° C. The mixture was stirred at 0° C. for 6 h, diluted with DCM (100 mL), washed with 0.25 M aq. citric acid (200 mL×2), sat. aq. NaHCO3 (50 mL×2), brine (50 mL×2), dried over Na2SO4, and concentrated to give the title compound. LC-MS: m/z=303 (M+H)+, RT=1.61 min.


Step 3: Synthesis of N-(1-(6-fluoropyridin-3-yl)-3-hydroxypropyl)-2-methylpropane-2-sulfinamide



embedded image


To a solution of methyl 3-(1,1-dimethylethylsulfinamido)-3-(6-fluoropyridin-3-yl)propanoate (3.32 g, 11.0 mmol) in dry THF (50 mL) was added 1 M LiAlH4 THF solution (22 mL, 22 mol) at 0° C. The mixture was stirred at 0° C. for 30 mins, diluted with EtOAc (200 mL), quenched with Na2SO410H2O (22 g) in portions. The mixture was stirred at r.t. for 30 mins and filtered. The solid was washed with MeOH (20 mL). The filtrate was dried over Na2SO4 and concentrated to give the crude title compound. LC-MS: m/z=275 (M+H)+; RT=1.60 min.


Step 4: Synthesis of 5-(1-(tert-butylsulfinyl) azetidin-2-yl)-2-fluoropyridine



embedded image


To a solution of N-(1-(6-fluoropyridin-3-yl)-3-hydroxypropyl)-2-methylpropane-2-sulfinamide (2.7 g, 9.85 mmol) in dry THF (50 mL) was added potassium hydroxide (1.65 g, 29.55 mmol) and 4-methylbenzene-1-sulfonyl chloride (2.25 g, 11.82 mmol). The mixture was stirred at reflux for 5 h and cooled to r.t. The mixture was diluted with DCM (200 mL), washed with brine (20 mL×2), dried over Na2SO4 and concentrated. The residue was purified by SGC (PE/EtOAc=2/1) to give the title compound. LC-MS: m/z=257 (M+H)+; RT=1.61 min.


Step 5: Synthesis of 5-(azetidin-2-yl)-2-fluoropyridine hydrochloride



embedded image


To a solution of 5-(1-(tert-butylsulfinyl)azetidin-2-yl)-2-fluoropyridine (1.14 g, 4.45 mmol) in DCM (20 mL) was added 4 M HCl/Dixoane solution (16.7 mL, 66.8 mmol) at 0° C. The mixture was stirred at r.t. for 30 mins then concentrated to give the title compound. LC-MS: m/z=124 (M−28)+, RT=0.308 min.


Preparation 6-cyclopropyl-3,6-diaza-bicyclo[3.1.1]heptane dihydrochloride



embedded image


Step 1: Synthesis of tert-butyl 6-cyclopropyl-3,6-diaza-bicyclo[3.1.1]heptane-3-carboxylate



embedded image


To a solution of tert-butyl 3,6-diaza-bicyclo[3.1.1]heptane-3-carboxylate (1.5 g, 7.58 mmol) and (1-ethoxycyclopropoxy)trimethylsilane (3.1 ml, 15.45 mmol) in 10 ml of MeOH and 10 ml of THF were added sodium cyanoborohydride (715 mg, 11.35 mmol) and acetic acid (2.2 ml, 38.50 mmol). The mixture was stirred at 60° C. under N2 for 12 h. After cooling to r.t., 1 ml of water was added and the mixture was stirred for 5 min. It was then treated with 1N NaOH (2.5 ml) and stirred for 15 min. The mixture was concentrated and the aqueous phase was extracted with DCM (100 ml). The organic phase was washed with 1N NaOH (50 ml). The combined aqueous phase was extracted with DCM (2×100 ml). The combined organics were washed with brine, dried over sodium sulphate and concentrated to give crude product which was used for the next step without further purification. LC-MS: m/z=239 (M+H)+, RT=2.26 min.


Step 2: Synthesis of 6-cyclopropyl-3,6-diaza-bicyclo[3.1.1]heptane dihydrochloride



embedded image


To a solution of tert-butyl 6-cyclopropyl-3,6-diaza-bicyclo[3.1.1]heptane-3-carboxylate (1.8 g crude, 7.56 mmol) in 40 mL of dichloromethane was added 25 mL of 4N HCl solution in 1,4-dioxane. The mixture was stirred at r.t. for 7 h and then stirred at 4° C. overnight. The upper clear solution was poured out and the sticky solid on the bottom of the flask was dried under vacuum to give the product. LC-MS: m/z=139 (M+H)+, RT=0.44 min.


Preparative Example 10—Formation of 4-(2,2,2-trifluoroethyl)piperidine



embedded image


Preparative Example 11—Formation of (1R,5S)-3-azabicyclo[3.1.0]hexan-1-ol



embedded image


Preparative Example 12—Formation of tert-butyl 4-(1H-indol-4-yl)piperidine-1-carboxylate



embedded image


Preparative Example 13—Formation of 1,1,1,3,3,3-hexafluoro-2-(piperidin-4-yl)propan-2-ol



embedded image


Preparative Example 14—Formation of 4-((3,4-difluorophenyl)sulfonyl)piperidine



embedded image


Preparative Example 15—Formation of 1-(2,2-difluorocyclopentyl)piperazine



embedded image


Preparative Example 16—4-(trifluoromethyl)azepane



embedded image


Preparative Example 17—2-(pyridin-4yl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine



embedded image


Examples 947-953

Examples 947-953 in Table 23 were prepared by coupling an appropriate carboxylic acid with an appropriate amine using the specified reaction conditions.















TABLE 23







LC-MS






Ex.
Ref.
(Retention
MS
LC-MS

Acid


No.
No.
Time)
(M + H)+
Method
Reaction Conditions
Scale






















947
Q-1127
1.553
419.2
A’
Acid (1 eqv.), amine (1.1 eqv.),
2.1
g







HATU (1.2 eqv.), HOAt (1.2









eqv.), NMM (3 eqv.), THF,









room temperature, 16 h




948
Q-1133
1.749
394.1
C’
Acid (1 eqv.), amine (1.1 eqv.),
1
g







HATU (1 eqv.), HOAt (1 eqv.),









TEA (4 eqv.), THF, room









temperature, 2 h




949
Q-1169
1.514
418.2
F’
Acid (1 eqv.), amine (1.1 eqv.),
820
mg







HATU (1 eqv.), HOAt (1 eqv.),









NMM (4 eqv.), THF, room









temperature, 16 h




950
Q-1195
1.302
380.2
J’
Acid (1 eqv.), amine (leqv.),
1.9
g







HATU (1.2 eqv.), HOAt (1.2









eqv.), NMM (7 eqv.), DMF,









room temperature, 3 h




951
Q-1204
1.579
419.1
C’
Acid (1 eqv.), amine (1.1 eqv.),
700
mg







HATU (1.1 eqv.), HOAt (1









eqv.), NMM (2.6 eqv.), THF,









60 C., 16h




952
Q-1242
1.771
394.1
C’
Acid (1 eqv.), amine (1.1 eqv.),
1
g







HATU (1.1 eqv.), HOAt (1









eqv.), NMM (4 eqv.), THF,









room temperature, 16 h




953
Q-1245
1.455
419.1
C’
Acid (1 eqv.), amine (1.1 eqv.),
800
mg







HATU (1 eqv.), HOAt (1 eqv.),









NMM (4 eqv.), THF, room









temperature, 16 h









Example 954—Assays of SPR Inhibitory Activity

Compounds were assayed for SPR inhibitory activity using a TR-FRET (homogeneous, time-resolved, fluorescence resonance energy transfer) assay according to the procedure described in Haruki et al., Science, 430:987 (2013). Terbium labelled SNAP-hSPR and SSZ (sulfasalazine) labelled SNAP-EGFP were used as the protein pair in this assay. Compounds were screened at different concentrations, and 1050 and Kd values calculated. SPR inhibitory activity of the compounds is provided in Table 24.


Compounds were assayed for SPR inhibitory activity using a SKN-N-BE (2) cellular assay according to the following procedure. SK-N-BE (2) cells were seeded in sterile, 96-well plates and incubated for 12-24 hours at 37° C. with 5% CO2 supply. Media was removed and fresh DMEM/F-12 media (containing Glutamine & Pen/Strep but no FBS) was added. Compounds (at different concentrations) were added to different wells. The plates were then incubated for 6-48 hours at 37° C. with 5% CO2 supply. Plates were then centrifuged and the supernatant was removed. The plates were then optionally washed once with PBS. They were then sealed and stored at −80° C. or immediately used in the next step. The cells were lysed and the levels of BH4 were assessed by LC-MS. SPR inhibitory activity of the compounds is provided in Table 24.


Compounds were assayed for inhibition of BH4 production using human peripheral blood mononuclear cells (PBMCs) according to the following procedure. PBMCs were either purchased or isolated from fresh human blood and used either as a fresh preparation or frozen for later use. The assay system was prepared by pre-treating the assay plates overnight with a solution containing anti-human CD3 antibody. Human PBMCs were suspended in assay medium and plated into the assay plates at a density of 1-4×105 cells per well. The desired concentration of the test compound was added to each well. A solution of human anti-CD28 antibody was also added to each well. Plates are incubated for 12-48 hours at 37° C. and 5% CO2. Assay plates were centrifuged for 5-15 minutes at 1-3000 RMP and supernatants were removed. The cells were lysed, sealed and used directly or frozen at −80° C. LC-MS was used to quantify the amount of inhibition of BH4 production and is provided in Table 24.













TABLE 24






hTR-FRET
SK-N-BE(2)
hPBMC
TR FRET



IC50
IC50
IC50
Kd


Compound
(μM)
(μM)
(μM)
(nM)



















Q-0001
0.02
2.7




Q-0002
0.03





Q-0003



14


Q-0004
0.07





Q-0005



33


Q-0006



41


Q-0007
0.10





Q-0008



48


Q-0009
0.3
22




Q-0010



72


Q-0011



77


Q-0012



81


Q-0013



88


Q-0014



88


Q-0015



100


Q-0016



101


Q-0017



118


Q-0018



125


Q-0019



129


Q-0020



129


Q-0021



133


Q-0022



139


Q-0023



141


Q-0024



153


Q-0025



268


Q-0026



295


Q-0027



326


Q-0028



364


Q-0029



406


Q-0030



484


Q-0031



495


Q-0055



7


Q-0214



1123


Q-0248
0.6


575


Q-0279
0.007
1.0
2.2



Q-0280
0.06
16




Q-0281
0.06
9.0




Q-0282
0.03
4.4




Q-0283
1.5





Q-0284
2.9





Q-0285
40





Q-0286
0.01





Q-0287
0.02





Q-0290
2.0





Q-0291
2.7





Q-0292
40





Q-0298
0.02
1.5




Q-0299
0.005
1.2




Q-0300
0.009
5.0




Q-0301
0.2





Q-0302
0.009
1.2




Q-0303
0.007
0.9




Q-0304
0.04
67




Q-0305
0.03
4.6




Q-0306
25





Q-0307
0.009
4.2




Q-0308
0.02
2.0




Q-0310
0.06
12




Q-0311
0.04
11




Q-0312
0.02
10




Q-0313
0.006
1.5




Q-0314
0.02
5.8




Q-0316
0.3





Q-0317
0.06
20




Q-0318
0.006
2.1




Q-0319
0.01
2.2




Q-0320
1.3





Q-0321
0.9





Q-0322
0.2





Q-0323
0.3
35




Q-0327
0.007
12




Q-0328
0.01
53




Q-0329
0.01
3.5




Q-0330
0.02
6.1




Q-0331
0.08
15




Q-0332
0.01
2.5




Q-0333
0.02
12




Q-0334
0.08
49




Q-0339
0.009
1.5




Q-0340
0.007
1.1




Q-0341
0.005
1.8




Q-0342
0.01
2.4




Q-0343
0.1
40




Q-0344
0.07
23




Q-0345
0.01
78




Q-0346
0.008
5.3




Q-0347
0.01
7.5




Q-0348
0.01
6.4




Q-0349
0.03
57




Q-0350
0.02
11




Q-0351
0.01
4.6




Q-0352
0.02
13




Q-0353
0.05
15




Q-0354
0.002
0.1
0.38



Q-0358
0.1
22




Q-0359
0.003
1.1




Q-0361
0.01
0.6




Q-0362
0.02
2.9




Q-0363
0.03
5.8




Q-0364
0.07
16




Q-0365
0.05
12




Q-0366
0.4
128




Q-0367
0.07
11




Q-0368
0.01
2.9




Q-0369
0.2
28




Q-0370
0.1
22




Q-0371
0.07
14




Q-0372
0.005
0.3




Q-0373
0.02
1.5




Q-0374
0.009
1.2




Q-0375
0.02
2.5




Q-0376
0.03
8.2




Q-0377
0.04
6.3




Q-0378
0.03
4.1
0.74



Q-0379
0.002
0.084
0.28



Q-0380
0.007
2.7




Q-0381
0.01
2.1




Q-0382
0.003
0.1




Q-0383
0.3
69




Q-0384
14





Q-0385
0.03
3.8




Q-0387
0.01
3.7




Q-0388
0.1
36




Q-0389
0.02
5.6




Q-0390
0.02
12




Q-0393
0.006
0.8




Q-0394
1.5





Q-0395
0.02
0.5




Q-0396
0.002
0.061




Q-0397
0.02
2.3




Q-0398
0.01
0.072




Q-0399
0.003
0.024




Q-0400
0.004
0.2




Q-0401
0.03
0.4




Q-0402
0.01
0.041




Q-0403
0.009
1.1




Q-0404
0.04
4.3




Q-0405
0.01
1.5




Q-0406
0.05
2.0




Q-0407
1.7





Q-0408
0.01
0.075




Q-0409
0.2
25




Q-0410
0.002
0.2




Q-0411
0.009
2.7




Q-0412
0.009
0.5




Q-0413
2.2





Q-0414
0.006
0.3




Q-0415
0.03
1.2




Q-0416
0.02
2.8




Q-0417
0.004
0.9




Q-0418
0.002
0.05
0.032



Q-0419
0.005
0.7




Q-0420
0.007





Q-0421
0.003
0.7




Q-0422
0.003
0.2




Q-0423
0.005
0.1
0.41



Q-0424
0.004
1.1




Q-0425
0.03
2.1




Q-0426
0.1
16




Q-0427
0.009
3.1
1.1



Q-0428
0.003
0.019




Q-0429
0.1
49




Q-0431
0.003
0.5




Q-0432
0.04
6.5




Q-0433
0.2
58




Q-0434
0.005
0.2




Q-0435
0.02
1.2




Q-0436
4.6





Q-0437
5.0





Q-0438
0.10
35




Q-0439
0.001
0.096




Q-0440
0.009
1.4




Q-0441
0.1
31




Q-0442
0.004
0.2




Q-0443
0.009
3.9




Q-0444
0.01
2.7




Q-0445
0.01
0.9




Q-0446
0.007
0.096




Q-0447
0.4





Q-0448
1.5





Q-0449
0.003
0.078




Q-0450
0.005
0.3




Q-0451
0.002
0.019
0.013



Q-0452
0.8





Q-0453
0.006
1.6
1.3



Q-0454
0.3





Q-0455
16





Q-0456
0.008
0.5




Q-0457
0.1





Q-0458
0.006
0.4




Q-0459
0.002
0.059




Q-0460
0.003
0.6




Q-0461
0.003
0.4




Q-0462
0.005
0.094




Q-0463
0.004
0.3




Q-0464
0.003
0.3




Q-0465
0.3
150




Q-0466
0.001
0.059




Q-0467
0.002
0.082
0.1



Q-0468
0.007
0.2




Q-0469
0.004
0.037




Q-0470
0.005
1.0




Q-0471
0.08
16




Q-0472
0.2
17




Q-0473
0.006
0.092




Q-0474
0.007
0.6




Q-0475
0.005
0.3




Q-0476
0.003
0.056




Q-0477
0.005
0.091




Q-0478
0.006
1.4




Q-0479
0.006
0.1




Q-0480
0.009
0.3




Q-0481
0.03
95




Q-0482
0.008
1.0




Q-0483
0.004
0.049




Q-0485
0.009
0.062




Q-0486
0.006
0.1




Q-0487
0.003
0.6




Q-0488
0.02
1.2




Q-0489
0.008
0.053




Q-0490
0.007
0.1




Q-0491
0.02
0.037




Q-0492
0.008
0.2




Q-0493
0.03
0.029




Q-0494
0.006
0.3




Q-0495
0.005
0.051




Q-0496
0.007
0.4




Q-0497
0.009
0.4




Q-0498
0.02
0.03




Q-0499
0.02
0.044




Q-0500
0.03
0.097




Q-0501
0.009
0.2




Q-0502
0.02
0.4




Q-0503
4.0





Q-0504
0.004
0.058




Q-0505
0.004
0.1




Q-0506
0.003
0.2




Q-0507
0.01
0.2




Q-0508
0.03
2.0




Q-0509
0.003
0.068




Q-0510
0.005
0.1




Q-0511
0.003
0.3




Q-0513
0.01
0.047




Q-0514
0.007
0.057




Q-0515
0.04
5.3




Q-0517
0.002
0.1




Q-0518
0.003
0.5
0.032



Q-0519
0.003
0.053
0.12



Q-0520
0.003
0.2




Q-0521
0.008
0.1




Q-0522
0.3
10




Q-0523
0.02
0.1




Q-0524
0.004
1.1




Q-0525
0.001
0.019
0.024



Q-0526
0.003
0.028




Q-0527
0.03
0.045




Q-0528
0.07
0.8




Q-0529
0.01
0.1




Q-0530
0.03
1.8




Q-0531
0.004
0.062




Q-0532
0.02
0.044




Q-0533
0.002
0.069




Q-0534
0.003
0.1




Q-0535
0.004
0.4




Q-0536
0.007
0.059




Q-0537
0.04
0.2




Q-0540
0.3





Q-0541
0.2





Q-0542
0.1





Q-0543
0.003
0.4




Q-0544
0.03





Q-0545
0.002
0.041




Q-0546
0.009
0.084




Q-0547
2.3
10




Q-0548
0.02
2.1




Q-0549
0.004
0.4




Q-0550
0.002
0.1




Q-0551
0.006
0.5




Q-0552
0.007
0.038




Q-0553
0.006
0.2




Q-0555
0.02
0.7




Q-0556
0.007
0.6




Q-0557
0.008
0.6




Q-0558
5.0
10




Q-0559
0.007
0.038




Q-0560
0.003
0.012




Q-0561
0.004
0.011




Q-0562
0.004
0.2




Q-0563
0.005
0.3




Q-0564
0.2
4.0




Q-0565
0.006
0.011




Q-0566
5.0
10




Q-0567
0.003
0.02




Q-0568
0.006
0.2




Q-0569
0.01
0.3




Q-0570
0.003
0.023




Q-0571
0.003
0.073
0.067



Q-0572
0.002
0.036
0.024



Q-0573
0.003
0.035




Q-0574
0.006
0.047




Q-0575
0.003
0.2




Q-0576
0.006
0.1




Q-0577
0.04
2.1




Q-0578
0.008
0.7




Q-0579
0.005
0.1




Q-0580
0.003
0.022




Q-0582
0.02
1.0




Q-0583
0.1
3.7




Q-0584
0.2
10




Q-0585
0.006
0.033




Q-0586
0.002
0.2
0.13



Q-0587
0.01
0.021




Q-0588
0.07
4.7




Q-0589
0.06
1.7




Q-0590
0.003
0.015




Q-0591
0.003
0.1
0.045



Q-0592
0.02
0.076




Q-0593
0.2
7.4




Q-0594
0.3
3.6




Q-0595
0.07
4.4




Q-0596
0.004
0.016




Q-0597
0.003
0.053




Q-0598
0.004
0.01




Q-0599
0.002
0.012




Q-0600
0.001
0.057




Q-0601
0.005
0.1




Q-0602
0.02
1.2




Q-0603
0.006
0.1




Q-0604
0.007
0.072




Q-0605
0.2
10




Q-0606
0.002
0.051




Q-0607
0.005
0.087




Q-0608
0.002
0.056




Q-0609
0.001
0.084




Q-0610
0.01
10




Q-0611
0.004
0.029




Q-0612
0.01
2.6




Q-0614
0.01
1.6




Q-0615
0.003
0.019




Q-0616
0.002
0.1




Q-0617
0.02
3.0




Q-0618
0.001
0.025




Q-0619
0.003
0.3




Q-0620
0.001
0.1




Q-0621
0.02
5.2




Q-0622
0.001
0.058




Q-0623
0.001
0.078




Q-0624
0.002
0.032




Q-0626
0.001
0.014




Q-0627
0.009
10




Q-0630
0.009
10




Q-0632
0.004
7.3




Q-0633
0.005
0.4




Q-0634
0.003
0.7




Q-0635
0.002
0.1
0.054



Q-0681
0.001
0.2




Q-0690
0.002
0.2
0.072



Q-0691
0.002
0.091




Q-0693
0.003
0.8
0.45



Q-0696
0.004
0.4




Q-0697
0.004
0.2




Q-0698
0.001
0.071




Q-0700
0.002
0.1




Q-0701
0.002
0.082




Q-0702
0.002
0.032




Q-0703
0.004
0.6
0.19



Q-0704
0.002
0.2




Q-0705
0.002
0.043




Q-0706
0.002
0.03




Q-0707
0.005
0.3




Q-0708
0.001
0.097




Q-0709
0.001
0.028




Q-0710
0.002
0.2




Q-0711
0.002
0.086




Q-0712
0.002
0.3




Q-0713
0.001
0.2




Q-0714
0.03
8.1




Q-0715
0.002
0.097




Q-0716
0.002
0.4




Q-0718
0.004
0.2




Q-0719
0.002
0.2




Q-0720
0.001
0.3




Q-0721
0.001
0.035
0.026



Q-0722
0.02
3.3




Q-0723
0.003
0.2




Q-0724
0.002
0.2




Q-0725
0.001
0.1




Q-0726
0.001
0.074




Q-0727
0.001
0.081




Q-0730
0.001
0.2




Q-0731
0.002
0.053




Q-0732
0.001
0.1




Q-0734
0.004
0.3




Q-0735
0.003
0.095




Q-0736
0.002
0.2




Q-0737
0.005
0.2
0.037



Q-0738
0.001
0.1




Q-0739
0.002
0.3




Q-0741
0.004
0.4




Q-0743
0.004
0.4




Q-0744
0.003
0.1




Q-0745
0.004
0.2




Q-0746
0.004
0.6




Q-0747
0.008
0.8




Q-0748
0.004
0.9




Q-0749
0.003
0.05




Q-0750
0.003
0.5
0.18



Q-0751
0.003
0.2




Q-0752
0.004
0.5




Q-0753
0.002
0.2




Q-0754
0.009
0.1




Q-0755
0.004
0.5




Q-0756
0.004
0.8




Q-0757
0.002
0.2




Q-0758
0.002
0.09




Q-0759
0.001
0.2




Q-0760
0.001
0.4
0.075



Q-0761
0.002
0.2
0.14



Q-0762
0.002
0.2




Q-0764
0.002
0.3
0.10



Q-0765
0.005
0.3




Q-0768
0.002
0.2
0.045



Q-0770
0.002
0.2




Q-0771
0.001
0.2




Q-0772
0.001
0.2
0.072



Q-0773
0.006
1.7




Q-0774
0.2
10




Q-0775
0.002
1.0




Q-0777
0.001
0.3
0.055



Q-0779
0.02
10




Q-0780
0.001
0.2




Q-0781
0.001
0.2




Q-0782
0.001
0.1
0.038



Q-0783
0.002
0.3




Q-0784
0.001
0.3
0.12



Q-0785
0.001
0.2




Q-0788
0.01
3.6




Q-0789
0.008
2.5
0.44



Q-0790
0.007
1.4




Q-0791
0.002
0.6




Q-0792
0.006
2.1




Q-0793
0.003
1.0




Q-0794
0.01
3.5
0.41



Q-0795
0.002
0.5




Q-0796
0.001
0.2




Q-0797
0.001
0.1
0.027



Q-0798
0.002
0.3




Q-0799
0.001
0.3




Q-0800
0.002
0.6
0.047



Q-0802
0.001
0.067




Q-0803
0.001
0.2




Q-0804
0.001
0.3
0.094



Q-0805
0.004
2.3




Q-0806
0.003
1.2




Q-0807
0.002
0.4




Q-0808
0.001
0.2




Q-0809
0.006
0.9




Q-0812
0.003
1.0
0.15



Q-0813
0.001
0.1
0.065



Q-0814
0.002
0.4




Q-0815
0.001
0.1
0.072



Q-0816
0.001
0.6
0.17



Q-0817
0.001
0.2
0.044



Q-0818
0.002
0.9




Q-0819
0.001
0.2




Q-0820
0.001
0.04




Q-0821
0.001
0.1
0.051



Q-0822
0.002
0.4
0.13



Q-0823
0.001
0.066




Q-0824
0.005
1.8




Q-0825
0.002
0.4
0.15



Q-0826
0.001
0.1




Q-0827
0.002
0.065




Q-0828
0.004
0.05




Q-0829
0.001
0.08




Q-0830
0.001
0.041




Q-0831
0.002
0.4




Q-0832
0.001
0.2




Q-0833
0.006
0.2




Q-0835
0.002
0.1
0.039



Q-0836
0.005
0.3
0.052



Q-0837
0.001
0.2
0.063



Q-0839
0.008
1.5




Q-0840
0.003
0.2




Q-0842
0.002
0.7




Q-0843
0.001
0.2




Q-0844
0.001
0.2




Q-0845
0.003
0.4




Q-0846
0.002
0.2




Q-0847
0.02
8.8




Q-0848
0.002
10




Q-0849
0.001
0.3
0.044



Q-0850
0.001
0.3
0.074



Q-0851
0.002
0.5
0.13



Q-0852
0.002
0.8




Q-0853
0.03
10




Q-0854
0.003
0.2




Q-0855
0.001
0.1




Q-0856
0.004
1.1




Q-0857
0.003
0.8




Q-0858

0.044




Q-0859
0.02
8.3




Q-0860

1.0




Q-0861

0.4




Q-0862

10




Q-0863

0.6




Q-0865

0.1




Q-0866

6.7




Q-0867
0.002
0.4
0.07



Q-0868

10




Q-0869

0.1




Q-0870

0.3




Q-0871

4.0




Q-0872

10




Q-0873

10




Q-0874

1.1




Q-0875

0.076




Q-0876

0.088




Q-0877

0.2




Q-0878

0.8




Q-0879

10




Q-0880

0.087




Q-0881

2.3




Q-0882

0.2




Q-0883

1.3




Q-0884

0.2




Q-0885

0.4




Q-0886

5.4




Q-0887
0.001
0.2
0.057



Q-0888
0.005
0.4
0.24



Q-0890






Q-0891
0.004
0.9
0.24



Q-0892
0.002
0.4
0.076



Q-0893

0.3




Q-0894

0.1




Q-0895

1.4




Q-0896
0.001
0.3
0.049



Q-0897

0.5




Q-0899
0.001
0.3
0.048



Q-0900

2.3




Q-0901

10




Q-0902

0.1




Q-0905

0.6




Q-0906
0.003
0.8
0.19



Q-0907

0.4




Q-0908
0.001
0.3
0.13



Q-0909

0.1




Q-0910
0.002
0.5
0.074



Q-0911
0.002
0.4
0.11



Q-0912

0.9




Q-0913
0.002
0.5
0.087



Q-0914

0.6




Q-0915
0.002
0.5
0.092



Q-0916

0.7




Q-0917
0.003
0.7
0.10



Q-0918
0.002
0.6
0.12



Q-0919

1.7




Q-0920

0.5




Q-0921
0.002
0.4
0.047



Q-0922

1.0




Q-0923

1.3




Q-0924
0.002
0.2
0.051



Q-0925

0.5




Q-0926
0.001
0.2
0.045



Q-0927
0.001
0.2
0.081



Q-0928

0.2




Q-0929

2.0




Q-0930
0.001
0.3
0.058



Q-0931

0.2




Q-0932

0.7




Q-0933

0.2




Q-0934

0.3




Q-0935

1.6




Q-0936

0.2




Q-0937
0.004
0.8
0.13



Q-0938

0.1




Q-0939

0.083




Q-0940

0.8




Q-0941
0.001
0.3
0.013



Q-0942

9.1




Q-0943
0.002
0.018
0.038



Q-0944
0.001
0.028
0.036



Q-0945

1.0




Q-0946

1.1




Q-0947

1.0




Q-0948
0.001
0.1
0.053



Q-0949

0.2




Q-0950

6.2




Q-0951
0.002
0.4
0.045



Q-0952
0.001
0.3
0.083



Q-0953
0.001
0.058
0.021



Q-0954

9.0




Q-0955

10




Q-0956
0.001
0.086
0.014



Q-0957

1.0




Q-0958

10




Q-0959

1.0




Q-0960

0.2




Q-0961

0.7




Q-0962

0.3




Q-0963

4.0




Q-0964

8.9




Q-0965

0.1




Q-0966

1.3




Q-0967

1.9




Q-0968

0.4




Q-0969
0.001
0.2
0.16



Q-0970

0.4




Q-0971

7.2




Q-0972
0.001
0.065
0.014



Q-0973
0.001
0.7
0.08



Q-0974

0.1




Q-0975

1.3




Q-0976

1.1




Q-0977
0.001
0.5
0.086



Q-0978
0.001
0.081
0.059



Q-0979

1.4




Q-0980

1.3




Q-0981

1.4




Q-0982

10




Q-0983

10




Q-0984

0.4




Q-0985

9.2




Q-0986
0.002
0.7
0.11



Q-0987

1.1




Q-0988

0.069




Q-0989

0.9




Q-0990

0.2




Q-0991

0.1




Q-0992
0.003
0.8
0.098



Q-0993
0.003
1.1
0.16



Q-0994

3.0




Q-0995
0.002
0.6
0.18



Q-0996

1.9




Q-0997

1.0




Q-0998
0.001
0.3
0.092



Q-0999

0.2




Q-1000

0.9




Q-1001

1.8




Q-1002

3.4




Q-1003
0.001
0.1
0.051



Q-1004

3.1




Q-1005
0.001
0.3
0.1



Q-1006

1.4




Q-1007
0.001
0.5
0.12



Q-1008

0.3




Q-1009

2.0




Q-1010

4.0




Q-1011

0.8




Q-1012

1.3




Q-1013

1.5




Q-1014

1.4




Q-1015

0.4




Q-1016

2.4




Q-1017

0.3




Q-1018

0.7




Q-1019

0.4




Q-1020
0.002
0.3
0.20



Q-1021

1.0




Q-1022
0.002
0.1
0.041



Q-1023

0.7




Q-1024
0.001
0.3
0.056



Q-1025

1.2




Q-1026

1.7




Q-1027

3.1




Q-1028

1.1




Q-1029

1.0




Q-1030

3.1




Q-1031

2.3




Q-1032

10




Q-1033
0.008
0.4
0.26



Q-1034
0.002
0.2
0.16



Q-1035

0.1




Q-1036

0.07




Q-1037

0.071




Q-1038
0.002
0.3
0.34



Q-1039

0.3




Q-1040

0.3




Q-1041
0.001
0.046
0.028



Q-1042

1.0




Q-1043

1.4




Q-1044

1.0




Q-1045

0.1




Q-1046
0.001
0.1
0.083



Q-1047
0.001
0.2
0.066



Q-1048
0.001
0.2
0.05



Q-1049
0.002
0.072
0.025



Q-1050

1.4




Q-1051
0.001
0.053
0.027



Q-1052
0.001
0.044
0.083



Q-1053
0.001
0.2
0.23



Q-1054
0.001
0.028
0.06



Q-1055
0.001
0.7
0.16



Q-1056
0.003
0.016
0.055



Q-1057
0.001
0.1
0.067



Q-1058
0.002
0.093
0.15



Q-1059
0.002
1.3
2.1



Q-1060
0.002
0.2
0.22



Q-1061
0.003
0.4
0.21



Q-1062
0.001
0.1
0.097



Q-1063
0.002
0.055
0.12



Q-1064
0.002
0.2
0.22



Q-1065
0.001
0.058
0.074



Q-1066
0.001
0.3
0.082



Q-1067
0.002
0.1
0.16



Q-1070
0.002

0.20



Q-1071
0.006

0.032



Q-1072
0.002

0.055



Q-1073
0.003

0.055



Q-1074
0.001

0.022



Q-1075
0.002

0.017



Q-1076
0.001

0.035



Q-1077
0.005

0.16



Q-1078
0.005

0.036



Q-1079
0.003

0.074



Q-1080
0.002

0.025



Q-1081
0.002

0.13



Q-1082
0.004

0.12



Q-1083
0.001

0.068



Q-1084
0.002

0.013



Q-1085
0.001

0.063



Q-1086
0.001

0.084



Q-1087
0.002

0.029



Q-1088
0.004

0.29



Q-1089
0.003

0.35



Q-1090
0.001





Q-1091
0.002

0.13



Q-1092
0.001

0.33



Q-1093
0.001

0.095



Q-1094
0.001

0.099



Q-1095
0.001

0.027



Q-1096
0.001

0.018



Q-1097
0.001

0.024



Q-1098
0.001

0.21



Q-1099
0.001

0.06



Q-1100
0.001

0.031



Q-1101
0.001

0.041



Q-1102
0.001

0.058



Q-1103
0.001

0.10



Q-1104
0.003

0.11



Q-1105
0.001

0.018



Q-1106
0.001

0.093



Q-1107
0.001

0.058



Q-1108
0.001

0.05



Q-1109
0.001

0.046



Q-1110
0.002

0.043



Q-1111
0.001

0.015



Q-1112
0.001

0.037



Q-1113
0.001

0.016



Q-1114
0.001

0.024



Q-1115
0.001

0.045



Q-1116
0.001

0.076



Q-1117
0.001

0.02



Q-1118
0.001

0.11



Q-1119
0.002

0.37



Q-1120
0.001

0.097



Q-1121
0.001

0.07



Q-1122
0.001

0.025



Q-1123
0.001

0.057



Q-1124
0.001

0.035



Q-1125
0.006

0.1



Q-1126
0.001

0.048



Q-1127
0.001

0.015



Q-1128
0.002

0.048



Q-1129
0.002

0.05



Q-1130
0.001

0.057



Q-1131
0.001

0.027



Q-1132
0.001

0.04



Q-1133
0.002

0.022



Q-1134
0.003

0.025



Q-1135
0.01

0.045



Q-1136
0.002

0.014



Q-1137
0.003

0.16



Q-1138
0.02

0.36



Q-1139
0.02

0.42



Q-1140
0.008

0.23



Q-1141
0.001

0.019



Q-1142
0.001

0.075



Q-1143
0.003

0.31



Q-1144
0.001

0.07



Q-1145
0.003

0.19



Q-1146
0.005

0.38



Q-1147
0.007

0.52



Q-1148
0.01

0.54



Q-1149
0.005

0.21



Q-1150
0.001





Q-1151
0.008

0.31



Q-1152
0.008

0.38



Q-1153
0.008

0.63



Q-1154
0.005

0.35



Q-1155
0.01

0.27



Q-1156
0.006

0.11



Q-1157
0.004

0.49



Q-1158
0.002

0.13



Q-1159
0.02

0.60



Q-1160
0.003

0.11



Q-1161
0.003

0.31



Q-1162
0.001

0.095



Q-1163
0.002

0.068



Q-1164
0.001

0.037



Q-1165
0.006

0.19



Q-1166
0.005

0.02



Q-1167
0.01

0.081



Q-1168
0.003

0.058



Q-1169
0.001

0.077



Q-1170
0.001

0.16



Q-1171
0.01

0.14



Q-1172
0.003

0.18



Q-1173
0.02

0.29



Q-1174
0.001

0.022



Q-1175
0.02

0.45



Q-1176
0.009

0.28



Q-1177
0.009

1.3



Q-1178
0.009

2.6



Q-1179
0.002

0.11



Q-1180
0.002

0.047



Q-1181
0.002

0.011



Q-1182
0.001

0.048



Q-1183
0.004

0.11



Q-1184
0.002

0.037



Q-1185
0.001

0.11



Q-1186
0.001

0.036



Q-1187
0.004

0.19



Q-1188
0.006

0.29



Q-1189






Q-1190
0.01

0.059



Q-1191
0.001

0.02



Q-1192
0.001

0.04



Q-1193
0.007

0.16



Q-1194
0.002

0.06



Q-1195
0.002

0.047



Q-1196
0.003

0.052



Q-1197
0.003

0.026



Q-1198
0.001

0.017



Q-1199
0.001

0.029



Q-1200
0.001

0.15



Q-1201
0.001

0.069



Q-1202
0.005

0.26



Q-1203
0.006

0.18



Q-1204
0.001

0.017



Q-1205
0.003

0.035



Q-1206
0.001

0.07



Q-1207
0.001

0.029



Q-1208
0.001

0.061



Q-1209
0.001

0.92



Q-1210
0.002

0.084



Q-1211
0.01

0.16



Q-1212
0.001

0.013



Q-1213
0.003

0.89



Q-1214
0.006

1.0



Q-1215
0.001

0.017



Q-1216
0.001

0.046



Q-1217
0.003

0.27



Q-1218
0.003

0.13



Q-1219
0.001

0.079



Q-1220
0.001

0.022



Q-1221
0.001

0.037



Q-1222
0.001

0.025



Q-1223
0.003

0.024



Q-1224
0.009

0.37



Q-1225
0.001

0.029



Q-1226
0.007

0.41



Q-1227
0.001

0.014



Q-1228
0.001

0.017



Q-1229
0.002

0.1



Q-1230
0.01

0.18



Q-1231
0.003

0.062



Q-1232
0.001

0.056



Q-1233
0.001

0.023



Q-1234
0.002

0.027



Q-1235
0.005

0.018



Q-1236
0.006

0.048



Q-1237
0.003

0.70



Q-1238
0.002

0.079



Q-1239
0.002

0.027



Q-1240
0.001

0.035



Q-1241
0.002

0.02



Q-1242
0.005

0.032



Q-1243
0.02

0.051



Q-1244
0.001

0.036



Q-1245
0.001

0.026



Q-1246
0.004

0.10



Q-1247
0.002

0.15



Q-1249
0.002

0.046



Q-1250
0.001

0.024



Q-1251
0.05





Q-1254
0.1

0.87



Q-1255
0.1

0.58



Q-1256
0.03

0.33



Q-1259
0.1

0.36



Q-1260
0.03

0.081



Q-1263
0.1

0.37



Q-1266
0.2





Q-1269
0.005

0.053



Q-1288
0.008

0.60



Q-1289
0.002

0.07



Q-1291
0.2

2.4



Q-1292
5.0





Q-1295
2.4





Q-1296
0.6





Q-1301
0.01

0.82



Q-1305
0.1

1.2



Q-1306
0.5





Q-1311
5.0





Q-1313
5.0





Q-1320
0.02





Q-1322
0.4





Q-1341
5.0





Q-1343
0.07





Q-1344
0.009

0.32



Q-1345
1.4





Q-1346
0.05





Q-1362
0.001

0.043



Q-1365
1.0





Q-1483
0.03





Q-1535
0.001

0.11



Q-1539
0.004

0.78



Q-1558
0.002

0.092



Q-1560
0.8





Q-1563
5.0





Q-1564
5.0





Q-1565
5.0





Q-1581
0.004

0.17



Q-1591
0.003

0.11



Q-1597
5.0





Q-1641
5.0





Q-1728
0.001

0.086



Q-1794
0.002

0.25



Q-1796
0.001

0.26



Q-1797
0.001

0.079



Q-1798
0.002





Q-1799
0.001

0.10



Q-1800
0.002





Q-1801
0.002





Q-1804
0.002





Q-1805
0.001

0.13



Q-1807
0.001

0.11



Q-1814
0.002





Q-1815
0.002





Q-1818
0.001

0.095



Q-1819
0.001

0.091



Q-1820
0.001

0.094



Q-1821
0.001

0.13



Q-1822
0.001

0.12



Q-1823
0.001

0.11



Q-1824
0.003





Q-1825
0.002





Q-1826
0.002





Q-1827
0.001





Q-1829
0.002





Q-1830
0.002





Q-1831
0.003





Q-1832
0.003





Q-1833
0.001





Q-1834
0.001





Q-1835
0.004





Q-1836
0.001

0.27



Q-1837
0.001





Q-1838
0.001

0.17



Q-1839
0.002





Q-1840
0.003





Q-1841
0.001

0.087



Q-1842
0.001

0.15



Q-1845
0.002





Q-1846
0.001

0.17



Q-1847
0.001

0.064



Q-1848
0.001

0.21



Q-1857
0.001

0.15



Q-1858
0.001

0.26



Q-1859
0.001

0.16



Q-1861
0.001

0.098



Q-1862
0.002

0.25



Q-1864
0.004





Q-1866
0.002

0.08



Q-1875
0.001

0.11



Q-1876
0.001

0.11



Q-1882
0.002

0.092



Q-1884
0.001

0.084



Q-1885
0.01





Q-1886
0.002

0.11



Q-1889
0.001

0.036



Q-1925
0.001

0.17



Q-1932
0.003

2.7



Q-1984
0.001





Q-1985
0.002





Q-2007
0.001





Q-2008
0.002

0.30



Q-2009
0.002

0.37



Q-2016
0.001

0.045



Q-2017
0.002

0.17



Q-2031
0.003





Q-2032
0.006





Q-2041
0.003





Q-2043
0.005





Q-2048
0.004





Q-2054
0.004





Q-2055
0.007









Example 955—Behavioral Pharmacology Models

Compounds were tested in standard behavioral pharmacology models for pain in rats as described in the literature (see, e.g., Latremoliere et al., Neuron, 86:1393-1406 (2015); Tegeder et al., Nature Medicine, 12:1269-1277 (2006)). Compounds were administered by oral gavage to rats that had undergone one of two nerve injury surgeries: spared nerve injury to injure two of the three peripheral branches of the sciatic nerve (SNI, Decosterd et al., Pain, 87:149-158 (2000)) or chronic constriction injury of the sciatic nerve (CCI, Bennett et al., Pain, 33:87-107 (1988)). Paw withdrawal thresholds to mechanical stimulation using calibrated von Frey filaments were used as measurement of neuropathic pain-like behaviors. Effect on pain behavior in these models is provided in Table 25.















TABLE 25










Be-
Behavior







havior
Signif-


Com-

Dose
Dosing
Behavior
Time
icant


pound
Model
(mpk)
Schedule
Endpoint
Point
effect





















Q-1127
SNI
20
QD 3 days
mechanical
4 hrs
yes


Q-1133
CCI
10
QD 3 days
mechanical
4 hrs
yes


Q-1169
CCI
9.5
QD 3 days
mechanical
4 hrs
yes


Q-1195
SNI
15
QD 3 days
mechanical
4 hrs
yes


Q-1204
SNI
10
QD 3 days
mechanical
4 hrs
yes


Q-1242
SNI
10
QD 3 days
mechanical
4 hrs
yes


Q-1245
CCI
9.5
QD 3 days
mechanical
4 hrs
yes





mpk = mg per kg


QD 3 days = daily for 3 days






The present invention is described in connection with preferred embodiments. However, it should be appreciated that the invention is not limited to the disclosed embodiments. It is understood that, given the description of the embodiments of the invention herein, various modifications can be made by a person skilled in the art. Such modifications are encompassed by the claims below.

Claims
  • 1. A compound of formula V or V′, or a pharmaceutically acceptable salt thereof:
  • 2. The compound of claim 1, wherein
  • 3. The compound of claim 1, wherein
  • 4. The compound of claim 1, wherein
  • 5. The compound of claim 3, wherein
  • 6. The compound of claim 1, wherein
  • 7. The compound of claim 6, wherein
  • 8. The compound of claim 1, wherein R3 and R4, taken together with nitrogen atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered ring having 1 or 2 heteroatom ring atoms selected from nitrogen, oxygen, and sulfur.
  • 9. The compound of claim 8, wherein the 3-, 4-, 5-, 6-, or 7-membered ring is piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl, oxaziridinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, azepanyl, diazepanyl, or diazabicycloheptane.
  • 10. The compound of claim 1, wherein
  • 11. The compound of claim 1, wherein
  • 12. The compound of claim 11, wherein R7 or R9 is selected from the group consisting of C3-5cycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, aryl, and heteroaryl.
  • 13. The compound of claim 12, wherein R7 is oxazolyl or pyridinyl, each of which is optionally substituted with CN or F.
  • 14. The compound of claim 13, wherein R7 is selected from the group consisting of
  • 15. The compound of claim 12, wherein R9 is C3-5cycloalkyl.
  • 16. The compound of claim 15, wherein R9 is cyclopropyl or cyclobutyl, each of which is optionally substituted with 1, 2, 3, or 4 F atoms.
  • 17. The compound of claim 16, wherein R9 is selected from the group consisting of
  • 18. The compound of claim 1, wherein the compound is
  • 19. The compound of claim 1, wherein the compound is
  • 20. The compound of claim 1, wherein the compound is
  • 21. The compound of claim 1, wherein the compound is
  • 22. The compound of claim 1, wherein the compound is
  • 23. The compound of claim 1, wherein the compound is
  • 24. The compound of claim 1, wherein the compound is
  • 25. A method of treating a subject suffering from pain, comprising administering to the subject a therapeutically effective amount of the compound of claim 1.
  • 26. The compound of claim 3, wherein
  • 27. The compound of claim 7, wherein
US Referenced Citations (28)
Number Name Date Kind
3040047 Sirakawa Jun 1962 A
5852019 Ejima et al. Dec 1998 A
6274581 Gross Aug 2001 B1
6869952 Bhide et al. Mar 2005 B2
6933386 Bhide et al. Aug 2005 B2
6969717 Bhide et al. Nov 2005 B2
7030118 Lombardo et al. Apr 2006 B2
7160882 Bouyssou et al. Jan 2007 B2
7265113 Bhide et al. Sep 2007 B2
7306631 Glenn, Jr. et al. Dec 2007 B2
7375104 Bouyssou et al. May 2008 B2
7521450 Bhide et al. Apr 2009 B2
7534882 Bhattacharya et al. May 2009 B2
7632834 Bouyssou et al. Dec 2009 B2
7820814 Bhide et al. Oct 2010 B2
7906520 Woolf et al. Mar 2011 B2
8080666 Berdini et al. Dec 2011 B2
8198438 Sampognaro et al. Jun 2012 B2
8642609 Makings et al. Feb 2014 B2
9174995 Dorsch et al. Nov 2015 B2
20020058816 Kordik et al. May 2002 A1
20060058304 Bhide et al. Mar 2006 A1
20080176744 Schwogler et al. Jul 2008 A1
20080188666 Berger et al. Aug 2008 A1
20120252791 Blagg Oct 2012 A1
20120322800 Blagg Dec 2012 A1
20150291593 Su et al. Oct 2015 A1
20150307520 Su et al. Oct 2015 A1
Foreign Referenced Citations (18)
Number Date Country
1454897 Sep 2004 EP
2844659 Mar 2015 EP
2388594 Nov 2003 GB
S35-3032 Apr 1960 JP
H04182636 Jun 1992 JP
H05341428 Dec 1993 JP
WO-2006035061 Apr 2006 WO
WO-2008055709 May 2008 WO
WO-2008092861 Aug 2008 WO
WO-2008107478 Sep 2008 WO
WO-2008131050 Oct 2008 WO
WO-2008138876 Nov 2008 WO
WO-2010093727 Aug 2010 WO
WO-2011035009 Mar 2011 WO
WO-2011047156 Apr 2011 WO
WO-2011138142 Nov 2011 WO
WO-2013132253 Sep 2013 WO
WO-2013164061 Nov 2013 WO
Non-Patent Literature Citations (21)
Entry
Ambinter Stock Screening Collection, Database Accession Nos. 1172018-24-4, 1172354-13-0, 1170845-46-1, 1172864-02-6, 1169952-04-8, 1171450-23-9, 1172540-63-4, 1171768-20-9, 1171151-28-2, and 1172397-00-2 (Sep. 15, 2014).
Auerbach et al., The 1.25 A crystal structure of sepiapterin reductase reveals its binding mode to pterins and brain neurotransmitters, EMBO J., 16(24):7219-30 (1997).
Badawey et al., Nonsteroidal antiinflammatory agents—Part I: Antiinflammatory, analgesic and antipyretic activity of some new 1-(pyrimidin-2-yl)-3-pyrazolin-5-ones and 2-(pyrimidin-2-yl)-1,2,4,5,6,7-hexahydro-3H-indazol-3-ones, Eur. J. Med. Chem., 33:349-61 (1998).
Bennett et al., A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man, Pain, 33(1):87-107 (1988).
Chemical Abstracts Service, Database Accession No. 1961:8238, “2-(1-Pyrazolyl)pyrmidines”, Kenzo Shirakawa, Japanese Patent No. JPS353032B (Apr. 4, 1960).
Chen et al., A tandem copper (II)—promoted synthesis of 2-substituted pyrrolo[2,1-f][1,2,4] triazin-4(3H)-ones, Tetrahedron 69(13):2714-9 (2013).
Costigan et al., Analgesia by inhibiting tetrahydrobiopterin synthesis, Curr. Opin. Pharmacol., 12(1):92-9 (2012).
Decosterd et al., Spared nerve injury: an animal model of persistent peripheral neuropathic pain, Pain, 87(2):149-58 (2000).
El-Hawash et al., Nonsteroidal antiinflammatory agents-part 2 antiinflammatory, analgesic and antipyretic activity of some substituted 3-pyrazolin-5-ones and 1,2,4,5,6,7-3H-hexahydroindazol-3-ones, Eur. J. Med. Chem., 41(2):155-65 (2006).
EMolecules, Screening Compounds catalog, Catalog No. F5649-0081. (Jan. 3, 2017).
Haruki et al., Tetrahydrobiopterin biosynthesis as an off-target of sulfa drugs, Science, 340(6135):987-91 (2013).
International Search Report and Written Opinion, International Application No. PCT/US2016/054657, dated Jan. 9, 2017.
Konishi et al., Fungicidal Activity of Pyrazolylpyrimidines Studies on Fungicidal Pyrimidinylhydrazones (Part 5), J. Pesticide Sci., 15(1):13-22 (1990).
Ladzik et al., Regioselective synthesis of 5-ethoxycarbonyl-, 5-acetyl- and 5-trifluoroacetyl-6-trifluoromethylsalicylates by one-pot cyclizations of 1,3-bis(trimethylsilyloxy)-1,3-butadienes with 3-alkoxy-2-alken-1-ones, J. Fluorine Chem., 136:38-42 (2012).
Latremoliere et al., Reduction of Neuropathic and Inflammatory Pain through Inhibition of the Tetrahydrobiopterin Pathway, Neuron., 86:1393-406 (2015).
Sampognaro et al., Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,24][1,2,4]triazine inhibitors of IGF-1 R kinase and IR kinase, Bioorg. Med. Chem. Lett., 20(17):5027-30 (2010).
Sirakawa et al., Pyrimidine derivatives. XI. 2-(1-Pyrazolyl)pyrimidines. 1, Takeda Kenkyusho Nenpo, 22:19-26 (1963).
Sirakawa et al., Pyrimidine derivatives. XII. 2-(1-Pyrazolyl)pyrimidines, Takeda Kenkyusho Nenpo, 22:27-46 (1963).
Smith et al., New inhibitors of sepiapterin reductase. Lack of an effect of intracellular tetrahydrobiopterin depletion upon in vitro proliferation of two human cell lines, J. Biol. Chem., 267(8):5599-607 (1992).
Tegeder et al., GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence, Nat. Med., 12(11):1269-77 (2006).
Zanatta et al., Synthesis and structural study of N-methyl-2-methylthiopyrimidine derivatives from trihalomethylated enones, J. Heterocyclic Chem., 47(5):1234-9 (2010).
Related Publications (1)
Number Date Country
20170096435 A1 Apr 2017 US
Provisional Applications (1)
Number Date Country
62235191 Sep 2015 US